

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

ORAL ARGUMENT REQUESTED

PLAINTIFFS' MOTION FOR A PRELIMINARY INJUNCTION

TABLE OF CONTENTS

INTRODUCTION	1
BACKGROUND	5
I. PFAS IS A BROAD CATEGORY ENCOMPASSING SUBSTANCES USED IN MANY EVERYDAY PRODUCTS WITH NO ESTABLISHED HEALTH RISK.	5
II. NEW MEXICO PFAS PROTECTION ACT AND CHALLENGED REGULATION.....	7
A. The New Mexico Legislature imposes a ban on many PFAS, while authorizing the EIB to require labeling.....	7
B. The EIB imposes a sweeping labeling mandate.	7
LEGAL STANDARD	10
ARGUMENT	11
I. PLAINTIFFS ARE LIKELY TO SUCCEED ON THE MERITS.	11
A. The Regulation does not satisfy any elements of the <i>Zauderer</i> test.	12
1. The required pictograph does not convey purely factual information.	12
2. The science concerning the risks posed by all PFAS is at best unsettled.	16
3. <i>Zauderer</i> does not permit the State to compel speech premised on impacts disconnected from the service provided to the consumer.....	18
4. The Regulation is unduly burdensome.	19
B. The Regulation cannot survive First Amendment scrutiny.....	22
II. THE REMAINING FACTORS SUPPORT PRELIMINARY INJUNCTIVE RELIEF.	25
A. Plaintiffs’ member companies will suffer irreparable harm.	26
B. The public interest favors a preliminary injunction.....	26
III. AT A MINIMUM, THE COURT SHOULD ENJOIN THE REGULATION WITH RESPECT TO FLUOROPOLYMERS AND PFAS TO WHICH CONSUMERS ARE NOT EXPOSED	27
CONCLUSION.....	27

TABLE OF AUTHORITIES

Cases

<i>Am. Beverage Ass’n v. City & Cnty. of S.F.</i> , 916 F.3d 749 (9th Cir. 2019)	19
<i>Aptive Env’t, LLC v. Town of Castle Rock</i> , 959 F.3d 961 (10th Cir. 2020)	23
<i>Ass’n of Home Appliance Mfrs. v. Weiser</i> , 2025 WL 4642378 (D. Colo. Dec. 19, 2025)	13, 16, 22, 23, 24
<i>Att’y Gen. of Okla. v. Tyson Foods, Inc.</i> , 565 F.3d 769 (10th Cir. 2009)	11
<i>Awad v. Ziriax</i> , 670 F.3d 1111 (10th Cir. 2012).....	26
<i>Brewer v. City of Albuquerque</i> , 18 F.4th 1205 (10th Cir. 2021)	23, 25
<i>Cal. Chamber of Com. v. Bonta</i> , 781 F. Supp. 3d 1071 (E.D. Cal. 2025)	23
<i>Cal. Chamber of Com. v. Council for Educ. & Rsch. on Toxics (“CERT”)</i> , 29 F.4th 468 (9th Cir. 2022)	16, 23
<i>Cent. Hudson Gas & Elec. Corp. v. Public Serv. Comm’n of N.Y.</i> , 447 U.S. 557 (1980)	23
<i>Disc. Tobacco City & Lottery, Inc. v. United States</i> , 674 F.3d 509 (6th Cir. 2012)	15, 22
<i>Elam Constr., Inc. v. Reg’l Transp. Dist.</i> , 129 F.3d 1343 (10th Cir. 1997)	26
<i>Elrod v. Burns</i> , 427 U.S. 347 (1976)	4, 26
<i>Ent. Software Ass’n v. Blagojevich</i> , 469 F.3d 641 (7th Cir. 2006)	22
<i>Free Speech Coalition, Inc. v. Paxton</i> , 95 F.4th 263 (5th Cir. 2024)	12
<i>Hobby Lobby Stores, Inc. v. Sebelius</i> , 723 F.3d 1114 (10th Cir. 2013).....	27

<i>Hurley v. Irish-Am. Gay, Lesbian & Bisexual Grp. of Bos.</i> , 515 U.S. 557 (1995)	19
<i>Ibanez v. Fla. Dep't of Bus. & Pro. Regul., Bd. of Acct.</i> , 512 U.S. 136 (1994)	12
<i>Iowa Ass'n of Bus. & Indus. v. Ommen</i> , 799 F. Supp. 3d 795 (S.D. Iowa 2025)	19
<i>Janus v. Am. Fed'n of State, Cnty., & Mun. Emps., Council 31</i> , 585 U.S. 878 (2018)	11
<i>Kansas ex rel. Kansas Dep't for Child. & Fams. v. SourceAmerica</i> , 874 F.3d 1226 (10th Cir. 2017)	26
<i>Kimberly-Clark Corp. v. Dist. of Columbia</i> , 286 F. Supp. 3d 128 (D.D.C. 2017)	13, 24
<i>McCullen v. Coakley</i> , 573 U.S. 464 (2014)	25
<i>Nat'l Ass'n of Mfs. v. SEC</i> , 800 F.3d 518 (D.C. Cir. 2015)	13
<i>Nat'l Ass'n of Wheat Growers v. Bonta</i> , 85 F.4th 1263 (9th Cir. 2023)	13, 16, 23, 24
<i>Nat'l Inst. of Fam. and Life Advocs.</i> , 585 U.S. 755 (2018)	18, 19, 23, 24
<i>Pac. Frontier v. Pleasant Grove City</i> , 414 F.3d 1221 (10th Cir. 2005)	26
<i>Pers. Care Prods. Council v. Bonta</i> , 799 F. Supp. 3d 1075 (E.D. Cal. 2025)	13, 15, 23
<i>R.J. Reynolds Tobacco Co. v. FDA</i> , 696 F.3d 1205 (D.C. Cir. 2012)	13, 15, 23, 24
<i>Reed v. Town of Gilbert</i> , 576 U.S. 155 (2015)	11
<i>Rocky Mtn. Gun Owners v. Polis</i> , 121 F.4th 96 (10th Cir. 2024)	11, 26
<i>Sorrell v. IMS Health Inc.</i> , 564 U.S. 552 (2011)	11

<i>United States v. Stevens</i> , 559 U.S. 460 (2010)	27
<i>Utah Licensed Beverage Ass’n v. Leavitt</i> , 256 F.3d 1061 (10th Cir. 2001)	26
<i>Verlo v. Martinez</i> , 820 F.3d 1113 (10th Cir. 2016)	25
<i>Wooley v. Maynard</i> , 430 U.S. 705 (1977)	11
<i>Zauderer v. Off. of Disciplinary Couns.</i> , 471 U.S. 626 (1985)	1, 11, 12, 13, 16, 18, 19

Statutes

Cal. Health & Safety Code § 109011	25
Cal. Health & Safety Code § 109011(a)	25
Cal. Health & Safety Code § 109011(c)	25
Colo. Rev. Stat. § 25-15-604	25
Colo. Rev. Stat. § 25-15-604(2)(a)	25
Colo. Rev. Stat. § 25-15-604(2)(c)	25
Colo. Rev. Stat. § 25-15-604(2.5)	25
Conn. Gen. Stat. § 22a-903c	25
Conn. Gen. Stat. § 22a-903c(c)(1)	25
Conn. Gen. Stat. § 22a-903c(c)(3)	25
NMSA 1978, § 74-15-3	7
NMSA 1978, § 74-15-4(B)	7
NMSA 1978, § 74-15-7	7, 10

Regulations


NMAC § 20.13.2.6	7
NMAC § 20.13.2.9(C)	7

NMAC § 20.13.2.13.....	1
NMAC § 20.13.2.13(A).....	10
NMAC § 20.13.2.13(B).....	9
NMAC § 20.13.2.13(C).....	7, 8, 9, 10
NMAC § 20.13.2.13(D).....	10
NMAC § 20.13.2.23.....	10

INTRODUCTION

The First Amendment protects both the right to speak and the right *not* to speak. The Supreme Court created a limited exception to this rule in *Zauderer v. Office of Disciplinary Counsel*, 471 U.S. 626 (1985), allowing governments to require companies to deliver specific messages to consumers only if the messages are (1) purely factual, (2) uncontroversial, (3) related to the terms under which services are being offered, and (4) not unduly burdensome. If a government-mandated message fails any part of that test, then it is subject to normal First Amendment scrutiny for content-based laws. Courts applying this framework repeatedly have held that government-mandated warning labels are unconstitutional if they require anything more than the straightforward presentation of facts or if the existence of the underlying risk is debatable.

This case is being brought by trade associations representing companies in broad segments of the American economy to challenge a regulation proposed by the New Mexico Environment Department (“NMED”) and adopted by the New Mexico Environmental Improvement Board (“EIB”). *See* NMAC § 20.13.2.13 (the “Regulation”). The Regulation compels Plaintiffs’ member companies to mark products that contain *any* amount of *any* per- or poly-fluoroalkyl substances, or “PFAS,” with an image of an Erlenmeyer flask labeled “PFAS”:



This pictographic warning label is not “purely factual,” but instead is designed to invoke fear of chemicals. The supposed dangers of PFAS about which the label warns are not “uncontroversial.” For many PFAS, the warning has nothing to do with alleged risks posed to consumers themselves. And compliance with the mandate will be incredibly burdensome on Plaintiffs’ member

companies—financially, reputationally, and by forcing companies to deliver a message with which they disagree. The Regulation therefore fails the *Zauderer* test and is unconstitutional.

By this motion, Plaintiffs are asking the Court to enjoin enforcement of the Regulation well in advance of its January 1, 2027 compliance deadline, before Plaintiffs’ member companies must incur hundreds of millions of dollars in unrecoverable compliance costs. Each prong of the four-factor test for preliminary injunctive relief is satisfied here.

First, Plaintiffs are likely to succeed on the merits. PFAS are a broad category comprising thousands of very different substances that are commonly found in a wide number of products, including razor blades, non-stick cookware, water-resistant fabrics, home appliances, vehicles, air conditioners, power tools, medical devices, consumer electronics, and cosmetics. While health and environmental concerns have been raised for *some* types of PFAS, the evidence does not support such concerns for all types of PFAS. Despite this, the labeling mandate applies to products with *any* type of PFAS in *any* amount, and whether or not consumers are exposed to the PFAS.

The labeling mandate does not come close to satisfying the *Zauderer* standard. First, the pictograph does not convey “purely factual” information—commercial-scale factories do not use Erlenmeyer flasks. The pictograph instead is designed to incite consumers’ fears, by exploiting a belief that chemicals are dangerous. Indeed, while countless other products contain man-made chemical substances, Plaintiffs cannot find *any* mandate imposed by *any* government with respect to *any* other chemical that it be called to consumers’ attention with an Erlenmeyer flask. Many consumers will therefore understand the label to be a warning that, among the universe of chemicals, all PFAS are *especially* dangerous in some unspecified way.

Second, whether PFAS *as a category* pose heightened risks to which consumers should be alerted is far from “uncontroversial.” While manufacturers have phased out some PFAS materials,

fluoropolymers such as polytetrafluoroethylene (“PTFE”) are widely and safely used in consumer products as diverse as non-stick cookware and razor blades. There is no scientific consensus that fluoropolymers pose any risk to human health or the environment. And NMED officials have acknowledged that the science with respect to many other PFAS, such as certain newer-generation PFAS, is at best nascent. New Mexico’s first of its kind mandated warning applicable to all PFAS thus rests on an intensely disputed scientific foundation.

Third, the mandated warning is not tied to the terms under which companies are offering products to consumers. Forced to concede during the rulemaking that not all PFAS in all products pose direct risks to consumers, NMED officials pivoted to arguing that fluoropolymers, and PFAS inside a product, pose a risk to the environment during product manufacturing and disposal. But the evidence does not support that claim, because modern controls at factories and incinerators can keep PFAS releases to a *de minimis* amount. Manufacturing may occur in states and countries far from New Mexico consumers, so that hypothetical environmental concern does not relate to the transaction between manufacturers and consumers. And concerns about *disposal* have nothing to do with the manufacturers who are subject to the Regulation.

Fourth, the burden that the Regulation will impose on Plaintiffs’ member companies is staggering—likely hundreds of millions of dollars or more. The Regulation requires that products themselves be labeled, and in many cases requires the packaging to be labeled too. Companies will need to retool manufacturing lines producing thousands or millions of products per day to change existing labels or to add new labels. And because many of these companies have national or global distribution networks, they will need to do this for *all* the PFAS-containing products they make, not just those that find their way to New Mexico. Companies also will bear the burden of communicating a controversial message—that all PFAS are dangerous—with which many

fundamentally disagree.

Because the Regulation fails under *Zauderer*, it can survive only if it is narrowly tailored to further a compelling or substantial governmental interest. It is not. Courts considering similar state warning labels have noted that governments can communicate their concerns to consumers through government websites, public service announcements, and other media. Other states have enacted far less onerous labeling requirements for PFAS, which further shows that New Mexico's mandate fails the narrow-tailoring standard. And NMED has no good explanation why the consumer-facing labeling mandate must cover products that pose no risk to consumers, such as products with only fluoropolymers or PFAS to which consumers are not exposed.

The remaining factors also strongly favor preliminary injunctive relief. "The loss of First Amendment freedoms, for even minimal periods of time, unquestionably constitutes irreparable injury." *Elrod v. Burns*, 427 U.S. 347, 373 (1976). It also will be disruptive and expensive for Plaintiffs' member companies to retool their factories to create products and packaging bearing the confusing mandated warning label by the January 1, 2027 deadline. New Mexico, on the other hand, has no legitimate interest in enforcing a law that is likely unconstitutional. And the requested injunction would not bar New Mexico from making its own statements concerning PFAS.

Plaintiffs and their member companies share a commitment to making safe, environmentally-responsible products. But the EIB greatly overstepped the bounds here. The Court should quickly enjoin enforcement of the Regulation's labeling mandate while this case is pending. At a minimum, it should enjoin enforcement of the Regulation as to products containing only fluoropolymers or PFAS to which consumers are not exposed.

BACKGROUND

I. PFAS IS A BROAD CATEGORY ENCOMPASSING SUBSTANCES USED IN MANY EVERYDAY PRODUCTS WITH NO ESTABLISHED HEALTH RISK.

PFAS is a catchall term for a broad category of substances with diverse physical, chemical, and toxicological properties. *See* Korzeniowski Decl. ¶ 17. The term has several different definitions, ranging from broad definitions that capture more than 14,000 substances, to more precise definitions that encompass as few as hundreds of substances. *See id.* ¶ 21. In its most general definition, this class of substances is characterized simply by the presence of covalent bonds between carbon and fluorine atoms, the strongest single bond in organic chemistry. *See id.* ¶ 18. This strong bond imparts a combination of properties, including thermal stability, corrosion-resistance, and water and grease repellency, making PFAS uniquely useful across industries worldwide. *See id.* ¶ 19.

Many applications of PFAS “involve highly technical materials that serve as critical enablers of industries underpinning modern life.” Korzeniowski Decl. ¶ 20. “In numerous contexts—such as healthcare, energy systems, transportation, electronics, and other infrastructure—these substances are essential to safety, durability, or performance, and viable alternatives are not reasonably available without compromising function or introducing other risks.” *Id.*; *see also, e.g.*, Espinoza Decl. ¶¶ 7–8.

There is ongoing scientific debate regarding the toxicity and bioaccumulation of certain types of PFAS, leading companies to phase out the use of those PFAS. *See* Rackl Decl. ¶¶ 34, 51–52; Korzeniowski Decl. ¶ 45. But other types of PFAS are not associated with such concerns. Experts have acknowledged the diversity of PFAS with respect to properties, behavior, hazards, and risks and agree that statements suggesting all PFAS are bioaccumulative and toxic are overgeneralized. Rackl Decl. ¶¶ 51–52. Most experts “agree that PFAS should not be grouped

together for risk assessment purposes” and further agree “that it is scientifically inappropriate to assume equal toxicity/potency across the diverse class of PFAS.” Korzeniowski Decl. ¶ 33.

For example, fluoropolymers are a subcategory of PFAS that includes materials such as PTFE. Fluoropolymers like PTFE are used in a wide range of consumer products, such as non-stick cookware, razor blades, and many others. Rackl Decl. ¶¶ 39-40, 43; Bhalla Decl. ¶¶ 15-16. In addition, PTFE has been used in medical devices implanted into humans since the 1950s, including devices like stents and pacemakers. U.S. Food and Drug Administration (“FDA”), *PFAS in Medical Devices* (Aug. 6, 2025). Fluoropolymers are chemically and toxicologically distinct from other PFAS. *See* Rackl Decl. ¶¶ 26-28, 34, 38-40, 45. Fluoropolymers are high-molecular-weight substances; are not bioavailable, toxic, bioaccumulative, mobile, water-soluble, or volatile; and so do not share the same hazard or exposure profiles as some other PFAS. *See* Korzeniowski Decl. ¶ 52; Rackl Decl. ¶¶ 38, 47. Experts consider fluoropolymers to be of low concern for human health and the environment. *See* Rackl Decl. ¶¶ 38-40, 47. Further, fluoropolymers do not degrade into other types of PFAS that may be toxic or bioaccumulative. *See id.* ¶¶ 28, 41, 49.

Some products contain PFAS that are entirely enclosed or sequestered within the product. *See* Rackl Decl. ¶¶ 41, 45-46. These sequestered PFAS pose no meaningful risk to human health or the environment. *See id.* ¶¶ 19-21.

International and federal entities, such as the Organisation for Economic Co-operation and Development (“OECD”) and the Department of Defense, have advised against broad-brush approaches to regulating PFAS. Snyder Decl., Ex. 11, at 8; *id.*, Ex. 12, at 16. The FDA has recognized that fluoropolymers specifically “are very unlikely to cause toxicity to patients.” *Id.*, Ex. 13. And the U.S. Environmental Protection Agency (“EPA”) has stated that fluoropolymers are “believed to pose less risk to human and ecological health relative to

nonpolymer PFAS.” *Id.*, Ex. 14, ¶ 3.1.2.

II. NEW MEXICO PFAS PROTECTION ACT AND CHALLENGED REGULATION

A. The New Mexico Legislature imposes a ban on many PFAS, while authorizing the EIB to require labeling.

In April 2025, New Mexico enacted the Per- and Poly-Fluoroalkyl Substances Protection Act (the “PFAS Act”). NMSA 1978, § 74-15-3. The PFAS Act’s core feature is a phased ban on the sale, offering for sale, and distribution for sale of products containing certain types of intentionally-added PFAS, which begins in January 2027 and is completed by 2032. *Id.* § 74-15-3; NMAC § 20.13.2.9(C). But the ban is not universal. The PFAS Act exempts many types of products from the ban. As particularly relevant to this litigation, the PFAS Act exempts any “product that contains fluoropolymers,” such as PTFE. NMSA 1978, . § 74-15-3(A)(16).

The PFAS Act delegates rulemaking authority to the EIB, providing, in most relevant part, that the EIB “may” “adopt rules ... requiring the labeling of products in English and Spanish.” NMSA 1978, § 74-15-4(B). The Act also authorizes enforcement mechanisms, including steep civil penalties, for each day a violation occurs. *Id.* § 74-15-7.

B. The EIB imposes a sweeping labeling mandate.

In October 2025, NMED petitioned the EIB to adopt a proposed rule mandating labeling of products containing intentionally-added PFAS. Snyder Decl., Ex. 1. The proposed rule did not differentiate between PFAS or provide the same exemptions as the statutory ban, so the labeling mandate applies to products containing any kind of PFAS, including fluoropolymers. *Id.* § 20.13.2.6. Under the initially proposed rule, any product sold, offered for sale, distributed or distributed for sale in New Mexico containing any intentionally-added PFAS would need to include “words and symbols approved by [NMED] that the product contains intentionally added per- and poly-fluoroalkyl substances.” *Id.*, § 20.13.2.13(C)(1). As initially proposed, consumer-

facing products also would need to provide a link to an NMED website stating NMED’s anti-PFAS views. *Id.*, § 20.13.2.13(C)(3).

Many trade associations and others submitted comments in response to NMED’s proposed rule. *See generally* EIB Dkt. No. 25-61(R), available at <https://www.env.nm.gov/opf/docketed-matters/> (“EIB Docket”). They explained that there are many types of PFAS with different properties, and they do not all pose risks to human health or the environment. *See generally, e.g.*, Snyder Decl., Ex. 2 at 2 (ACC comment). Imposing a labeling mandate for *all* types of PFAS, commenters explained, would create costly and complex challenges for manufacturers, while forcing them to label their products with warnings falsely and controversially signaling that all PFAS are dangerous. *See, e.g., id.*

NMED issued revisions to the proposed rule in January 2026 and again a month later. *See id.*, Ex. 3; *id.*, Ex. 4. The amended proposal dropped the website requirement, but included a mandate that covered products be labeled with a pictograph comprising “an outline of an Erlenmeyer flask with the word ‘PFAS’ inside the flask.” *Id.*, Ex. 4 § 20.13.2.13(C)(1). According to NMED, it made this change in response to industry comments. *Id.*, Ex. 5 at 9-10.

Trade associations again commented on the revised proposal, explaining that it still did not address their concerns about requiring manufacturers to warn that all PFAS are dangerous. *See generally* EIB Docket. During an evidentiary hearing before the EIB, industry organizations presented evidence regarding the scientific community’s lack of a consensus view as to what even constitutes PFAS, as well as the wide body of scientific literature demonstrating that certain PFAS, like fluoropolymers or PFAS entirely sealed within a product, pose little to no risk to human health or the environment. *See* Snyder Decl., Ex. 9, at 1225, 1237, 1272, 1285.

In testimony before the EIB, NMED witnesses admitted that “[t]he vast majority of PFAS

have not been studied at all,” and that the study of PFAS “continue[s] to evolve as additional data becomes available.” *Id.*, Ex. 7 at 383; *id.*, Ex. 6 at 301. NMED witnesses further admitted that “[i]f there is zero exposure” to PFAS from a product then “there is zero risk.” *Id.*, Ex. 7 at 430. But they insisted the labeling mandate was needed because no PFAS exposure supposedly is safe, and fluoropolymers and even fully-sequestered PFAS still posed environmental risks from upstream manufacture or downstream disposal. *Id.*, Ex. 6 at 118-19. Multiple NMED witnesses therefore urged the EIB to adopt the labeling mandate “to turn off the spigot at the source of PFAS entering New Mexico through consumer products.” *Id.* at 81-82; *see also id.* at 52-53, 60, 104, 106, 109, 111, 129, 165, 166, 224-25; *id.*, Ex. 8 at 792, 795. According to NMED, the PFAS warning label will “empower consumers to choose to reduce their exposure and environmental release.” *Id.*, Ex. 5 at 29. Regarding use of the flask symbol specifically, NMED witnesses said they believed it “will convey the message that there is a chemical that goes by the acronym or initials ‘PFAS’ in this product,” and that it “would be an excellent element that would convey to the consumer that there is a chemical that they might want to know about,” *id.*, Ex. 7 at 630, 632.

In May 2026, the EIB adopted a final version of the Regulation, requiring manufacturers to label numerous categories of products containing any amount of any PFAS, even in purely internal components, with the Erlenmeyer flask pictographic warning. NMAC § 20.13.2.13(C)(1). The EIB explained that it had explicitly considered and determined that “PFAS should be regulated as a class.” Snyder Decl., Ex. 10 ¶ 78 (EIB Final Order and Statement of Reasons). The final label mandate includes only narrow exemptions for complex durable goods, used products, and certain products regulated by federal labeling requirements. NMAC § 20.13.2.13(B).

The Regulation provides that the label must be “printed, mounted, molded, engraved, embossed, or otherwise affixed to the product.” *Id.* § 20.13.2.13(C)(2). And “[i]f the product is

sold in consumer packaging that obscures the label on the product,” the product packaging must “also” be labeled. *Id.* § 20.13.2.13(C)(3). The Regulation also imposes size specifications. The label must be “clearly visible and legible prior to sale” and “displayed with such conspicuousness as compared with other words, statements, design or devices on the product as to render the label likely to be seen, read, and understood by an ordinary individual under customary conditions of purchase or use.” *Id.* § 20.13.2.13(C)(1). The label’s text must “be no smaller than the largest font used for other consumer information on the product.” *Id.*

The Regulation also includes labeling requirements that apply when a consumer cannot see the product or packaging at the time of sale, such as when products are sold online. *See id.* § 20.13.2.13(C)(4). In those circumstances, the manufacturer or retailer must “clearly” present the Erlenmeyer flask pictograph to the consumer at the time of purchase by, for example, including the pictograph on the website. *Id.* And the Regulation includes a separate, but similar, labeling requirement for what it calls “complex commercial goods.” Manufacturers of those goods must include the Erlenmeyer-flask pictograph in the consumer facing product specification sheet available to potential consumers prior to purchase, and the consumer facing operation and maintenance manual associated with the complex durable good. *Id.* § 20.13.2.13(D).

The labeling mandate becomes effective on January 1, 2027. *Id.* § 20.13.2.13(A). Starting then, any product sold, offered for sale, distributed, or distributed for sale in New Mexico without the mandated label is unlawful and will be subject to civil penalties of, *e.g.*, \$15,000 for each day a violation occurs. N.M. Stat. § 74-15-7. NMED and the New Mexico Attorney General are responsible for enforcing the Regulation. NMAC § 20.13.2.23; N.M. Stat. § 74-15-7.

LEGAL STANDARD

“To obtain a preliminary injunction, the moving party must demonstrate: (1) a likelihood

of success on the merits; (2) a likelihood that the movant will suffer irreparable harm in the absence of preliminary relief; (3) that the balance of equities tips in the movant’s favor; and (4) that the injunction is in the public interest.” *Att’y Gen. of Okla. v. Tyson Foods, Inc.*, 565 F.3d 769, 776 (10th Cir. 2009) (quotation marks omitted). When a state agency is the defendant, the third and fourth factors “merge.” *Rocky Mtn. Gun Owners v. Polis*, 121 F.4th 96, 112 (10th Cir. 2024).

ARGUMENT

I. PLAINTIFFS ARE LIKELY TO SUCCEED ON THE MERITS.

Under the First Amendment, “[c]ontent based laws—those that target speech based on its communicative content—are presumptively unconstitutional.” *Reed v. Town of Gilbert*, 576 U.S. 155, 163 (2015). This rule applies to commercial speech: “The commercial marketplace, like other spheres of our social and cultural life, provides a forum where ideas and information flourish,” and “[t]he State may not burden the speech of others in order to tilt public debate in a preferred direction.” *Sorrell v. IMS Health Inc.*, 564 U.S. 552, 578-79 (2011) (quotation marks omitted).

The First Amendment “includes both the right to speak freely and the right to refrain from speaking at all.” *Wooley v. Maynard*, 430 U.S. 705, 714 (1977). Indeed, laws that compel speakers to communicate a message raise particularly serious First Amendment concerns, because they are inherently content-based. *See Janus v. Am. Fed’n of State, Cnty., & Mun. Emps., Council 31*, 585 U.S. 878, 892 (2018). The Supreme Court has recognized a limited exception for laws that compel commercial speech, but *only* if the disclosure is limited to “purely factual and uncontroversial information about the terms under which ... services will be available.” *Zauderer*, 471 U.S. at 651. If a law satisfies those conditions, there is no First Amendment violation, provided the compelled disclosures are not “unjustified or unduly burdensome.” *Id.* By contrast, if the mandated commercial speech falls outside the *Zauderer* exception, then it is subject to heightened scrutiny, which requires the government to show, at a minimum, that the law is narrowly tailored

to directly advance a substantial government interest. *See Free Speech Coalition, Inc. v. Paxton*, 95 F.4th 263, 283 (5th Cir. 2024).

New Mexico’s mandate that products with any intentionally-added PFAS include a pictograph of an Erlenmeyer flask labeled “PFAS” does not meet the requirements for the *Zauderer* exception. That is fatal to the State’s case, because the mandate fails any level of First Amendment scrutiny. Plaintiffs are therefore likely to succeed in their claim that the mandate is facially unconstitutional. At a minimum, the mandate is clearly unconstitutional as applied to products containing only fluoropolymers or PFAS to which consumers are not exposed.

A. The Regulation does not satisfy any elements of the *Zauderer* test.

For the State to rely on *Zauderer*, it must show that the compelled disclosures are “purely factual and uncontroversial,” relate to “the terms under which” services are provided, and are not unduly burdensome. 471 U.S. at 651. The State has the burden to justify compelling commercial speech. *See Ibanez v. Fla. Dep’t of Bus. & Pro. Regul., Bd. of Acct.*, 512 U.S. 136, 142-43 (1994). Here, the Regulation satisfies none of the *Zauderer* conditions.

1. The required pictograph does not convey purely factual information.

The narrow *Zauderer* exception is built on the premise that, since the value of commercial speech inheres in “the information such speech provides” to consumers, the government has greater leeway to compel a company to provide consumers “purely factual and uncontroversial information about the terms under which [its services] will be available.” *Zauderer*, 471 U.S. at 651. Thus, in *Zauderer*, the Court upheld a requirement that attorney advertising disclose that clients could be liable for costs after an unsuccessful contingent-fee action, explaining that a requirement to provide “accurate information regarding [an attorney’s] services” was “reasonably related to the State’s interest in preventing deception of consumers.” *Id.* & n.14.

Critically, “[t]he disclosures approved in *Zauderer*” and other Supreme Court precedents

have been “clear statements that were both indisputably accurate and not subject to misinterpretation by consumers.” *R.J. Reynolds Tobacco Co. v. FDA*, 696 F.3d 1205, 1216 (D.C. Cir. 2012). Courts have recognized that even if a compelled disclosure is “factually accurate,” “a statement may be literally true but nonetheless misleading.” *Nat’l Ass’n of Wheat Growers v. Bonta*, 85 F.4th 1263, 1276 (9th Cir. 2023) (quotation marks omitted). Courts therefore do not review compelled messages in isolation, but rather “consider whether the totality of the disclosure is misleading.” *Ass’n of Home Appliance Mfrs. v. Weiser*, 2025 WL 4642378, at *6 (D. Colo. Dec. 19, 2025). They exercise care not to “miss[] the forest for the trees” in assessing “the overall message” conveyed. *Pers. Care Prods. Council v. Bonta*, 799 F. Supp. 3d 1075, 1085-86 (E.D. Cal. 2025) (quotation marks omitted). And they have explained that graphic warnings raise particular concerns, since they may serve as attempts to “evoke an emotional response” rather than merely convey unbiased information. *See R.J. Reynolds*, 696 F.3d at 1216.

Applying those principles here, the mandated pictograph of an Erlenmeyer flask labeled “PFAS” does not present “purely factual” information. *Zauderer*, 471 U.S. at 651. No manufacturer is making products at commercial scale using Erlenmeyer flasks, and there is scientific debate about what substances even qualify as PFAS. Korzeniowski Decl. ¶ 21. NMED witnesses in the EIB proceeding tried to sidestep this debate by noting that the PFAS Act contains its own definition of PFAS. Snyder Decl., Ex. 6 at 161-63. But courts have rejected this argument—a government cannot sidestep factual debates by definitional *diktat*, particularly as consumers are unlikely to know obscure governmental definitions. *Kimberly-Clark Corp. v. Dist. of Columbia*, 286 F. Supp. 3d 128, 142 (D.D.C. 2017); *Nat’l Ass’n of Mfs. v. SEC*, 800 F.3d 518, 530 (D.C. Cir. 2015).

Rather than convey purely factual information, the label conveys a *warning*: this product

contains a chemical known as PFAS that, more than other chemicals, should concern you. Wilcox Decl. ¶ 29. After all, consumers are accustomed to seeing pictographic *warnings* on products: a skull and crossbones for poison, or a stylized fire for something flammable or explosive. *See id.* ¶ 31. Many consumers are therefore likely to assume that the Erlenmeyer flask is a warning. *Id.* ¶ 29, 31. On top of this, many consumers will be familiar with Erlenmeyer flasks from chemistry classes in school, where they learned that chemicals are potentially dangerous—*e.g.*, they may be caustic, warranting the use of safety goggles and gloves. *Id.* ¶ 29. Consumers also know that many consumer products contain chemicals of one kind or another, but only PFAS is being singled out for their attention with the Erlenmeyer flask pictograph. *Id.* ¶¶ 31, 40. Many consumers will therefore assume that PFAS must be unusually dangerous, and that is why it, alone in the universe of chemicals, is being called to their attention with the flask graphic. *Id.* ¶¶ 31-33.

Recognizing that the Regulation raises First Amendment issues, NMED witnesses strained during the EIB hearings to contend that the label is “not designed to communicate about hazards,” but rather only to note that the product contains “a chemical that goes by the acronym or initials ‘PFAS,’” that consumers might want to learn more about. *See* Snyder Decl, Ex. 7 at 618, 630; *id.* at 632 (the label “convey[s] to the consumer that there is a chemical that they might want to know about”); *id.*, Ex. 6 at 110-111 (similar). For the reasons given above, that testimony does not pass the straight face test. New Mexico does not require the Erlenmeyer flask graphic for any other chemical on the neutral theory that consumers “might want to know about” it. The flask is plainly designed as a warning about the presence of PFAS. Research also shows that consumers are quick to make in-store purchasing decisions for everyday products. Wilcox Decl. ¶¶ 12, 16-17. A consumer picking up a product with the PFAS pictographic warning will not stand in the aisle doing research on PFAS and their highly varying properties. *Id.* ¶¶ 17, 28-29. Confronted with a

warning label on a product, consumers will quickly make a gut decision whether to purchase that product or an alternative lacking the warning label. *Id.* ¶¶ 18-19.

Because “it is reasonable for the average consumer” to read the pictograph as communicating a hazard, it cannot be characterized as “purely factual.” *Pers. Care Prods.*, 799 F. Supp. 3d at 1086-87. Indeed, the Erlenmeyer flask itself does not even convey *any* actual “information,” because it says *nothing* about the risk PFAS supposedly poses. Wilcox Decl. ¶¶ 28-29. A consumer seeing the label will have no idea whether PFAS are supposedly toxic, flammable, explosive, environmentally deleterious, or present some other risk of harm entirely. *Id.* ¶¶ 27, 37. They will only assume it poses some unspecified risk of harm. *Id.* ¶ 38. For this reason, it is clear that the flask image is designed to invoke fear in consumers, not to educate them. *See id.* ¶¶ 38, 42, 44-45. That is fatal under *Zauderer*. Other courts have recognized that images are vulnerable to “misinterpretation by consumers,” as they work in part by “evok[ing] an emotional response” rather than merely providing neutral, factual information. *R.J. Reynolds*, 696 F.3d at 1216-17 (holding that the use of graphic images to supplement warning statements “fall outside the ambit of *Zauderer*”). That is the whole purpose of graphic labels: to “create a visceral reaction.” *Disc. Tobacco City & Lottery, Inc. v. United States*, 674 F.3d 509, 528-29 (6th Cir. 2012) (Clay, J., dissenting in part).

The lack of any real information in the flask image is especially problematic when it comes to fluoropolymers like PTFE or to PFAS to which a consumer will not be exposed. At the EIB hearing, NMED witnesses conceded that fluoropolymers and sequestered PFAS pose no direct risk to consumers. *See Snyder Decl.*, Ex. 7 at 416-17, 430. But they argued that the warning label is still justified, because other types of PFAS may either escape the factory when products are made, or from an incinerator when products are destroyed. *See id.* at 436-37. Putting aside that those

propositions are debatable, *see infra*, pp. 16-18, nothing in the Erlenmeyer flask pictograph tells a consumer what kind of PFAS is present, where, or what type of risk it poses. A consumer might reasonably assume that the product carries the warning label because it poses a direct risk to them, even if that is not the case. Wilcox Decl. ¶¶ 27-38. This risk of consumer confusion is fatal under *Zauderer*'s "purely factual" requirement. *See Wheat Growers*, 85 F.4th 1263, 1278; *Cal. Chamber of Com. v. Council for Educ. & Rsch. on Toxics* ("CERT"), 29 F.4th 468, 472-73, 479 (9th Cir. 2022).

The origin of the Erlenmeyer flask mandate also is revealing. Under NMED's initially proposed rule, there was no required graphic, but products instead needed to provide directions to an NMED website attacking PFAS. *See supra*, pp. 7-8. In an apparent acknowledgement the website provision was patently unconstitutional, *see Ass'n of Home Appliance Mfrs.*, 2025 WL 4642378, at *7, NMED dropped that provision but added the Erlenmeyer flask graphic in its place. Snyder Decl., Ex. 6 at 113-14. But that change did not cure the basic First Amendment problem: pictographic warnings that suggest to consumers that a product poses some unspecified risk because it contains any kind of PFAS anywhere in the product are not "purely factual."

2. The science concerning the risks posed by all PFAS is at best unsettled.

The Regulation also fails *Zauderer* because the required warning message is not "uncontroversial." *See* 471 U.S. at 651. "A compelled statement is 'uncontroversial' for purposes of *Zauderer* where the truth of the statement is not subject to good-faith scientific or evidentiary dispute and where the statement is not an integral part of a live, contentious political or moral debate." *Ass'n of Home Appliance Mfrs.*, 2025 WL 4642378, at *6 (alteration and citation omitted)). By contrast, "controversy" exists where an "objective evaluation" demonstrates that there is "robust disagreement by reputable scientific sources." *Wheat Growers*, 85 F.4th at 1277 (quoting *CERT*, 29 F.4th at 478). If there is no "strong scientific consensus" to support a warning

label, then the label fails under *Zauderer*. *Id.* at 1278.

Here, the scientific evidence concerning PFAS as a class is unsettled at best. The evidence shows that PFAS widely vary in their characteristics and they have not all been shown to pose risks, whether to human health or to the environment, yet the Regulation requires them all to carry the identical “PFAS” pictographic warning. As recounted above, both international organizations and the federal government agree that broad generalizations about PFAS should not be used to make regulatory decisions. *See supra*, pp. 6-7. In the specific case of fluoropolymers, for example, the available evidence strongly suggests that their use in products presents little to no risk to human health and the environment. *See Rackl Decl.* ¶¶ 38-40. FDA has continued to approve the use of fluoropolymers in medical devices embedded in patients. *Snyder Decl.*, Ex. 7, at 390. Many experts also have concluded that because fluoropolymers are chemically and biologically inert, they pose little risk of contaminating the environment. *See Rackl Decl.* ¶¶ 20-21, 38.

At the EIB hearing, NMED witnesses debated whether fluoropolymers are actually safe, suggesting the science is not yet settled on this point. *E.g.*, *Snyder Decl.*, Ex. 6 at 90, 116. But even if NMED is correct that the science around fluoropolymers is uncertain, that *uncertainty* does not help Defendants, because it means that the question is not “uncontroversial.” *Korzeniowski Dec.* ¶¶ 38-46; *Rackl Decl.* ¶¶ 32-35. Under *Zauderer*, the existence of this scientific debate means the government cannot require third parties to communicate the government’s preferred viewpoint. If the government wants to present its position concerning an unsettled scientific topic to consumers, then it must do so itself.

NMED witnesses also opined at the EIB hearing that even if fluoropolymers do not themselves pose a risk, other PFAS may be used during the manufacture of fluoropolymers or generated during their disposal, and these other PFAS could escape into the environment from

factories and incinerators. Snyder Decl., Ex. 7, at 416-17. They opined similarly about PFAS within a product to which consumers are not exposed. *Id.*, Ex. 6 at 119. But these assertions are also contested. Modern emissions controls at factories result in, at worst, only a negligible amount of PFAS entering the environment, if any at all. Rackl Decl. ¶¶ 53-55. And modern incinerators are capable of destroying up to 99.9999% of PFAS in products, to keep it from entering the environment. *Id.* ¶ 54. Thus, to the extent NMED intends the Erlenmeyer flask symbol to convey to consumers that the manufacture and disposal of the product pose environmental concerns, that message too is far from “uncontroversial.”

3. *Zauderer* does not permit the State to compel speech premised on impacts disconnected from the service provided to the consumer.

Defendants may try to argue that the labeling mandate is supported by the alleged manufacturing (upstream) and disposal (downstream) impacts of PFAS. But the alleged upstream and downstream impacts of PFAS cannot support the Regulation because messaging on such topics falls outside the *Zauderer* framework entirely.

In applying *Zauderer*, the Supreme Court has instructed that the doctrine only applies to speech relating to “the terms under which ... services will be available.” *Nat’l Inst. of Fam. and Life Advoc.*, 585 U.S. 755, 768 (2018) (“*NIFLA*”) (quoting *Zauderer*, 471 U.S. at 651). The doctrine provides no basis for a government to use a company as its mouthpiece for other concerns, even if factual. In *NIFLA*, for example, the Court held that clinics providing services to pregnant women could not be required to post notices regarding the availability of free or low-cost services provided by the State, including abortions. *Id.* at 775. Among other problems with the law, the Court explained that because the mandatory notice “in no way relates to the services that licensed clinics provide,” “*Zauderer* ha[d] no application.” *Id.* at 769. “[O]utside that context,” a “speaker

has the right to tailor [its] speech,” including to omit “statements of fact the speaker would rather avoid.” *Hurley v. Irish-Am. Gay, Lesbian & Bisexual Grp. of Bos.*, 515 U.S. 557, 573 (1995).

Put simply, the *Zauderer* exception exists to ensure that consumers receive accurate information related to their transactions, and nothing more than that. Here, the alleged upstream and downstream environmental impacts on which NMED witnesses relied do not concern the transaction between Plaintiffs’ member companies and consumers, within the meaning of precedents such as *Zauderer* and *NIFLA*. Those alleged upstream and downstream impacts sometimes involve third parties—manufacturers of components containing intentionally-added PFAS and the emissions controls *they* used at *their* factories to prevent PFAS from escaping into the environment. Those impacts may be based on hypothetical, future events—how some third party *might* dispose of the product, and again what emissions controls they might use. Those impacts, which are the subject of regulation and oversight in the relevant jurisdictions, are simply too far afield from consumer transaction in question to allow New Mexico to invoke them as the basis for a labeling requirement. *Zauderer* does not allow the EIB to force Plaintiffs’ member companies to warn consumers about these potential upstream and downstream issues.

4. The Regulation is unduly burdensome.

Finally, the Regulation fails to satisfy *Zauderer* because it imposes undue burdens on Plaintiffs’ members and other regulated entities. “Even under *Zauderer*, a disclosure requirement cannot be ‘unjustified or unduly burdensome.’” *NIFLA*, 585 U.S. at 776 (quoting *Zauderer*, 471 U.S. at 651). “[A] government-compelled disclosure that imposes an undue burden fails for that reason alone.” *Am. Beverage Ass’n v. City & Cnty. of S.F.*, 916 F.3d 749, 757 (9th Cir. 2019).

Here, the Regulation imposes staggering “implementation costs and competitive ramifications” that “exceed constitutional boundaries.” *Iowa Ass’n of Bus. & Indus. v. Ommen*, 799 F. Supp. 3d 795, 851 (S.D. Iowa 2025). As detailed in the accompanying declarations from

some of Plaintiffs' member companies, it will be extraordinarily expensive, disruptive and time-consuming for those companies to come into compliance with the Regulation's labeling mandate. *See* Bhalla Decl. ¶¶ 22-30; Yon Decl. ¶¶ 12-19; Hall Decl. ¶¶ 14-22; Bowers Decl. ¶¶ 15-20; Thompson Decl. ¶¶ 10-20; Espinoza Decl. ¶ 11. Modern product manufacturers use highly automated systems which move products smoothly and automatically through each step of the manufacturing process and often directly into packaging and off for shipment. *E.g.*, Bhalla Decl. ¶ 22. For a product that was *itself* not previously labeled—for which all labeling was provided on the associated packaging—the new labeling mandate will require completely reworking manufacturing lines to add a new labeling step. *E.g.*, *id.* ¶¶ 22-27; Hall Decl. ¶¶ 15-18. For products that were previously labeled, the mandate will still require manufacturers to rework molds, dies, and etching machinery to add the new pictographic warning to the existing label. *E.g.*, Thompson Decl. ¶ 12-13. For products on which the new pictographic warning does not easily fit, the product itself may need to be altered in dimension or layout to accommodate the label. *E.g.*, *id.* And where permanent solutions to all this cannot be implemented by January 1, 2027, manufacturers will need to quickly introduce disruptive, temporary solutions. *E.g.*, Bhalla Decl. ¶ 27. Many of these problems are then repeated for those manufacturers who must also include the mandated warning on their product packaging. *E.g.*, *id.* ¶¶ 28-30; Thompson Decl. ¶¶ 14-16.

The burden the Regulation imposes on manufacturers is multiplied by the fact that many companies operate with national and global supply chains, or sell to major retailers with national and global distribution chains. A manufacturer may make a product and sell it to a major retail chain not knowing whether the retailer will ship that specific product to Santa Fe, New Mexico; Rancho Santa Fe, California; or the Santa Fe district of Mexico City, Mexico. *E.g.*, Bhalla Decl. ¶¶ 31-33; Bowers Decl. ¶ 23; Yon Decl. ¶ 18. For such companies, the only way to avoid the fines

imposed by the Regulation may be to label *all* their products with New Mexico's mandated label. *E.g.*, Thompson Decl. ¶¶ 17-20; Yon Decl. ¶ 19.

The cost of this for Plaintiffs' member companies and other regulated entities will likely stretch into the hundreds of millions of dollars or more. NMED's witness in the EIB proceeding conducted a survey of literature concerning labeling compliance costs for genetically-engineered foods, and opined that median estimates of compliance costs *for that one industry alone* were about \$2.30 per consumer. *See* Snyder Decl., Ex. 7 at 602. Because the Regulation will result in many affected companies changing their labeling on a nationwide basis, that alone suggests compliance costs approaching \$1 billion. And that estimate was just for the food industry, whereas the Regulation impacts each of the highly varied industries represented by the Plaintiff trade associations (and more besides). The declarations from companies filed in support of this motion, suggesting compliance costs in the tens of millions of dollars for even a single company, confirm the immense financial burden the regulation will impose. *E.g.*, Bhalla Decl. ¶ 30.

Even beyond the cost of coming into compliance, the Regulation is certain to impose ongoing losses on Plaintiffs' member companies. As discussed above, the pictographic warning is clearly designed to trigger an emotional reaction in consumers with the intent of causing them not to purchase the labeled products. *See supra*, pp. 13-16. Hence, the Regulation requires Plaintiffs' member companies to include a message that actively turns consumers *against* those companies' own products and potentially toward their competitors' products, leading to lost sales.

Relatedly, the Regulation's requirement that the Erlenmeyer flask label be included on websites imposes its own set of burdens. Many manufacturers and retailers maintain a single website page for items. As a result, retailers generally display California's Proposition 65 warnings nationwide, rather than only to consumers in California. *See, e.g.*, Hall Decl. ¶ 17. Complying

with the Regulation's online labeling mandate would therefore require displaying the Erlenmeyer flask label to any consumer nationwide who views a covered product, not just consumers in New Mexico. Consumers outside New Mexico will have even less context for understanding the label than consumers in New Mexico.

These burdens are fatal under *Zauderer*. But accepting, for sake of argument, NMED's assertion that the pictograph is not even meant to be a warning (*see supra*, p. 14), makes the imposition of these burdens on manufacturers all the more unreasonable. American industry should not be required to incur hundreds of millions of dollars in compliance costs for the purpose of neutrally informing consumers that their products contain a chemical they might just want to learn more about. *Supra*, p. 14. The *Zauderer* exception does not exist so that governments can impose tremendous costs on companies to satisfy consumers' mere curiosity.

For all these reasons, Defendants cannot show that the Regulation's labeling mandate fits within the *Zauderer* exception. New Mexico cannot force Plaintiffs' member companies to spend hundreds of millions of dollars relabeling their products to communicate a controversial warning based on unsettled science with which many of the member companies fundamentally disagree.

B. The Regulation cannot survive First Amendment scrutiny.

As a form of compelled speech that does not satisfy the *Zauderer* standard, the Regulation's labeling mandate is subject to strict scrutiny. *See Disc. Tobacco City & Lottery, Inc.*, 674 F.3d at 554; *Ent. Software Ass'n v. Blagojevich*, 469 F.3d 641, 652 (7th Cir. 2006); *Ass'n of Home Appliance Mfrs.*, 2025 WL 4642378, at *6. At a minimum, the Regulation faces intermediate scrutiny under *Central Hudson Gas & Electric Corp. v. Public Service Commission of New York*,

447 U.S. 557 (1980).¹ Yet the Regulation comes nowhere close to satisfying either form of scrutiny. Indeed, in the Proposition 65 context, courts have uniformly struck down labeling mandates after determining they do not qualify under *Zauderer*. See, e.g., *Wheat Growers*, 85 F.4th at 1282-83; *CERT.*, 29 F.4th at 480; *Pers. Care Prods. Council*, 799 F. Supp. 3d at 1094-95; *Cal. Chamber of Com. v. Bonta*, 781 F. Supp. 3d 1071, 1088-89 (E.D. Cal. 2025).

A law survives strict scrutiny only “if the government proves that [it is] narrowly tailored to serve compelling state interests.” *NIFLA*, 585 U.S. at 766. And under the intermediate scrutiny test, the government must show that the regulation “directly advances” a “substantial” government interest and “is not more extensive than is necessary to serve that interest.” *Central Hudson*, 447 U.S. at 566. Even that test “is significantly more stringent than *Zauderer*’s standard,” including because the government bears the burden of proof under any form of heightened scrutiny. *R.J. Reynolds*, 696 F.3d at 1212, 1218; see also *Brewer v. City of Albuquerque*, 18 F.4th 1205, 1221 (10th Cir. 2021) (the government “bears the burden of making the requisite narrow tailoring showing” under intermediate scrutiny). Under either form of scrutiny, the government “must demonstrate that the harms it recites are real and that its restriction will in fact alleviate them to a material degree.” *Aptive Env’t, LLC v. Town of Castle Rock*, 959 F.3d 961, 987-89 (10th Cir. 2020).

The Regulation fails to satisfy either standard. To start, Defendants cannot identify a compelling or substantial interest in requiring products containing *any* type of PFAS *anywhere* in the product to bear the mandated warning. The prospect that a State interest in safety or

¹ Mandated commercial speech that falls outside the *Zauderer* exception is subject to strict scrutiny as a content-based restriction. See *NIFLA*, 585 U.S. at 766. Some courts have concluded that compelled commercial speech that does not qualify for the *Zauderer* exception is evaluated under *Central Hudson* intermediate scrutiny instead. See *Wheat Growers*, 85 F.4th at 1282; *R.J. Reynolds*, 696 F.3d at 1217. That is wrong because “*Central Hudson* only applies to speech restrictions and not compulsions.” *Ass’n of Home Appliance Mfrs.*, 2025 WL 4642378, at *6.

environmental protection is advanced by this categorical requirement is “purely hypothetical,” not “potentially real.” *NIFLA*, 585 U.S. at 776. As noted above, NMED has admitted that “the vast majority of PFAS have not been studied at all.” *Supra*, pp. 8-9. Moreover, there is no evidence of material risk associated with some broad categories of PFAS like fluoropolymers, and NMED agreed that PFAS within a product do not endanger consumers. *Supra*, pp. 9, 17-18. Therefore, on the evidence, the mandated warning label does not solve “an actual concrete problem.” *Ass’n of Home Appliance Mfrs.*, 2025 WL 4642378, at *9 (citation omitted). Nor can the label mandate be justified on the basis of a putative neutral interest in encouraging New Mexico’s citizens simply to learn more about PFAS. It is doubtful such an interest would qualify as compelling or substantial, and regardless, New Mexico “has not provided a shred of evidence” showing that the Erlenmeyer flask symbol will “directly advance” that interest. *R.J. Reynolds*, 696 F.3d at 1219.

New Mexico also could pursue its objectives in a more targeted fashion. It could require a warning only for products with PFAS demonstrated to directly harm consumers. New Mexico also could rely on its own “advertising campaign” about PFAS without conscripting product manufacturers to serve as the State’s mouthpiece. *Wheat Growers*, 85 F.4th at 1283; *see also NIFLA*, 585 U.S. at 775; *Kimberly-Clark Corp.*, 286 F. Supp. 3d at 145.

“[T]here is no indication the State tried—or even considered—less burdensome alternatives,” confirming that the Regulation is not narrowly tailored. *Ass’n of Home Appliance Mfrs.*, 2025 WL 4642378, at *10. For example, NMED never evaluated the “cost to implement the Labeling portion” of the rule, Snyder Decl., Ex. 8 at 838, and its labeling expert professed ignorance about whether there were other “mechanisms through which the State could provide information about the contents of PFAS product, *see id.*, Ex. 7 at 646 (“I don’t really feel like I can speak to other methods of communication.”). “That the [State] barely considered less-restrictive

means—if it considered them at all—merely underscores the fact that the [State] did not meaningfully tailor” the Regulation to any substantial interest. *Brewer*, 18 F.4th at 1226.

The absence of tailoring is further underscored by the sweeping nature of New Mexico’s approach compared to those of other jurisdictions. Only a minority of states (13) have any laws specifically addressing PFAS, and just three (California, Connecticut, and Colorado) have adopted any sort of labeling mandate. *See* Cal. Health & Safety Code § 109011; Colo. Rev. Stat. § 25-15-604; Conn. Gen. Stat. § 22a-903c. Those states limited their labeling mandates to narrower product categories than New Mexico did. *See* Cal. Health & Safety Code § 109011(a); Colo. Rev. Stat. § 25-15-604(2)(a); Conn. Gen. Stat. § 22a-903c(c)(1). And none of those states requires the inclusion of anything like the Regulation’s pictographic warning. Rather, they require only disclosure of the presence of PFAS in a product. *See* Cal. Health & Safety Code § 109011(a); Colo. Rev. Stat. § 25-15-604(2)(a), (2.5); Conn. Gen. Stat. § 22a-903c(c)(3). Moreover, California and Colorado explicitly exempt products that are too small to accommodate a label and do not have exterior packaging that can be labeled. *See* Cal. Health & Safety Code § 109011(c); Colo. Rev. Stat. § 25-15-604(2)(c). The EIB was apprised of these alternative approaches and never explained why they are insufficient. *See, e.g.,* Snyder Decl., Ex. 8 at 956. The State’s failure to “consider[] different methods that other jurisdictions have found effective” confirms a lack of narrow tailoring. *McCullen v. Coakley*, 573 U.S. 464, 495 (2014).

II. THE REMAINING FACTORS SUPPORT PRELIMINARY INJUNCTIVE RELIEF.

Because Plaintiffs are likely to succeed on their claim that the Regulation violates the First Amendment, the remaining preliminary injunction factors also are readily satisfied. Indeed, “[i]n the First Amendment context, the likelihood of success on the merits will often be the determinative factor because of the seminal importance of the interests at stake.” *Verlo v. Martinez*, 820 F.3d 1113, 1126 (10th Cir. 2016) (quotation marks omitted).

A. Plaintiffs’ member companies will suffer irreparable harm.

Plaintiffs’ member companies will suffer irreparable harm if the Regulation is not promptly enjoined. The Regulation will compel them to speak in violation of their First Amendment rights, and “[t]he loss of First Amendment freedoms, for even minimal periods of time, unquestionably constitutes irreparable injury.” *Elrod*, 427 U.S. at 373; *see also Awad v. Ziriya*, 670 F.3d 1111, 1131 (10th Cir. 2012) (“[W]hen an alleged constitutional right is involved, most courts hold that no further showing of irreparable injury is necessary.”). This “presumption of irreparable injury” fully applies “in commercial speech cases,” if the law results in “the deprivation of ... commercial speech rights.” *Utah Licensed Beverage Ass’n v. Leavitt*, 256 F.3d 1061, 1076 (10th Cir. 2001).

Preliminary injunctive relief is needed well before January 1, 2027, because of the lead time Plaintiffs’ members otherwise will need to come into compliance. As discussed above, it will be extraordinarily expensive for those companies to rework their manufacturing processes, and many may need to institute costly temporary fixes to meet the January 1 deadline. *See supra*, p. 19-22. These costs constitute irreparable harm because, in light of sovereign immunity, Plaintiffs’ members will have no way to recover damages from the State even if Plaintiffs prevail. *See Kansas ex rel. Kansas Dep’t for Child. & Fams. v. SourceAmerica*, 874 F.3d 1226, 1251 (10th Cir. 2017).

B. The public interest favors a preliminary injunction.

The balance of hardships and the public interest factors “merge” in this case where the Defendants are state actors. *Rocky Mtn. Gun Owners*, 121 F.4th at 112. Those factors support preliminary injunctive relief given Plaintiffs’ likelihood of success. “Vindicating First Amendment freedoms is clearly in the public interest.” *Pac. Frontier v. Pleasant Grove City*, 414 F.3d 1221, 1237 (10th Cir. 2005); *see also Elam Constr., Inc. v. Reg’l Transp. Dist.*, 129 F.3d 1343, 1347 (10th Cir. 1997) (“[t]he public interest ... favors plaintiffs’ assertion of their First Amendment rights.”). And “when a law ... is likely unconstitutional, the interests of those the government represents,

such as voters, do not outweigh a plaintiff’s interest in having its constitutional rights protected.”

Hobby Lobby Stores, Inc. v. Sebelius, 723 F.3d 1114, 1145 (10th Cir. 2013) (citation omitted).

III. AT A MINIMUM, THE COURT SHOULD ENJOIN THE REGULATION WITH RESPECT TO FLUOROPOLYMERS AND PFAS TO WHICH CONSUMERS ARE NOT EXPOSED

For the reasons given above, the Regulation’s labeling mandate is overly broad on its face and should be enjoined in its entirety—no one should be compelled to communicate the controversial message that all PFAS are dangerous. Even if NMED could craft a limited labeling mandate targeting some products containing some types of PFAS, that is not what NMED did and so the entire mandate is unconstitutional. *E.g., United States v. Stevens*, 559 U.S. 460, 473 (2010) (“In the First Amendment context ... this Court recognizes a second type of facial challenge, whereby a law may be invalidated as overbroad if a substantial number of its applications are unconstitutional, judged in relation to the statute’s plainly legitimate sweep.”).

If, however, the Court decides not to enjoin the mandate in its entirety, then it should at least enjoin Defendants from enforcing it as applied to products containing only fluoropolymers and PFAS to which consumers will not be exposed. The New Mexico legislature distinguished between fluoropolymers and other PFAS, when it carved fluoropolymers out of the PFAS Act’s statutory ban. *See supra*, p. 7. And NMED witnesses repeatedly conceded before the EIB that fluoropolymers, and PFAS to which consumers are not exposed, do not pose a direct risk to consumers. *See supra*, pp. 8-9. Plaintiffs therefore have a high likelihood of success in challenging the constitutionality of the labeling mandate as applied to products falling in those two categories.

CONCLUSION

Plaintiffs respectfully request that the Court grant their request for a preliminary injunction. At a minimum, the Court should enjoin enforcement of the mandate with respect to products containing only fluoropolymers, or PFAS to which consumers will not be exposed.

Dated: July 1, 2026

Respectfully submitted,

/s/ John C. Anderson

JOHN C. ANDERSON
HOLLAND & HART LLP
215 Lincoln Ave., Suite 100
Santa Fe, NM 87501
Phone: +1 505 988 4421
jcanderson@hollandhart.com

KEVIN P. MARTIN (*pro hac vice pending*)
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, MA 02210
Phone: +1 617 570 1000
KMartin@goodwinlaw.com

BRIAN T. BURGESS (*pro hac vice pending*)
ANDREW KIM (*pro hac vice pending*)
CASSANDRA SNYDER (*pro hac vice pending*)
NOELLE WILSON (*pro hac vice pending*)
GOODWIN PROCTER LLP
1900 N Street NW
Washington, DC 20036
Phone: +1 202 346 4000
BBurgess@goodwinlaw.com
AndrewKim@goodwinlaw.com
CassandraSnyder@goodwinlaw.com
NWilson@goodwinlaw.com

Counsel for Plaintiffs

CERTIFICATE OF SERVICE

I hereby certify that on July 1, 2026, a true and correct copy of the foregoing was electronically filed and served on all parties of record via the Court's CM/ECF system.

/s/ John C. Anderson
John C. Anderson

**THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATING
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

**DECLARATION OF CASSANDRA M. SNYDER IN SUPPORT OF PLAINTIFFS’
MOTION FOR PRELIMINARY INJUNCTION**

I, Cassandra M. Snyder, declare as follows pursuant to 28 U.S.C. § 1746:

1. I am an attorney at the law firm of Goodwin Procter LLP, which represents Plaintiffs American Chemistry Council, Alliance for Automotive Innovation, American Coating Association, Association of Home Appliance Manufacturers, National Association of Manufacturers, National Electrical Manufacturers Association, National Federation of Independent Business, New Mexico Retail Association, and Power Tool Institute in the above-captioned action.

2. I submit this declaration in support of Plaintiffs’ Motion for Preliminary Injunction.

3. Provided as Exhibit 1 is a true and correct link to *Exhibit B, Proposed New Rule § 20.13.2 NMAC, Petition for Regulatory Change to Adopt 20.13.2 NMAC and Request for Hearing* filed in New Mexico Environment Department's ("NMED") Environmental Improvement Board ("EIB") Docket 25-61(R), dated October 8, 2025, and available at <https://perma.cc/8BER-RRJ5>.

4. Provided as Exhibit 2 is a true and correct link to the American Chemistry Council's comment letter filed in NMED EIB Docket 25-61(R), dated October 22, 2025, and available at <https://perma.cc/PY2C-PTBD>.

5. Provided as Exhibit 3 is a true and correct link to NMED's *Revised Proposed New Rule 20.13.2 NMAC* filed in NMED EIB Docket 25-61(R), dated January 16, 2026, and available at <https://perma.cc/4ZFQ-H6VC>.

6. Provided as Exhibit 4 is a true and correct link to NMED's *Rebuttal Proposed New Rule 20.13.2 NMAC* filed in NMED EIB Docket 25-61(R), dated February 16, 2026, and available at <https://perma.cc/6UY6-EYLB>.

7. Provided as Exhibit 5 is a true and correct link to NMED's *Rebuttal Testimony of Dr. Eric J. Chapman*, filed in NMED EIB Docket 25-61(R), dated February 16, 2026, and available at <https://perma.cc/HLC2-8CPA>.

8. Attached as Exhibit 6 hereto is a true and correct copy of excerpts of Volume I of the transcript from the evidentiary hearing before the New Mexico Environment Department in the Matter of Proposed Adoption of 20.13.2 NMAC, Per- and Polyfluoroalkly Substances in Consumer Products, EIB 25-61(R), dated February 23, 2026.

9. Attached as Exhibit 7 hereto is a true and correct copy of excerpts of Volume II of the transcript from the evidentiary hearing before the New Mexico Environment Department in

the Matter of Proposed Adoption of 20.13.2 NMAC, Per- and Polyfluoroalkly Substances in Consumer Products, EIB 25-61(R), dated February 24, 2026.

10. Attached as Exhibit 8 hereto is a true and correct copy of excerpts of Volume III of the transcript from the evidentiary hearing before the New Mexico Environment Department in the Matter of Proposed Adoption of 20.13.2 NMAC, Per- and Polyfluoroalkly Substances in Consumer Products, EIB 25-61(R), dated February 25, 2026.

11. Attached as Exhibit 9 hereto is a true and correct copy of excerpts of Volume IV of the transcript from the evidentiary hearing before the New Mexico Environment Department in the Matter of Proposed Adoption of 20.13.2 NMAC, Per- and Polyfluoroalkly Substances in Consumer Products, EIB 25-61(R), dated February 26, 2026.

12. Provided as Exhibit 10 is a true and correct link to the EIB's *Final Order and Statement of Reasons*, filed in NMED EIB Docket 25-61(R), dated April 17, 2026, and available at <https://perma.cc/E4YJ-3B27>.

13. Provided as Exhibit 11 is a true and correct link to the Organisation for Economic Co-operation and Development's *Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances: Recommendations and Practical Guide*, dated July 9, 2021, and available at <https://tinyurl.com/33y86et2>.

14. Provided as Exhibit 12 is a true and correct link to the U.S. Department of Defense's *Report on Critical Per- and Polyfluoroalkyl Substance Uses*, dated August 2023, and available at <https://tinyurl.com/5d2z8rrp>.

15. Provided as Exhibit 13 is a true and correct link to the U.S. Food and Drug Administration's *PFAS in Medical Devices*, dated August 6, 2025, and available at <https://tinyurl.com/2s4z3xrs>.

16. Provided as Exhibit 14 is a true and correct link to the U.S. Environmental Protection Agency's *Multi-Industry Per- and Polyfluoroalkyl Substances (PFAS) Study - 2021 Preliminary Report*, dated 2021 and available at <https://perma.cc/7XXT-9V4E>.

I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge and belief. Executed this 1st day of July, 2026.

By: /s/ Cassandra M. Snyder
Cassandra M. Snyder

Exhibit 6

BEFORE HONORABLE FELICIA L. ORTH

Deposition of : VOL I HEARING

taken on: February 23, 2026



531 Harkle Road, Suite A
Santa Fe, NM 87505

505-984-2244

www.cumbrecourtreporting.com

BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

1 STATE OF NEW MEXICO
2 ENVIRONMENTAL IMPROVEMENT BOARD
3
4 IN THE MATTER OF PROPOSED) EIB NO.:
ADOPTION OF 20.13.2 NMAC,))
5 Per- and Poly-Fluoroalkyl) 25-61(R)
Substances in Consumer)
6 Products.)
_____)

7
8 BEFORE THE HONORABLE FELICIA L. ORTH
9
10 MONDAY, FEBRUARY 23, 2026
11 9:04 A.M.
12 EVIDENTIARY HEARING VOLUME I

13 **CERTIFIED**
14 **TRANSCRIPT**
15
16
17
18
19

20 REPORTED BY:
21 DAVID M. LEE, RMR, CCR,
Certificate Number 50391
22 New Mexico CCR Number 537
Cumbre Court Reporting Services, LLC
513 Harkle Road
23 Suite A
Santa Fe, New Mexico 87505
24 (505) 984-2244
cumbrecourt@comcast.net
25



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 2

1 APPEARANCES

2 FOR THE ENVIRONMENTAL IMPROVEMENT BOARD:

3 SANDRA ELY, BOARD CHAIR

4 PHOEBE SUINA, BOARD VICE CHAIR

5 J. BARRY BITZER, BOARD MEMBER

6 GUADALUPE CARRASCO, BOARD MEMBER

7 RONALD CURRY, BOARD MEMBER

8 KAREN GARCIA, BOARD MEMBER

9 FELICIA L. ORTH, HEARING OFFICER
felicia.l.orth@gmail.com

10 NEW MEXICO DEPARTMENT OF JUSTICE

11 BY: EDUARDO UGARTE, II, ESQ.

12 BOARD COUNSEL
eugarte@nm DOJ.gov

13 Post Office Box 1508
Santa Fe, New Mexico 87504-1508
(505) 264-5741

14 FOR NEW MEXICO ENVIRONMENT DEPARTMENT:

15 NEW MEXICO ENVIRONMENT DEPARTMENT

16 BY: GREGORY S. SMITHKIER, ESQ.
gregory.smithkier@env.nm.gov

17 ANDREW P. KNIGHT, ESQ.
18 andrew.knight@env.nm.gov

19 MARK F. ROSEBROUGH, ESQ.
20 mark.rosebrough@env.nm.gov

21 PAMELA JONES, PARALEGAL
pamela.jones@env.nm.gov

22 LUIS LOPEZ, PARALEGAL
23 luis.lopez@env.nm.gov

24 1190 South St. Francis Drive
Suite N-4050
Albuquerque, New Mexico 87507
25 (505) 531-7736



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 3

1 FOR CROPLIFE AMERICA AND AMERICAN
CHEMISTRY COUNCIL:

2

GALLAGHER & KENNEDY, P.A.

3 BY: DALVA L. MOELLENBERG, ESQ.
dlm@gknet.com

4

ANTHONY J. TRUJILLO, ESQ.
ajt@gknet.com

5

6 SERAFINA SELUJA, ESQ.
serafina.seluja@gknet.com

7

1239 Paseo de Peralta
8 Santa Fe, New Mexico 87501-2758
(505) 989-7278

9

10 FOR PFAS PHARMACEUTICAL WORKING GROUP
(PPWG):

11 MODRALL, SPERLING, ROEHL, HARRIS &
SISK, P.A.

12 BY: STUART R. BUTZIER, ESQ.
stuart.butzier@modrall.com

13

STANLEY HARRIS, ESQ.
14 stan.harris@modrall.com

15 BENJAMIN C. ROSSI, ESQ.
benjamin.rossi@modrall.com

16

Post Office Box 2168
17 Albuquerque, New Mexico 87103-2168
(505) 848-1823
18 (505) 848-9710 (Facsimile)

19 FOR HOUSEHOLD & COMMERCIAL PRODUCTS
ASSOCIATION:

20

HOUSEHOLD & COMMERCIAL PRODUCTS
21 ASSOCIATION

BY: STEVEN BENNETT, PH.D.
22 Executive Vice President
SCIENTIFIC & REGULATORY AFFAIRS
23 sbennett@thehcpa.org
1625 I Street Northwest
24 Suite 700
Washington, D.C. 20006

25



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 4

1 FOR COMPLEX PRODUCTS MANUFACTURERS
COALITION:

2

WILEY REIN, L.L.P.

3 BY: HENRY M. RIVERA, ESQ.
hrivera@wiley.law

4

REBECCA J. FIEBIG, ESQ.
rfiebig@wiley.law

5

6 MARTHA MARRAPESE, ESQ.
marrapese@wiley.law

7 2050 M Street Northwest
Washington, D.C. 20036
8 (202) 719-7000

9 FOR ALLIANCE FOR AUTOMOTIVE INNOVATION:

10 WILEY REIN, L.L.P.
BY: HENRY M. RIVERA, ESQ.
11 hrivera@wiley.law

12 REBECCA J. FIEBIG, ESQ.
rfiebig@wiley.law

13

MARTHA MARRAPESE, ESQ.
14 marrapese@wiley.law

15 2050 M Street Northwest
Washington, D.C. 20036
16 (202) 719-7000

17 FOR BRUCE WETHERBEE, PRO SE:

18 BY: BRUCE WETHERBEE
editor@thecandlepublishing.com
19 60 Thoreau Street
Suite 103
20 Concord, Massachusetts 01742
(505) 501-1570

21

ALSO PRESENT: LISA O'GRADY
22 INTERPRETER

23 AMELIA CARDEÑA
INTERPRETER

24

MELINDA MAASS
25 INTERPRETER



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 5

1	I N D E X	
2	EXAMINATION	PAGE
3	ERIC JOHN CHAPMAN, PH.D.	
4	Direct Examination By Mr. Smithkier	78
5	Cross-Examination By Mr. Trujillo	130
6	Cross-Examination By Ms. Fiebig	218
7	Redirect Examination By	
8	Mr. Smithkier	260
9	Examination By Chair Ely	262
10	Examination By Mr. Ugarte	268
11	MITCHELL R. OLSON, P.E., PH.D.	
12	Direct Examination By Mr. Knight	275
13	Cross-Examination By Ms. Seluja	302
14	Cross-Examination By Mr. Wetherbee	309
15	ANDREW PAUL JOCHEMS	
16	Direct Examination By Mr. Knight	314
17	Cross-Examination By Mr. Trujillo	325
18	Cross-Examination By Mr. Wetherbee	329
19	Redirect Examination By Mr. Knight	331
20	Examination By Chair Ely	332
21	Examination By Board Member Curry	334
22		
23		
24		
25		



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 28

1 Notice had already issued. At that
2 point the parties were already
3 preparing their cases, retaining
4 experts, and developing Testimony based
5 on what the Agency told the public was
6 its technical information. That is
7 precisely the harm the Statute is
8 designed to prevent.

9 NMED argues that Section
10 14-4-5.2A(7) establishes only a floor
11 for disclosure, but that argument
12 fails for 3 reasons:

13 First, it contradicts the plain
14 language of the Statute. The Statute
15 does not require the disclosure of
16 some technical information; it
17 requires disclosure of technical
18 information "... that serve as the
19 basis for the Proposed Rule..."

20 Second, NMED's interpretation
21 would nullify the Notice requirement
22 entirely.

23 Third, this reading creates
24 exactly the kind of absurd result the
25 Uniform Statute and Rules Construction



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 29

1 Act forbids; a system where the Agency
2 controls when and whether the public
3 ever sees the real technical
4 justification for the Rule.

5 The Legislature did not design
6 Public Notice as a sneak peek to the
7 rest of the story, it is supposed to
8 be the full and fair disclosure of the
9 Rule's technical foundation.

10 NMED also argues that ACC's
11 interpretation of Section 14-4-5.2A(7)
12 renders Section 14-4-5.4 superfluous.
13 It does not. The 2 provisions serve
14 different functions at different
15 stages.

16 Section 14-4-5.2A(7) governs
17 what must be disclosed before hearing
18 so the public can prepare. Section
19 14-4-5.4 governs what must be included
20 in the final Rulemaking record
21 reflecting what was ultimately relied
22 upon. Those provisions work together,
23 they are not substitutes for one
24 another.

25 The prejudice here is not



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 30

1 hypothetical. Once Public Notice
2 issues, parties are immediately
3 constrained by deadlines, expert
4 retention, Testimony preparation, and
5 evidentiary strategy. When the
6 technical basis expands dramatically
7 after Notice to regulated entities, it
8 presents a significant problem.

9 This is especially problematic
10 in Rulemakings of this scope where
11 technical literature defines the reach
12 of the regulation, including which PFAS
13 compounds were implicated and why. If
14 certain classes of compounds were not
15 supported by disclosed technical
16 information on Notice, the Regulated
17 Parties were entitled to assume those
18 compounds were not within the Rule's
19 intended scope. Late disclosure
20 changes the game midstream. That is
21 not meaningful participation, that is
22 a procedural ambush.

23 What ACC is and is not asking
24 for, and let me be clear about the
25 remedy ACC seeks:



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 51

1 For now it's denied, but I
2 don't want to suggest to you that these
3 questions have been resolved. We will
4 proceed with the hearing, and I believe
5 the fullness of the record will help
6 the Board make its decisions on these
7 questions, but thank you for that.

8 All right. Is there anything
9 else before we move to Opening
10 Statements?

11 No. All right.

12 Mr. Smithkier, would you like
13 to offer the first Opening Statement
14 as Petitioner, and if you will
15 remember you have 20 minutes.

16 MR. SMITHKIER: Thank you.

17 Good morning, Madam Hearing
18 Officer, Chair Ely, and Members of the
19 Board:

20 My name is Greg Smithkier, and
21 I'm here today on behalf of the New
22 Mexico Environment Department's Office
23 of Strategic Initiatives. I'm joined
24 here today by Christine Keyes, Acting
25 Director of the Office of Strategic



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 52

1 Initiatives, as well as my Co-Counsel
2 Mark Rosebrough and Andrew Knight.

3 My Co-Counsel and I are here
4 to assist an incredible group of
5 Department staff and experts to put
6 forward explanations and support for
7 this Board to adopt 20.13.2 NMAC, a
8 Rule relating to Per- and Poly-
9 Fluoroalkyl Substances in Consumer
10 Products. This Rule implements the
11 landmark PFAS Protection Act that was
12 signed into law by Governor Luján
13 Grisham on April 8, 2025.

14 The PFAS Protection Act was a
15 clear directive from the New Mexico
16 Legislature to protect our citizens,
17 our water, and our environment from
18 the forever chemicals known as PFAS.

19 The ambitious timetable that
20 has been set forth by the Legislature
21 in the implementation of the PFAS
22 Protection Act underscores the urgency
23 of addressing PFAS in consumer products,
24 and this Hearing is an important step
25 towards turning off the spigot of PFAS



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 53

1 in New Mexico.

2 The first product prohibitions
3 contained in the PFAS Protection Act go
4 into effect on January 21, 2027.

5 Because of that, time is of the essence
6 with respect to adopting a Rule to
7 implement the Act's requirements.

8 The Rule that NMED has proposed
9 incorporates all the statutorily
10 mandated requirements, and aligns with
11 the Legislature's goals as expressed
12 in the PFAS Protection Act and the
13 recently passed House Joint Memorial 3.

14 Specifically the Proposed Rule
15 fulfills the requirements of the
16 Legislature that the Board:

17 1: Adopt rules that detail
18 the information that a manufacturer
19 must report to NMED;

20 2: Adopt rules to exempt
21 products from the statutory reporting
22 requirements if those products are
23 already exempt under the Act;

24 3: Adopt rules creating a
25 series of ranges of the amount of PFAS



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 54

1 in a product for reporting purposes

2 unless they are exempt; and,

3 4: Adopt rules to identify the
4 currently unavoidable uses of PFAS that
5 are essential for health, safety, or
6 the function of society, and for which
7 there are no reasonably available
8 alternatives.

9 In addition to these
10 requirements, NMED's Proposed Rule
11 requires Labeling of products
12 containing intentionally added PFAS in
13 both English and Spanish as authorized
14 by the Legislature.

15 The Rule also requires the
16 Labeling of exempt products, which
17 aligns with the will of the Legislature
18 as expressly stated in House Joint
19 Memorial 3, which was passed just last
20 week.

21 The introduction of a PFAS
22 label for consumer products will allow
23 New Mexicans to make informed
24 decisions with respect to the products
25 that they purchase and bring into



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 59

1 proposed Labeling requirements.

2 Experts will provide evidence on:

3 How clear and conspicuous

4 Labeling influences consumer behavior;

5 Provides tangible benefits to

6 consumers; and,

7 Gives New Mexicans the

8 transparency that they deserve.

9 By informing the public about

10 which products contain intentionally

11 added PFAS the State can empower

12 residents to protect their own health

13 and the environment.

14 Through this week of Expert

15 Testimony NMED will prove that this

16 Rule is a necessary and an overdue

17 intervention to protect the future of

18 New Mexico's land, water, and its

19 people.

20 The Rule before you today is

21 a practical balance and legally sound

22 framework. It fulfills the mandate of

23 the PFAS Protection Act and honors the

24 urgency expressed by the Legislature.

25 By adopting this Rule the Board will



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 60

1 provide the Department with the
2 necessary tools to:

3 Track these chemicals;

4 Inform our citizens through
5 transparent Labeling; and,

6 Ultimately prevent further
7 contamination of the groundwater that
8 80% of New Mexicans rely on for
9 drinking.

10 We are not just asking you to
11 adopt the regulation, we are asking
12 you to turn off the spigot of PFAS in
13 New Mexico. We have:

14 The science to prove the
15 risk;

16 The Legislative authority to
17 take action; and,

18 A clear path forward that
19 protects both human health and the
20 environment without placing an undue
21 burden on manufacturers.

22 On behalf of the New Mexico
23 Environment Department we urge the
24 Board to adopt the Proposed Rule in its
25 entirety.



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 61

1 Thank you for your time and
2 your service to the State of New Mexico.

3 HEARING OFFICER ORTH: Thank
4 you, Mr. Smithkier.

5 I realized we did not, in our
6 second Prehearing Conference, arrange
7 the industry parties. Have you
8 decided on an order yourselves that
9 you would like to proceed under?

10 Mr. Moellenberg.

11 MR. MOELLENBERG: Thank you,
12 Madam Hearing Officer.

13 I believe that, with other
14 Counsel's concurrence, American
15 Chemistry Council will go first. We
16 can follow that, of course, with
17 CropLife, and then probably proceed to
18 the Complex Products Manufacturers
19 Coalition.

20 HEARING OFFICER ORTH: Thank
21 you very much; let's do that.

22 Will you be offering an Opening
23 Statement at this time or would you
24 like to reserve?

25 MR. MOELLENBERG: Madam Hearing



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 80

1 institution in Minnesota. I taught
2 over 1,000 students Introductory and
3 Upper-Level Biology courses on Human
4 Impacts on the Environment, with a
5 focus on Chemicals of Emerging Concern
6 including PFAS.

7 Q. Did you file both Direct and
8 Rebuttal Written Testimony?

9 A. I did.

10 Q. Okay.

11 Do you have any corrections
12 that you would like to make to that
13 Written Testimony?

14 A. Yes.

15 I stated that the PFAS
16 Protection Act requires the EIB to
17 adopt rules for testing products for
18 PFAS. To clarify, the Statute requires
19 testing, and authorizes the EIB to
20 adopt rules for testing.

21 Q. With that noted correction do
22 you adopt that written Testimony as
23 your Testimony here today?

24 A. I do.

25 Q. Okay. Can you please provide



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 81

1 a summary of your Written Testimony.

2 A. I present this Testimony on
3 behalf of the Department in support of
4 the Department's Petition and Rebuttal
5 Rule.

6 I will provide a high-level
7 overview of the Rule and how engagement
8 with interested parties led to the
9 development of the Rule.

10 I will also discuss sources of
11 PFAS in the environment;

12 How consumer products
13 contribute to environmental PFAS
14 contamination and environmental
15 transformation; and,

16 Transport of PFAS across
17 different media.

18 My Testimony will show that,
19 once released into the environment,
20 PFAS contamination becomes widespread
21 creating a multitude of indirect
22 exposure pathways that are difficult
23 to remediate.

24 I will end with a call for
25 adopting the Rebuttal Rule to turn off



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 82

1 the spigot at the source of PFAS
2 entering New Mexico through consumer
3 products.

4 Q. Why is it important to regulate
5 PFAS in consumer products in New
6 Mexico?

7 A. One of the many catalysts for
8 New Mexico's actions regulating PFAS
9 is the bioaccumulative persistent and
10 toxic nature of many PFAS.

11 Another is the extent of
12 contamination, including places such
13 as Holloman Lake, with some of the
14 highest levels of PFAS ever observed
15 in plant and animal tissues globally.
16 Surface water concentrations were
17 measured to be over 100,000 parts per
18 trillion, or 25,000 times the EPA
19 drinking water standard for PFAS.
20 Consuming one gram of duck meat from
21 the lake would exceed the recommended
22 lifetime exposure to PFOS.

23 Prohibiting consumer products
24 containing PFAS can turn off the PFAS
25 spigot at its source. Consumer



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 83

1 products are a major direct source of
2 PFAS exposure to humans, and an
3 indirect source once released into the
4 environment.

5 Humans are directly exposed to
6 PFAS in:

7 Cleaning products;
8 Cosmetics;
9 Cookware; and,
10 Fabric treatments.

11 The production, use, and
12 disposal of consumer products can
13 result in PFOS emissions that
14 contaminate the environment.

15 Passive receivers, such as:
16 Wastewater Treatment Plants;
17 Wells and septic systems;
18 Soils from biosolid application;
19 and,

20 Landfills further spread this
21 contamination to water, soil, and air.
22 Regulating PFAS in consumer products
23 can lessen the burden of contamination
24 by downstream passive receivers.

25 The PFAS Protection Act allows



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 89

1 released into the environment.

2 The family contains both non-
3 polymer and polymer PFAS. Within
4 classes there are many subclasses which
5 include:

6 Per- and poly-fluoroalkyl
7 substances;

8 Fluoropolymers; and,
9 Side-chain fluorinated polymers.

10 For clarity, the PFAS
11 Protection Act provides us with a
12 definition:

13 "'PFAS' means a substance
14 in a class of fluorinated
15 organic chemicals containing
16 at least 1 fully fluorinated
17 carbon atom."

18 Much attention is focused on
19 the non-polymer group of PFAA,
20 containing the subgroup of PFCA and
21 PFSA, because of the well-established
22 detrimental effects of legacy
23 substances such as PFOA and PFOS.

24 Legacy PFAS are in water, soils,
25 and biological samples including human



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 90

1 tissue, fish, and other foods.

2 Concerns about legacy PFAS has
3 led to newer classes of alternatives,
4 though there are emerging concerns of
5 this new class. Some alternatives,
6 such as PFNA, show higher toxicity
7 across developmental stages in zebra
8 fish, and can accumulate in plants and
9 animals and food webs. These
10 alternatives illustrate shared concerns
11 across all PFAS, such as persistence,
12 mobility, and potential toxicity.

13 Q. Can you please tell us a
14 little more about polymeric PFAS?

15 A. The fluoropolymer subclass may
16 not be as inert as originally
17 understood.

18 PTFE is a fluoropolymer
19 commonly used in non-stick pans.
20 Exposure to PTFE microplastics and
21 PFAS can occur with food contact
22 products through regular use.

23 At expected cooking
24 temperatures, PTFE-coated cookware and
25 cooking utensils emit various gases



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 91

1 that can contain PFAS. For instance,
2 emissions of PFCA can reach 12,000
3 ng/hr.

4 PFAS are also used during
5 fluoropolymer production, and can
6 expose humans through production, use,
7 and disposal of consumer products.

8 Additionally, studies stating
9 that fluoropolymers should be
10 considered "polymers of low concern,"
11 are authored by representatives from
12 fluoropolymer production companies and
13 contain Conflict of Interest statements.

14 Q. Can you describe how PFAS'
15 chain length influences transport
16 through the environment?

17 A. "Chain length" refers to the
18 number of carbon atoms in PFAS and
19 affects movement in the environment.

20 Long-chain are typically
21 suspended in particular matter or in
22 sediments, whereas short-chain tend to
23 be in the water column.

24 Long-chain can also aggregate
25 on clay particles, in soil, and



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 102

1 treatment; however, Wastewater
2 Treatment Plants were not historically
3 designed to remove PFAS resulting in
4 PFAS-free release into the environment.

5 Despite their phaseout and
6 restricted use in the U.S., PFOA is
7 commonly detected in landfill
8 leachate.

9 Landfills have elevated air
10 concentrations of volatile PFAS. FTOH
11 is the dominant PFAS in landfill gas,
12 with a median concentration of 19,000
13 ng/m3.

14 U.S. landfills produce over 800
15 kilograms per year of PFAS in landfill
16 gases, which is similar to the 600
17 kilograms per year in leachate from
18 landfills.

19 Wastewater Treatment Plants
20 serve as passive receivers of
21 environmental PFAS contamination. They
22 enter Wastewater Treatment Plants from:

23 Industrial waste;
24 Firefighting waste;
25 Landfill leachate; and,



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 103

1 Municipal sludge.

2 Globally Wastewater Treatment

3 Plants have low or even negative

4 removal efficiencies that result in

5 effluent concentrations being higher

6 than influent.

7 In a global study of Wastewater

8 Treatment Plants researchers found:

9 Influent concentrations as high

10 as 2,000 nanograms of PFAS per liter;

11 Effluent concentrations

12 approaching 5,000 ng/L; and,

13 Biosolids as high as 500,000

14 ng/g.

15 Short-chain are prevalent in

16 influent and effluent, and long-chain

17 are dominant in biosolids.

18 Individual Wastewater Treatment

19 Plants can emit hundreds of pounds of

20 PFAS per year, and ultimately passive

21 receivers spread PFAS contamination far

22 and wide.

23 Q. Do Wastewater Treatment Plants

24 provide conditions for precursor PFAS

25 transformation?



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 104

1 A. As I mentioned with AFFF, PFAS
2 are subject to transformation in the
3 environment. Wastewater Treatment
4 Plants can be sites of precursor to
5 terminal PFAS transformation. The
6 negative removal efficiencies of PFAS
7 in Wastewater Treatment Plants are a
8 result of these transformation
9 processes.

10 This slide highlights precursor
11 to intermediate and terminal product
12 transformations through different
13 matrices and conditions in Wastewater
14 Treatment Plants.

15 Through no fault of their own,
16 Wastewater Treatment Plants passively
17 receive PFAS, and can even increase
18 levels released into downstream
19 environments, which is another reason
20 we need to turn off the spigot of PFAS
21 in New Mexico.

22 Q. How does PFAS contamination
23 impact water?

24 A. PFAS are widespread and are
25 circulated through the globe's



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 105

1 hydrological cycle. PFAS enter the
2 atmosphere from industrial emissions,
3 dust, and when surface water is
4 aerosolized, and PFAS may be
5 redeposited through either wet or dry
6 deposition.

7 Rainwater contains both legacy
8 and emerging short-chain PFAS, and can
9 transport PFAS over long distances.
10 Stormwater runoff can also contribute
11 to surface water contamination.

12 PFAS contamination in surface
13 water is widespread. Concentrations
14 can vary up to 8 orders of magnitude
15 at our highest sites near industrial
16 and manufacturing facilities. PFAS in
17 urban watersheds can be over 2,000
18 ng/L, or 500 times the EPA limit for
19 PFOA and PFOS.

20 Surface water PFOS can move
21 to: Sediment;

22 Animal tissue; or,

23 Groundwater depending on the
24 chain length.

25 PFAS can accumulate in



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 106

1 groundwater downstream from Wastewater
2 Treatment Plants.

3 Air/water interface absorption
4 can control long-chain transport to
5 groundwater. Absorption and
6 transformation can alter the movement
7 of precursors into downstream
8 groundwater.

9 PFAS transformation increases
10 mobility and lowers the absorption
11 potential, which increases transport
12 to groundwater. Further, soil microbes
13 can mediate PFAS transformation, which
14 can explain fluorinated intermediaries
15 that are not often measured at
16 contaminated sites.

17 The widespread distribution
18 and movement of PFAS through global
19 hydrological cycle is another reason
20 to turn off the PFAS spigot at its
21 source.

22 Q. Will you please tell us about
23 PFAS in soil.

24 A. PFAS are found in soils
25 globally, and cycle through: Soil



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 107

1 microbes;
2 Plants; and,
3 Terrestrial food webs.
4 Soils can be contaminated with:
5 AFFF;
6 Manufacturing plants;
7 Biosolids, and,
8 From atmospheric deposition.
9 Hydrogen bonding;
10 Hydrophobic interactions;
11 Ligand exchange; and,
12 Electrostatic attraction
13 influence how PFAS move in soil.
14 Electrostatic attraction
15 between positive soil particles and
16 negatively charged constituents in PFAS
17 leads to PFAS soil retention.
18 Soils high in organic matter
19 are negatively charged, and can inhibit
20 sorption of anionic PFAS, which results
21 in transport.
22 PFAS movement in surface and
23 groundwater, soils, and sediment is
24 highly dependant on site-specific
25 factors including: Soil properties;



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 108

1 pH;
2 Temperature; and,
3 PFOS type.
4 Indirect exposure pathways
5 through soil represent another
6 justification to stem the flow of PFAS
7 into the environment.

8 Q. Can you please tell us about
9 PFAS and dust.

10 A. PFAS distribution in dust is
11 also widespread. Sand and dust storms
12 contribute to PFAS dust generation and
13 are affected through: Anthropogenic
14 land use;

15 Properties of soil;
16 Types of vegetation; and,
17 Climate.

18 Sources include: Fire
19 stations;

20 Military bases and other
21 aviation sites;

22 Fluoro-chemical manufacturing
23 plants;

24 Indoor dust in landfills;

25 Wastewater Treatment Plants;



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 109

1 and,

2 Road dust.

3 Landfills can also be a
4 significant source of PFAS dust from
5 discarded products such as carpets.

6 Biosolid generation and subsequent land
7 application can also generate PFAS
8 dust from dust storms.

9 Q. Can you please end with
10 providing context for the importance
11 of the Rebuttal Rule?

12 A. The Rebuttal Rule reflects a
13 balance between:

14 Human and environmental health;
15 Interested party concerns; and,
16 Statutory mandates.

17 My Testimony provides the
18 technical basis for turning off the
19 PFAS spigot at its source. PFAS
20 contamination becomes more diffuse,
21 leading to challenges with containment
22 and remediation, and highlighting the
23 importance of stemming the flow of
24 PFAS into the State.

25 Prohibiting consumer products



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 110

1 containing PFAS is a practical and
2 technically feasible way to:

3 Reduce difficult-to-remediate
4 PFAS contamination;

5 Decrease PFAS movement through
6 plants, animals, and humans; and,

7 One of the only ways to
8 realistically decrease PFAS exposure.

9 When House Bill 212 passed the
10 New Mexico House of Representatives 62
11 to 1;

12 The Senate 37 to 3; and,

13 Governor Lujan Grisham signed
14 PFAS Protection Act into law, our State
15 leaders took unified and decisive
16 action to protect New Mexicans and our
17 environment from PFAS in consumer
18 products.

19 Adopting the Rebuttal Rule will
20 implement the PFAS Protection Act and
21 tackle environmental contamination at
22 the source. The Rule empowers
23 consumers to learn more about PFAS from
24 a simple Erlenmeyer flask symbol and
25 optional non-controversial statements



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 111

1 of fact disclosing the presence of
2 PFAS.

3 We can turn off the PFAS
4 spigot from consumer products. I
5 respectfully encourage the EIB to adopt
6 the Rebuttal Rule.

7 HEARING OFFICER ORTH: At this
8 point, Mr. Smithkier, before you move
9 into Rebuttal, I think it would be
10 good to take a break.

11 MR. SMITHKIER: Thank you,
12 Madam Hearing Officer.

13 HEARING OFFICER ORTH: Were you
14 about to do that?

15 MR. SMITHKIER: I was.

16 HEARING OFFICER ORTH: Okay.
17 Let's take 15 minutes and come back at
18 10:50.

19 (The Evidentiary Hearing
20 recessed from 10:35 a.m. to 10:52 a.m.)

21 HEARING OFFICER ORTH: All
22 right. We are back after a short
23 break, and Dr. Chapman has returned to
24 the witness seat.

25 Mr. Smithkier, I believe you



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 112

1 are about to lead him through his
2 Rebuttal Testimony. You have 15
3 minutes.

4 MR. SMITHKIER: Thank you,
5 Madam Hearing Officer.

6 Q. Dr. Chapman, how does your
7 Direct Testimony relate to your
8 Rebuttal Testimony, and what is the
9 purpose of your Rebuttal Testimony?

10 A. Do we have the slideshow
11 going?

12 Q. It's on my screen; let me...
13 Is the slideshow sharing?

14 MR. LOPEZ: Counsel, I don't
15 see you on the WebEx platform any more.

16 MR. SMITHKIER: I'm showing
17 I'm on the WebEx platform, but I can
18 log out and log back in.

19 MS. JONES: I see him on.

20 MR. LOPEZ: Okay. Counsel, you
21 should be able to get in now; sorry
22 about that.

23 Q. BY MR. SMITHKIER: Dr. Chapman,
24 how does your Direct Testimony relate
25 to your Rebuttal Testimony, and what is



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 113

1 the purpose of your Rebuttal Testimony?

2 A. The overall message of my
3 Direct Testimony was that the full
4 environmental impact of a consumer
5 product with PFAS must consider PFAS
6 emissions from production, use, and
7 disposal.

8 The purpose of my Rebuttal
9 Testimony is to provide the Board with
10 an overview of revisions in the
11 Proposed Rule since filing on January
12 16, and to address environmental
13 science claims in the Direct Written
14 Testimony provided by the Complex
15 Products Manufacturers Coalition, or
16 CPMC, and the American Chemistry
17 Council.

18 Q. Has the Department continued
19 to engage with interested parties?

20 A. Yes, engagement continued in
21 the lead-up to the Rulemaking Hearing,
22 which shaped important revisions in
23 the Rebuttal Rule. Most notably, the
24 Department removed language about the
25 health and environmental effects on the



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 114

1 proposed Label, and removed a link to
2 the Department's website.

3 The Rebuttal Rule proposes to
4 require a symbol of an Erlenmeyer
5 flask with the word "PFAS" inside.
6 Directly adjacent are optional non-
7 controversial statements of fact, such
8 as "Made with PFAS" or "Contains
9 PFAS." This Label revision honors the
10 statutory definition and simply states
11 whether a consumer product contains
12 PFAS.

13 Q. Did you review the Technical
14 Testimony of Dr. Stanton and
15 Ms. Marrapese?

16 A. Yes.

17 Q. Did you identify any
18 inaccuracies with their Direct Written
19 Testimony?

20 A. Yes.

21 Q. Can you please describe for us
22 the inaccuracies that you identified?

23 A. Overall Dr. Stanton's Testimony
24 is sparse, overly general, and ignores
25 environmental realities. Most



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 115

1 glaringly this Testimony ignores that
2 PFAS emissions from consumer products
3 occur from product manufacturing, use,
4 and disposal. The brief Testimony
5 argues that, as a class, PFAS are not
6 harmful and:

7 "... nor are they 'forever
8 chemicals.'"

9 First, this downplays the
10 common phrase in the popular press with
11 the biochemical reality that PFAS are
12 subject to degradation and are not
13 truly "forever."

14 This also acknowledges that
15 PFAS are subject to environmental
16 transformation, which may lead to the
17 generation of particularly harmful
18 PFAS.

19 Additionally PFAS, as a class,
20 do have shared characteristics such as
21 persistence and varying levels of
22 mobility, which contributes to
23 environmental concerns.

24 Dr. Stanton adopts a narrow
25 view of environmental release of PFAS



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 116

1 in fluoropolymers. Dr. Stanton
2 states: "Fluoropolymers are an
3 entirely separate entity."
4 As defined by Statute,
5 fluoropolymers are PFAS. The claim
6 that insolubility in water means that
7 they cannot contaminate the environment
8 is false. If you think of
9 microplastics for instance, it shows
10 that polymeric PFAS persist in the
11 environment.

12 It also ignores that another
13 polymeric PFAS -- side-chain
14 fluorinated polymers -- can transform
15 into the persistent group of PFAA.

16 Finally, fluoropolymers can
17 also emit PFAS, such as the highly
18 persistent and mobile trifluoroacetic
19 acid, or TFA, during thermal processing
20 and incineration. Biothermal stability
21 and insolubility in water are not
22 magical properties that exempt
23 fluoropolymers from contaminating the
24 environment.

25 Dr. Stanton's Testimony also



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 117

1 ignores that PFAS emissions from
2 fluoropolymer production contaminates
3 the air, soil, and water. The European
4 Chemicals Agency proposes to restrict
5 all PFAS, demonstrating that there is
6 sufficient concern to regulate PFAS as
7 a class, which contradicts
8 Dr. Stanton's Testimony.

9 Dr. Stanton's discussion on
10 Labeling of complex durable goods also
11 contains various inaccuracies:

12 First, the Rebuttal Rule does
13 not require the vehicle to be labeled,
14 only the owner's manual.

15 Second, Dr. Stanton ignores
16 that complex durable goods with
17 internal components can contain
18 consumer-facing PFAS, such as vehicle
19 seats.

20 Third, the Label provisions in
21 the Rebuttal Rule do not "...
22 communicate hazard...", as she states.
23 The proposed Labeling program provides
24 consumers with a simple symbol such
25 that the consumer can choose to bring



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 118

1 that product into their home.

2 Finally, Dr. Stanton states:

3 "Requiring all PFAS-

4 containing products to include

5 a Label suggesting that they

6 pose such risks is inaccurate,

7 or at the very least the

8 subject of ongoing scientific

9 research and debate, as even

10 the Physical Impact Report to

11 HB 212 acknowledges."

12 One can see, given a more

13 thorough reading, the proper

14 interpretation of the Physical Impact

15 Report to HB 212 is that there is no

16 level of exposure to PFAS that can be

17 considered safe.

18 Like Dr. Stanton, Ms. Marrapese

19 attempts to minimize the environmental

20 risks associated with PFAS in consumer

21 products. Ms. Marrapese generalizes

22 across all complex durable goods that

23 components are: Sequestered inside;

24 Removed from consumer exposure;

25 and,



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 119

1 Safe from environmental release.

2 This assumes that all PFAS are

3 only contained in internal components.

4 This also completely ignores the

5 environmental contamination pathways

6 from production to disposal of a

7 product.

8 Electronic waste can be a

9 significant source of PFAS emissions

10 into the environment, leading to the

11 contamination in: Water;

12 Soil;

13 Leachate;

14 Human blood; and,

15 Rainwater.

16 As an example, recycling

17 emissions from vehicles can be as high

18 as 5,000 micrograms of PFAS per

19 kilogram of vehicle residue. As well,

20 Stormwater related to vehicle recycling

21 can emit 520 nanograms of PFAS per

22 liter of water, which is over 100

23 times higher than the EPA drinking

24 water standard for PFOA and PFOS.

25 Q. Did you review the Technical



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 120

1 Testimony of Dr. Korzeniowski?

2 A. Yes.

3 Q. Did you identify any
4 inaccuracies in his Direct Written
5 Testimony?

6 A. Yes.

7 Q. Can you please describe for us
8 the inaccuracies that you identified?

9 A. The Direct Testimony from the
10 American Chemistry Council makes
11 erroneous claims that:

12 The Department treats all PFAS
13 the same;

14 Narrowly focuses on polymers;
15 and,

16 Ignores PFAS emissions
17 throughout a product's life cycle.

18 The 3-page Direct Testimony of
19 Dr. Steven Korzeniowski, an Organic
20 Chemist for PFAS manufacturer DuPont
21 for the majority of his career, claims
22 that the Proposed Rule treats all PFAS
23 the same.

24 First, it is clear from the
25 exemptions provided in the PFAS



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 128

1 continue.

2 A. Okay.

3 The Testimony I rebut makes
4 narrow, inaccurate, and unsubstantiated
5 claims. They argue that the Department
6 treats all PFAS the same while ignoring
7 product exemptions, CUUs, and pathways
8 for Labeling exemptions. They narrowly
9 focus on fluoropolymers and ignore PFAS
10 emissions that occur during: PFOS
11 production;

12 Consumer product manufacturing;
13 Product use; and,
14 Product disposal.

15 PFAS transforms in the
16 environment resulting in indirect
17 exposure pathways in the air, dust,
18 water, and soil.

19 One could argue that the
20 Testimony for ACC and CPMC treat all
21 PFAS the same;

22 That all PFAS is "of low
23 concern";

24 That PFAS exposure results only
25 from direct consumer contact with a



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 129

1 product during use;

2 You can ignore PFAS emissions
3 during a product's life cycle; and,

4 The Department should not
5 impose Labeling requirements on
6 consumer products containing PFAS.

7 The Department has engaged in
8 good-faith collaborations with
9 interested parties resulting in the
10 Rebuttal Rule for the EIB's
11 consideration. It is my hope that the
12 Board adopts the Rebuttal Rule in order
13 to turn off the PFAS spigot from
14 consumer products.

15 Requiring simple labels on
16 consumer products will allow consumers
17 to choose whether they purchase
18 products containing PFAS. Help New
19 Mexico empower consumer choice to
20 reduce their exposure and environmental
21 release by adopting the Rule for PFAS
22 Labeling.

23 Turning off the spigot today
24 will help relieve the long-term burden
25 faced by our State's largely rural



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 130

1 infrastructure that provides New
2 Mexicans with clean and safe water.

3 MR. SMITHKIER: Thank you,
4 Dr. Chapman.

5 HEARING OFFICER ORTH: Thank
6 you, Mr. Smithkier.

7 We will move to questioning of
8 Dr. Chapman.

9 Mr. Moellenberg, would you like
10 to go first?

11 MR. TRUJILLO: Madam Hearing
12 Officer, I will be doing the
13 questioning.

14 HEARING OFFICER ORTH: Thank
15 you, Mr. Trujillo. Go ahead.

16

17 CROSS-EXAMINATION

18 BY MR. TRUJILLO:

19 Q. Dr. Chapman, before we begin
20 do you have access to your Direct and
21 Rebuttal Testimony? I think it's NMED
22 Exhibit 3 and Exhibit 71.

23 A. (No audible response.)

24 Q. Do you have those before you?

25 A. I do.



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 160

1 Is it at the top, the middle,
2 or the bottom?

3 Q. I'll go find it myself; my
4 notes indicate that it is on page 44.

5 It would be the second
6 complete paragraph, and it starts
7 with:

8 "Within this family..."

9 Do you see what I'm speaking
10 to?

11 A. Yes.

12 Q. Why don't you go ahead and read
13 this paragraph for us, because I'm
14 going to ask you several questions
15 about it.

16 A. (No audible response.)

17 Q. Read it out loud so we're
18 familiar with it, because I have,
19 again, several questions, and I want to
20 make sure we are familiar with the
21 entire context.

22 A. You would like me to read it
23 out loud?

24 Q. Yes, please.

25 A. (Reading:) "Within this family



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 161

1 of fluorinated organic
2 compounds there is wide
3 variation in chemical
4 structure, which can
5 ultimately influence
6 biological, chemical, and
7 physical properties when
8 released into the environment.

9 Within the family there
10 are 2 classes, non-polymers
11 and polymers. Within classes
12 there are many subclasses,
13 which include per-fluoroalkyl
14 substances, poly-fluoroalkyl
15 substances, fluoropolymers,
16 polymeric perfluoropolyethers,
17 and side-chain fluorinated
18 polymers.

19 "For the sake of my
20 Testimony and this Rulemaking
21 hearing, the PFAS Protection
22 Act provides us with the
23 following definition:

24 "'Per-' or 'poly-
25 fluoroalkyl substances' means



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 162

1 a substance in a class of
2 fluorinated organic chemicals
3 containing at least 1 fully
4 fluorinated carbon atom.'" "

5 Q. In this paragraph, Dr. Chapman,
6 as I read your Testimony, you are
7 trying to point to the statutory
8 definition because it's different than
9 something else. Is that correct?

10 A. (No audible response.)

11 Q. Am I interpreting your
12 paragraph here correctly?

13 A. I don't agree with that.

14 Q. Why was it important to point
15 out the statutory definition
16 specifically in this paragraph?

17 A. Statutory definitions are
18 important to provide context.

19 Q. Are there non-statutory or
20 scientific definitions of PFAS?

21 A. Can you repeat the question?

22 Q. Are there non-statutory or
23 scientific definitions of PFAS?

24 A. Yes, I would imagine so.

25 Q. Dr. Chapman, isn't it true that



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 163

1 the structure-based statutory
2 definition of PFAS that captures all
3 substances "with at least 1 fully
4 fluorinated carbon" does not align with
5 the scientific method of defining PFAS?

6 A. I disagree.

7 Q. Do you agree or disagree with
8 me on this:

9 "Scientific conclusions
10 relating to PFAAs do not
11 automatically extend to all
12 PFAS-containing products"?

13 A. (No audible response.)

14 Q. Is that correct?

15 A. Yes.

16 Q. Dr. Chapman, let me have you
17 turn to page 46 of Exhibit 3.

18 A. (Witness complies.)

19 Q. Are you there?

20 A. Yes.

21 Q. On page 46 you state:

22 "Beyond PFOA and PFOS
23 alternatives there is growing
24 scientific evidence that the
25 fluoropolymer subclass of PFAS



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 164

1 may not be as inert as
2 originally understood."

3 Is that correct?

4 A. Yes, I wrote that.

5 Q. Your best attempt to discredit
6 these studies dealing with
7 fluoropolymers is to point out
8 Conflicts of Interest by the authors;
9 correct?

10 A. No.

11 Q. Did you point that out?

12 A. I did.

13 Q. I'm going to ask you some
14 questions outside of my outline here
15 because there is some additional
16 comments that you made, so I'm going
17 to ask you some questions on various
18 topics:

19 If the Department does not
20 treat all PFAS the same, as you
21 previously indicated in your verbal
22 Testimony today, why is it requiring
23 PFAS Labeling for all PFAS, including
24 the exemptions?

25 A. That is the matter of Testimony



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 165

1 from Dr. Deb Dickerson, as well as the
2 Department's perspective that Labels
3 informed consumers.

4 Q. But it was your Testimony,
5 though, or critique that the Department
6 treats all PFAS the same, or it does
7 not treat all PFAS the same?

8 A. I'm rebutting the claim that we
9 did.

10 Q. And you still maintain that.

11 A. Correct.

12 Q. Dr. Chapman, as you stated,
13 NMED's purpose for the Proposed Rule is:

14 "... to turn off the
15 spigot of PFAS at its source."

16 Is that correct?

17 A. Yes.

18 Q. Does the Department intend to
19 discourage manufacturers of PFAS-
20 containing products from distribution
21 in New Mexico?

22 MR. SMITHKIER: Objection;
23 outside the scope.

24 MR. TRUJILLO: Madam Hearing
25 Officer, as the witness indicated, I



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 166

1 believe it goes into the Policy choices
2 they have made, and he has testified
3 extensively on various Policy choices.

4 HEARING OFFICER ORTH: Thank
5 you.

6 Dr. Chapman, can you answer the
7 question within the scope of your
8 earlier Testimony?

9 THE WITNESS: Can you repeat
10 the question?

11 Q. BY MR. TRUJILLO: Absolutely.

12 As you testified earlier,
13 NMED's purpose of the Proposed Rule
14 is:

15 "... to turn off the spigot
16 of PFAS at its source."

17 Is that correct?

18 A. Yes.

19 In my Testimony I have provided
20 that consumer products are one avenue
21 or source of PFAS in the environment.

22 Q. As part of that are you
23 intending to discourage manufacturers
24 of PFAS-containing products from
25 distribution in New Mexico?



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 167

1 A. I believe there is pathways for
2 the continued distribution of products
3 containing PFAS to operate under the
4 Currently Unavoidable Use proposal, and
5 there are exemptions as well.

6 Q. I don't remember whether I
7 asked, of these other states that you
8 talked to, did any of them indicate how
9 long it takes to get an Unavoidable
10 Use determination on average?

11 A. No.

12 Q. Do you have any idea as to how
13 long it's going to take in New Mexico,
14 or have you guys estimated that at all?

15 A. No.

16 Q. Dr. Chapman, are you aware of
17 any PFAS manufacturing within New
18 Mexico?

19 A. I don't know; I'm not sure.

20 MR. TRUJILLO: Can I have a
21 time check?

22 HEARING OFFICER ORTH: I was
23 about to tell you that you have about 3
24 minutes now.

25 MR. TRUJILLO: Thank you,



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 223

1 a study about cosmetic emissions in
2 Europe, and I mentioned other studies.
3 I think that was a 2023 article that I
4 pulled that figure from in my summary
5 today.

6 Q. Okay. A 2023 article on what
7 type of products?

8 A. Consumer products.

9 Q. And when you're using the term
10 "Consumer products," are you speaking
11 of any particular subset, or is that
12 the sort of panoply of "Consumer
13 products" at large?

14 A. As indicated by the Testimony
15 I provided this morning, that spans a
16 wide variety of different consumer
17 products. Some of those are cosmetics,
18 paints, and stuff like that.

19 Q. Okay. You do not attempt to
20 quantify the impact that's attributable
21 specifically to "Consumer products,"
22 do you.

23 A. I disagree.

24 Q. Could you specify where you
25 quantified the impact that is



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 224

1 attributable to "Consumer products"
2 and PFAS contamination in New Mexico?

3 A. I am speaking broadly about
4 that study about cosmetics in Europe
5 with respect to their relative
6 contribution to contamination.
7 Testimony with respect to New-Mexico-
8 specific effects of PFAS will be the
9 subject of another expert.

10 Q. Okay. Just to reorient I was
11 asking you about the catalyst for the
12 regulation, which was:

13 "... to avoid making
14 existing contamination issues
15 worse"; right?

16 A. Yes.

17 Q. And so presumably, as a New
18 Mexico regulatory body, you focused on
19 existing contamination issues in New
20 Mexico; right?

21 A. Again, part of the goal here is
22 "... to turn off the PFAS spigot" in
23 the state.

24 It is extremely difficult to
25 remediate diffuse pollution throughout



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 225

1 the environment, and so one of the
2 strategies is "... to turn off the
3 spigot..." through consumer products.

4 Q. Okay. Let's talk a little bit
5 about the Labeling provision:

6 The EIB is not required to
7 impose any Labeling requirement by
8 Statute, is it.

9 MR. SMITHKIER: Objection;
10 calls for a legal conclusion.

11 HEARING OFFICER ORTH: Your
12 response, Ms. Fiebig.

13 MS. FIEBIG: I think it's a
14 fair question. He's putting
15 substantial Testimony in his Written
16 Testimony about the Rulemaking process,
17 and his understanding is relevant to
18 the proceedings.

19 HEARING OFFICER ORTH: Thank
20 you.

21 Dr. Chapman, if you can answer
22 the question as a member of management
23 for a regulatory agency rather than as
24 a Lawyer, go ahead.

25 THE WITNESS: It is my



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 226

1 understanding that the EIB is
2 authorized to adopt Rules for Labeling
3 consumer products.

4 Q. BY MS. FIEBIG: Do you have an
5 understanding as to whether they are
6 required to impose Labeling
7 requirements?

8 A. It is not a requirement.

9 Q. And the purpose of the
10 Labeling provisions in the Proposed
11 Rule is to allow consumers to make
12 informed choices about the products
13 they bring into their home. Is that
14 fair?

15 A. I would say that Labels provide
16 some clarity to consumers as to what is
17 in their products.

18 Q. And you stated in your Written
19 Testimony, it's the Department's view
20 that Labeling is a:

21 "Critical piece of the
22 Rule that will help restrict
23 the flow of new PFAS from
24 entering the State"; right?

25 A. Yes.



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 300

1 substances;

2 Effectiveness as surfactants;

3 and,

4 Effectiveness in extinguishing
5 flammable liquid fires.

6 Key chemical considerations
7 with important implications for PFAS
8 management include:

9 The carbon-fluorine bond;

10 Chain length distinction
11 between PFAAs and PFAA precursors;
12 and,

13 Polymer versus non-polymer
14 chemistry.

15 The carbon-fluorine bond is
16 among the strongest bonds encountered
17 in organic chemistry and contributes
18 to the high chemical stability for
19 PFAS.

20 Chain length influences PFAS
21 mobility in water systems, treatment
22 efficacy, bioavailability and
23 bioaccumulation.

24 PFAAs are an important group
25 within the PFAS family that includes



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 301

1 most of the PFAS compounds that are
2 regulated and included in standard
3 analytical methods.

4 PFAA precursors present another
5 PFAS management challenge, as they can
6 play an important role in PFAS mobility
7 and contribute to increases in PFAA
8 concentrations after certain treatment
9 processes.

10 PFAS are produced in both
11 polymer and non-polymer forms, while
12 polymer PFAS are generally less mobile
13 than non-polymer PFAS. Non-polymer
14 PFAS might be used as processing aids
15 during fluoropolymer production, and
16 side-chain polymers may function as
17 PFAA precursors under certain
18 conditions.

19 Finally, our understanding of
20 PFAS chemistry and associated
21 implications have evolved considerably
22 over the last 15 years, and continue to
23 evolve as additional data becomes
24 available. The information provided
25 attempts to summarize the best



BEFORE HONORABLE FELICIA L. ORTH
VOL I HEARING,

Page 302

1 available information into the current
2 state of the science.

3 Those looking for more
4 information on PFAS nomenclature,
5 chemistry, fate and transport,
6 analytical methods, treatment
7 technologies, or other areas of
8 interest are referred to the ITRC
9 Guidance Document as a comprehensive
10 consensus-based resource.

11 Q. Thank you.

12 MR. KNIGHT: Madam Hearing
13 Officer, this witness is now available
14 for questions.

15 HEARING OFFICER ORTH: Thank
16 you very much, Mr. Knight and Dr. Olson.

17 Mr. Trujillo, or is it
18 Ms. Seluja?

19 All right. Thank you. Go
20 ahead.

21

22 CROSS-EXAMINATION

23 BY MS. SELUJA:

24 Q. Good afternoon, Dr. Olson; I'm
25 Ms. Seluja.



Exhibit 7

BEFORE HONORABLE FELICIA L. ORTH

Deposition of : VOL II HEARING

taken on: February 24, 2026



531 Harkle Road, Suite A
Santa Fe, NM 87505

505-984-2244

www.cumbrecourtreporting.com

BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

1 STATE OF NEW MEXICO
2 ENVIRONMENTAL IMPROVEMENT BOARD
3
4 IN THE MATTER OF PROPOSED) EIB NO.:
ADOPTION OF 20.13.2 NMAC,))
5 Per- and Poly-Fluoroalkyl) 25-61(R)
Substances in Consumer)
6 Products.)
_____)

7
8 BEFORE THE HONORABLE FELICIA L. ORTH
9
10 TUESDAY, FEBRUARY 24, 2026
11 9:02 A.M.
12 EVIDENTIARY HEARING VOLUME II

13 **CERTIFIED**
14 **TRANSCRIPT**
15
16
17
18
19

20 REPORTED BY:
21 DAVID M. LEE, RMR, CCR,
Certificate Number 50391
22 New Mexico CCR Number 537
Cumbre Court Reporting Services, LLC
513 Harkle Road
23 Suite A
Santa Fe, New Mexico 87505
24 (505) 984-2244
cumbrecourt@comcast.net
25



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 348

1 APPEARANCES

2 FOR THE ENVIRONMENTAL IMPROVEMENT BOARD:

3 SANDRA ELY, BOARD CHAIR

4 PHOEBE SUINA, BOARD VICE CHAIR

5 J. BARRY BITZER, BOARD MEMBER

6 GUADALUPE CARRASCO, BOARD MEMBER

7 RONALD CURRY, BOARD MEMBER

8 KAREN GARCIA, BOARD MEMBER

9 FELICIA L. ORTH, HEARING OFFICER
felicia.l.orth@gmail.com

10 NEW MEXICO DEPARTMENT OF JUSTICE

11 BY: EDUARDO UGARTE, II, ESQ.

12 BOARD COUNSEL
eugarte@nm DOJ.gov

13 Post Office Box 1508
Santa Fe, New Mexico 87504-1508
(505) 264-5741

14 FOR NEW MEXICO ENVIRONMENT DEPARTMENT:

15 NEW MEXICO ENVIRONMENT DEPARTMENT

16 BY: GREGORY S. SMITHKIER, ESQ.
gregory.smithkier@env.nm.gov

17 ANDREW P. KNIGHT, ESQ.
andrew.knight@env.nm.gov

18 MARK F. ROSEBROUGH, ESQ.
mark.rosebrough@env.nm.gov

19 PAMELA JONES, PARALEGAL
20 pamela.jones@env.nm.gov

21 LUIS LOPEZ, PARALEGAL
22 luis.lopez@env.nm.gov

23 1190 South St. Francis Drive
24 Suite N-4050
Albuquerque, New Mexico 87507
25 (505) 531-7736



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 349

1 FOR CROPLIFE AMERICA AND AMERICAN
CHEMISTRY COUNCIL:

2

GALLAGHER & KENNEDY, P.A.

3 BY: DALVA L. MOELLENBERG, ESQ.
dlm@gknet.com

4

ANTHONY J. TRUJILLO, ESQ.

5 ajt@gknet.com

6

SERAFINA SELUJA, ESQ.

serafina.seluja@gknet.com

7

1239 Paseo de Peralta

8 Santa Fe, New Mexico 87501-2758
(505) 989-7278

9

10 FOR PFAS PHARMACEUTICAL WORKING GROUP
(PPWG):

11 MODRALL, SPERLING, ROEHL, HARRIS &
SISK, P.A.

12 BY: STUART R. BUTZIER, ESQ.
stuart.butzier@modrall.com

13

STANLEY HARRIS, ESQ.

14 stan.harris@modrall.com

15

BENJAMIN C. ROSSI, ESQ.

benjamin.rossi@modrall.com

16

Post Office Box 2168

17 Albuquerque, New Mexico 87103-2168
(505) 848-1823

18 (505) 848-9710 (Facsimile)

19 FOR HOUSEHOLD & COMMERCIAL PRODUCTS
ASSOCIATION:

20

HOUSEHOLD & COMMERCIAL PRODUCTS

21 ASSOCIATION

BY: STEVEN BENNETT, PH.D.

22 Executive Vice President

SCIENTIFIC & REGULATORY AFFAIRS

23 sbennett@thehcupa.org

1625 I Street Northwest

24 Suite 700

Washington, D.C. 20006

25



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 350

1 FOR COMPLEX PRODUCTS MANUFACTURERS
COALITION:

2

WILEY REIN, L.L.P.

3 BY: HENRY M. RIVERA, ESQ.
hrivera@wiley.law

4

REBECCA J. FIEBIG, ESQ.
rfiebig@wiley.law

5

6 MARTHA MARRAPESE, ESQ.
marrapese@wiley.law

7 2050 M Street Northwest
Washington, D.C. 20036
8 (202) 719-7000

9 FOR ALLIANCE FOR AUTOMOTIVE INNOVATION:

10 WILEY REIN, L.L.P.
BY: HENRY M. RIVERA, ESQ.
11 hrivera@wiley.law

12 REBECCA J. FIEBIG, ESQ.
rfiebig@wiley.law

13

MARTHA MARRAPESE, ESQ.
14 marrapese@wiley.law

15 2050 M Street Northwest
Washington, D.C. 20036
16 (202) 719-7000

17 FOR BRUCE WETHERBEE, PRO SE:

18 BY: BRUCE WETHERBEE
editor@thecandlepublishing.com
19 60 Thoreau Street
Suite 103
20 Concord, Massachusetts 01742
(505) 501-1570

21

ALSO PRESENT: LISA O'GRADY
22 INTERPRETER

23 AMELIA CARDEÑA
INTERPRETER

24

MELINDA MAASS
25 INTERPRETER



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 383

1 Next slide.

2 What do all of these mean?

3 This is a bit of a summary slide. I
4 hope I've shown that PFAS are used in
5 many different products, including
6 products that we might encounter in
7 our homes and workplaces. When PFAS
8 are made, applied, used, and disposed
9 of, they can be emitted into the
10 environment throughout that life cycle.

11 We can be exposed to PFAS in
12 many different ways across different
13 pathways and different routes of
14 exposure, and yes, there are many
15 different PFAS. The vast majority of
16 PFAS have not been studied at all. In
17 fact, many of them have just been
18 discovered in the environment.

19 I am still learning about PFAS
20 that have been discovered in the
21 environment from my chemistry
22 colleagues. The ones that have been
23 studied have many concerns to
24 toxicologists, including adverse health
25 outcomes in exposed people and in



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 384

1 experimental rodent models.

2 It is inappropriate to assume
3 that those that have not yet been
4 studied are completely safe, because
5 data indicates that these understudied
6 PFAS do have toxicities similar to
7 those well-studied.

8 The National Toxicology
9 Program recently released data from
10 28-day studies of some shorter chain
11 PFAS, and they did acknowledge that the
12 potency of these PFAS was less than the
13 ones that are longer chain, but that
14 they still impacted the same systems as
15 the longer chain compounds. A shift
16 in potency just means it takes more of
17 the short-chain compound to create the
18 toxicity or produce the toxicity.

19 It is my opinion consumers
20 have the right to know what products
21 contain PFAS, even if the risk of
22 exposure to the PFAS in that product is
23 low. Some consumers might want to
24 protect their fellow people from being
25 exposed to the PFAS as they are



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 389

1 This is also factually incorrect.
2 PFAS had been used in Aqueous Film-
3 Forming Foams as flame suppressants.
4 This might seem like a minor
5 distinction, but it is actually a
6 quite serious distinction. Flame
7 retardants have very different
8 properties than flame suppressants.

9 Dr. Stanton also tries to
10 assert that short-chain PFAS are
11 without toxicological concern because
12 they're not as well-studied as the
13 longer chain or more well-studied
14 PFAS. I think in my direct Testimony
15 I write why I disagree with that.

16 She also asserts that consumers
17 are unlikely to be exposed to PFAS in
18 consumer products. There may be a low
19 likelihood of exposure from PFAS in
20 consumer products, but there is
21 evidence that PFAS are found in dust of
22 people's homes, and consumer products
23 would be the source of that dust.

24 This also assumes that
25 consumers aren't concerned about the



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 390

1 life cycle issues associated with PFAS.
2 Dr. Stanton also cited a Press
3 Release by the U.S. Food and Drug
4 Administration stating that PFAS in
5 medical devices was allowable, and so
6 she used that Press Release to assert
7 that fluoropolymers are without safety
8 concerns, where the U.S. FDA actually
9 stated that they found no conclusive
10 evidence of patient health issues
11 associated with fluoropolymers. They
12 found no reason that the continued use
13 of PFAS in medical devices should be
14 discontinued, but they also asserted
15 that they would continue to monitor
16 safety of medical devices.

17 Those are the points that I
18 have with respect to Dr. Stanton.

19 With respect to
20 Dr. Korzeniowski's Direct Testimony,
21 he includes references to 2 manuscripts
22 that assert PFAS shouldn't be grouped.
23 I was actually a co-author on 1 of
24 those manuscripts, it's an Anderson,
25 et al., manuscript, and I think he left



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 391

1 out some important details about that
2 manuscript:

3 The title of the manuscript
4 does assert that PFAS should not be
5 grouped, but the nuts and bolts of the
6 manuscript are specific to human health
7 risk assessments using toxicological
8 data.

9 I think I would agree we have
10 insufficient toxicological data to
11 group all PFAS by their toxicological
12 properties, but I have been part of
13 publications that indicate that
14 concerns about their persistence
15 warrants grouping them, and concerns
16 about their persistence warrants
17 grouping them, and concerns about their
18 persistence and/or bioaccumulation and/
19 or mobility and/or toxicity are
20 sufficient for grouping from a
21 scientific perspective.

22 I would also like to point out
23 that Dr. Korzeniowski's statement on
24 fluoropolymers also ignores life cycle
25 concerns that have been brought up in



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 415

1 talking about end of life?

2 A. (No audible response.)

3 Q. Could you be more specific as
4 to what you mean by "... life recycle
5 concerns...", with respect to consumer
6 products specifically?

7 A. On the slide that I had in my
8 Direct Testimony, which is actually
9 from a paper that I co-authored by
10 Lohmann, et al., it is a paper that
11 challenges the concept that
12 fluoropolymers are of low concern
13 because of these life cycle concerns.

14 One way that PFAS can be
15 emitted to the environment is when they
16 are produced by the companies that
17 manufacture PFAS.

18 Another way that PFAS can be
19 emitted into the environment is when
20 those PFAS are purchased by another
21 company and they are applied to a
22 product.

23 Probably one of the most well-
24 known cases is in Dalton, Georgia,
25 where PFAS had been applied to textiles.



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 416

1 Water was contaminated from the
2 application of the PFAS to the textiles
3 even though the carpet manufacturers
4 did not produce the PFAS.

5 There have also been studies to
6 indicate that when materials containing
7 PFAS are disposed of in landfills, for
8 example, PFAS can be detected in the
9 water from the landfill, known as
10 leachate.

11 As far as I understand, when
12 PFAS are manufactured and applied to
13 products, used, and disposed of, they
14 can be emitted into the environment
15 from a life recycle perspective.

16 Q. Got it.

17 With respect to fluoropolymers
18 in particular, the greatest source of
19 concern for contamination arises in
20 the manufacturing process, at the front
21 end when the product designer, or when
22 the PFAS itself is being created or
23 applied to a product, or at the end of
24 the product's life when it is being
25 disposed of. Is that fair?



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 417

1 A. Given our current state of
2 scientific understanding of
3 fluoropolymers and how they behave,
4 yes.

5 I, as a consumer, would want to
6 know whether or not a product I am
7 purchasing had those life cycle
8 concerns, and it would allow me to make
9 an informed decision about my own
10 personal environmental footprint.

11 Q. Okay.

12 In terms of the risk of
13 potential contamination in your home,
14 would you agree that the risk is
15 relatively low, assuming you've
16 purchased that product and brought it
17 into your home after the time that the
18 manufacturer has completed it and
19 before the time that it is potentially
20 going into a landfill?

21 A. If I assume my home is a bubble
22 and my actions have no impact on people
23 in the environment around me, then yes,
24 my risk from exposure in my own home to
25 those PFAS in consumer products is



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 418

1 likely low.

2 However, why not give me the
3 opportunity to make a choice to reduce
4 my exposure in the places that I can
5 reduce my exposure? Because I likely
6 can't reduce my exposure to PFAS in
7 contaminated drinking water or
8 contaminated food, or in the air.

9 Q. Sure.

10 Do you think it would be
11 helpful to have that level of context
12 for you to be able to make an informed
13 decision as to whether this particular
14 product was presenting you with a
15 direct risk of a health outcome, you
16 know, a toxicological concern, versus
17 a broader environmental concern?

18 A. (No audible response.)

19 Q. In other words do you see a
20 distinction between those?

21 A. I do see a distinction.

22 As a scientist who studies PFAS I
23 am often very frustrated on how
24 challenging it is to get information on
25 what products I bring into my home or



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 429

1 A. That's correct.

2 Q. And the basis of your concern
3 is that "risk" is a term of art and
4 encompasses a balance of hazard and
5 exposure; right?

6 A. That is how I use it as a
7 toxicologist, yes.

8 Q. And of course you don't know
9 whether Ms. Marrapese intended to use
10 that as a toxicologist; right?

11 A. She made assertions that led me
12 to understand she was talking about
13 hazards from the toxicological
14 properties of PFAS.

15 Q. Okay. And whether something
16 is hazardous is not dependant on
17 exposure; right?

18 A. Hazard is an inherent property.

19 Q. Yeah, if it's hazardous, it's
20 hazardous, and that's kind of the end
21 of it.

22 A. That's my understanding.

23 Q. But exposure is the factor that
24 goes into the assessment of risk;
25 right?



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 430

1 A. Exposure is a feature of
2 understanding risk to a hazard, yes.

3 Q. And that's because the degree
4 to which a hazard is likely to be
5 harmful to humans or the environment
6 depends on the level of exposure that
7 humans or the environment have to that
8 hazard; right?

9 A. If we want to qualify or
10 quantify risk, exposure is a feature of
11 that.

12 Q. Okay. So you would agree that
13 impacts associated with hazards might
14 be limited if there is limited exposure.

15 A. If there is zero exposure,
16 there is zero risk to a hazard.

17 Q. And if -- okay.

18 If there is limited exposure,
19 would that potentially also limit the
20 risk?

21 A. I think I asserted that in my
22 Written Rebuttal to Ms. Marrapese's
23 Testimony that risk can be increased
24 or decreased by increases or decreases
25 in exposure.



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 431

1 Q. Okay. What is the proper
2 terminology if "less risky" is not the
3 correct term?

4 A. Low risk/high risk/medium risk.

5 Q. Okay.

6 A. She could have quantified
7 "risk," too, in terms of a percentage,
8 but that would have taken a great deal
9 of effort.

10 MS. FIEBIG: I'm just looking
11 through some of the notes that I took
12 from the Testimony today.

13 Q. You mentioned earlier that PFAS
14 is in a lot of products; right?

15 A. To the best of my knowledge,
16 yes.

17 Q. Would you agree that's because
18 they have unique properties?

19 A. I wish I knew the answer to
20 that because PFAS seem to be in many
21 products, but we, as a scientific
22 community, don't always fully
23 understand why PFAS was added to the
24 product.

25 I'm part of a group that wrote



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 435

1 and again this is my interpretation of
2 the Stewardship Agreement, was that
3 PFAS with fewer carbons, compared to
4 PFOA and PFOS, had fewer toxicological
5 concerns based on the evidence
6 available at the time of the
7 Stewardship Agreement.

8 Q. Okay. Is there a comparable
9 study being done on fluoropolymers?

10 A. I don't know if the National
11 Toxicology Program is exploring
12 fluoropolymers.

13 I know that the U.S. FDA
14 recently came out with a lengthy report
15 on the use of fluoropolymers in
16 cosmetics. My evaluation of that
17 report indicates that not all
18 toxicities have been explored for
19 fluoropolymers, but I'm not aware of
20 any scientists right now conducting
21 those studies to fill the gap.

22 MS. FIEBIG: Okay. I think I
23 may be done, but if I may just have a
24 moment to confer with my Co-Counsel.

25 HEARING OFFICER ORTH: Yes.



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 436

1 MS. FIEBIG: Thank you.

2 Q. BY MS. FIEBIG: Dr. DeWitt, I
3 just have one more question. I wanted
4 to get a little bit more clarity on
5 the life cycle concerns that you were
6 talking about with fluoropolymers in
7 particular:

8 I know that one concern is at
9 the end of life, fluoropolymers may end
10 up in a landfill and potentially
11 degrade into some other substance. Is
12 that fair?

13 A. Yes.

14 Q. I think you indicated that
15 fluoropolymers degrade to nanoplastics
16 and microplastics. Is that right?

17 A. There is at least one study
18 that I cite in my report that indicates
19 that PTFE is part of the milieu of
20 compounds that could be classified as
21 micro- and nanoplastics.

22 Q. Okay. Is there evidence that
23 fluoropolymers degrade to the long-
24 chain persistent PFAS?

25 A. I believe that there have been



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 437

1 scientific studies demonstrating that
2 when they are incinerated, there can
3 be PFAS, long-chain and short-chain,
4 that degrade.

5 Evidence from landfill leachate
6 indicates that the PFAS found in
7 landfill leachate likely arise from
8 fluoropolymers or side-chain
9 fluorinated polymers.

10 MS. FIEBIG: All right. Thank
11 you.

12 No further questions.

13 HEARING OFFICER ORTH: Thank
14 you, Ms. Fiebig.

15 Mr. Butzier, do you have any
16 questions?

17 MR. BUTZIER: Thank you, Madam
18 Hearing Officer, Members of the Board.

19 Thank you, Dr. DeWitt, for your
20 Testimony and welcome to New Mexico.

21 I'm Stuart Butzier and I represent
22 PPWG in this proceeding, and I just
23 have a few questions.

24 ///

25 ///



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 438

1 CROSS-EXAMINATION

2 BY MR. BUTZIER:

3 Q. My question: Is it your
4 understanding that the Rule, as
5 proposed by the New Mexico Environment
6 Department, contains certain exemptions
7 from phaseout requirements, reporting
8 requirement, and labeling requirements?

9 MR. SMITHKIER: Objection,
10 your Honor; calls for a legal opinion.

11 HEARING OFFICER ORTH: So
12 Dr. DeWitt, do not offer a legal
13 opinion, since I understand that's not
14 your expertise.

15 However, knowing that this is
16 establishing a regulatory program, to
17 the extent you have something to offer
18 to those who are looking for what it
19 would mean as a regulator, you can
20 answer.

21 THE WITNESS: To the best of my
22 understanding there are various
23 exemptions under the Labeling
24 requirement, and that's all that I
25 understand.



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 602

1 The Universal Product Code or
2 the UPC bar code;

3 The on-product label; and,
4 The sales unit label.

5 The findings were that "Label-
6 Related Costs" occur only once in a
7 product's life cycle and that this
8 will not increase the ongoing
9 production costs.

10 On the next slide, in doing
11 this review, they found 6 relevant
12 genetically engineered "Label-Related
13 Cost" studies. Now this is back in
14 2014 when all of this was just being
15 discussed by different states so there
16 were not that many studies, but they
17 found 6. They converted all of the
18 cost data to per capita values such
19 that they could end up with a cost per
20 consumer.

21 The median cost associated with
22 labeling GE-containing products were
23 found to be \$2.30 per consumer as a 1-
24 time cost.

25 The authors stated that their



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 616

1 my understanding.

2 I'm not an expert on GE foods,
3 but from my reading, that is my
4 understanding.

5 Q. That class of products as
6 opposed to a broad range, potentially,
7 of products.

8 A. Well that is a broad range of
9 products.

10 Q. Limited to food products.

11 A. But in the food sector, yes.

12 Q. Yes.

13 In the second column of that
14 table it lists a range of costs in, as
15 I read it, "Dollars Per State Or
16 Country." Is that correct?

17 A. That is correct. Some of these
18 were nationwide analyses and some were
19 regional or state-specific.

20 Q. I was just trying to make
21 sense of that for myself.

22 A. Yeah.

23 Q. Would you agree it looks like
24 that shows a range of \$6.3 million
25 to \$950 million per state or country?



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 617

1 A. Yes. Yes.

2 Q. Then it looks like they just
3 divided those numbers by the population
4 of a particular state, as shown in the
5 fourth column, to get to "Per Capita
6 Cost." Is that how that --

7 A. Yeah. Yeah.

8 Q. -- works? Okay.

9 A. And then they adjusted the cost
10 for 2014 dollars.

11 Q. Yeah, fair enough.

12 Those cost ranges are \$0.32 to
13 around \$0.15 per capita; right?

14 A. That's correct.

15 Q. Okay. Again, I'm just trying
16 to figure out how this would compare
17 to what would happen under this Rule.
18 I don't know if it's very easy to
19 compare, but there is obviously some
20 pretty high costs here.

21 Now the "Per Capita
22 Costs" -- well I'm not going to ask
23 that.

24 I don't know if I can sort
25 this out any further, but let's see.



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 618

1 In your conclusion you state
2 that in your view:

3 "The consuming public has
4 a right to know about these
5 hazards and the products that
6 contain them."

7 That statement assumes that
8 there are, of course, hazards in the
9 products. Is that fair?

10 A. Yeah, you know, I would have
11 to say that might be a bit of a typo.
12 You know, I suppose I should have
13 said, you know, they have a right to
14 know of the presence of these materials
15 in their products.

16 Q. Regardless of whether the
17 products pose any hazards.

18 A. Well it's my understanding that
19 this label is not designed to
20 communicate about hazards, it's just
21 designed to communicate about their
22 presence in these products.

23 Q. Is it your understanding that
24 the Department's intent is to deter
25 consumers from purchasing products



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 619

1 labeled with PFAS?

2 A. I don't really know an answer
3 to that.

4 Q. Okay. Fair enough.

5 Let me take a quick look, but
6 I believe that's all my questions.

7 Let me check a message here.

8 Yeah, thank you,

9 Dr. Dickerson.

10 MR. MOELLENBERG: That's all
11 my questions.

12 THE WITNESS: Thank you.

13 HEARING OFFICER ORTH: Thank
14 you, Mr. Moellenberg.

15 Ms. Fiebig, do you have
16 questions?

17 MS. FIEBIG: Yes, Madam
18 Hearing Officer. Thank you.

19

20 EXAMINATION

21 BY MS. FIEBIG:

22 Q. Good afternoon, Dr. Dickerson.

23 I'm Rebecca Fiebig and I'm here on

24 behalf of the Complex Products

25 Manufacturers Coalition and the



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 629

1 shaking your head. You are certainly
2 free to say that you don't have an
3 opinion, or what you might need to do
4 to form an opinion. If it's outside
5 the scope of your Testimony, just say
6 that.

7 THE WITNESS: Yeah, that's
8 outside the scope.

9 While I did see that phrase, I
10 don't have enough information to answer
11 that question.

12 Q. BY MS. FIEBIG: Okay. In your
13 experience, do most consumers assume
14 that a substance is harmful if it's
15 identified on a label?

16 A. I'm sorry; can you repeat the
17 question?

18 Q. I said in your experience do
19 most consumers assume that a substance
20 is harmful if it is identified on the
21 label?

22 A. No.

23 Q. I think you provided in your
24 report that 50% of respondents have
25 never heard of PFAS; right?



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 630

1 A. That's right.

2 Q. And another 30% have heard the
3 term, but they have no idea what it is;
4 right?

5 A. Right.

6 Q. The Environment Department is
7 proposing to add an image of a flask
8 with "PFAS" in it on product labels.
9 Do you believe consumers will perceive
10 that as a suggestion that the product
11 may cause harm?

12 A. I do not. I believe that will
13 convey the message that there is a
14 chemical that goes by the acronym or
15 initials "PFAS" in this product.
16 That's the totality of that message.

17 Q. In a universe where the public
18 doesn't even know what PFAS is, do you
19 think that telling them simply that the
20 product contains PFAS is informative?

21 A. That's a very good question:

22 I don't know the answer to
23 that, but I would conjecture that might
24 prompt some to seek more information.

25 Q. Okay. Would you expect



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 631

1 consumers to maybe go to the
2 Environment Department's website to get
3 more information?

4 A. I don't know; I can't answer
5 where they would go, yeah.

6 Q. Okay.

7 I believe you said you have
8 looked at the current proposed Labeling
9 provisions in subsection C(1) to put
10 in the flask with "PFAS."

11 A. Yes, uh-huh.

12 Q. Do you think that is sufficient
13 from a design perspective to constitute
14 an effective label?

15 A. I do. I do. I think...

16 Would you like me to go into
17 more detail about what I see there
18 that's beneficial --

19 Q. Yes, please.

20 A. -- to design an effective
21 label?

22 I'm looking at the Rule at
23 Section...

24 Q. Are you looking at Exhibit 69?

25 A. I am looking at the Labeling



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 632

1 section, so 20.13.2.13, paragraph to
2 be determined.

3 Q. I was asking you about C(1).

4 A. Yeah, C.

5 Okay. It says that the label
6 should clearly inform the consumer
7 that the product contains that
8 substance.

9 It talks about 2 languages,
10 which is good, so that's looking at
11 comprehensibility of the label.

12 It says there should be a
13 pictogram, as we just discussed, of an
14 Erlenmeyer flask with the initials
15 "PFAS." I think that would be an
16 excellent element that would convey to
17 the consumer that there is a chemical
18 that they might want to know about.

19 It does discuss conspicuousness
20 at the bottom of that paragraph, and it
21 goes into several requirements for
22 conspicuousness which I identified in
23 my Testimony as being very important.

24 Then what I liked was that it
25 does discuss Paragraph 4 where the



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 633

1 consumer is unable to view the labels
2 on the product or consumer packaging
3 at the time of purchase because they
4 are making an online purchase, or a
5 catalog purchase, or over the telephone,
6 so it covers all of the bases, and they
7 should be provided that information.

8 This is that last key factor I
9 was talking about, or the remote or
10 online information.

11 Q. "Promotional Preactivation."

12 A. Thank you.

13 Q. Yeah, I think there is also a
14 provision in here saying:

15 "The text shall be no
16 smaller than the font used
17 for other consumer information
18 on the products."

19 A. Right.

20 Q. I'm guessing that's the
21 "Conspicuousness" component.

22 A. "Conspicuousness" and
23 "Comprehension." That would go to both
24 of those, yeah.

25 Q. Okay. Let's talk about cost;



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 645

1 A. I was just looking at this
2 analysis that EConorthwest had done.
3 There were...

4 I did try to find analyses of
5 PFAS labeling, but as you know there is
6 just a couple of states that are
7 considering that at this time, so there
8 was really not an opportunity to do
9 those studies. I was trying to find
10 an analog, and the GE labeling seemed
11 similar enough.

12 Again, it was hard to find
13 studies on that, so I found this one
14 just to give us a rough thumbnail
15 sketch of what the cost ballpark might
16 be.

17 Q. Okay.

18 MS. FIEBIG: May I have one
19 moment to confer with my Co-Counsel?

20 HEARING OFFICER ORTH: Yes,
21 and you have 4 minutes.

22 MS. FIEBIG: Oh, well...

23 Q. I think I have 1 more question:

24 Are there other mechanisms
25 through which the State could provide



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 646

1 information about the contents of PFAS
2 products to their citizens besides
3 putting it on the product label?

4 A. My expertise is in product
5 labeling, so I don't really feel like
6 I can speak to other methods of
7 communication.

8 MS. FIEBIG: Okay. Thank you
9 so much.

10 HEARING OFFICER ORTH: Thank
11 you, Ms. Fiebig.

12 Mr. Butzier, do you have
13 questions?

14 MR. BUTZIER: No questions.

15 HEARING OFFICER ORTH: He
16 said, "No questions."

17 Mr. Wetherbee, do you have
18 questions of Dr. Dickerson?

19 MR. WETHERBEE: I do, Madam
20 Hearing Officer. Thank you.

21

22 CROSS-EXAMINATION

23 BY MR. WETHERBEE:

24 Q. Dr. Dickerson, thank you very
25 much for your Testimony.



BEFORE HONORABLE FELICIA L. ORTH
VOL II HEARING,

Page 647

1 I would like to kind of visit
2 a little bit about some of the other
3 areas you're an expert in".

4 You're a Certified Industrial
5 Hygienist. Is that correct?

6 A. That's correct.

7 Q. And currently certified. Is
8 that correct?

9 A. That's correct.

10 Q. And Certified Safety
11 Professional for over 20 years. Is
12 that correct?

13 A. Yeah, I guess so.

14 I don't remember the date, but
15 yes, it's about that long.

16 Q. Well it says:

17 "2003 to present"; correct?

18 A. Yes, that's correct.

19 Q. And Certified Hazardous
20 Material Manager. Is that correct?

21 A. That's not current; I let that
22 lapse in 2021, but yes.

23 Q. But you had extensive
24 experience in that area; is that fair
25 to say?



Exhibit 8

BEFORE HONORABLE FELICIA L. ORTH

Deposition of : VOL III HEARING

taken on: February 25, 2026



531 Harkle Road, Suite A
Santa Fe, NM 87505

505-984-2244

www.cumbrecourtreporting.com

BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

1 STATE OF NEW MEXICO
2 ENVIRONMENTAL IMPROVEMENT BOARD
3
4 IN THE MATTER OF PROPOSED) EIB NO.:
ADOPTION OF 20.13.2 NMAC,))
5 Per- and Poly-Fluoroalkyl) 25-61(R)
Substances in Consumer)
6 Products.)
_____)

7
8 BEFORE THE HONORABLE FELICIA L. ORTH
9
10 WEDNESDAY, FEBRUARY 25, 2026
11 9:00 A.M.
12 EVIDENTIARY HEARING VOLUME III

13 **CERTIFIED**
14 **TRANSCRIPT**
15
16
17
18
19

20 REPORTED BY:
21 DAVID M. LEE, RMR, CCR,
Certificate Number 50391
22 New Mexico CCR Number 537
Cumbre Court Reporting Services, LLC
513 Harkle Road
23 Suite A
Santa Fe, New Mexico 87505
24 (505) 984-2244
cumbrecourt@comcast.net
25



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 736

1 APPEARANCES

2 FOR THE ENVIRONMENTAL IMPROVEMENT BOARD:

3 SANDRA ELY, BOARD CHAIR

4 PHOEBE SUINA, BOARD VICE CHAIR

5 J. BARRY BITZER, BOARD MEMBER

6 GUADALUPE CARRASCO, BOARD MEMBER

7 RONALD CURRY, BOARD MEMBER

8 KAREN GARCIA, BOARD MEMBER

9 FELICIA L. ORTH, HEARING OFFICER
felicia.l.orth@gmail.com

10 NEW MEXICO DEPARTMENT OF JUSTICE

11 BY: EDUARDO UGARTE, II, ESQ.

12 BOARD COUNSEL
eugarte@nm DOJ.gov

13 Post Office Box 1508
Santa Fe, New Mexico 87504-1508
(505) 264-5741

14 FOR NEW MEXICO ENVIRONMENT DEPARTMENT:

15 NEW MEXICO ENVIRONMENT DEPARTMENT

16 BY: GREGORY S. SMITHKIER, ESQ.
gregory.smithkier@env.nm.gov

17 ANDREW P. KNIGHT, ESQ.
18 Andrew.knight@env.nm.gov

19 MARK F. ROSEBROUGH, ESQ.
20 mark.rosebrough@env.nm.gov

21 PAMELA JONES, PARALEGAL
pamela.jones@env.nm.gov

22 LUIS LOPEZ, PARALEGAL
23 luis.lopez@env.nm.gov

24 1190 South St. Francis Drive
Suite N-4050
Albuquerque, New Mexico 87507
25 (505) 531-7736



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 737

1 FOR CROPLIFE AMERICA AND AMERICAN
CHEMISTRY COUNCIL:

2

GALLAGHER & KENNEDY, P.A.

3 BY: DALVA L. MOELLENBERG, ESQ.
dlm@gknet.com

4

ANTHONY J. TRUJILLO, ESQ.

5 ajt@gknet.com

6

SERAFINA SELUJA, ESQ.

serafina.seluja@gknet.com

7

1239 Paseo de Peralta

8 Santa Fe, New Mexico 87501-2758
(505) 989-7278

9

10 FOR PFAS PHARMACEUTICAL WORKING GROUP
(PPWG):

11 MODRALL, SPERLING, ROEHL, HARRIS &
SISK, P.A.

12 BY: STUART R. BUTZIER, ESQ.
stuart.butzier@modrall.com

13

STANLEY HARRIS, ESQ.

14 stan.harris@modrall.com

15

BENJAMIN C. ROSSI, ESQ.

benjamin.rossi@modrall.com

16

Post Office Box 2168

17 Albuquerque, New Mexico 87103-2168
(505) 848-1823

18 (505) 848-9710 (Facsimile)

19 FOR HOUSEHOLD & COMMERCIAL PRODUCTS
ASSOCIATION:

20

HOUSEHOLD & COMMERCIAL PRODUCTS

21 ASSOCIATION

BY: STEVEN BENNETT, PH.D.

22 Executive Vice President

SCIENTIFIC & REGULATORY AFFAIRS

23 sbennett@thehcpa.org

1625 I Street Northwest

24 Suite 700

Washington, D.C. 20006

25



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 738

1 FOR COMPLEX PRODUCTS MANUFACTURERS
COALITION:

2

WILEY REIN, L.L.P.

3 BY: HENRY M. RIVERA, ESQ.
hrivera@wiley.law

4

5 REBECCA J. FIEBIG, ESQ.
rfiebig@wiley.law

6 MARTHA MARRAPESE, ESQ.
marrapese@wiley.law

7 2050 M Street Northwest
Washington, D.C. 20036
8 (202) 719-7000

9 FOR ALLIANCE FOR AUTOMOTIVE INNOVATION:

10 WILEY REIN, L.L.P.
BY: HENRY M. RIVERA, ESQ.
11 hrivera@wiley.law

12 REBECCA J. FIEBIG, ESQ.
rfiebig@wiley.law

13

MARTHA MARRAPESE, ESQ.
14 marrapese@wiley.law

15 2050 M Street Northwest
Washington, D.C. 20036
16 (202) 719-7000

17 FOR BRUCE WETHERBEE, PRO SE:

18 BY: BRUCE WETHERBEE
editor@thecandlepublishing.com
19 60 Thoreau Street
Suite 103
20 Concord, Massachusetts 01742
(505) 501-1570

21

ALSO PRESENT: LISA O'GRADY
22 INTERPRETER

23 AMELIA CARDEÑA
INTERPRETER

24

MELINDA MAASS
25 INTERPRETER



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 739

1	I N D E X	
2	EXAMINATION	PAGE
3	RICHARD T. MELSTROM, PH.D.	
4	Direct Examination By	
	Mr. Rosebrough	753
5	Cross-Examination By	
6	Mr. Moellenberg	768
7	Cross-Examination By Ms. Fiebig	772
8	CABINET SECRETARY JAMES C. KENNEY	
9	Direct Examination By	
	Mr. Smithkier	790
10	Cross-Examination By Mr. Trujillo	814
11	Cross-Examination By Mr. Wetherbee	861
12	Redirect Examination By	
13	Mr. Smithkier	888
14	Examination By Vice Chair Suina	888
15	Examination By Chair Ely	901
16	Examination Continued By	
	Chair Ely	954
17	Examination By Board Member Curry	968
18	Examination By Mr. Ugarte	975
19	Examination Continued By	
20	Vice Chair Suina	990
21	MANOJIT BASU, PH.D.	
22	Direct Examination By Mr.	
	Trujillo	1001
23	Cross-Examination By	
24	Mr. Rosebrough	1006
25		



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 740

1 ALEX STANTON, PH.D.
2 MARTHA MARRAPESE, ESQ.
3 KEMBA SOLOMON
4 Direct Examination By Ms. Fiebig 1013
5 Cross-Examination By
Mr. Rosebrough 1069
6 Cross-Examination By
7 Mr. Smithkier 1098
8 KEMBA SOLOMON 1119
9 Redirect Examination By Ms. Fiebig
10
11 MARTHA MARRAPESE, ESQ.
12 Redirect Examination By Ms. Fiebig 1122
13

14 E X H I B I T S
15 NUMBER DESCRIPTION PAGE
16 CPMC Document Bearing Title, 1065
Exhibit 1 "Written Technical
17 Testimony of Alex
Stanton Ph.D.," in Re
18 EIB 25-61(R) (5 Pages)
19 CLA Document Depicting 1010
Exhibit 1 Curriculum Vitae Re
20 Manojit Basu, Ph.D.,
21 Vice President/Chief
22 Science & Food Safety
Executive, in Re EIB
25-61(R) (2 Pages)
23 CLA Document Bearing Title, 1010
Exhibit 2 "Direct Testimony of
24 Dr. Manojit Basu on
25 Behalf of CropLife
America (CLA)," Dated



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 790

1 DIRECT EXAMINATION

2 BY MR. SMITHKIER:

3 Q. Secretary Kenney, where are
4 you employed?

5 A. The New Mexico Environment
6 Department.

7 Q. How long have you been employed
8 there and what is your current
9 position?

10 A. Seven years, or just over
11 7 years, and my current position is
12 Cabinet Secretary.

13 Q. Can you briefly describe your
14 education and professional
15 qualifications for us.

16 A. Sure.

17 As indicated on my Resumé I
18 hold a Master's in Environmental
19 Engineering from Temple University in
20 Philadelphia; and,

21 A Bachelor of Science in
22 Environmental Engineering and
23 Technology also from Temple University.

24 In terms of my professional
25 qualifications I have 3 decades of



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 791

1 federal and state regulatory experience
2 in developing and implementing:

3 Laws;
4 Regulations;
5 Policies; and,
6 Budgets.

7 My professional experience
8 stems from over 20 years of employment
9 at U.S. EPA, but I've also worked as a
10 consultant to the U.S. Department of
11 Justice Environment and Natural
12 Resource Division, as well as an
13 environmental consulting firm in
14 Denver, McCoy & Associates.

15 Q. Thank you.

16 Did you file Direct and
17 Rebuttal Written Testimony in this
18 matter?

19 A. Yes.

20 Q. Do you have any corrections
21 you would like to make to that Written
22 Testimony?

23 A. No.

24 Q. Do you adopt that Written
25 Testimony as your Testimony here today?



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 792

1 A. Yes.

2 Q. Thank you.

3 Will you please provide us with
4 a summary of your Written Testimony.

5 A. Sure.

6 In summary, my Written
7 Testimony focuses on 3 broad areas:

8 First, the Testimony makes the
9 case for turning off the spigot to
10 protect public health, the environment,
11 and our economy.

12 The PFAS Protection Act and
13 the Rebuttal Rule target the sources
14 of PFAS pollution by phasing out and
15 prohibiting the sale of consumer
16 products containing intentionally added
17 PFAS, such as:

18 Cookware;

19 Textiles; and,

20 Furniture.

21 Without stopping PFAS
22 contamination at its source, the State
23 will likely continue to incur greater
24 liabilities.

25 Second, my Written Testimony



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 793

1 focuses on safeguarding New Mexico's
2 economy:

3 PFAS contamination risks:

4 New Mexico's \$3.7 billion
5 agricultural industry;

6 Our \$2.4 billion outdoor
7 recreation industry; and,

8 The municipal and private
9 sector infrastructure related to
10 drinking water, wastewater, and waste
11 management.

12 Third, my Written Testimony
13 focuses on the implementation and
14 administration of the Act and Rebuttal
15 Rule:

16 Consistent with State law and
17 budget direction, NMED is pursuing a
18 Fee-based approach to ensure that
19 manufacturers, rather than taxpayers,
20 cover the cost of implementation.

21 Q. Thank you.

22 How has the Department changed
23 during your tenure relevant to the
24 implementation of this Rule?

25 A. The Department has changed



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 794

1 significantly over the last 7 years.

2 Our budget has grown from \$90 million

3 in 2019, to over \$235 million currently.

4 Our workforce has also grown

5 from over 500 employees in 2019, to

6 close to 700 employees today. Those

7 budget and staffing increases reflect

8 an expanding mission of the Department

9 through an increase in federal programs,

10 and an ever-expanding breadth of State

11 programs.

12 The increases in budget and

13 staffing also reflect the urgency by

14 which the Governor, the Legislature,

15 and consumers expect the Department to

16 take proactive approaches to protecting

17 communities and our economy for current

18 and future generations.

19 To do so the Department has

20 developed advanced new laws, rules,

21 and programs all while modernizing its

22 operations to improve our performance.

23 These modernization efforts include

24 things like:

25 Paperless processing to



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 795

1 expedite services we render;
2 Rulemaking efforts;
3 Report submissions;
4 Fee payments; and,
5 Public record requests just to
6 highlight a few.

7 Q. Can you tell us why NMED is
8 focusing specifically on consumer
9 products rather than just cleaning up
10 existing water contamination?

11 A. Yes.

12 To use a term that we've heard
13 a lot in this hearing, because turning
14 off the spigot is the only affordable
15 way to prevent PFAS contamination. The
16 signing of the PFAS Protection Act into
17 law was the endorsement of this
18 approach by the Governor and the
19 Legislature.

20 Merely addressing water
21 contamination at a home or business is
22 just a Band-Aid. Remediating
23 groundwater does not prevent
24 recontamination of the same groundwater.
25 We must continue to address the source



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 796

1 of PFAS contamination.

2 Q. Can you give the Board concrete
3 examples of how PFAS has already harmed
4 New Mexico's economy and its citizens?

5 A. Yes, and these impacts are
6 staggering to say the least:

7 In 2022 a fifth-generation New
8 Mexico dairy farmer had to euthanize
9 his entire herd of 3600 dairy cows due
10 to PFAS poisoning.

11 Neighbors have literally lost
12 the farm in terms of their property
13 values.

14 In the tourism and recreation
15 sectors we have seen unprecedented
16 levels of contamination in wildlife
17 around Lake Holloman, and impacting
18 areas adjacent to White Sands National
19 Park.

20 Most recently we discovered a
21 groundwater plume affecting 1 in 3
22 homes in La Cieneguilla and La Cienega
23 communities just outside of Santa Fe.
24 That plume has devastated those
25 families as well as their home values.



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 837

1 Is that correct?

2 A. That was correct at that time.

3 Q. Just to be clear, the \$1.4

4 million was just to implement all

5 aspects of the PFAS Protection Act

6 without the additional requirement of

7 Labeling; correct?

8 A. I would need to confirm that

9 the Fiscal Impact Report we submitted

10 was not updated post the revision to

11 the committee sub in order to line up

12 your question about the \$1.4 million

13 and when Labeling was required.

14 Now that I'm saying that out

15 loud, it probably...

16 Well I'm not going to speculate;

17 I would just need to verify.

18 Q. I believe if I represented to

19 you that the FR was updated and went

20 from \$1.4 to \$1.8 million, would you

21 have any reason to disagree with me on

22 that?

23 MR. SMITHKIER: Objection;

24 calls for speculation.

25 HEARING OFFICER ORTH: You're



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 838

1 right; he's already said he won't
2 speculate.

3 Q. BY MR. TRUJILLO: At that
4 point in time did you have an estimate
5 that you gave to the Legislative
6 Finance Committee as to what it would
7 cost to implement the Labeling portion?

8 A. We tend not to.

9 We provide a Fiscal Impact
10 Report based on the totality of our
11 understanding of what the Act says and
12 not portions thereof, so I wouldn't be
13 able to break down the Labeling portion
14 separate from the total for the Act
15 itself.

16 I don't believe I included our
17 Fiscal Impact Reports as part of my
18 Testimony, and I don't...

19 That's probably as far as I can
20 go on the Fiscal Impact Report and its
21 broad statements related to the Act, as
22 opposed to portions thereof.

23 Q. In Exhibit 57, on pages 6 and
24 7, you indicate that the Legislature
25 did not provide you with recurring



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 839

1 General Fund revenue to implement the
2 PFAS Act, instead the Legislature
3 provided you startup funding. Is that
4 correct?

5 A. That is correct.

6 Q. And that was for \$1 million to
7 get things set up. Is that correct?

8 A. That's correct.

9 Q. Is it really going to cost you
10 a million bucks?

11 A. Maybe; it depends on how long
12 this goes on for.

13 In all seriousness, with the
14 appropriation we received, you heard a
15 number of people moving into new roles
16 who are experts. You heard from
17 Dr. Eric Chapman, who was a hire that
18 got started under this money.

19 We have an ERG contract that
20 got started under this funding to
21 build the IT system.

22 This hearing would be inclusive
23 of paying for that.

24 The work that our team has done
25 to go across the country and meet with



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 954

1 DR. BASU: I can wait for
2 another 30 minutes.

3 MR. TRUJILLO: Thank you very
4 much. Thanks for accommodating the
5 Secretary; I appreciate that.

6 HEARING OFFICER ORTH: Thank
7 you.

8 Let's see if we can wrap up
9 the Secretary's examination in that
10 time.

11 Thank you, Mr. Secretary, for
12 rejoining us here at the front.

13 When we broke, Chair Ely was
14 pursuing her line of Examination.

15 Go ahead, Chair.

16 CHAIR ELY: Thank you, Madam
17 Hearing Officer and Secretary.

18

19 EXAMINATION CONTINUED

20 BY CHAIR ELY:

21 Q. When we broke I asked a very
22 poorly worded question about Labeling
23 in asking you to compare the
24 requirements in the Proposed Rule
25 regarding Labeling with Labeling



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 955

1 requirements in other states if you
2 know them. In particular I was
3 interested in whether other states were
4 requiring products that were exempt
5 from distribution and sale to also be
6 labeled. Do you have an answer to
7 that?

8 A. Yes, thank you, Chair Ely. I
9 appreciate having something to do over
10 lunch.

11 Just a quick synopsis:

12 There are various Labeling
13 requirements out there, specifically
14 Colorado and Connecticut might be more
15 analogous. Minnesota -- what am I
16 saying?

17 Connecticut does not
18 have -- they have Exemptions in the
19 Statute, but they don't have a pathway
20 like we have through Rulemaking to
21 continue to allow to sell products
22 through a Label Exemption. They don't
23 have an analogous pathway.

24 It seems like everybody texts
25 me when I sit down.



BEFORE HONORABLE FELICIA L. ORTH
VOL III HEARING,

Page 956

1 They don't have -- it's not
2 analogous, but the point being is that
3 maybe they don't have labels on
4 exempted products in Connecticut; okay?

5 Then Colorado, they have
6 approached their law a little bit
7 differently, and I'll take cookware as
8 an example:

9 They have required labels on
10 cookware until it sunsets, and then at
11 that point there is no -- it sunsets,
12 the difference being that in New
13 Mexico fluoropolymers, and the next
14 generation of PFAS known as
15 fluoropolymers that are added to
16 cookware, have the ability to be sold
17 here; whereas in Colorado, my
18 understanding is that they are not
19 going to be sold there, so I think
20 there is a distinction between what
21 will still be in commerce here as a
22 new product and what there would be
23 there.

24 Maybe one last highlight for
25 you, Chair Ely, to point towards is I



Exhibit 9

BEFORE HONORABLE FELICIA L. ORTH

Deposition of : VOL IV HEARING

taken on: February 26, 2026



531 Harkle Road, Suite A
Santa Fe, NM 87505

505-984-2244

www.cumbrecourtreporting.com

BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

1 STATE OF NEW MEXICO
2 ENVIRONMENTAL IMPROVEMENT BOARD
3
4 IN THE MATTER OF PROPOSED) EIB NO.:
ADOPTION OF 20.13.2 NMAC,))
5 Per- and Poly-Fluoroalkyl) 25-61(R)
Substances in Consumer)
6 Products.)
_____)

7

8

BEFORE THE HONORABLE FELICIA L. ORTH

9

THURSDAY, FEBRUARY 26, 2026

10

9:01 A.M.

11

EVIDENTIARY HEARING VOLUME IV

12

13

14

15

**CERTIFIED
TRANSCRIPT**

16

17

18

19

REPORTED BY:

20

DAVID M. LEE, RMR, CCR,
21 Certificate Number 50391
New Mexico CCR Number 537
22 Cumbre Court Reporting Services, LLC
513 Harkle Road
23 Suite A
Santa Fe, New Mexico 87505
24 (505) 984-2244
cumbrecourt@comcast.net

25



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1140	Page 1142
1 APPEARANCES 2 FOR THE ENVIRONMENTAL IMPROVEMENT BOARD: 3 SANDRA ELY, BOARD CHAIR 4 PHOEBE SUINA, BOARD VICE CHAIR 5 J. BARRY BITZER, BOARD MEMBER 6 GUADALUPE CARRASCO, BOARD MEMBER 7 RONALD CURRY, BOARD MEMBER 8 KAREN GARCIA, BOARD MEMBER 9 FELICIA L. ORTH, HEARING OFFICER felicia.l.orth@gmail.com 10 NEW MEXICO DEPARTMENT OF JUSTICE 11 BY: EDUARDO UGARTE, II, ESQ. BOARD COUNSEL eugarte@nmdoj.gov Post Office Box 1508 Santa Fe, New Mexico 87504-1508 (505) 264-5741 12 FOR NEW MEXICO ENVIRONMENT DEPARTMENT: 13 NEW MEXICO ENVIRONMENT DEPARTMENT 14 BY: GREGORY S. SMITHKIER, ESQ. Gregory.smithkier@env.nm.gov 15 ANDREW P. KNIGHT, ESQ. Andrew.knight@env.nm.gov 16 MARK F. ROSEBROUGH, ESQ. Mark.rosebrough@env.nm.gov 17 PAMELA JONES, PARALEGAL Pamela.jones@env.nm.gov 18 LUIS LOPEZ, PARALEGAL luis.lopez@env.nm.gov 19 1190 South St. Francis Drive Suite N-4050 Albuquerque, New Mexico 87507 (505) 531-7736	1 FOR COMPLEX PRODUCTS MANUFACTURERS COALITION: 2 WILEY REIN, L.L.P. 3 BY: HENRY M. RIVERA, ESQ. hrivera@wiley.law 4 REBECCA J. FIEBIG, ESQ. rfiebig@wiley.law 5 MARTHA MARRAPESE, ESQ. marrapese@wiley.law 6 2050 M Street Northwest Washington, D.C. 20036 (202) 719-7000 7 FOR ALLIANCE FOR AUTOMOTIVE INNOVATION: 8 WILEY REIN, L.L.P. 9 BY: HENRY M. RIVERA, ESQ. hrivera@wiley.law 10 REBECCA J. FIEBIG, ESQ. rfiebig@wiley.law 11 MARTHA MARRAPESE, ESQ. marrapese@wiley.law 12 2050 M Street Northwest Washington, D.C. 20036 (202) 719-7000 13 FOR BRUCE WETHERBEE, PRO SE: 14 BY: BRUCE WETHERBEE editor@thecandlepublishing.com 15 60 Thoreau Street Suite 103 Concord, Massachusetts 01742 (505) 501-1570 16 ALSO PRESENT: LISA O'GRADY INTERPRETER 17 AMELIA CARDEÑA INTERPRETER 18 MELINDA MAASS INTERPRETER
Page 1141	Page 1143
1 FOR CROPLIFE AMERICA AND AMERICAN CHEMISTRY COUNCIL: 2 GALLAGHER & KENNEDY, P.A. 3 BY: DALVA L. MOELLENBERG, ESQ. dlm@gknet.com 4 ANTHONY J. TRUJILLO, ESQ. ajt@gknet.com 5 SERAFINA SELUJA, ESQ. serafina.seluja@gknet.com 6 1239 Paseo de Peralta Santa Fe, New Mexico 87501-2758 (505) 989-7278 7 FOR PFAS PHARMACEUTICAL WORKING GROUP (PPWG): 8 MODRALL, SPERLING, ROEHL, HARRIS & SISK, P.A. 9 BY: STUART R. BUTZIER, ESQ. stuart.butzier@modrall.com 10 STANLEY HARRIS, ESQ. stan.harris@modrall.com 11 BENJAMIN C. ROSSI, ESQ. benjamin.rossi@modrall.com 12 Post Office Box 2168 Albuquerque, New Mexico 87103-2168 (505) 848-1823 (505) 848-9710 (Facsimile) 13 FOR HOUSEHOLD & COMMERCIAL PRODUCTS ASSOCIATION: 14 HOUSEHOLD & COMMERCIAL PRODUCTS ASSOCIATION 15 BY: STEVEN BENNETT, PH.D. Executive Vice President SCIENTIFIC & REGULATORY AFFAIRS sbennett@thehcpa.org 16 1625 I Street Northwest Suite 700 Washington, D.C. 20006	1 I N D E X 2 EXAMINATION PAGE 3 ALEX STANTON, PH.D. 4 Cross-Examination By Mr. Smithkier1149 5 ALEX STANTON, PH.D. 6 MARTHA MARRAPESE, ESQ. 7 Examination By Chair Ely 1162 8 Examination By Vice Chair Suina 1168 9 Examination By Mr. Ugarte 1176 10 BARBARA JAYNE HENRY, PH.D. 11 Direct Examination By Mr. Trujillo1210 12 Cross-Examination By Mr. Rosebrough 1226 13 Cross-Examination By Mr. Wetherbee1239 14 Examination By Board Member Bitzer1247 15 STEPHEN H. KORZENIOWSKI, PH.D. 16 Direct Examination By Mr. Trujillo1251 17 Cross-Examination By Ms. Fiebig 1293 18 Cross-Examination By Mr. Knight 1328 19 Redirect Examination By Mr. Trujillo 1343 20 Examination By Chair Ely 1346 21 ERIC CHAPMAN, PH.D. 22 Examination By Chair Ely 1355 23 Cross-Examination By Ms. Fiebig 1358 24 Examination By Mr. Ugarte 1362



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1220 1 are the only polymeric PFAS that are 2 identified by the OECD as precursors 3 to per-fluoroalkyl acids. 4 Fluoropolymers and 5 perfluoropolyethers do not degrade, 6 therefore, they cannot be precursors. 7 If we go to the next slide, 8 please. 9 In this slide we're contrasting 10 the per-fluoroalkyl acids and 11 fluoropolymers: 12 On the left, you see "Non- 13 Polymers"; on the right you see 14 "Polymeric PFAS." 15 On the left, "Non-Polymers, 16 Low Molecular Weight"; on the right, 17 "Polymeric PFAS, Very Large Molecular 18 Weights." 19 On the left, per-fluoroalkyl 20 acids are water soluble and are 21 volatile; on the right, you see 22 fluoropolymers that are neither water 23 soluble nor volatile. This slide, 24 however, only shows chemical and 25 physical properties. The next slide	Page 1222 1 PFAS are not PFAS that into per- 2 fluoroalkyl acids, poly-fluoroalkyl 3 acids, per-fluoroalkyl acid precursors, 4 and "other PFAS." That last category 5 of other PFAS includes fluoropolymers 6 and perfluoropolyethers. 7 Next slide, please. 8 So the chemical, physical, and 9 biological data are significantly 10 different for fluoropolymers and all 11 other PFAS, and Toxicologists don't 12 see PFAS the same way. 13 The major subclass differences 14 are recognized, as is the importance 15 of using the same terminology to 16 distinguish between molecular 17 structures. 18 As the OECD stressed in their 19 2021 terminology paper, fit-for-purpose 20 working scopes for risk communication 21 and risk management are recognized. 22 Effective risk management requires 23 differentiation. 24 Next slide please. 25 This slide reinforces the
Page 1221 1 will show biological properties. 2 Per-fluoroalkyl acids on the 3 left have toxicity concerns, such as 4 those outlined in the green boxes. We 5 have "Repeated Dose of Chronic 6 Toxicity" shown here. 7 There is a row on 8 carcinogenicity, and one on biological 9 half-life. That means how long it 10 takes for one-half of the substance 11 within the human body to be eliminated. 12 We see that the half-life differs 13 among per-fluoroalkyl acids. 14 HFPO dimer acid is measured in 15 hours, whereas as PFOS is measured in 16 years. Per-fluoroalkyl acids are 17 toxic and bioaccumulative. 18 Next slide, please. 19 On the right I compare 20 fluoropolymers to per-fluoroalkyl 21 acids. We see fluoropolymers are very 22 different; they are not toxic and they 23 don't bioaccumulate. 24 On the next slide -- I'm 25 hoping that you recognize now that all	Page 1223 1 significant differences between per- 2 fluoroalkyl acids and fluoropolymers. 3 They are not all bioavailable; they 4 are not all bioaccumulative. The 5 excellent stability and resistance to 6 degradation, otherwise known as 7 "persistence," does not equal toxicity 8 or bioaccumulation. 9 Because of the chemical and 10 physical property differences: 11 Not all PFAS are taken up into 12 plants; 13 Not all are water soluble; and, 14 Not all will volatilize or 15 absorb to soil. 16 Mobility differs across the 17 umbrella of PFAS. 18 Last slide, please. 19 Should Exemptions be excluded 20 from Labeling as proposed by ACC? 21 Yes. 22 Risk is a function of 23 bioavailable exposure and hazard. 24 Without bioavailable exposure there can 25 be no risk by definition.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1224 1 The term "PFAS" is not 2 intended to communicate risk and the 3 OECD has made that clear. 4 Telling a New Mexico customer 5 of the presence of 1 fully fluorinated 6 carbon does not inform about: 7 Bioavailable exposure; 8 Hazard; or, 9 Risk. 10 The term "PFAS" itself is too 11 imprecise to be health-protective. 12 Fluoropolymers are too large 13 for passive transport into the cell; 14 they lack: 15 Lipid solubility to penetrate 16 the cell membrane; and, 17 They are highly hydrophobic 18 and have no hydrogen bond-donating 19 potential. 20 They are not structurally 21 similar to steroids or peptides or 22 other substances larger than 1,000 23 daltons that are exceptions to the 24 bioavailability described by Lipinski's 25 Rule of 5.	Page 1226 1 you, Mr. Trujillo. Thank you, 2 Dr. Henry. 3 Ms. Fiebig, do you have 4 questions of Dr. Henry? 5 MS. FIEBIG: No questions. 6 HEARING OFFICER ORTH: Thank 7 you. 8 Mr. Rosebrough or 9 Mr. Smithkier. 10 MR. ROSEBROUGH: Yes, thank 11 you, Madam Hearing Officer. 12 13 CROSS-EXAMINATION 14 BY MR. ROSEBROUGH: 15 Q. Dr. Henry, good morning. My 16 name is Mark Rosebrough. I am an 17 Attorney for the New Mexico Environment 18 Department. 19 You're Testifying today as a 20 Toxicologist. Is that correct? 21 A. Yes. 22 Q. Thank you. 23 Are you aware of the definition 24 of per- or poly-fluoroalkyl substance 25 in New Mexico's PFAS Protection Act?
Page 1225 1 Fluoropolymers do not enter 2 cells by active transport; that depends 3 on chemical structural properties like: 4 Molecular shape; 5 Volume; and, 6 Size. 7 Fluoropolymers are extremely 8 large molecules. They lack rotational 9 bonds and functional groups that 10 interact with transporter proteins. 11 They do not fit into cell surface 12 receptors to bind and signal a cascade 13 of events within the cell. 14 Fluoropolymers are not 15 bioavailable like per-fluoroalkyl 16 acids. Again, without bioavailable 17 exposure even very persistent 18 substances are not a risk. 19 Thank you very much for the 20 opportunity to speak with you today. 21 MR. TRUJILLO: Thank you, 22 Dr. Henry. 23 At this time, Madam Chair, we 24 turn over our witness for questioning. 25 HEARING OFFICER ORTH: Thank	Page 1227 1 A. I believe it says that a PFAS 2 is a substance, an organic substance 3 with 1 or more fully fluorinated carbon 4 atoms. 5 Q. Yeah, that's correct. I'm 6 going to read it exactly into the 7 record just so we're all on the same 8 page, and I'm quoting here: 9 "'Per- or poly-fluoroalkyl 10 substance' means a substance 11 in a class of fluorinated 12 organic chemicals containing 13 at least 1 fully fluorinated 14 carbon atom." 15 So with that definition in 16 mind I would ask you whether New 17 Mexico's statutory definition is a 18 chemistry-based definition. 19 A. It's a molecular-structural- 20 chemical-based definition, yes. 21 Q. Thank you. 22 Are fluoropolymers a substance 23 in a class of fluorinated organic 24 chemicals containing at least 1 fully 25 fluorinated carbon atom?



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1228 1 A. Yes. 2 Q. Thank you. 3 Are you aware of the language 4 that the Department has proposed for 5 its PFAS label? 6 A. Yes. 7 Q. Okay. 8 Specifically the label, just 9 again, so we are all clear, requires 10 the placement of an Erlenmeyer flask 11 and the letters "PFAS" on the inside 12 of it. I want to talk to you about 13 those letters, "PFAS." 14 Is it true that a label placed 15 on a product containing fluoropolymers 16 which states only "PFAS" would be 17 scientifically correct? 18 A. If the intent of the label is 19 to identify the presence of a per- and 20 poly-fluoroalkyl substance, yes. If 21 the purpose is to inform about a hazard, 22 or a risk, or potential bioavailable 23 exposure, no. 24 Q. Okay. I did note that you 25 talked about those OECD	Page 1230 1 today. 2 Dr. DeWitt testified that OECD 3 utilizes a scientific definition 4 similar to that used by the New Mexico 5 Legislature, but that OECD allows for 6 the possibility that other definitions 7 may be used in a regulatory or 8 management context. Do you agree with 9 that general assessment of the OECD 10 definition framework? 11 A. Yes. In fact, I think the OECD 12 2023 terminology paper specifically 13 says that the OECD definition of PFAS 14 is not intended to communicate harm or 15 risk. 16 Q. Okay. Thank you. 17 In your Testimony here today, 18 are you proposing the use of a 19 different science-based definition from 20 that used by OECD, or a non-science 21 definition for regulatory purposes? 22 A. I think that the OECD intended 23 for there to be a chemistry molecular 24 structural definition of a PFAS, which 25 is what New Mexico adopted as their
Page 1229 1 differentiations, but let's just stick, 2 if we could, to science for a moment, 3 so I'll ask that again: 4 Is a label on a product 5 containing fluoropolymers which states 6 only "PFAS" scientifically correct? 7 MR. TRUJILLO: Madam Chair; I 8 would object; it's been asked and 9 answered. 10 THE WITNESS: Yes. 11 HEARING OFFICER ORTH: All 12 right. I think she just answered. 13 Go ahead, Mr. Rosebrough. 14 MR. ROSEBROUGH: Thank you. 15 Q. In addition to New Mexico's 16 statutory definition of PFAS, I would 17 like to discuss the scientific 18 definition of PFAS: 19 We heard Testimony from 20 Dr. DeWitt, and I know you're here 21 today to rebut that Testimony, and I'm 22 also aware that you are familiar with 23 the Organisation for Economic Co- 24 operation and Development, or OECD, 25 because you testified about them	Page 1231 1 definition of PFAS. 2 I think OECD clearly explains 3 this concept of fit-for-purpose working 4 scope in which another terminology, to 5 communicate risk and to manage risk, 6 was acceptable. 7 In fact, the OECD used the 8 example of exemptions of certain PFAS 9 substances from the European PFAS 10 restriction proposal as an example of 11 such fit-for-purpose terminology. 12 I think that you can be 13 scientifically accurate and have a 14 terminology intended for molecular and 15 structural purposes, such as the OECD 16 definition of 1 fully fluorinated 17 carbon being a PFAS, and at the same 18 time have a parallel definition 19 intended for risk communication and 20 risk management that is "fit-for- 21 purpose working scope." 22 Q. Understood. Thank you. 23 But a label which only says 24 "PFAS" doesn't communicate risk, does 25 it.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1232 1 A. No, and I thank you for saying 2 that, because that's exactly what I 3 was trying to communicate. 4 If the purpose of this Rule is 5 to inform customers so that they can 6 make choices on consumer products that 7 would reduce their risk or risk to the 8 environment, the Erlenmeyer flask with 9 those four letters is, in my opinion, 10 not adequate to do that. 11 Q. Thank you. 12 Let's move into discussing risk 13 to the environment and fluoropolymers: 14 In this proceeding Drs. 15 Chapman and DeWitt presented evidence 16 on the toxic effects caused by 17 fluoropolymer production and disposal 18 in addition to their use during their 19 product life. They referred to this 20 as the life cycle approach to 21 considering fluoropolymers. I would 22 like to talk to you about this life 23 cycle concept: 24 Are you knowledgeable about 25 the process of fluoropolymer	Page 1234 1 technology is allowing for some 2 fluoropolymers to be made in the 3 absence of polymerization, fluorinated 4 polymerization aids, which is a long 5 way of saying, yes, HFPO dimer acid is 6 used in the manufacture of some 7 fluoropolymers. 8 Q. Thank you. 9 Is HFPO dimer acid itself a 10 PFAS? 11 A. Yes. 12 Q. Does HPFO dimer acid have any 13 known toxic effects? 14 A. Yes. 15 Q. So then considering that, is 16 it an overgeneralization to state that 17 all fluoropolymers are non-toxic? 18 A. If I may, I would like to refer 19 to the life cycle of a fluoropolymer. 20 Q. Please. 21 A. The beginning stage of the 22 life cycle in manufacturing is 1 stage. 23 The end-use stage, when you actually 24 have the fluoropolymer, is another 25 stage. Then end-of-life, or disposal
Page 1233 1 production? 2 A. I'm not a Polymer Chemist, but 3 yes, I am. 4 Q. Is it your understanding that 5 hexafluoropropylene oxide dimer acid, 6 which is known as HFPO-DA or GenX, is 7 used in the production of 8 fluoropolymers? 9 A. There are -- fluoropolymers, 10 like most of the chemicals we have 11 talked about today, is not a monolithic, 12 one-recipe, one-size-fits-all category. 13 HFPO dimer acid is 1 type of 14 polymerization aid used by those 15 fluoropolymer manufacturers who are 16 making what's known as "fine powder 17 fluoropolymers." 18 Fine powder fluoropolymers, or 19 fine powder PPFE, are intended to have 20 specific properties that enable them 21 to be processed in a particular way. 22 Other types of fluoropolymers that can 23 be molded, for example, don't need to 24 be manufactured in that way. 25 A recent evolution in	Page 1235 1 after the end of the intended useful 2 life of the product is another stage 3 of the life cycle. 4 When we talk about whether or 5 not a fluoropolymer is hazardous, I'm 6 talking about the fluoropolymer itself. 7 Q. Okay. Thank you. 8 You're not looking at the life 9 cycle of the... 10 Let's say your Testimony here 11 today only considers the fluoropolymer 12 in between production and disposal; 13 correct? 14 A. Well, yes and no. 15 In 2025 one of the papers that 16 I referenced in my Testimony, my 17 Written Testimony that was submitted, 18 in 2025, Dr. Timmer and I published a 19 paper in a peer-reviewed journal in 20 which we looked at environmental fate 21 and transport of a fluoropolymer. We 22 demonstrated or provided data that 23 shows that the fluoropolymer is not 24 subject to biotic or abiotic 25 degradation:



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1236 1 It doesn't degrade; 2 It doesn't hydrolyze; 3 It doesn't photolyze; 4 It doesn't have oxidative 5 degradation. 6 Microbial bacteria, whether 7 it's aerobic or anaerobic, does not 8 degrade the polymer and it doesn't 9 absorb to soil. 10 We did that for the purpose of 11 showing that it's possible to have a 12 very persistent polymer that does not 13 transform to a non-polymeric PFAS, and 14 also to demonstrate that without that 15 transformation and subsequent release 16 of non-polymeric PFAS or substances of 17 concern, persistence alone does not 18 demonstrate toxicity or bioaccumulation. 19 It was an interesting process 20 because we had to make this enormous 21 supplement, which involved the 22 publication of all of the reports from 23 the laboratory, the independent 24 accredited laboratory. 25 I included chemical analyses.	Page 1238 1 A. That's a very interesting 2 question. 3 In recent publications, recent 4 studies have shown that incineration at 5 the appropriate temperatures and 6 residence time within the incinerator 7 are capable of destroying or 8 mineralizing the fluoropolymer to an 9 efficiency of 99.9999 -- that's four 10 9s -- percent. 11 MR. ROSEBROUGH: May I ask a 12 follow-up? 13 HEARING OFFICER ORTH: Yes. 14 MR. ROSEBROUGH: Thank you. 15 Q. What if they are done at an 16 inappropriate temperature? 17 A. Incineration at temperatures 18 less than that can produce what's 19 known as polymers or products of 20 incomplete combustion. 21 Q. And is that a non-polymer 22 PFAS? 23 A. Yes, it could be, yes. 24 MR. ROSEBROUGH: Okay. No 25 further questions. Thank you.
Page 1237 1 I included the Reports and the data, 2 as well as the publication of the 3 manuscript which interpreted the data 4 and showed application through polymer 5 hazard assessment. 6 When we look at the chemical, 7 physical, and biological properties 8 that have been historically used for 9 polymer hazard assessment dating back 10 to the beginning of the Toxic Substance 11 Control Act through the present, the 12 chemical, physical, and biological 13 properties of fluoropolymers are 14 consistent with those polymers 15 demonstrated to have low health and 16 environmental hazard. In that respect 17 that would be covering life as well as 18 end-of-life. 19 Q. Thank you. I'm going to 20 interrupt because I'm running short on 21 time, and I want to ask you one more 22 question: 23 Is it possible for non-polymer 24 PFAS to be created when a fluoropolymer 25 is incinerated?	Page 1239 1 HEARING OFFICER ORTH: All 2 right. Thank you, Mr. Rosebrough. 3 We need to take our morning 4 break, so let's come back at 10:55. 5 (The Evidentiary Hearing 6 recessed from 10:40 a.m. to 10:55 a.m.) 7 HEARING OFFICER ORTH: Thank 8 you, Dr. Henry. 9 Let's come back from the 10 break. 11 Let's see here. Mr. Harris, 12 do you have questions of Dr. Henry? 13 MR. HARRIS: No questions, 14 Madam Hearing Officer. 15 HEARING OFFICER ORTH: He said, 16 "No questions..." 17 Mr. Wetherbee, do you have 18 questions of Dr. Henry? 19 MR. WETHERBEE: I do have 1 or 20 2 questions, Madam Hearing Officer. 21 HEARING OFFICER ORTH: Go 22 ahead. 23 MR. WETHERBEE: All right. 24 Thank you very much. 25 CROSS-EXAMINATION



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1268 1 the reasons I'm talking today, is that 2 PFAS is so big. Unless you tell people 3 what you're talking about, they don't 4 know. They assume it's all the same. 5 PFAS includes hundreds, if not 6 thousands of compounds, so my motto is 7 pretty simple, and I said that I think 8 in my Testimony and elsewhere. To be 9 clear, be specific and be descriptive 10 when you're talking about PFAS. 11 Next chart. 12 You've heard this from us and 13 you've heard this from Barb: 14 Fluoropolymers are 15 fundamentally different. They meet 16 the criteria of what we call "polymer 17 of low concern," and as Barb said, and 18 you might have missed it, but it's 19 defined as: 20 "Polymer properties 21 predictive of low health and 22 environmental hazard." 23 I'll elaborate more when I do 24 my Rebuttal, but you don't see the 25 word "no" there. These are not	Page 1270 1 fluoropolymers because they are solids 2 and they don't have solubility and 3 they don't have vapor pressure. 4 Now is that an absolute? I 5 can't say it's an absolute, but it's 6 pretty good. It holds pretty good. 7 All right. One of things I 8 want to talk about here, and I'm going 9 to say it again in the Rebuttal in a 10 little bit more detail, but there are 11 2 papers, one by Dr. Henry and her 12 global colleagues in 2018, and another 13 paper in 2022 by myself and 7 other 14 global companies where we talk about 15 "polymers of low concern." 16 These studies combined cover 17 about 96% of the major global 18 fluoropolymers, and include all the 19 properties; residuals, monomers, 20 extractables, and all the fundamental 21 properties. 22 I am going to come back to 23 that because it's really important, 24 because there was a lot of questions 25 yesterday and even today about life
Page 1269 1 "polymers of no concern," they are 2 "polymers of low concern," and that's 3 an important distinction. 4 What you need to do is you need 5 to assess -- which is what we've done, 6 and Barb did with her group in 2018. 7 I did that with my colleagues in 8 2022 -- the world of fluoropolymers 9 against 12, 13 different criteria. 10 What we look at is molecular 11 weight or size. 12 We look at solubility in 13 water. 14 We look at whether the 15 structures are large and stable. Barb 16 was talking about that in terms of 17 degradation either in soil or in air. 18 Are they bioavailable? 19 Are they bioaccumulative? 20 Do they degrade into smaller 21 pieces? 22 Are they precursors, which is 23 a really, really important concept. 24 Environmental mobility concern 25 generally does not apply to	Page 1271 1 cycle. 2 Next chart. 3 There we go; two more charts, 4 this one and the next one. 5 Before I finish with my final 6 2 slides, I want to reiterate that in 7 both of the "polymer concern" papers 8 both 2018 and 2022, that was online, 9 and in 2023 in print. We not only 10 discuss the end of life, which we 11 heard today, the end of life 12 properties of the fluoropolymer life 13 cycle, but we also discuss beginning 14 of life, which is how they are made, 15 and end of life. I'll talk about the 16 life cycle in a few minutes. 17 What do we see as the problems 18 with the proposed Labeling? We've all 19 talked about that for the past four 20 days. 21 "All PFAS have the same 22 properties and the same 23 risk." 24 No, they don't, And a label 25 that covers all of them, which is



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1272 1 what's proposed, even though there are 2 exceptions, doesn't make scientific 3 sense in my view, and I am a 4 scientist. 5 The scientific reality is that 6 PFAS vary very significantly. 7 Fluoropolymers differ fundamentally 8 from the very small water soluble PFAS 9 or the PFAAs that Barb talked about 10 this morning. 11 There is growing scientific 12 consensus that PFAS are diverse. As I 13 said earlier, there are different 14 groups that think about these, and I'm 15 not sure we're ever going to get 16 together. We, in good spirit, have 17 spirited discussions and we end up 18 agreeing to disagree. 19 Fluoropolymers -- and you 20 heard this also -- are materially 21 different from other PFAS because of 22 the properties I talked about. 23 NMED's Warning Label approach 24 fails to differentiate amongst the 25 chemicals. It is inconsistent with	Page 1274 1 of PFAS on the commercial 2 market." 3 Well that's not really true 4 and not conducive to classic risk 5 assessment, and that's one of the 6 reasons why we did our 2021 paper. We 7 wanted to put perspective on how many 8 of these chemicals really there were. 9 The big barrier, my view -- 10 and I'm not an Epidemiologist, I'm an 11 Organic Chemist. The big barrier to 12 doing risk assessment is there's too 13 many of them. The answer is no, 14 there's not; that's what we concluded 15 in 2021, but There's still a lot. Can 16 you subgroup them and then do them as 17 a risk assessment? That was our 18 message coming out of that 2021 paper. 19 "The intrinsic property of 20 persistence alone is 21 sufficient justification." 22 That's what the one group 23 thinks. 24 What you also heard Monday or 25 Tuesday is that there's increased
Page 1273 1 current scientific understanding, some 2 of which I talked about today. It's 3 not scientific and robust. 4 You know, my question is, and 5 we all have many questions, but I'm 6 still trying to figure out what an 7 Erlenmeyer flask with a "PFAS" symbol 8 in it is really going to do here. I 9 am not a label expert, but I've used 10 many Erlenmeyer flasks in my day with 11 "PFAS" in them. We're going to need 12 to figure out what it really means in 13 the end; not an expert there. 14 Last chart. 15 I'll finish up with the concept 16 we've talked about 3 times already in 17 this. It's important Because there's 18 2 major schools of thought: 19 The premise for treating PFAS 20 the same as one, well, if you take it 21 historically, historic or legacy long- 22 chain, and you substitute it with 23 another PFAS, that's called a 24 "regrettable substitution." 25 "There is a large number	Page 1275 1 probability of adverse effects in 2 human health and the environment if 3 these are put in the environment Even 4 if they are not bioavailable, not 5 soluble, not bioaccumulative, and too 6 big to do anything, but then there is 7 the other side. 8 The other side is persistence 9 is an intrinsic property, but not an 10 intrinsic hazard, and it does not, by 11 itself, imply an adverse effect just 12 because it's persistent. It is not 13 scientifically justified to classify 14 inert solids, salts, liquids, and 15 gases in a single class as 1, where 16 properties like vapor pressure, 17 environmental partitioning, aqueous 18 solubility and hazard itself, as well 19 as surface and material properties 20 vary greatly. Thank you. 21 Q. Thank you, Dr. Korzeniowski. 22 Let me next turn to Rebuttal 23 and ask you a few questions, and then 24 we'll get into your summary. 25 A. All right.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1276 1 Q. Did you review the Direct 2 Written Testimony of NMED's witnesses 3 filed in this matter, particularly 4 Dr. Chapman's, Dr. Olson's, and 5 Dr. Ling's Testimonies? 6 A. I did. 7 Q. Did you also provide written 8 Rebuttal Testimony of these NMED 9 witnesses that was filed in this matter 10 as ACC Exhibit 3? 11 A. I did. 12 Q. Do you have any corrections to 13 your written Rebuttal Testimony? 14 A. They are not corrections, but 15 what I did, and I discussed this with 16 Dal, is I didn't change the headings, 17 I didn't change the references, I just 18 added some more text, so I'm happy to 19 provide a copy of that to the Board 20 and to the group. 21 Q. Okay. Thank you. 22 A. No corrections, it's just, 23 again, the same references; no change 24 in references, no change in context. 25 Q. Do you adopt your written	Page 1278 1 only a small subset of substances 2 classified as PFAS are actually in 3 commerce or of commercial relevance. 4 This set of commercially 5 relevant PFAS, as I said a few minutes 6 ago, likely numbers in the hundreds 7 and not tens of thousands, and that's 8 the Buck, et al., as a co-author with 9 Bob and 2 others in 2021. 10 The Department's Testimony 11 appeared to largely rely on data 12 specific to PFAAs, or the per- 13 fluoroalkyl acids, yet framed 14 conclusions as applying to PFAS 15 broadly. That approach does not 16 reflect the scientific distinctions 17 among PFAS subclasses and may create 18 confusion in risk communication. 19 It would be helpful, and in 20 most cases necessary, to be clear, 21 specific, and descriptive when talking 22 about PFAS and which ones are being 23 referred to in each case. 24 As an example is the statement 25 that:
Page 1277 1 Rebuttal Testimony, then, with those 2 additions, as your own Testimony here 3 today? 4 A. I do. 5 Q. Let's proceed with your 6 summary. 7 For this round, before we 8 begin, I'm going to ask you questions, 9 and when you're done with your answer 10 I'll ask you the next question? 11 A. Please do. Thank you. 12 Q. Thank you. 13 In your opinion, did the 14 Testimony presented by NMED in this 15 proceeding use scientifically precise 16 terminology when referring to PFAS? 17 A. No. 18 The term "PFAS" is an umbrella 19 term encompassing more than 14,000 20 substances, which we just talked about 21 a few minutes ago, as included in 22 databases and lists, but not in 23 commerce, with very diverse chemical, 24 physical, and toxicological properties. 25 To the best of my knowledge	Page 1279 1 "PFAS are persistent and 2 mobile." 3 This is an overgeneralization, 4 as many PFAS are not considered mobile 5 due to their very limited solubility 6 and lack of vapor pressure. 7 Q. Does the scientific evidence 8 presented by NMED support regulating 9 or Labeling all products containing 10 any substance with 1 fully fluorinated 11 carbon atom in the same manner? 12 A. No. 13 A structure-based definition, 14 which is what we're talking about, of 15 PFAS that captures all substances with 16 at least 1 fully fluorinated carbon 17 does not align with hazards, exposure, 18 and risk conclusions presented. 19 Much of the Department's Expert 20 Testimony focused on PFAAs and certain 21 related compounds. Extending those 22 conclusions to all PFAS-containing 23 products is not supported by the 24 scientific data discussed in this 25 proceeding.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1280 1 Q. What types of PFAS substances 2 have been phased out voluntarily or 3 restricted via regulation in the 4 United States? 5 A. I'm going to go off script for 6 just a second: 7 We've heard that PFOA and PFOS 8 are still sort of used and back in the 9 U.S., and we can comment on that at 10 some point. 11 PFOA and PFOS, and closely 12 related substances, have been 13 voluntarily phased out by industry. 14 PFAS and related long-chain PFASs, 15 perfluorosulfonic acids, were phased 16 out by the sole U.S. manufacturer in 17 the early 2000s. 18 Nd PFOA and its related higher 19 homologues and precursors were phased 20 out through the U.S. EPA 2010/2015 21 PFOA voluntary Stewardship Program. 22 This Program was global in nature and 23 included the 8 major global 24 manufacturers. The Program included 25 both products and plant emissions.	Page 1282 1 PFAS by restricting the distribution 2 and selling of such products, and we've 3 talked about this; Maine and Minnesota 4 are 2 examples. 5 Q. How does this apply to 6 international agreements such as the 7 Stockholm Convention on Persistent 8 Organic Pollutants? 9 A. The Stockholm Convention 10 addresses specific non-polymeric PFAS, 11 such as PFOA and PFOS, and other per- 12 fluoroalkyl acids, normally hyperchain 13 links like C9 to C20, or C9 to C21. 14 The Stockholm Convention does 15 not address PFAS as a single 16 undifferentiated class. Its listings 17 reflect evaluations based on the 18 combination of persistence, 19 bioaccumulation, and toxicity rather 20 than a blanket approach to all PFAS. 21 Q. Why is this distinction 22 important for accurately characterizing 23 the current Proposed Rule by the 24 Department? 25 A. Suggesting that PFAS broadly
Page 1281 1 The U.S. EPA, however, did 2 grant a few SNUR Exemptions for 3 PFOS-type products to be used until 4 replacements were found. This could 5 be the thinking that PFOS products are 6 still coming back into the United 7 States. 8 It has not been discussed here, 9 but many of these products were used 10 in very specific formulations. Like 11 in the photographic industry, 12 photolithography, the hydraulic fluid 13 in your jets and your aircraft. There 14 were no replacements even in the 15 2000s. 16 EPA provided at least 4 PFOS 17 compound Exemptions, and then the 18 right to manufacture outside the U.S., 19 so that's like 5 SNURs. That might be 20 the source of... 21 Listen, I don't know whether 22 there's replacements yet; some of 23 these were very difficult to requalify. 24 Some states are regulating 25 products containing intentionally added	Page 1283 1 have been phased out or restricted 2 implies a scientific and regulatory 3 consensus that all PFAS present 4 comparable risk. 5 In reality most regulatory 6 actions have been narrowly focused on 7 specific non-polymeric PFAS based on 8 substance-specific evidence. 9 It should be noted that the New 10 Mexico Legislature itself determined 11 that certain classes of PFAS, such as 12 fluoropolymers that are solids at 13 standard temperature and pressure, do 14 not present risk warning regulation, 15 and NMED appropriately recognized that 16 implementing Legislative judgment in 17 the Proposed Rule. 18 It is important that the record 19 and supporting Testimony accurately 20 characterize those substances and not 21 conflate them with PFAS classes that 22 the Legislature expressly chose to 23 treat differently. 24 Q. I'm going to move on to 25 Labeling requirements now.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1284 1 A. Sure. 2 Q. Would Labeling all PFAS- 3 containing products in the same manner 4 accurately reflect differences in 5 hazard, exposure, and potential risk? 6 A. No. 7 PFAS encompasses substances 8 with significantly different chemical, 9 physical, and toxicological properties 10 that inform their uses and potential 11 exposure and risk profiles. Applying 12 a single uniform warning, like an 13 Erlenmeyer flask with "PFAS" embedded 14 in the middle implies comparable risk 15 across all PFAS, which is not supported 16 by the scientific distinctions 17 discussed in this proceeding. 18 Q. How does that concern, then, 19 apply to fluoropolymers? 20 A. Recognizing the diversity of 21 physical and chemical properties within 22 the PFAS family of chemistries is 23 critical for understanding whether a 24 particular PFAS, or subgroup of PFAS, 25 might be of potential concern to human	Page 1286 1 statements and Testimony on Monday, to 2 label these important publication as 3 tainted or conflicted because industry 4 did them is a clear mischaracterization 5 of the compelling analytical testing 6 and toxicological data presented in 7 these publications. 8 Another generalization noting 9 that fluoropolymers in use or in life 10 are not safe is directly contrary to 11 what is published in the 2 journal 12 articles cited above. 13 Directly contrary to what you 14 have read in Exhibit 71 and heard on 15 Monday in Testimony, fluoropolymer 16 manufacturers have recognized that 17 there are potential emissions of 18 fluorinated species across the complete 19 life cycle, manufacturing, which is 20 beginning of life; end use or end 21 life; and end of life disposal. That 22 can be recycled; that can be 23 incineration. 24 There are no disingenuous 25 claims about no emissions and no
Page 1285 1 health or the environment. 2 Fluoropolymers do have a 3 markedly different physical and 4 toxicological characteristics compared 5 to non-polymeric PFAS, such as PFOA or 6 PFOS, even versus what you heard talked 7 about this morning; these side-chain 8 fluorinated polymers. 9 A general statement or 10 pronouncement that, as a whole, PFAS 11 are bioaccumulative, persistent, and 12 mobile is simply incorrect and 13 misleading. 14 In addition, 2 recently peer- 15 reviewed publications that we talked 16 about a few minutes ago -- 1 in 2018 17 by Dr. Barb Henry and her colleagues 18 at Gore, and the other in 2022 online, 19 and 2023 in print by myself and 20 members of 7 global fluorocarbon 21 manufacturers -- made a compelling 22 case that fluoropolymers have a unique 23 set of properties that set them apart 24 from the other PFAS. 25 From one of the witness	Page 1287 1 claims about polymers of no versus low 2 concern. 3 For example, the fluoropolymer 4 manufacturing group in Europe called 5 FPG have created and are executing a 6 Manufacturing Emissions Reduction 7 Program with defined goals. 8 You have also heard a fair 9 amount of talk about the use of 10 fluorinated polymerization aids. You 11 heard that this morning, FPAs. They 12 are no longer in use. These particular 13 ones are generally no longer in use, 14 not by at least the Stewardship 15 companies. Some companies have 16 replaced them with short-chain, and 17 you heard that this morning also. 18 What is more important, 19 though, about that is that the 20 fluoropolymer industry has been 21 working for years to eliminate the use 22 of these fluorinated polymerization 23 aids, and as of 2022 -- I don't have 24 new data -- when we published our 25 paper, about 55% of those FPAs have



**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS, NATIONAL
ASSOCIATION OF MANUFACTURERS,
NATIONAL ELECTRICAL
MANUFACTURERS ASSOCIATION,
NATIONAL FEDERATION OF INDEPENDENT
BUSINESS, INC., NEW MEXICO RETAIL
ASSOCIATION, and POWER TOOL
INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity as
Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his official
capacity as Attorney General of New Mexico*,

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF STEPHEN H. KORZENIOWSKI, PH.D.

I, Stephen H. Korzeniowski, hereby declare and state as follows:

1. I have been retained by counsel for Plaintiffs as an expert in connection with the above-captioned litigation. I am a private consultant with nearly 50 years of experience in the chemical industry, including over 35 years in working with fluorotelomers and the last 10 years also working with fluoropolymers. I have over 25 years of experience in various industry groups, including multiple chair positions.

2. I have been asked to provide my expert opinions on: (1) the physical and chemical properties of PFAS as a class; (2) the diversity of physical and chemical properties within the PFAS class; and (3) the current state of scientific debate regarding how to define PFAS as a class.

3. I have actual knowledge of the matters stated herein. If called to testify in this matter, I would testify truthfully and based on my expert opinions.

4. In preparing this declaration, I reviewed the New Mexico Per- and Poly-Fluoroalkyl Substances Protection Act (the “PFAS Act”), N.M. Stat. § 74-15-1 *et seq.*, the New Mexico Environment Improvement Board’s (the “EIB”) implementing regulation, NMAC § 20.13.2, and all other documents cited herein. I am also relying on my scientific education and training, my industry experience, my research experience, and my knowledge of the scientific literature in the pertinent fields, as set out in my curriculum vitae, attached hereto as **Exhibit A**.

5. I served as an expert witness for Plaintiff American Chemistry Council in proceedings before the EIB regarding adoption of the PFAS labeling regulation. In that capacity, I provided both written testimony, as well as live testimony before the EIB. That testimony is attached hereto as **Exhibit B**.

6. The materials I have relied upon in preparing this declaration are the same types of materials that experts in my field regularly rely upon when forming opinions on these subjects. These materials are listed in **Exhibit C** to this Declaration.

7. I may wish to supplement the opinions stated in this declaration or the bases for them as a result of new scientific research or publications or in response to statements and issues that may arise in my area of expertise.

I. BACKGROUND AND QUALIFICATIONS

A. Qualifications

8. I hold a BA in Chemistry from Rutgers University (1972), a PhD in organic chemistry from Penn State University (1977), and an MBA from Widener University (1985). For the majority of my career, I was employed by DuPont. My roles at DuPont included Global Technology Manager for Surface Protection Solutions, and Global Business Manager for fluoroadditives and custom chemicals. I have extensive, first-hand knowledge of the regulatory, commercial, and scientific dimensions of fluorinated chemistries. Since leaving Chemours (a DuPont spinoff) in July 2015, I have remained active in matters related to fluorochemistry science and regulation. Currently, I am a self-employed consultant at BeachEdge Consulting, where I help businesses understand global trends in fluorotechnology and provide technical/scientific help as needed. I have published more than 50 papers, posters, and major talks throughout my industrial career, including 20 peer-reviewed journal articles, a majority of them focused on the topic of fluorotelomers.

B. Compensation

9. I am being compensated at a rate of \$400 per hour. My compensation does not depend on the outcome of this litigation, the opinions I express, or the testimony I provide.

C. Previous Testimony

10. I have previously testified as an expert witness, including in the proceedings before the EIB regarding the regulation at issue in this litigation. My curriculum vitae, attached hereto as **Exhibit A**, identifies the proceedings in which I have previously provided expert testimony.

II. SUMMARY OF OPINIONS

11. PFAS is a broad category that may include more than 14,000 substances. The scientific community is still divided as to how to identify PFAS. The substances that fall under

the broad umbrella term “PFAS” all vary with respect to chemical and physical properties. And the differences across substances have a direct impact on how each PFAS interacts with human health and the environment.

12. I understand that New Mexico law defines PFAS broadly: as a “substance in a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.” N.M. Stat. § 74-15-2(S). That is a very broad definition, and it is not the only one used to define PFAS. I also understand that New Mexico bans the sale and distribution of certain products that it defines as PFAS, but it has exemptions for certain categories and any products designated by regulators as a “currently unavoidable use”—meaning the use of PFAS in the product is “essential for health, safety, or the functioning of society” and “alternatives are not reasonably available.” *Id.* §§ 74-15-2(H), 74-15-3(A)(15).

13. I also understand that, using the very broad definition provided by state law, the EIB adopted a rule requiring a warning label on *all* products containing intentionally added PFAS, even those exempted from the PFAS Act’s phased statutory ban.

14. This approach fails to provide for any differentiation among different types of PFAS, including hazards, toxicity, or means of exposure. There is no scientific basis for treating all PFAS alike. To the contrary, New Mexico’s approach contradicts the growing scientific consensus that all PFAS are not the same and should not be assumed to possess the same properties.

15. For example, fluoropolymers—a subcategory of PFAS that includes PTFE (polytetrafluoroethylene)—are large molecules that are neither water-soluble nor fat-soluble. This means they do not get into your drinking water. These high molecular weight polymers are too large to cross cell membranes. As a result, they are neither absorbed into nor accumulated in the human body. They are also regarded as stable and resist environmental degradation. This makes

them different from other types of PFAS—for example, non-polymeric, water-soluble PFAS, and precursors to perfluorocarboxylates (PFCAs), many of which have been voluntarily phased out by manufacturers.

16. PFAS encompass substances with significantly different chemical, physical, and toxicological properties that inform their uses, potential exposure, and risk profiles. Applying a single, uniform warning overtly implies comparable risk across all PFAS, which is not supported by any of the publicly available scientific evidence.

III. BACKGROUND

A. PFAS is a Broad Category of Substances and Encompasses Materials that are Critical Components in Everyday Products

17. Per- and polyfluoroalkyl substances—collectively referred to as “PFAS”—is a broad term for a category of more than 14,000 substances with diverse physical, chemical, and toxicological properties.

18. There is no universal definition of a “PFAS.” At their most general definition, however, PFAS are characterized simply by the presence of covalent bonds between carbon and fluorine atoms, the strongest single bond in organic chemistry. The broadest definition says that a PFAS must have one single fully fluorinated carbon, such as a -CF₃ or -CF₂-. A simple figure that

shows the evolution of the definition is given below.




Figure 1. PFAS Definition and Evolution

19. As a result of this strong bond and other properties, many PFAS are water-resistant, grease-resistant, and chemically and thermally stable. These properties make PFAS uniquely useful across industries worldwide. Fluoropolymers, for example, are often characterized as having a unique combination of properties that provide the performance properties required in many end-use applications.

20. Many applications of PFAS involve highly technical materials that serve as critical enablers of industries underpinning modern life. In numerous contexts—such as healthcare, energy systems, transportation, electronics, and other infrastructure—these substances are essential to safety, durability, or performance, and viable alternatives are not reasonably available without compromising function or introducing other risks. As noted above, fluoropolymers have a set of properties that make them unique. While non-fluorinated polymers can offer some of the

desired properties, none of them can match the required end-use properties such as durability, dielectric properties, mechanical strength, low coefficient of friction, weatherability, barrier properties, optical clarity, chemical and thermal stability, among others. And fluoropolymers are used in critical applications precisely because they possess these properties, in a range of different products essential to everyday life: in the automotive industry, aerospace, medical devices, oil and gas and chemical/pharmaceutical processing, filtration media, electronics, batteries, semiconductors and internet and wireless communications (*i.e.*, 5G technology in our cell phones).

B. There is an Unresolved Scientific Debate About What Substances Qualify as “PFAS”

21. There is a legitimately unresolved scientific debate about how to define which substances can be described as PFAS. Some scientists, regulators, non-governmental organizations, and others apply broad definitions that capture more than 14,000 potential PFAS substances, while others use more precise definitions that encompass hundreds of substances. But these definitions ultimately do not reflect the differences in chemical properties, toxicology, health hazards, or environmental fate-and-transport effects.

22. One of the earliest definitions of PFAS was developed in 2011 by a multidisciplinary group of scientists led by Dr. Robert C. Buck. Under that definition, PFAS were defined as “aliphatic substances containing one or more C atoms on which all the H substituents presented in the nonfluorinated analogues from which they are notionally derived have been replaced by F atoms, in such a manner that ... [a molecule] contains the perfluoroalkyl moiety C_nF_{2n+1} .” I refer to this as the “Buck Definition.” Or, in plain English, a PFAS molecule has a tail or backbone made entirely of carbon and fluorine, with no hydrogens. This fully fluorinated structure, either tail or backbone, is not expected to break down under normal operating or generally expected or encountered environmental conditions. Robert C. Buck et al., *Perfluoroalkyl*

and Polyfluoroalkyl Substances in the Environment: Terminology, Classification, and Origins, 7 Integrated Env'n. Assessment & Mgmt. 513, 515 (2011). See Figure 1.

23. The Organisation for Economic Co-operation and Development defines “PFAS” as “fluorinated substances that contain at least one fully fluorinated methyl or methylene carbon atom (without any H/Cl/Br/I atom attached to it), i.e., with a few noted exceptions, any chemical with at least a perfluorinated methyl group ($-\text{CF}_3$) or a perfluorinated methylene group ($-\text{CF}_2-$).” Zhanyun Wang et al., *A New OECD Definition for Per- and Polyfluoroalkyl Substances*, 55 Env'tl. Sci & Tech. 15575, 15576 (2021). Again, in plain English, that means a chemical is a PFAS if the molecule contains at least one carbon atom that is fully fluorinated—the carbon can carry three fluorines ($-\text{CF}_3$), or two ($-\text{CF}_2-$). The OECD definition differs from the Buck Definition because it does not require the entire tail to be fully fluorinated, and it does not require the molecule to be shaped like a chain. See Figure 1.

24. Fluoxetine, the active ingredient in the antidepressant Prozac, is one example of a chemical that would qualify as a PFAS under the OECD definition, but not the Buck Definition. Emily Hammel et al., *Implications of PFAS Definitions Using Fluorinated Pharmaceuticals*, 25 iScience 104020 (2022).

25. The U.S. Environmental Protection Agency has a different view of how to define PFAS. In 2021, as part of the process for putting out a reporting rule under the Toxic Substances Control Act, the EPA provided a structural definition of PFAS: “per- and polyfluorinated substances that structurally contain the unit $\text{R}-(\text{CF}_2)-\text{C}(\text{F})(\text{R}')\text{R}''$. Both the CF_2 and CF moieties are saturated carbons and none of the R groups (R, R' or R'') can be hydrogen.” *TSCA Section 8(a)(7) Reporting and Recordkeeping Requirements for Perfluoroalkyl and Polyfluoroalkyl Substances*, 86 Fed. Reg. 33,926, 33,929 (June 28, 2021). The EPA’s 2021 definition differs from

the Buck and OECD definitions because it requires a pair of adjacent carbon-based moieties—one with two fluorines, the other with one—that are linked to one another.

26. In 2023, when EPA finalized the rule, it expanded the definition of PFAS to adopt two other structures: (1) “R–CF₂OCF₂–R′, where R and R′ can either be F, O, or saturated carbons,” and (2) “CF₃C(CF₃)R′R″, where R′ and R″ can either be F or saturated carbons.” *Toxic Substances Control Act Reporting and Recordkeeping Requirements for Perfluoroalkyl and Polyfluoroalkyl Substances*, 88 Fed. Reg. 70,516, 70,518 (2023). The first definition captures two fluorinated carbons that are connected by oxygen; the second is intended to cover a bundle of fluorinated carbons. In adopting the final rule, the EPA stated that it deliberately decided that it was “not appropriate” to adopt the OECD definition, because the “chemical substances covered by the OECD definition are unlike the structures of the PFAS of concern ... which have more fluorinated carbons are more likely to be present in the environment.” *Id.* at 70,533.

27. Applying just these three definitions of PFAS would lead to inconsistent results for a broad range of products. Take, for example, HFO-1234yf (2,3,3,3-tetrafluoropropene, or “R-1234yf”). R-1234yf is the refrigerant used for the air conditioning systems in most cars manufactured in the United States today; it is considered an eco-friendly successor to R-134a, which is commonly known as Freon.

28. R-1234yf is a three-carbon molecule. One carbon holds two hydrogen atoms, and it is double-bonded to another carbon that holds a single fluorine. The single-fluorine carbon is bonded on the other side to a carbon holding three fluorine.

29. R-1234yf would not be considered PFAS at least under the EPA’s definition, because it does not meet any of the three physical structures identified by the EPA. The EPA definition excludes unsaturated fluorinated compounds (olefins) and single fluorinated

compounds. Buck et al.'s 2011 classic peer-reviewed publication did exclude compounds that were registered and regulated by other agencies such as the FDA and those that fall under the Montreal Protocol (i.e., refrigerants).

30. New Mexico, in effect, adopted the definition of PFAS put forth by OECD. All New Mexico requires is “at least one fully fluorinated carbon atom.” The OECD’s definition is also based on a fully fluorinated carbon atom.

31. Needless to say, because the scientific community does not yet have a consensus on what a PFAS is, there is no consensus that all PFAS should be assumed to have the same properties and treated the same. To the contrary, if any consensus is emerging, it is that all PFAS are *not* the same, and that PFAS chemicals should not be uniformly assumed to possess the same properties.

32. PFAS chemicals are grouped together mainly because of their inherent persistent quality and the common carbon-fluorine bond, but that does not mean the same broad brush should be used to paint all PFAS as toxic and hazardous. Persistence, by itself, does not make a substance hazardous, and calling a chemical hazardous based on its persistent quality alone contradicts the existing science.

33. For example, Anderson et al. reports on the opinions of an expert panel “convened to provide insight and guidance on per- and polyfluoroalkyl substances (PFAS) grouping for the purposes of protecting human health from drinking water exposures, and how risks to PFAS mixtures should be assessed.” Janet K. Anderson, et al., *Grouping of PFAS for human health risk assessment: Findings from an independent panel of experts*, Regul. Toxic. & Pharmacol., Oct. 2022, at 1. Most of the panelists agreed that PFAS should not be grouped together for risk

assessment purposes and that it is scientifically inappropriate to assume equal toxicity/potency across the diverse class of PFAS. *Id.* at 7.

34. The OECD, for its part, also recognizes that not all PFAS are the same. In 2021, it issued a report developed under the auspices of its Chemicals and Biotechnology Committee that states, “PFASs are a chemical class with diverse molecular structures and physical, chemical and biological properties, it is highly recommended that such diversity be properly recognized and communicated in a clear, specific and descriptive manner. The term ‘PFASs’ is a broad, general, non-specific term, which does not inform whether a compound is harmful or not, but only communicates that the compounds under this term share the same trait for having a fully fluorinated methyl or methylene carbon moiety.” OECD, *Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances: Recommendations and Practical Guidance* 8 (July 9, 2021), [https://one.oecd.org/document/ENV/CBC/MONO\(2021\)25/En/pdf](https://one.oecd.org/document/ENV/CBC/MONO(2021)25/En/pdf).

35. The Drinking Water and Groundwater Protection Division of Vermont’s Department of Environmental Conservation was specifically charged by the state legislature to develop a class regulation or to explain why such a regulation was not possible. In its final report, the Department said: “The Review Team spent over a year deliberating, researching, and discussing the potential to regulate PFAS as a Class. After reviewing the current peer-reviewed literature, as well as the available toxicology data for PFAS, the Review Team determined that at the current time it is not feasible to regulate PFAS as a Class.” Agency of Nat. Res., Dep’t of Env’t Conservation, *Drinking Water and Groundwater Protection Division. Advance Notice on the Regulation of Perfluoroalkyl, Polyfluoroalkyl Substances (PFAS) as a Class* (August 14, 2020), <https://dec.vermont.gov/sites/dec/files/PFAS/20180814-PFAS-as-a-Class.pdf>.

36. In a Congressionally-mandated report, the U.S. Department of Defense recognized the diversity of PFAS chemistries, cautioning that “Congress and the Federal regulatory agencies should avoid taking a broad, purely ‘structural’ approach to restricting or banning PFAS. It is critical that future laws and regulations consider and balance the range of environmental and health risks associated with different individual PFAS, their essentiality to the U.S. economy and society, and the availability of viable alternatives.” Dep’t of Def., *Report on Critical Per- and Polyfluoroalkyl Substance Uses* (Aug. 2023), <https://www.acq.osd.mil/eie/eer/ecc/pfas/docs/reports/Report-on-Critical-PFAS-Substance-Uses.pdf>.

37. The U.S. Food and Drug Administration (“FDA”) has similarly recognized that all PFAS are not the same. Based on a review of more than 1,700 published and peer-reviewed scientific articles, FDA concluded that fluoropolymers do not present health or safety concerns when used in medical devices. FDA, *PFAS in Medical Devices* (Aug. 6, 2025), <https://www.fda.gov/medical-devices/products-and-medical-procedures/pfas-medical-devices>.

C. Fluoropolymers are Chemically Distinct From Other Categories of PFAS

38. As noted above, fluoropolymers are a category of PFAS known as fluorinated polymers and include materials such as PTFE (polytetrafluoroethylene) and PVDF (polyvinylidene fluoride). These two fluoropolymers are the number-one and number-two fluoropolymers globally. They provide an example of why the identification of PFAS is such a complicated and controversial area, transcending chemical and physical properties alone given how unique these two compounds are and their myriad use cases (which are valuable and important).

39. Fluoropolymers do meet the structural definitions for PFAS. But knowing the structure alone is not nearly enough to determine whether a molecule is harmful to human health and the environment. And making assumptions about hazard is simply bad science.

40. I was the lead author of a paper first published in 2022, which explained why fluoropolymers should be of low concern despite the fact that they meet some definitions of PFAS. Stephen H. Korzeniowski et al., *A critical review of the application of polymer of low concern regulatory criteria to fluoropolymers II: Fluoroplastics and fluoroelastomers*, 19 Integrated Env't Assessment & Mgmt. 326 (2023). I, along with my co-authors (including Dr. Buck, who was the lead author of the study that provided the Buck Definition), concluded that structural makeup was not enough to determine what might cause harm. Instead, we proposed evaluation of a broad range of chemical properties to assess the level of concern that should be ascribed to a PFAS chemical: (1) polymer composition (structure and elemental composition); (2) molecular weight; (3) molecular weight distribution; (4) particle size; (5) percent of low molecular weight oligomers; (6) electrical charge; (7) reactive functional groups; (8) presence of low molecular weight residues that might leach from the PFAS; (9) resistance to physical, chemical, and biological transformation; and (10) thermal stability. This scientific work built on the prior peer-reviewed paper of Dr. Barb Henry and her colleagues. Barbara J. Henry et al., *A critical review of the application of polymer of low concern and regulatory criteria to fluoropolymers*, 14 Integrated Env't Assessment & Mgmt. 316 (2018).

41. In the 2022 Korzeniowski et al. publication, the various fluoropolymers were assessed against over ten criteria to determine whether these polymers would be considered “polymers of low concern.” Each of the 14 assessed fluoropolymers met the criteria to be considered polymers of low concern for human health and the environment. This and the prior study noted above by Henry et al. in 2018 encompass approximately 96% of the global fluoropolymer market. These two studies are considered to be “In-Life” studies that deal with the fluoropolymers during their industrial and consumer use.

42. These fluoropolymers are large molecules, meaning they have a large molecular weight. The European Union has concluded that “most potential health concern polymers have an average molecular weight” of less than 1,000 Da (Daltons), and oligomer content of more than 1%. *See* Henry et al. at 323. Fluoropolymers are somewhere between *50 to 300 times larger* than the molecules identified as polymers of health concern. Large molecules such as fluoropolymers are not water-soluble and cannot cross cell membranes, meaning their ability to adversely affect critical bodily functions has a low to no probability.

43. Another factor is the degree of reactivity of the polymer: the more reactive the polymer is, the higher the association with adverse effects on human health and the environment. Fluoropolymers don’t have the atoms or group of atoms necessary for a reaction to occur—what our paper described as “reactive functional groups.”

44. Fluoropolymers are also resistant to physical, chemical, and biological transformation—in other words, they remain stable and do not break down. They are abiotically stable, meaning sunlight, water, and oxygen do not cause fluoropolymers to break down. They are biotically stable, meaning bacteria and enzymes (and other organisms and biological molecules) cannot break down fluoropolymers, either. And they are thermally stable up to certain specified high temperatures that significantly exceed the range of normal use conditions. Each fluoropolymer has a given operating temperature, and these guidelines must be followed to maintain the fluoropolymer integrity. That means the current evidence shows fluoropolymers do not break down in a manner that they can become a risk to human health or the environment under normal operating conditions.

45. However, not all PFAS have these “low concern” characteristics, even if they may have some structural similarities with fluoropolymers (because they have one or more fully

fluorinated carbons). Consider perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). PFOA and PFOS share some overlap with fluorinated polymers in that all three are made of several fully fluorinated carbons—the carbon-fluorine bond makes them “persistent.” But PFOA and PFOS differ vastly on the factors described above. They are, for example, much, much smaller in size than fluoropolymers—small enough to enter the human body in various environmental compartments (air and water). Because of their size and water solubility, they are much more mobile in the environment. Both PFOA and PFOS have been voluntarily phased out by industry. *See* EPA, *Fact Sheet: 2010-2015 PFOA Stewardship Program* (Feb. 26, 2026), <https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/fact-sheet-20102015-pfoa-stewardship-program>; EPA, *EPA And 3M Announce Phase Out of PFOS* (May 16, 2000), <https://perma.cc/KA6N-WANC>.

46. Because of these differences, I, along with other scientists who study fluoropolymers and other chemicals that might be categorized as “PFAS,” disagree with any approach to PFAS that groups fluoropolymers with other characteristically different chemicals, like PFOA and PFOS. New Mexico’s approach to PFAS does just that.

IV. OPINIONS

47. The regulation’s generalization of PFAS is not supported by science and runs contrary to a growing scientific consensus that all PFAS are not the same and they should not be assumed to possess the same properties.

48. The regulation’s warning labeling provisions are based on an incorrect understanding and interpretation of PFAS chemistry. A single PFAS label does not differentiate between the various types of PFAS and therefore implies all PFAS are the same—which is directly contrary to the current scientific evidence.

49. EIB's approach appears to be based on an assumption that all PFAS are the same and therefore possess the same properties and potential risk to human health and the environment. As explained above, that is simply not the case.

50. PFAS encompass substances with significantly different chemical, physical, and toxicological properties that inform their uses, potential exposure, and risk profiles. There is a legitimately unresolved scientific debate about what substances qualify as "PFAS," with some definitions encompassing more than 14,000 substances and others encompassing significantly fewer substances.

51. At the same time, there is a growing scientific consensus around the diversity of PFAS chemistries and that such diversity should have been accounted for in PFAS regulation. Experts agree that PFAS should not be grouped together for risk assessment purposes and that it is scientifically inappropriate to assume equal toxicity/potency across the diverse class of PFAS. *See supra* ¶¶ 33-37.

52. Recognizing the diversity of physical and chemical properties within the PFAS family of chemistries is critical for understanding whether a particular PFAS or subgroup of PFAS might be of potential concern to human health or the environment. For example, fluoropolymers have markedly different physical and toxicological characteristics compared to non-polymeric PFAS. As peer-reviewed journal articles have shown, fluoropolymers have a unique combination of properties that set them apart from other PFAS. In particular, fluoropolymers are neither bioavailable nor bioaccumulative, nor do they transform into non-polymeric PFAS under normal environmental conditions. As such, they are properly classified as polymers of low concern for human health or environment.

53. EIB's approach, which fails to differentiate among different types of PFAS, stands in stark contrast to the scientific consensus that PFAS is a diverse class of substances with vastly different physical and chemical properties.

54. PFAS are not monolithic in their properties or uses. A uniform, one-size-fits-all warning would obscure these distinctions and could mislead consumers into believing all of these materials pose similar risks, which is not consistent with the available scientific evidence.

55. In many contexts—such as healthcare, medical devices and implants, electronics, telecommunications, automotive and aerospace transportation, and energy systems, chemical processing and pharmaceuticals—viable alternatives to PFAS are not reasonably available without significantly compromising critical functionality or introducing other often substantial risks.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on this 1st day of July, 2026, in Media, Pennsylvania.

DocuSigned by:

51FA74897414441...
Stephen H. Korzeniowski, Ph.D.

EXHIBIT A

STEPHEN H. KORZENIOWSKI

Media, PA 19063 and Point Pleasant Beach, NJ 08742
www.beachedgeconsulting.com shkorzo@gmail.com

610.316.8205

Consulting Business: Aug 2015 - Present

Adjunct Professor at Penn State Brandywine teaching Corporate Finance	Jan 2016-May 2021
Consultant in Fluorotechnology Industry with two major active clients, one in the AFFF industry and the other in various fluorotechnology end-uses	Jan 2016 - Present
Participant and Member of the Fire Fighting Foam Coalition	Jan 2016 - Present
Participant in the Industry Group FluoroCouncil (now PFP and ATCS) for the two noted clients advising on Global PFAS Regulatory and Science Matters	Jan 2016 - Present
Science Work Group Chairman of FluoroCouncil	Jan 2017-Dec 2019
ITRC PFAS Team, Analytical and AFFF Workgroup	2017 - Present

EXPERIENCED TECHNOLOGY AND BUSINESS MANAGER: 1994 - 2015

Project Management & Major Technology Program Leader

Led multiple cross-functional teams through complex projects and a global technology transformation, meeting critical milestones and driving delivery of on-time, sustainable results. Expert in business and technology strategic options creation and execution, with critical results delivered year-over-year. Recognized subject matter expert in fluorotelomer technology industry; sought out to tackle and resolve difficult issues by business and industry groups. Forward thinker who fosters collaboration and has demonstrated multiple team development successes.

Core competencies:

- Plant project and integrated supply chain management
- Complete global transformation of 'long-chain' to 'short-chain' Capstone® fluorotelomer products
- Technology and business interface with global regulatory agencies
- Leadership roles in Telomer Research Program, FluoroCouncil and Fire Fighting Foam Coalition
- Product stewardship and advocacy
- Profit & loss and strategy development for surfactants & coatings business
- Commercial business development, including acquisition expertise

PROFESSIONAL EXPERIENCE

THE CHEMOURS COMPANY, Wilmington, DE (July 2015)
E.I. DU PONT DE NEMOURS & CO, INC., Wilmington, DE

Global Technology Manager, Surface Protection Solutions 2002 – 2015

- Oversaw research & development and plant project execution for 4 major projects, including: 2 at plants, 1 integrated complete supply chain transformation and 1 international technology transfer.
- Led completion of Capstone® products technology development and market introductions in textiles, coatings, AFFF surfactants and telomer intermediates.
- Acted as a global regulatory agency interface primarily in USA, Germany, Canada, England as well as Australia, S. Korea and China.

- Led fluorotelomer business' US EPA 2010 / 2015 voluntary product stewardship program through developing and execution of detailed plant and product changes to essentially eliminate unwanted impurities, unwanted long-chain materials and minimize all global plant emissions.
- Led fluorotelomer technology global stewardship program and supply chain transformation that helped provide for a sustainable product line and meet all critical regulatory deadlines for both the US and Canada.
- Earned Corporate Marketing Excellence, Engineering Excellence and Sustainable Growth awards. Selected as the only DuPont "Triple Crown" award winner.

Global Business Manager, Fluoroadditives and Custom Chemicals 1996 – 2002

- Directed business and marketing responsibility for multiple complex small business units with total revenues of >\$50MM.
- Detailed fluoroadditives business analysis and strategy development, laying foundation for significant future growth.
- Managed DuPont Chemoswed Active Pharmaceutical Intermediates site in Malmo, Sweden, directing all business and marketing activities.
- Received Corporate Marketing Excellence Award for Stone & Tile business development.

Business Development Manager, Specialty Chemicals 1994 – 1996

- Performed commercial business development to scope out custom chemicals as a strategic segment. Ultimately decided not to move forward.
- Completed long-range strategic planning, resulting in complete restructuring of business unit into a significantly healthier set of businesses.
- Executed pharmaceutical acquisition to help build out custom chemicals capability.

Prior Positions Held: 1977 - 1994

Marketing Manager, White Pigments

Regional Sales Manager, White Pigments

Tech Service / Market Development / R&D Manager

Field Sales, Industrial Chemicals

Research & Development/Technical Service / Market Development

Business and Financial Analysis

EDUCATION

MBA, Finance / Marketing, Widener University, Chester, PA

PhD, Organic Chemistry, Penn State University, University Park, PA

BA, Chemistry, Rutgers University, New Brunswick, NJ

ADDITIONAL TRAINING / EXPERIENCE

Industry group leadership: Global Regulatory Interface Experiences (2000 – 2015)

Former business manager of spouse-owned veterinary business; responsibility for all business, marketing and personnel matters of 6-doctor AAHA-certified hospital (1984 – 2011)

Stephen H. Korzeniowski, Ph.D

Record of Expert Testimony (as of July 1, 2026)

1. *In Re Aqueous Film-Forming Foams Products Liability Litigation*, No. 2:18-mn-2873 (D.S.C.) (deposition testimony).
2. *City of Rome, Georgia v. 3M Company*, No. 19CV02405JFL003 (Ga. Super. Ct., Floyd Cnty.) (deposition testimony).
3. *Parris v. The 3M Company*, No. 4:21-cv-40 (N.D. Ga.) (deposition testimony).
4. *State of Vermont v. 3M Company*, No. 2:25-cv-660 (D. Vt.) (deposition testimony).
5. *Woodward Iodine Corporation vs. E. I. du Pont de Nemours and Company* (deposition and arbitration hearing testimony).
6. *New Jersey Dep't of Env't Protection v. E. I. Du Pont de Nemours & Co.*, No. 1:19-cv-14758 (D.N.J.) (deposition and in-court testimony).
7. *Town of Lyerly v. 3M Company*, No. 24SCA4052 (Ga. Super. Ct., Chattooga Cnty.); *Moss Land Co., LLC v. City of Calhoun*, No. 24CV73929 (Ga. Super. Ct., Gordon Cnty.); *Brooks v. City of Calhoun*, No. 24CV74289 (Ga. Super. Ct., Gordon Cnty.); *Stephens v. 3M Co.*, No. 25CV75072 (Ga. Super. Ct. Gordon Cnty.) (deposition testimony).
8. *Moss Land Co., LLC v. City of Calhoun*, No. 24CV73929 (Ga. Super. Ct., Gordon Cnty.) (deposition testimony).
9. *The Water Works and Sewer Board of the Town of Centre v. 3M Company*, (Ala, Cherokee Cnty.) (trial testimony).
10. *In the Matter of Proposed Adoption of 20.13.2 NMAC, Per- and Polyfluoroalkly Substances in Consumer Products*, N.M. Env. Dep't, Env't Improvement Bd. Dkt. No. 25-61(R) (administrative hearing testimony).

Upcoming:

1. *Christiana Ins. LLC EIDP, Inc. v. Everen Specialty Ltd.* (arbitration testimony)

EXHIBIT B

ACC Exhibit 2

**STATE OF NEW MEXICO
BEFORE THE ENVIRONMENTAL IMPROVEMENT BOARD**

**IN THE MATTER OF PROPOSED
ADOPTION OF 20.13.2 NMAC**

Per- and Poly-Fluoroalkyl Substances in Consumer Products

No. EIB 25-61(R)

**DIRECT TESTIMONY OF DR. STEPHEN KORZENIOWSKI
ON BEHALF OF AMERICAN CHEMISTRY COUNCIL**

January 16, 2026

DIRECT TECHNICAL TESTIMONY OF
DR. STEPHEN KORZENIOWSKI

EIB 25-61 (R)

1
2 My name is Stephen Korzeniowski, and I am submitting direct testimony on behalf of the American
3 Chemistry Council. I am a self-employed consultant. My company is BeachEdge Consulting. For the majority
4 of my career, I was employed by DuPont. Among my roles was Global Technology Manager for surface
5 protection solutions and Global Business Manager for fluoroadditives and custom chemicals. I have extensive,
6 first-hand knowledge of the regulatory, commercial, and scientific dimensions of fluorinated chemistries. Since
7 retiring in 2015, I have remained active in the matters related to fluorochemistry science and regulation. I hold
8 a PhD in organic chemistry from Penn State University. My resume and qualifications are provided in ACC
9 Exhibit 1.

10
11 I have reviewed the text of the proposed rule in this matter, particularly the text provided as an exhibit
12 to the Petition filed by the New Mexico Environment Department (“NMED”) on October 8, 2025. My testimony
13 will refer to that version as the “proposed rule.” The purpose of my testimony is to support the ACC’s position
14 that the warning label provisions in the proposed rule treat all PFAS as if they are the same, when PFAS are in
15 fact a diverse group of substances with different physical and chemical properties. The proposed rule would
16 require that all products, including those exempt from the reporting and currently unavoidable use provisions of
17 the law, bear a warning label, which implies that all types of PFAS and all types of products containing
18 intentionally added PFAS present similar concerns. However, recognizing the diversity of physical and chemical
19 properties within the PFAS family of chemistries is critical for understanding whether a particular PFAS or sub-
20 group of PFAS might be of potential concern to human health or the environment.

21
22 NMED’s generalization of PFAS is not supported by science and runs contrary to a growing scientific
23 consensus that all PFAS are not the same and should not be assumed to possess the same properties. For example,

- 24
25 a. Anderson et al. reports on the opinions of an expert panel “convened to provide insight and guidance on
26 per- and polyfluoroalkyl substances (PFAS) grouping for the purposes of protecting human health from
27 drinking water exposures, and how risks to PFAS mixtures should be assessed.” Most panelists agree
28 that PFAS should not be grouped together for risk assessment purposes and that it is scientifically
29 inappropriate to assume equal toxicity/potency across the diverse class of PFAS.
30
31 b. Two peer-reviewed scientific papers, one for which I was the primary author, demonstrate that
32 fluoropolymers, a specific subset of PFAS, meet criteria that can be used to identify polymers of low

DIRECT TECHNICAL TESTIMONY OF
DR. STEPHEN KORZENIOWSKI

EIB 25-61 (R)

concern for human health or environment.^{1,2} Those criteria include consideration of chemical properties such as:

- Polymer composition (structure and elemental composition);
- Molecular weight;
- Molecular weight distribution (consistency of molecule size in a sample);
- Particle size;
- Percent of low molecular weight oligomers;³
- Electrical charge;
- Reactive functional groups;
- Presence of low molecular weight residues that might leach from the fluoropolymer;
- Resistance to physical, chemical, and biological transformation; and
- Thermal stability.

The authors of the two papers conclude that fluoropolymers are large, stable, and insoluble substances that have properties fundamentally different from those of non-polymeric, water soluble PFAS. Because fluoropolymers are insoluble in water, concerns about environmental mobility do not apply to fluoropolymers. Fluoropolymers are neither bioavailable nor bioaccumulative and do not transform into non-polymeric PFAS in the environment.

- c. In 2021, the 38-nation Organisation for Economic Co-operation and Development (OECD) issued a report developed under the auspices of its Chemicals and Biotechnology Committee that states, “PFASs are a chemical class with diverse molecular structures and physical, chemical and biological properties, it is highly recommended that such diversity be properly recognized and communicated in a clear, specific and descriptive manner. The term “PFASs” is a broad, general, non-specific term, which does not inform whether a compound is harmful or not, but only communicates that the compounds under this term share the same trait for having a fully fluorinated methyl or methylene carbon moiety.”⁴

¹ Henry, B.J., Carlin, J.P., Hammerschmidt, J.A., Buck, R.C., Buxton, L.W., Fiedler, H., Seed, J. and Hernandez, O. (2018), A critical review of the application of polymer of low concern and regulatory criteria to fluoropolymers. *Integr Environ Assess Manag*, 14: 316-334, <https://doi.org/10.1002/ieam.4035>.

² Korzeniowski, S.H., Buck, R.C., Newkold, R.M., El kassmi, A., Leganis, E., Matsuoka, Y., Dinelli, B., Beauchet, S., Adamsky, F., Weilandt, K., Soni, V.K., Kapoor, D., Gunasekar, P., Malvasi, M., Brinati, G. and Musio, S. (2022), A critical review of the application of polymer of low concern regulatory criteria to fluoropolymers II: Fluoroplastics and fluoroelastomers. *Integr Environ Assess Manag*, <https://doi.org/10.1002/ieam.4646>.

³ Oligomers are a polymer or polymer intermediate containing relatively few structural units. See <https://www.merriam-webster.com/dictionary/oligomer>. Accessed January 14, 2026.

⁴ Organisation for Economic Co-operation and Development. Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances: Recommendations and Practical Guidance. 2021. OECD Environment, Health and Safety

DIRECT TECHNICAL TESTIMONY OF
DR. STEPHEN KORZENIOWSKI

EIB 25-61 (R)

- 1
- 2 d. The Drinking Water and Groundwater Protection Division of Vermont's Department of Environmental
- 3 Conservation was specifically charged by the state legislature to develop a class regulation or to explain
- 4 why such a regulation was not possible. In its final report, the Department said, "The Review Team
- 5 spent over a year deliberating, researching, and discussing the potential to regulate PFAS as a Class.
- 6 After reviewing the current peer-reviewed literature, as well as the available toxicology data for PFAS,
- 7 the Review Team determined that at the current time it is not feasible to regulate PFAS as a Class."⁵
- 8
- 9 e. In a Congressionally mandated report, the Department of Defense recognized the diversity of PFAS
- 10 chemistries, cautioning that "Congress and the Federal regulatory agencies should avoid taking a broad,
- 11 purely 'structural' approach to restricting or banning PFAS. It is critical that future laws and regulations
- 12 consider and balance the range of environmental and health risks associated with different individual
- 13 PFAS, their essentiality to the U.S. economy and society, and the availability of viable alternatives."⁶
- 14
- 15 f. The U.S. Food and Drug Administration (FDA) has similarly recognized that all PFAS are not the same
- 16 and based on a review of more than 1,700 published and peer reviewed scientific articles, FDA
- 17 concluded that fluoropolymers do not present health or safety concerns when used in medical devices.⁷
- 18
- 19

20 In conclusion, the warning labeling provisions in NMED's proposed rule are based on an incorrect

21 understanding of PFAS chemistry. NMED would require a warning label on all products containing intentionally

22 added PFAS, even those exempt from the public reporting and currently unavoidable use provisions of the law.

23 NMED's approach appears to be based on an assumption that all PFAS are the same and therefore possess the

24 same properties and potential risk to human health and the environment. The work cited previously on

25 fluoropolymers demonstrates that NMED's approach is not robust. The agency does not differentiate among

26 different types of PFAS with different physical and chemical properties, which is in stark contrast to the growing

Publications Series on Risk Management No. 61. Paris, France. Available at [https://one.oecd.org/document/ENV/CBC/MONO\(2021\)25/en/pdf](https://one.oecd.org/document/ENV/CBC/MONO(2021)25/en/pdf). Accessed January 14, 2026.

⁵ Agency of Natural Resources, Department of Environmental Conservation, Drinking Water and Groundwater Protection Division. Advance Notice on the Regulation of Perfluoroalkyl, Polyfluoroalkyl Substances (PFAS) as a Class. August 14, 2020. Available at <https://dec.vermont.gov/sites/dec/files/PFAS/20180814-PFAS-as-a-Class.pdf>. Accessed January 14, 2026.

⁶ Department of Defense. Report on Critical Per- and Polyfluoroalkyl Substance Uses. August 2023. Available at <https://www.denix.osd.mil/cmrmpp/denix-files/sites/14/2025/07/2025-DoD-Update-on-PFAS-Critical-Uses.pdf>. Accessed January 14, 2026.

⁷ U.S. Food and Drug Administration. PFAS in Medical Devices. Available at <https://www.fda.gov/medical-devices/products-and-medical-procedures/pfas-medical-devices>. Accessed January 15, 2026.

DIRECT TECHNICAL TESTIMONY OF
DR. STEPHEN KORZENIOWSKI

EIB 25-61 (R)

1 scientific consensus around the diversity of PFAS chemistries and that such diversity should be accounted for in
2 PFAS regulation.

3

4 /s/ Dr. Stephen Korzeniowski

5 Dr. Stephen Korzeniowski

**STATE OF NEW MEXICO
ENVIRONMENTAL IMPROVEMENT BOARD**

**IN THE MATTER OF PROPOSED
ADOPTION OF 20.13.2 NMAC**
*Per- and Poly-Fluoroalkyl Substances in
Consumer Products*

No. EIB 25-61 (R)

**NEW MEXICO ENVIRONMENT DEPARTMENT,
Office of Strategic Initiatives**

PETITIONER.

**REBUTTAL TESTIMONY OF
DR. STEPHEN KORZENIOWSKI
ON BEHALF OF AMERICAN CHEMISTRY COUNCIL (“ACC”)**

February 16, 2026

ACC Exhibit 3
Rebuttal Testimony of Dr. Stephen Korzeniowski

I. INTRODUCTION

Q. PLEASE STATE YOUR NAME AND BUSINESS ADDRESS.

A. My name is Stephen Korzeniowski. I am currently a self-employed consultant. My company is BeachEdge Consulting, located at 350 Darlington Rd, Media, PA 19063.

Q. ON WHOSE BEHALF ARE YOU SUBMITTING REBUTTAL TESTIMONY?

A. I am submitting rebuttal testimony on behalf of the American Chemistry Council (“ACC”).

Q. DID YOU PREVIOUSLY SUBMIT DIRECT TESTIMONY IN THIS CASE?

A. Yes. My direct testimony is identified as ACC Exhibit 2.

II. PURPOSE OF TESTIMONY

Q. WHAT IS THE PURPOSE OF YOUR TESTIMONY?

A. The purpose of my rebuttal testimony is to respond to the direct testimony of the New Mexico Environment Department (“NMED”) and other parties to this proceeding. More specifically, I will address the numerous PFAS generalizations and lack of specificity in the testimony of various NMED witnesses regarding the fact that PFAS are a diverse group of substances with different properties and should not be treated in regulation as if they are all the same.

Q. HAVE YOU REVIEWED THE NOTICES OF INTENT TO PRESENT TECHNICAL TESTIMONY AND EXHIBITS FILED BY NMED?

A. Yes.

III. REBUTTAL TESTIMONY

Q. HAVE YOU REVIEWED NMED’S WITNESS – DR. MITCHELL OLSON, DR. ERIC CHAPMAN, AND DR. ALISON LING’S WRITTEN TESTIMONY AND ASSOCIATED EXHIBITS?

ACC Exhibit 3
Rebuttal Testimony of Dr. Stephen Korzeniowski

1 A. Yes.

2 **Q. IN YOUR OPINION, DID THE TESTIMONY PRESENTED BY NMED IN THIS**
3 **PROCEEDING USE SCIENTIFICALLY PRECISE TERMINOLOGY WHEN**
4 **REFERRING TO “PFAS”?**

5 A. No. The term “PFAS” is an umbrella term encompassing more than 14,000 substances with
6 diverse physical, chemical, and toxicological properties, and, to the best of my knowledge,
7 only a small subset of substances classified as PFAS are in commerce.¹ The Department’s
8 testimony largely relied on data specific to perfluoroalkyl acids (PFAAs), yet framed
9 conclusions as applying to “PFAS” broadly². That approach does not reflect the scientific
10 distinctions among PFAS subclasses and may create confusion in risk communication. It
11 would be helpful, and in most cases necessary, to be clear, specific and descriptive when
12 talking about PFAS – which ones are being referred to in each case. An example is the
13 statement that PFAS are persistent and mobile.³ This is an over generalization as many
14 PFAS are not mobile in any manner i.e., fluoropolymers and fluoroelastomers.

15
16 **Q. DOES THE SCIENTIFIC EVIDENCE PRESENTED BY NMED SUPPORT**
17 **REGULATING OR LABELING ALL PRODUCTS CONTAINING ANY**
18 **SUBSTANCE WITH ONE FULLY FLUORINATED CARBON ATOM IN THE**
19 **SAME MANNER?**

¹ Buck et al. 2021. Identification and classification of commercially relevant per- and poly-fluoroalkyl substances (PFAS). *J. Integr Environ Assess Manag* 17(5):1045-1055. doi: 10.1002/ieam.4450.

² See e.g. *NMED Exhibit 32* at 2; *NMED Exhibit 3* at 6-8; *NMED Exhibit 57* at 6, 14

³ *NMED Exhibit 32* at 2

ACC Exhibit 3
Rebuttal Testimony of Dr. Stephen Korzeniowski

1 **A.** No. A structure-based definition of PFAS that captures all substances with at least one fully
 2 fluorinated carbon does not align with the hazard, exposure, and risk conclusions presented.
 3 Much of the Departments expert testimony focused on PFAAs and certain related
 4 compounds.⁴ Extending those conclusions to all PFAS-containing products is not
 5 supported by the scientific data discussed in this proceeding.

6 **Q. WHAT TYPES OF PFAS SUBSTANCES HAVE BEEN PHASED OUT**
 7 **VOLUNTARILY OR RESTRICTED VIA REGULATION IN THE UNITED**
 8 **STATES?**

9 **A.** PFOA, PFOS, and closely related substances have been voluntarily phased out by
 10 industry.⁵ PFOS was phased out by the sole U.S. manufacturer in 2000, and PFOA was
 11 phased out through a voluntary stewardship program with the U.S. EPA by 2015. Some
 12 states are regulating products containing intentionally added PFAS by restricting the
 13 distribution and selling of such products.

14 **Q. HOW DOES THIS DISTINCTION APPLY TO INTERNATIONAL**
 15 **AGREEMENTS SUCH AS THE STOCKHOLM CONVENTION ON PERSISTENT**
 16 **ORGANIC POLLUTANTS?**

17 **A.** The Stockholm Convention addresses specific non-polymeric PFAS, such as PFOS,
 18 PFOA, and other perfluoroalkyl acids. The Stockholm Convention does not address PFAS

⁴ See e.g. *NMED Exhibit 32* at 2; *NMED Exhibit 3* at 6-8; *NMED Exhibit 57* at 6, 14

⁵ United States Environmental Protection Agency, FACT SHEET: 2010-2015 PFOA STEWARDSHIP PROGRAM <https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/fact-sheet-20102015-pfoa-stewardship-program> (last accessed February 16, 2026); United States Environmental Protection Agency, EPA AND 3M ANNOUNCE PHASE OUT OF PFOS, May 16, 2000, https://www.epa.gov/archive/epapages/newsroom_archive/newsreleases/33aa946e6cb11f35852568e1005246b4.html

ACC Exhibit 3
Rebuttal Testimony of Dr. Stephen Korzeniowski

as a single, undifferentiated class.⁶ Its listings reflect evaluations based on persistence, bioaccumulation, and toxicity, rather than a blanket approach to all PFAS.

Q. WHY IS THIS DISTINCTION IMPORTANT FOR ACCURATELY CHARACTERIZING THE CURRENT PROPOSED RULE BY THE DEPARTMENT?

A. Suggesting that PFAS broadly have been phased out or restricted implies a scientific and regulatory consensus that all PFAS present comparable risks.⁷ In reality, most regulatory actions have been narrowly focused on specific non-polymeric PFAS based on substance-specific evidence.

⁶ United Nations Environment Programme. 2009. Decision SC-4/17. Listing of perfluorooctane sulfonic acid, its salts and perfluorooctane sulfonyl fluoride. In: Conference of the Parties to the Stockholm Convention on Persistent Organic Pollutants. Geneva (CH). <http://www.pops.int/Portals/0/download.aspx?d=UNEP-POPS-COP.4-SC-4-17.English.pdf>

United Nations Environment Programme. 2019a. Decision SC-9/4: Listing of perfluorooctane sulfonic acid, its salts and perfluorooctane sulfonyl fluoride. In: Conference of the Parties to the Stockholm Convention on Persistent Organic Pollutants. Geneva (CH). [accessed 2020 Sep 15]. <http://www.pops.int/Portals/0/download.aspx?d=UNEP-POPS-COP.9-SC-9-4.English.pdf>

United Nations Environment Programme. 2019b. Decision SC-9/12: Listing of perfluorooctanoic acid (2019), its salts and PFOA-related compounds. In: Conference of the Parties to the Stockholm Convention on Persistent Organic Pollutants. Geneva (CH). [accessed 2020 Sep 15]. <http://chm.pops.int/Portals/0/download.aspx?d=UNEP-POPS-COP.9-SC-9-12.English.pdf>

United Nations Environment Programme. 2019c. Decision SC-10/13. 2023. Listing of perfluorohexane sulfonic acid (PFHxS), its salts and PFHxS-related compounds. <http://chm.pops.int/Portals/0/download.aspx?d=UNEP-POPS-COP.10-SC-10-13.English.pdf>

United Nations Environment Programme. 2025. UNEP/POPS/COP.12/32/Add.1. Decisions adopted by the Conference of the Parties to the Stockholm Convention on Persistent Organic Pollutants at its twelfth meeting. <https://www.pops.int/TheConvention/ConferenceoftheParties/Meetings/COP12/tabid/9744/Default.aspx>

⁷ NMED Exhibit 46 at 12

ACC Exhibit 3
Rebuttal Testimony of Dr. Stephen Korzeniowski

1 It should be noted that the New Mexico Legislature itself determined that certain classes
2 of PFAS - such as fluoropolymers that are solids at standard temperature and pressure⁸ -
3 do not present risks warranting regulation, and NMED appropriately recognized and
4 implemented that legislative judgment in the proposed rule.⁹ It is important that the record
5 and supporting testimony accurately characterize those substances and not conflate them
6 with PFAS classes that the Legislature expressly chose to treat differently.

IV. LABELING REQUIREMENTS

9 **Q. WOULD LABELING ALL PFAS-CONTAINING PRODUCTS IN THE SAME**
10 **MANNER ACCURATELY REFLECT DIFFERENCES IN HAZARD, EXPOSURE,**
11 **AND POTENTIAL RISK?**

12 A. No. PFAS encompass substances with significantly different chemical, physical, and
13 toxicological properties that inform their uses and potential exposure, and risk profiles.
14 Applying a single, uniform warning implies comparable risk across all PFAS, which is not
15 supported by the scientific distinctions discussed in this proceeding.

16 **Q. HOW DOES THAT CONCERN APPLY TO FLUOROPOLYMERS?**

17 A. Recognizing the diversity of physical and chemical properties within the PFAS family of
18 chemistries is critical for understanding whether a particular PFAS or sub-group of PFAS
19 might be of potential concern to human health or the environment. Fluoropolymers have
20 markedly different physical and toxicological characteristics compared to non-polymeric
21 PFAS such as PFOA or PFOS. A general statement or pronouncement that ‘as a whole,

⁸ NMSA 1978 § 74-15-3 (A)(16)

⁹ NMED Exhibit 2 at 4

ACC Exhibit 3
Rebuttal Testimony of Dr. Stephen Korzeniowski

PFAS are bioaccumulative, persistent and mobile,' is simply incorrect and misleading.¹⁰

In addition, two recently peer-reviewed journal publications¹¹ make a compelling case that fluoropolymers have a unique set of properties that set them apart from other PFAS. For one of the witness statements to label these important publications as “tainted”¹² because industry did them, is a clear mischaracterization of the compelling property, analytical, testing and toxicology data presented in these publications. Another generalization noting that fluoropolymers are not safe¹³ is directly contrary to what is published in the two journal articles cited above. A uniform, one-size-fits-all warning could mislead consumers into believing all of these materials pose similar risks, which is not consistent with the available scientific evidence.

Q. HOW DOES THAT CONCERN APPLY TO THE OTHER EXEMPTIONS IN THE STATUTE?

A. The same concern about misleading consumers applies to blanket labeling of the other exemptions listed in the statute.¹⁴ PFAS are not monolithic in their properties or uses, and many of the exempted applications involve highly technical materials that serve as critical enablers of industries underpinning modern life. In numerous contexts - such as health care,

¹⁰ *NMED Exhibit 3* at 44

¹¹ Henry BJ, Carlin JP, Hammerschmidt JA, et al. 2018. A critical review of the application of polymer of low concern and regulatory criteria to fluoropolymers. *Integrated Environmental Assessment and Management* 14: 316–3

Korzeniowski SH, Buck RC, Newkold RM, et al. 2023. A critical review of the application of polymer of low concern regulatory criteria to fluoropolymers II: Fluoroplastics and fluoroelastomers. *Integrated Environmental Assessment and Management* 19: 326–54.

¹² *NMED Exhibit 3* at 48

¹³ *Id.* at 46

¹⁴ *NMED Exhibit 3* at 48

ACC Exhibit 3
Rebuttal Testimony of Dr. Stephen Korzeniowski

1 energy systems, transportation, electronics, and other infrastructure - these substances are
2 essential to safety, durability, or performance, and viable alternatives are not reasonably
3 available without compromising function or introducing other risks. Applying a uniform
4 label to these categories would obscure these distinctions, potentially confuse consumers,
5 and fail to reflect the careful policy judgments already embedded in the statutory
6 exemptions. Due to these concerns, the American Chemistry Council is proposing to
7 exclude the proposed exemptions in Section 20.13.2.10 NMAC¹⁵ from labeling
8 requirements.¹⁶

9
10 **Q. DOES THIS CONCLUDE YOUR TESTIMONY?**

11 **A.** Yes.

12
13 /s/ Stephen Korzeniowski

14 Stephen Korzeniowski

¹⁵ *NMED Exhibit 2* at 3


¹⁶ *See ACC Exhibit 6*

Proposed Adoption of PFAS in Consumer Products

Dr. Stephen Korzeniowski
American Chemistry Council

Purpose of Testimony

- Central concern:
 - Proposed rule treats **all PFAS as the same**
 - Requires warning labels on **all products with intentionally added PFAS**
 - Includes products otherwise exempt under reporting and unavoidable use provisions



PFAS Are Not One Uniform Substance

- PFAS = Diverse group of chemicals
- Significant variation in:
 - Physical properties
 - Chemical properties
 - Environmental behavior
 - Toxicological profiles
- Assuming equal risk across all PFAS is not scientifically supported

An Important Question - Are They All The Same?

A Big Universe of Very Different Substances




C-H Compounds

We would never group them together and say “they are the same,” because they are Not the same.

Fluorocarbons – Also a Big Universe of Very Different Substances

C-F Compounds



We should Not group them together, because they are Not “the same.”

Hydrocarbon Examples


Common Chemical Examples



Ethanol or
Ethyl Alcohol

Common Use: Alcoholic
Beverages; Beer; Wine

Ingestion Effects: Light
Headed; Intoxication




Methanol or
Methyl Alcohol

Common Use: Windshield
Washer Fluid

Ingestion Effects:
Abdominal Pain; Blurred
Vision and/or Blindness

Common Chemical Examples


Ethylene Glycol



Common Use: Automotive
Antifreeze & Engine
Coolant

Ingestion Effects: Toxic to
Humans & Wildlife; Dogs,
Cats – Kidney Damage,
Failure & Death

Propylene Glycol




Common Uses: “Non-toxic”
Antifreeze; Food & Pharma

Ingestion Effects: Generally
Regarded As Safe (GRAS) by
FDA and Much Safer



PFAS* include many different substances with very different properties

Similarities



1 fully fluorinated carbon
or $\text{CF}_2\text{-CF}_2\text{-CF}_2\text{-}$ or

Differences



***Per- and Poly-Fluoroalkyl Substances**

Be Clear, Specific and Descriptive

Fluoropolymers are Fundamentally Different

- Fluoropolymers meet “polymer of low concern*” criteria
- Key characteristics:
 - High molecular weight
 - Insoluble in water
 - Large, stable structures
 - Not bioavailable
 - Not bioaccumulative
 - Do not degrade into smaller PFAS
- Environmental mobility concerns do not apply to fluoropolymers.

*defined as polymer properties predictive of low health and environmental hazard

Problems with NMED's Proposed Labeling

- **Proposed Rule Assumption**
 - All PFAS = Same properties + Same risk
- **Scientific Reality**
 - PFAS vary significantly
 - Fluoropolymers differ fundamentally from small, water-soluble PFAS
- **Uniform warning labels imply uniform hazard**
 - Growing scientific consensus: PFAS are diverse
 - Fluoropolymers are materially different from other PFAS
- **NMED's warning label approach:**
 - Fails to differentiate among chemistries
 - Is inconsistent with current scientific understanding
 - Is not scientifically robust

PFAS Regulation and Grouping: As One Group or Class

- Premise for Treating All PFAS the Same – as ***One**** or “***The Chemical Class of PFAS***”
 - Regrettable substitution of long chains; large number of PFAS on commercial market; not conducive to classic risk assessment; intrinsic property of persistence alone is sufficient justification to group as ***One***; increased probability of adverse effects on human health and environment; irreversible and increasing contamination
- Considerations:
 - Persistence is an intrinsic property but not an intrinsic hazard and it does not by itself imply an adverse effect
 - Not scientifically justified to classify inert solids, salts, liquids and gases in a single class – as ***One*** – where properties like vapor pressure, environmental partitioning, hydrophobicity/lipophilicity, aqueous solubility and hazard itself**, as well as surface and material properties vary greatly

***Strategies for grouping per- and polyfluoroalkyl substances (PFAS) to protect human and environmental health**

Ian T. Cousins, Jamie C. DeWitt, Julianne Glüge, Gretta Goldenman, Dorte Herzke, Rainer Lohmann, Mark Miller, Carla A. Ng, Martin Scheringer, Lena Vierke and Zhanyun Wang *Environ. Sci.: Processes Impacts*, 2020,22, 1444-1460

***Scientific Basis for Managing PFAS as a Chemical Class** Carol F. Kwiatkowski, David Q. Andrews, Linda S. Birnbaum, Thomas A. Bruton, Jamie C. DeWitt, Detlef R. U. Knappe, Maricel V. Maffini, Mark F. Miller, Katherine E. Pelch, Anna Reade, Anna Soehl, Xenia Trier, Marta Venier, Charlotte C. Wagner, Zhanyun Wang, and Arlene Blum *Environmental Science & Technology Letters* 2020 7 (8), 532-543

****Application of a Framework for Grouping and Mixtures Toxicity Assessment of PFAS: A Closer Examination of Dose-Additivity Approaches**

Philip E. Goodrum, Janet K. Anderson, Anthony L. Luz, and Graham K. Ansell *Toxicological Sciences*, 2020: doi: 10.1093/toxsci/kfaa123

Rebuttal Testimony of Dr. Korzeniowski

A thick, hand-drawn style orange line that spans the width of the text above it.

Overgeneralization in NMED Testimony

- NMED relied primarily on data for **Perfluoroalkyl acids (PFAAs)**
- Conclusions framed as applying to **all PFAS**
- This approach:
 - Ignores PFAS subclasses
 - Risks misleading risk communication

ACC Recommendation

- Exclude statutory exemptions in **Section 20.13.2.10 NMAC** from labeling requirements
- Align labeling with:
 - Science
 - Risk-based regulation
 - Legislative judgments already embedded in statute

BEFORE HONORABLE FELICIA L. ORTH

Deposition of : VOL IV HEARING

taken on: February 26, 2026



531 Harkle Road, Suite A
Santa Fe, NM 87505

505-984-2244

www.cumbrecourtreporting.com

BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

1 STATE OF NEW MEXICO
2 ENVIRONMENTAL IMPROVEMENT BOARD
3
4 IN THE MATTER OF PROPOSED) EIB NO.:
ADOPTION OF 20.13.2 NMAC,) 25-61(R)
5 Per- and Poly-Fluoroalkyl)
Substances in Consumer)
6 Products.)
7

8
9 BEFORE THE HONORABLE FELICIA L. ORTH
10 THURSDAY, FEBRUARY 26, 2026
11 9:01 A.M.
12 EVIDENTIARY HEARING VOLUME IV
13
14

15 **CERTIFIED**
16 **TRANSCRIPT**
17
18

19 REPORTED BY:
20 DAVID M. LEE, RMR, CCR,
21 Certificate Number 50391
New Mexico CCR Number 537
22 Cumbre Court Reporting Services, LLC
513 Harkle Road
23 Suite A
Santa Fe, New Mexico 87505
24 (505) 984-2244
cumbrecourt@comcast.net
25



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1140	Page 1142
1 APPEARANCES 2 FOR THE ENVIRONMENTAL IMPROVEMENT BOARD: 3 SANDRA ELY, BOARD CHAIR 4 PHOEBE SUINA, BOARD VICE CHAIR 5 J. BARRY BITZER, BOARD MEMBER 6 GUADALUPE CARRASCO, BOARD MEMBER 7 RONALD CURRY, BOARD MEMBER 8 KAREN GARCIA, BOARD MEMBER 9 FELICIA L. ORTH, HEARING OFFICER 10 felicia.l.orth@gmail.com 11 NEW MEXICO DEPARTMENT OF JUSTICE 12 BY: EDUARDO UGARTE, II, ESQ. 13 BOARD COUNSEL 14 eugarte@nmdoj.gov 15 Post Office Box 1508 16 Santa Fe, New Mexico 87504-1508 17 (505) 264-5741 18 FOR NEW MEXICO ENVIRONMENT DEPARTMENT: 19 NEW MEXICO ENVIRONMENT DEPARTMENT 20 BY: GREGORY S. SMITHKIER, ESQ. 21 Gregory.smithkier@env.nm.gov 22 ANDREW P. KNIGHT, ESQ. 23 Andrew.knight@env.nm.gov 24 MARK F. ROSEBROUGH, ESQ. 25 Mark.rosebrough@env.nm.gov 26 PAMELA JONES, PARALEGAL 27 Pamela.jones@env.nm.gov 28 LUIS LOPEZ, PARALEGAL 29 luis.lopez@env.nm.gov 30 1190 South St. Francis Drive 31 Suite N-4050 32 Albuquerque, New Mexico 87507 33 (505) 531-7736	1 FOR COMPLEX PRODUCTS MANUFACTURERS 2 COALITION: 3 WILEY REIN, L.L.P. 4 BY: HENRY M. RIVERA, ESQ. 5 hrivera@wiley.law 6 REBECCA J. FIEBIG, ESQ. 7 rfiebig@wiley.law 8 MARTHA MARRAPESE, ESQ. 9 marrapese@wiley.law 10 2050 M Street Northwest 11 Washington, D.C. 20036 12 (202) 719-7000 13 FOR ALLIANCE FOR AUTOMOTIVE INNOVATION: 14 WILEY REIN, L.L.P. 15 BY: HENRY M. RIVERA, ESQ. 16 hrivera@wiley.law 17 REBECCA J. FIEBIG, ESQ. 18 rfiebig@wiley.law 19 MARTHA MARRAPESE, ESQ. 20 marrapese@wiley.law 21 2050 M Street Northwest 22 Washington, D.C. 20036 23 (202) 719-7000 24 FOR BRUCE WETHERBEE, PRO SE: 25 BY: BRUCE WETHERBEE 26 editor@thecandlepublishing.com 27 60 Thoreau Street 28 Suite 103 29 Concord, Massachusetts 01742 30 (505) 501-1570 31 ALSO PRESENT: LISA O'GRADY 32 INTERPRETER 33 AMELIA CARDEÑA 34 INTERPRETER 35 MELINDA MAASS 36 INTERPRETER
Page 1141	Page 1143
1 FOR CROPLIFE AMERICA AND AMERICAN 2 CHEMISTRY COUNCIL: 3 GALLAGHER & KENNEDY, P.A. 4 BY: DALVA L. MOELLENBERG, ESQ. 5 dlm@gknet.com 6 ANTHONY J. TRUJILLO, ESQ. 7 ajt@gknet.com 8 SERAFINA SELUJA, ESQ. 9 serafina.seluja@gknet.com 10 1239 Paseo de Peralta 11 Santa Fe, New Mexico 87501-2758 12 (505) 989-7278 13 FOR PFAS PHARMACEUTICAL WORKING GROUP 14 (PPWG): 15 MODRALL, SPERLING, ROEHL, HARRIS & 16 SISK, P.A. 17 BY: STUART R. BUTZIER, ESQ. 18 stuart.butzier@modrall.com 19 STANLEY HARRIS, ESQ. 20 stan.harris@modrall.com 21 BENJAMIN C. ROSSI, ESQ. 22 benjamin.rossi@modrall.com 23 Post Office Box 2168 24 Albuquerque, New Mexico 87103-2168 25 (505) 848-1823 26 (505) 848-9710 (Facsimile) 27 FOR HOUSEHOLD & COMMERCIAL PRODUCTS 28 ASSOCIATION: 29 HOUSEHOLD & COMMERCIAL PRODUCTS 30 ASSOCIATION 31 BY: STEVEN BENNETT, PH.D. 32 Executive Vice President 33 SCIENTIFIC & REGULATORY AFFAIRS 34 sbennett@thehcpa.org 35 1625 I Street Northwest 36 Suite 700 37 Washington, D.C. 20006	1 I N D E X 2 EXAMINATION PAGE 3 ALEX STANTON, PH.D. 4 Cross-Examination By Mr. Smithkier1149 5 ALEX STANTON, PH.D. 6 MARTHA MARRAPESE, ESQ. 7 Examination By Chair Ely 1162 8 Examination By Vice Chair Suina 1168 9 Examination By Mr. Ugarte 1176 10 BARBARA JAYNE HENRY, PH.D. 11 Direct Examination By Mr. Trujillo1210 12 Cross-Examination By 13 Mr. Rosebrough 1226 14 Cross-Examination By Mr. Wetherbee1239 15 Examination By Board Member Bitzer1247 16 STEPHEN H. KORZENIOWSKI, PH.D. 17 Direct Examination By Mr. Trujillo1251 18 Cross-Examination By Ms. Fiebig 1293 19 Cross-Examination By Mr. Knight 1328 20 Redirect Examination By 21 Mr. Trujillo 1343 22 Examination By Chair Ely 1346 23 ERIC CHAPMAN, PH.D. 24 Examination By Chair Ely 1355 25 Cross-Examination By Ms. Fiebig 1358 26 Examination By Mr. Ugarte 1362



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1248 1 A. Yes. 2 Q. Okay. I just wanted a little 3 clarification. I had heard "molecular 4 weight," and that makes sense to me. 5 BOARD MEMBER BITZER: That's 6 all I have. Thank you. 7 HEARING OFFICER ORTH: Thank 8 you. 9 Member Carrasco. 10 Let's see, Member Carrasco, do 11 you have questions of Dr. Henry? 12 Member Curry, do you have 13 questions of Dr. Henry? 14 BOARD MEMBER CURRY: I do not. 15 HEARING OFFICER ORTH: Thank 16 you. 17 Counsel. 18 MR. UGARTE: No questions, 19 Madam Hearing Officer. Just a comment 20 to tell Dr. Henry that I grew up in 21 Beaver Falls, Pennsylvania, so I 22 figured I'd get a smile from you. 23 THE WITNESS: I did; the land 24 of Joe Namath. 25 MR. UGARTE: Yes, and Geneva	Page 1250 1 I've got to get used to saying his 2 name; Dr. Korzeniowski. 3 Thank you, Dr. K. 4 HEARING OFFICER ORTH: All 5 right. 6 Dr. Korzeniowski, would you -- 7 good morning -- spell your first and 8 last name, please. 9 THE WITNESS: Stephen, 10 S-T-E-P-H-E-N; last name is 11 K-O-R-Z-E-N-I-O-W-S-K-I. 12 HEARING OFFICER ORTH: Thank 13 you. 14 Do you swear or affirm to tell 15 the truth. 16 THE WITNESS: I do. 17 HEARING OFFICER ORTH: Thank 18 you very much. 19 Go ahead, Mr. Trujillo. 20 21 STEPHEN H. KORZENIOWSKI, PH.D., 22 after having been first duly sworn, 23 was examined and testified as follows: 24 /// 25 ///
Page 1249 1 College. 2 THE WITNESS: And Geneva 3 College. 4 MR. UGARTE: Thank you. 5 HEARING OFFICER ORTH: All 6 right. Any reason not to excuse 7 Dr. Henry? 8 Will you offer exhibits? 9 MR. TRUJILLO: Madam Chair, I 10 move for the admission of the exhibits 11 associated with Dr. Henry. 12 HEARING OFFICER ORTH: I'll 13 pause for a moment in the event there 14 are objections. No. 15 They are admitted. Thank you. 16 (ACC Exhibit 4 was received in 17 evidence.) 18 (ACC Exhibit 5 was received in 19 evidence.) 20 HEARING OFFICER ORTH: Thank 21 you very much, Dr. Henry. 22 THE WITNESS: Thank you very 23 much. 24 MR. TRUJILLO: Madam Chair, 25 next we'd call -- I call him Dr. K.	Page 1251 1 DIRECT EXAMINATION 2 BY MR. TRUJILLO: 3 Q. Good morning, Dr. K. 4 Who is your current employer? 5 A. My current employer is my own 6 company, BeachEdge Consulting. I 7 started my company ON August 1st, 2015, 8 when I retired from my corporate job. 9 Q. And on whose behalf are you 10 Testifying today? 11 A. ACC, or the American Chemistry 12 Council. 13 Q. Did you provide a Resumé filed 14 as ACC Exhibit 1? 15 A. I did. 16 Q. And that states your employment 17 history, qualifications, and 18 experience. 19 A. Through today, yes. 20 Q. Can you briefly summarize your 21 relevant experience for the Board. 22 A. Yeah, I guess I can. 23 I started in this chemistry, 24 and they didn't call it "PFAS" at the 25 time, but I started in 1977. I worked



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1252 1 for about 7 years, 6, 7 years in the 2 lab and doing a few other things in 3 this kind of chemistry. 4 Like many large companies I got 5 the opportunity to do many other jobs 6 between 1984 and 1996. 7 Then I came back in 1996, and 8 for the last 30 years, I've been in 9 this business, so about 36 years 10 direct experience in fluorochemical 11 technology. 12 Q. Thank you. 13 Can you briefly describe any 14 peer-reviewed papers you have authored 15 that are important to this proceeding? 16 A. What I've done is as an 17 industry person you often don't get a 18 lot of chance to publish, but I was 19 fortunate. I got a chance to publish 20 as well as do a number of posters and 21 major talks, and so I have about 60, 22 about 20 of which are peer-reviewed 23 publications. 24 Those publications are on: 25 Analytical chemistry;	Page 1254 1 Q. Do you adopt your Written 2 Direct Testimony as your own Testimony 3 for this matter? 4 A. I do. 5 Q. What is the purpose of your 6 Direct Testimony? 7 A. What I wanted to do was to 8 take a few moments -- and I'm only 9 going to take about 15 or 16 in my 10 Direct, and I have about 11 or 12 in 11 the Rebuttal, just to frame for the 12 Board and those in the room some of 13 the things that I saw in the Testimony 14 that was given by others that didn't 15 quite make sense to me. 16 I wanted to take the 17 opportunity to give my point of view, 18 as did Dr. Henry, on what we see and 19 what the Board needs to hear from an 20 alternative point of view from 21 chemistry and science. 22 Q. Go ahead and please present 23 your summary of your Direct Testimony 24 today. 25 A. Okay. Madam Hearing Chair and
Page 1253 1 Toxicology; 2 Pharmacokinetics; 3 Degradation or biodegradation; 4 Sources; 5 Fate; and, 6 Transport. 7 We, me and 3 other authors, 8 did the first major publication to 9 figure out where PFOA came from, from 10 the companies and in the environment 11 in 2006. 12 Then we published one of the 13 "Polymers of Low Concern" papers in 14 2022/2023. 15 In that span I did a whole host 16 of different chemistries, but I think 17 my publication days are done. 18 Q. Thank you, Dr. K. 19 Did you provide Written 20 District Testimony that was filed in 21 this matter as ACC Exhibit 2? 22 A. I did. 23 Q. Do you have any corrections to 24 your Written Direct Testimony? 25 A. I do not.	Page 1255 1 the Members of the Board, good day to 2 you all. Thank you for allowing me to 3 be here today. 4 I'm an Organic Chemist, as you 5 heard, who started in fluorochemistry 6 in 1977. I have a Bachelor's of Arts 7 degree in Science and Chemistry from 8 Rutgers. I went and got a Ph.D. in 9 Organic Chemistry from Penn state 10 University. Then after 3 or 4 years 11 of working, I went back and got an MBA 12 in finance. 13 I transitioned to many roles, 14 as I described, and all of those roles 15 where science and business allowed me 16 to take the science as well as put in 17 perspective what it means in: 18 Business; 19 Environmental; and, 20 Other worlds. 21 I've been a member of ITRC, as 22 Dr. Olson had testified the other day, 23 the same thing since 2017. 24 I've been a member of the Fire 25 Fighting Foam Coalition since 2021;



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1256 1 that's the uses AFFF or firefighting 2 foam with fluorinated surfactants. 3 I've been a member of a number 4 of industry groups since 2000, of which 5 ACC has been a partner for many of 6 those years. 7 I'm here today on behalf of 8 ACC in support of the ACC position 9 that the Warning Label provisions in 10 the Proposed Rule treat all PFAS the 11 same, when PFAS, as we know, are quite 12 different. I'll spend a fair amount 13 of time describing that today: 14 There are very, very diverse 15 group of substances with vastly 16 different physical and chemical 17 properties. The central concern is 18 that this Proposed Rule treats all PFAS 19 the same despite the huge differences, 20 and I'll explain some of those 21 differences. 22 It requires a Warning Label on 23 all products with intentionally added 24 PFAS, but it includes products 25 otherwise exempt under Reporting and	Page 1258 1 There is no consensus. I'm not sure 2 there is ever going to be consensus. 3 You all have seen and agreed 4 on the definition of PFAS; that, over 5 the past few days in the Rule, I fully 6 fluorinated carbon, and Barb Henry 7 talked about that a few minutes ago. 8 This definition was proposed by OECD 9 in 2021. 10 As the definition has changed, 11 so have the number of potential number 12 of PFAS compounds in the list. You've 13 heard nonstop either today and the 14 past 3 days, as well as in all the 15 Testimony how many PFAS really are 16 there. 17 I put this chart together, and 18 it's evolved, obviously. The last 19 time I put this together was 2021, but 20 what's the definition and what does it 21 mean? Really, are there 14- or 15,000 22 PFAS compounds hanging around? The 23 answer is no. 24 There is lists and databases 25 where you can say there is 14,000, but
Page 1257 1 Unavoidable Use provisions. 2 As you've heard over the past 3 3 days of hearings, and in the 4 documents you have received, there are 5 several... 6 Well there is a few schools of 7 thought on how to treat the PFAS 8 chemicals. Since they all have carbon 9 and fluorine, they have a fully 10 fluorinated carbon in their structure, 11 and more on this in a minute. 12 One group says, and you've 13 heard this many times this week, that 14 if it meets the PFAS definition, and 15 given that persistence is sufficient, 16 PFAS should be grouped together and 17 treated as 1, group them as 1. 18 Others, like me myself, say 19 that PFAS are not the same. Even if 20 they have a fully fluorinated carbon, 21 they should not be treated -- they 22 should be treated separately and not 23 grouped as 1. 24 If the question is whether 25 there is a consensus, absolutely not.	Page 1259 1 the fact of the matter is, as the 2 definition has evolved, the number of 3 PFAS have evolved that are captured in 4 that list. 5 I mean I charted this back to 6 1994. There were no real numbers at 7 that point, and Hekster in the 8 Netherlands starting using "PFAS," but 9 only mentioned "perfluorinated 10 substance," not "PFAS" as we know it 11 today. 12 The OECD in 2007 created sort 13 of the first list. That was 982 when 14 the OECD in 2007. 982 compounds is a 15 far cry from where we are today. 16 Buck in 2011, they are credited 17 with the first creation of the 18 definition of PFAS in 2011, the 19 Buck/Franklin paper. 20 HEARING OFFICER ORTH: Please 21 keep it slow. 22 THE WITNESS: Okay. Then in 23 the OECD paper in 2018, which we base 24 one of our studies on, which I'll talk 25 about in a moment, because the



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1260 1 definition changed, and there was that 2 4730. 3 When the EU called for 4 evidence in 2020, it was about 8,000. 5 Then you have got the new OECD 6 definition from 2021 and EPA database 7 and lists, and now it's about 14,000. 8 I said this a minute ago, the 9 14,000 are based on lists and databases, 10 not a commercial context, and we heard 11 that this morning. 12 The EPA list was 7- or 800; 13 when we did our study it was 600, so 14 same ballpark. 15 The work we did and we 16 published in a peer-reviewed article 17 in 2021 took the OECD list from 2018, 18 and of the 4730, and we found 6%. The 19 survey we did, it was 256, but it was 20 only 3 companies, so we extrapolated 21 that to be maybe it was 6- or 700 22 directly on top of what you just heard 23 this morning. 24 If you're looking at what 25 compounds are relevant and important	Page 1262 1 and you heard this a few minutes ago 2 too, despite what I just said here, 3 many believe that if you have a PFAS 4 with a fully fluorinated carbon -- go 5 back one -- and given that they are 6 viewed as persistent, persistence is 7 sufficient. My view is it's not. I 8 am not in that camp; we are opposed to 9 the grouping as 1. 10 Now you can change the chart. 11 All right. Perspective: 12 I want to give you some 13 examples, and, you know, you hear me 14 say that they are not the same, but 15 give me a moment here to provide a 16 little education and then see if I can 17 help you as to why we believe they are 18 not the same: This is on Labeling and 19 grouping at a high level. After 20 this -- don't change yet -- I'm going 21 to go to a granular level: 22 An important question that 23 we've been asking for several days now 24 is are they all the same? Let me start 25 with carbon and hydrogen compounds:
Page 1261 1 in commerce and potentially consumer 2 products, it's hundreds, not thousands. 3 Next chart. 4 PFAS are not 1 uniform 5 substance; Dr. Henry gave you a little 6 flavor of that this morning. 7 Also Drs. Chapman and Olson 8 gave a broad overview of what PFAS is 9 with their Testimony, and I don't need 10 to repeat that. I don't think you 11 want a chemistry lesson this morning; 12 enough is enough. You will see some 13 chemistry in a few minutes. 14 You have heard that PFAS are a 15 diverse group of chemicals that vary 16 very significantly in their physical 17 and chemical properties: 18 Their environmental behavior; 19 Environmental fate and 20 effects; 21 Their toxicological profiles. 22 Assuming equal risk across all 23 PFAS is simply not scientifically 24 justified. 25 On the other hand, many believe,	Page 1263 1 You see the solid, which is 2 "polyethylene," which is a tubing that 3 you use in your home and water 4 systems. 5 You see "ethyl alcohol," and 6 we'll talk a little bit about that in 7 a minute. You know what ethyl alcohol 8 is and where it's used, and where it 9 comes from. 10 Then if you're like me at 11 home, I have no services in my house. 12 I have to have propane for heat so I 13 have gas. 14 These are carbon and hydrogen 15 compounds. Are they the same? Would 16 you group them the same just because 17 they have carbon and hydrogen in their 18 backbone? The answer is no. 19 That is the same question you 20 should ask for fluorocarbons. They 21 are also really a large universe of 22 very different, very diverse substances. 23 For the carbon and fluorine 24 compounds, you can say they're CF3s; 25 solid is PTFE,



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1264 1 polytetrafluoroethylene. 2 The liquid could be what we 3 call the 6:2 fluorotelomer alcohol. 4 This alcohol is what you've heard over 5 the past few days as the newer 6 chemistry, or the short chains, but 7 that's a liquid. 8 Then for gas would be 9 refrigerants or blowing agents. 10 And so, you know, you look at 11 these and you say, "Okay. Are these 12 compounds the same?" The answer is I 13 don't think so. 14 Let's go to a more granular 15 example, actually 2 of them on the 16 next chart. These substances will be 17 very familiar to you: 18 These are hydrocarbon 19 examples, and I'll follow with 20 fluorocarbon in just a second. 21 On the left-hand side you have 22 2 common chemical examples. You have 23 ethanol, and you know what ethanol is. 24 It's in your beer, your wine, your 25 spirits. It's used as a solvent.	Page 1266 1 However many years ago you may 2 remember there was an alternative 3 glycol called propylene glycol that 4 just had one more carbon, but had 5 vastly different properties such that 6 it's generally regarded as safe by the 7 FDA. 8 The fact that you have a 9 structure, 2 simple examples, doesn't 10 mean they have the same hazards and 11 they don't require the same labels. 12 Next chart please. 13 All right. You heard a fair 14 amount of this from Mark: 15 "PFAS include many 16 different substances with 17 very different properties." 18 They are similar, yes. They 19 have CF3, but from that point on it 20 changes because you do have gases, 21 liquids, and solids. I said that a 22 few minutes ago. 23 Barb started to highlight some 24 of the key features you have to really 25 think about when you think about PFAS
Page 1265 1 Then if you just change the 2 structure and you get rid of that CH2 3 in the middle, you have ethanol. They 4 look the same. They are carbon, 5 hydrogen, and oxygen, they are alcohols, 6 but they have vastly different hazards. 7 Ethanol you can drink; methanol, if 8 you drink it, you go blind. 9 Saying something is in the 10 same family implying the same hazards 11 makes no sense with 2 simple 12 hydrocarbon examples. 13 Let me give you one more on 14 the right-hand side: 15 For those of you who have ever 16 worked on a car, you know you need 17 antifreeze. Ethylene glycol was the 18 common antifreeze that's been used for 19 years and years and years. It's great 20 if you don't have a pet, because if 21 that antifreeze is leaking and your 22 dog or cat licks that antifreeze, they 23 can have kidney failure or die. My 24 wife's a veterinarian, so I get this 25 story all the time.	Page 1267 1 as a class. In this case you've got 2 stability from seconds to thousands of 3 years. Do they degrade? 4 Do they photolyze? 5 Do they degrade in soil? 6 Mobility? Barb talked about 7 this also. 8 Are they insoluble or are they 9 highly mobile and soluble in the 10 environment, either in the air or in 11 water? 12 Toxicity. 13 There is different grades. 14 You heard Dr. DeWitt talk about the 15 gradation. This is low to high. 16 There is gradients in between, and 17 size. 18 How big are these? From really 19 large back to really small; Barb 20 highlighted that in several of her 21 charts. 22 One of the things that I have 23 been saying and my colleagues have 24 been saying over the years, and that's 25 one of my major criticisms and one of



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1268 1 the reasons I'm talking today, is that 2 PFAS is so big. Unless you tell people 3 what you're talking about, they don't 4 know. They assume it's all the same. 5 PFAS includes hundreds, if not 6 thousands of compounds, so my motto is 7 pretty simple, and I said that I think 8 in my Testimony and elsewhere. To be 9 clear, be specific and be descriptive 10 when you're talking about PFAS. 11 Next chart. 12 You've heard this from us and 13 you've heard this from Barb: 14 Fluoropolymers are 15 fundamentally different. They meet 16 the criteria of what we call "polymer 17 of low concern," and as Barb said, and 18 you might have missed it, but it's 19 defined as: 20 "Polymer properties 21 predictive of low health and 22 environmental hazard." 23 I'll elaborate more when I do 24 my Rebuttal, but you don't see the 25 word "no" there. These are not	Page 1270 1 fluoropolymers because they are solids 2 and they don't have solubility and 3 they don't have vapor pressure. 4 Now is that an absolute? I 5 can't say it's an absolute, but it's 6 pretty good. It holds pretty good. 7 All right. One of things I 8 want to talk about here, and I'm going 9 to say it again in the Rebuttal in a 10 little bit more detail, but there are 11 2 papers, one by Dr. Henry and her 12 global colleagues in 2018, and another 13 paper in 2022 by myself and 7 other 14 global companies where we talk about 15 "polymers of low concern." 16 These studies combined cover 17 about 96% of the major global 18 fluoropolymers, and include all the 19 properties; residuals, monomers, 20 extractables, and all the fundamental 21 properties. 22 I am going to come back to 23 that because it's really important, 24 because there was a lot of questions 25 yesterday and even today about life
Page 1269 1 "polymers of no concern," they are 2 "polymers of low concern," and that's 3 an important distinction. 4 What you need to do is you need 5 to assess -- which is what we've done, 6 and Barb did with her group in 2018. 7 I did that with my colleagues in 8 2022 -- the world of fluoropolymers 9 against 12, 13 different criteria. 10 What we look at is molecular 11 weight or size. 12 We look at solubility in 13 water. 14 We look at whether the 15 structures are large and stable. Barb 16 was talking about that in terms of 17 degradation either in soil or in air. 18 Are they bioavailable? 19 Are they bioaccumulative? 20 Do they degrade into smaller 21 pieces? 22 Are they precursors, which is 23 a really, really important concept. 24 Environmental mobility concern 25 generally does not apply to	Page 1271 1 cycle. 2 Next chart. 3 There we go; two more charts, 4 this one and the next one. 5 Before I finish with my final 6 2 slides, I want to reiterate that in 7 both of the "polymer concern" papers 8 both 2018 and 2022, that was online, 9 and in 2023 in print. We not only 10 discuss the end of life, which we 11 heard today, the end of life 12 properties of the fluoropolymer life 13 cycle, but we also discuss beginning 14 of life, which is how they are made, 15 and end of life. I'll talk about the 16 life cycle in a few minutes. 17 What do we see as the problems 18 with the proposed Labeling? We've all 19 talked about that for the past four 20 days. 21 "All PFAS have the same 22 properties and the same 23 risk." 24 No, they don't, And a label 25 that covers all of them, which is



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1272 1 what's proposed, even though there are 2 exceptions, doesn't make scientific 3 sense in my view, and I am a 4 scientist. 5 The scientific reality is that 6 PFAS vary very significantly. 7 Fluoropolymers differ fundamentally 8 from the very small water soluble PFAS 9 or the PFAAs that Barb talked about 10 this morning. 11 There is growing scientific 12 consensus that PFAS are diverse. As I 13 said earlier, there are different 14 groups that think about these, and I'm 15 not sure we're ever going to get 16 together. We, in good spirit, have 17 spirited discussions and we end up 18 agreeing to disagree. 19 Fluoropolymers -- and you 20 heard this also -- are materially 21 different from other PFAS because of 22 the properties I talked about. 23 NMED's Warning Label approach 24 fails to differentiate amongst the 25 chemicals. It is inconsistent with	Page 1274 1 of PFAS on the commercial 2 market." 3 Well that's not really true 4 and not conducive to classic risk 5 assessment, and that's one of the 6 reasons why we did our 2021 paper. We 7 wanted to put perspective on how many 8 of these chemicals really there were. 9 The big barrier, my view -- 10 and I'm not an Epidemiologist, I'm an 11 Organic Chemist. The big barrier to 12 doing risk assessment is there's too 13 many of them. The answer is no, 14 there's not; that's what we concluded 15 in 2021, but There's still a lot. Can 16 you subgroup them and then do them as 17 a risk assessment? That was our 18 message coming out of that 2021 paper. 19 "The intrinsic property of 20 persistence alone is 21 sufficient justification." 22 That's what the one group 23 thinks. 24 What you also heard Monday or 25 Tuesday is that there's increased
Page 1273 1 current scientific understanding, some 2 of which I talked about today. It's 3 not scientific and robust. 4 You know, my question is, and 5 we all have many questions, but I'm 6 still trying to figure out what an 7 Erlenmeyer flask with a "PFAS" symbol 8 in it is really going to do here. I 9 am not a label expert, but I've used 10 many Erlenmeyer flasks in my day with 11 "PFAS" in them. We're going to need 12 to figure out what it really means in 13 the end; not an expert there. 14 Last chart. 15 I'll finish up with the concept 16 we've talked about 3 times already in 17 this. It's important Because there's 18 2 major schools of thought: 19 The premise for treating PFAS 20 the same as one, well, if you take it 21 historically, historic or legacy long- 22 chain, and you substitute it with 23 another PFAS, that's called a 24 "regrettable substitution." 25 "There is a large number	Page 1275 1 probability of adverse effects in 2 human health and the environment if 3 these are put in the environment Even 4 if they are not bioavailable, not 5 soluble, not bioaccumulative, and too 6 big to do anything, but then there is 7 the other side. 8 The other side is persistence 9 is an intrinsic property, but not an 10 intrinsic hazard, and it does not, by 11 itself, imply an adverse effect just 12 because it's persistent. It is not 13 scientifically justified to classify 14 inert solids, salts, liquids, and 15 gases in a single class as 1, where 16 properties like vapor pressure, 17 environmental partitioning, aqueous 18 solubility and hazard itself, as well 19 as surface and material properties 20 vary greatly. Thank you. 21 Q. Thank you, Dr. Korzeniowski. 22 Let me next turn to Rebuttal 23 and ask you a few questions, and then 24 we'll get into your summary. 25 A. All right.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1276 1 Q. Did you review the Direct 2 Written Testimony of NMED's witnesses 3 filed in this matter, particularly 4 Dr. Chapman's, Dr. Olson's, and 5 Dr. Ling's Testimonies? 6 A. I did. 7 Q. Did you also provide written 8 Rebuttal Testimony of these NMED 9 witnesses that was filed in this matter 10 as ACC Exhibit 3? 11 A. I did. 12 Q. Do you have any corrections to 13 your written Rebuttal Testimony? 14 A. They are not corrections, but 15 what I did, and I discussed this with 16 Dal, is I didn't change the headings, 17 I didn't change the references, I just 18 added some more text, so I'm happy to 19 provide a copy of that to the Board 20 and to the group. 21 Q. Okay. Thank you. 22 A. No corrections, it's just, 23 again, the same references; no change 24 in references, no change in context. 25 Q. Do you adopt your written	Page 1278 1 only a small subset of substances 2 classified as PFAS are actually in 3 commerce or of commercial relevance. 4 This set of commercially 5 relevant PFAS, as I said a few minutes 6 ago, likely numbers in the hundreds 7 and not tens of thousands, and that's 8 the Buck, et al., as a co-author with 9 Bob and 2 others in 2021. 10 The Department's Testimony 11 appeared to largely rely on data 12 specific to PFAAs, or the per- 13 fluoroalkyl acids, yet framed 14 conclusions as applying to PFAS 15 broadly. That approach does not 16 reflect the scientific distinctions 17 among PFAS subclasses and may create 18 confusion in risk communication. 19 It would be helpful, and in 20 most cases necessary, to be clear, 21 specific, and descriptive when talking 22 about PFAS and which ones are being 23 referred to in each case. 24 As an example is the statement 25 that:
Page 1277 1 Rebuttal Testimony, then, with those 2 additions, as your own Testimony here 3 today? 4 A. I do. 5 Q. Let's proceed with your 6 summary. 7 For this round, before we 8 begin, I'm going to ask you questions, 9 and when you're done with your answer 10 I'll ask you the next question? 11 A. Please do. Thank you. 12 Q. Thank you. 13 In your opinion, did the 14 Testimony presented by NMED in this 15 proceeding use scientifically precise 16 terminology when referring to PFAS? 17 A. No. 18 The term "PFAS" is an umbrella 19 term encompassing more than 14,000 20 substances, which we just talked about 21 a few minutes ago, as included in 22 databases and lists, but not in 23 commerce, with very diverse chemical, 24 physical, and toxicological properties. 25 To the best of my knowledge	Page 1279 1 "PFAS are persistent and 2 mobile." 3 This is an overgeneralization, 4 as many PFAS are not considered mobile 5 due to their very limited solubility 6 and lack of vapor pressure. 7 Q. Does the scientific evidence 8 presented by NMED support regulating 9 or Labeling all products containing 10 any substance with 1 fully fluorinated 11 carbon atom in the same manner? 12 A. No. 13 A structure-based definition, 14 which is what we're talking about, of 15 PFAS that captures all substances with 16 at least 1 fully fluorinated carbon 17 does not align with hazards, exposure, 18 and risk conclusions presented. 19 Much of the Department's Expert 20 Testimony focused on PFAAs and certain 21 related compounds. Extending those 22 conclusions to all PFAS-containing 23 products is not supported by the 24 scientific data discussed in this 25 proceeding.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1280 1 Q. What types of PFAS substances 2 have been phased out voluntarily or 3 restricted via regulation in the 4 United States? 5 A. I'm going to go off script for 6 just a second: 7 We've heard that PFOA and PFOS 8 are still sort of used and back in the 9 U.S., and we can comment on that at 10 some point. 11 PFOA and PFOS, and closely 12 related substances, have been 13 voluntarily phased out by industry. 14 PFAS and related long-chain PFASs, 15 perfluorosulfonic acids, were phased 16 out by the sole U.S. manufacturer in 17 the early 2000s. 18 Nd PFOA and its related higher 19 homologues and precursors were phased 20 out through the U.S. EPA 2010/2015 21 PFOA voluntary Stewardship Program. 22 This Program was global in nature and 23 included the 8 major global 24 manufacturers. The Program included 25 both products and plant emissions.	Page 1282 1 PFAS by restricting the distribution 2 and selling of such products, and we've 3 talked about this; Maine and Minnesota 4 are 2 examples. 5 Q. How does this apply to 6 international agreements such as the 7 Stockholm Convention on Persistent 8 Organic Pollutants? 9 A. The Stockholm Convention 10 addresses specific non-polymeric PFAS, 11 such as PFOA and PFOS, and other per- 12 fluoroalkyl acids, normally hyperchain 13 links like C9 to C20, or C9 to C21. 14 The Stockholm Convention does 15 not address PFAS as a single 16 undifferentiated class. Its listings 17 reflect evaluations based on the 18 combination of persistence, 19 bioaccumulation, and toxicity rather 20 than a blanket approach to all PFAS. 21 Q. Why is this distinction 22 important for accurately characterizing 23 the current Proposed Rule by the 24 Department? 25 A. Suggesting that PFAS broadly
Page 1281 1 The U.S. EPA, however, did 2 grant a few SNUR Exemptions for 3 PFOS-type products to be used until 4 replacements were found. This could 5 be the thinking that PFOS products are 6 still coming back into the United 7 States. 8 It has not been discussed here, 9 but many of these products were used 10 in very specific formulations. Like 11 in the photographic industry, 12 photolithography, the hydraulic fluid 13 in your jets and your aircraft. There 14 were no replacements even in the 15 2000s. 16 EPA provided at least 4 PFOS 17 compound Exemptions, and then the 18 right to manufacture outside the U.S., 19 so that's like 5 SNURs. That might be 20 the source of... 21 Listen, I don't know whether 22 there's replacements yet; some of 23 these were very difficult to requalify. 24 Some states are regulating 25 products containing intentionally added	Page 1283 1 have been phased out or restricted 2 implies a scientific and regulatory 3 consensus that all PFAS present 4 comparable risk. 5 In reality most regulatory 6 actions have been narrowly focused on 7 specific non-polymeric PFAS based on 8 substance-specific evidence. 9 It should be noted that the New 10 Mexico Legislature itself determined 11 that certain classes of PFAS, such as 12 fluoropolymers that are solids at 13 standard temperature and pressure, do 14 not present risk warning regulation, 15 and NMED appropriately recognized that 16 implementing Legislative judgment in 17 the Proposed Rule. 18 It is important that the record 19 and supporting Testimony accurately 20 characterize those substances and not 21 conflate them with PFAS classes that 22 the Legislature expressly chose to 23 treat differently. 24 Q. I'm going to move on to 25 Labeling requirements now.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1284 1 A. Sure. 2 Q. Would Labeling all PFAS- 3 containing products in the same manner 4 accurately reflect differences in 5 hazard, exposure, and potential risk? 6 A. No. 7 PFAS encompasses substances 8 with significantly different chemical, 9 physical, and toxicological properties 10 that inform their uses and potential 11 exposure and risk profiles. Applying 12 a single uniform warning, like an 13 Erlenmeyer flask with "PFAS" embedded 14 in the middle implies comparable risk 15 across all PFAS, which is not supported 16 by the scientific distinctions 17 discussed in this proceeding. 18 Q. How does that concern, then, 19 apply to fluoropolymers? 20 A. Recognizing the diversity of 21 physical and chemical properties within 22 the PFAS family of chemistries is 23 critical for understanding whether a 24 particular PFAS, or subgroup of PFAS, 25 might be of potential concern to human	Page 1286 1 statements and Testimony on Monday, to 2 label these important publication as 3 tainted or conflicted because industry 4 did them is a clear mischaracterization 5 of the compelling analytical testing 6 and toxicological data presented in 7 these publications. 8 Another generalization noting 9 that fluoropolymers in use or in life 10 are not safe is directly contrary to 11 what is published in the 2 journal 12 articles cited above. 13 Directly contrary to what you 14 have read in Exhibit 71 and heard on 15 Monday in Testimony, fluoropolymer 16 manufacturers have recognized that 17 there are potential emissions of 18 fluorinated species across the complete 19 life cycle, manufacturing, which is 20 beginning of life; end use or end 21 life; and end of life disposal. That 22 can be recycled; that can be 23 incineration. 24 There are no disingenuous 25 claims about no emissions and no
Page 1285 1 health or the environment. 2 Fluoropolymers do have a 3 markedly different physical and 4 toxicological characteristics compared 5 to non-polymeric PFAS, such as PFOA or 6 PFOS, even versus what you heard talked 7 about this morning; these side-chain 8 fluorinated polymers. 9 A general statement or 10 pronouncement that, as a whole, PFAS 11 are bioaccumulative, persistent, and 12 mobile is simply incorrect and 13 misleading. 14 In addition, 2 recently peer- 15 reviewed publications that we talked 16 about a few minutes ago -- 1 in 2018 17 by Dr. Barb Henry and her colleagues 18 at Gore, and the other in 2022 online, 19 and 2023 in print by myself and 20 members of 7 global fluorocarbon 21 manufacturers -- made a compelling 22 case that fluoropolymers have a unique 23 set of properties that set them apart 24 from the other PFAS. 25 From one of the witness	Page 1287 1 claims about polymers of no versus low 2 concern. 3 For example, the fluoropolymer 4 manufacturing group in Europe called 5 FPG have created and are executing a 6 Manufacturing Emissions Reduction 7 Program with defined goals. 8 You have also heard a fair 9 amount of talk about the use of 10 fluorinated polymerization aids. You 11 heard that this morning, FPAs. They 12 are no longer in use. These particular 13 ones are generally no longer in use, 14 not by at least the Stewardship 15 companies. Some companies have 16 replaced them with short-chain, and 17 you heard that this morning also. 18 What is more important, 19 though, about that is that the 20 fluoropolymer industry has been 21 working for years to eliminate the use 22 of these fluorinated polymerization 23 aids, and as of 2022 -- I don't have 24 new data -- when we published our 25 paper, about 55% of those FPAs have



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1288 1 already been eliminated from use in 2 manufacture; I don't know whether it's 3 70 today or 75. I don't know what the 4 percentage is, but it's clear the 5 industry understands there is potential 6 emissions and is doing what it needs 7 to do to eliminate them. 8 As far as end of life -- you 9 heard about it this morning also -- 10 there have been several incineration 11 studies since 2019 with several more 12 in the works. Many of these studies 13 show, as Barb said, several '9s 14 destruction -- I think she said 15 99.9999%, something like that -- of 16 the fluoropolymer and what they call 17 PICs, or "Products of Incomplete 18 Combustion." 19 The studies that have been 20 done recently are done in commercial- 21 waste-to-energy plants, and they are 22 getting several '9s destruction. 23 Now can you get incomplete 24 destruction in PICs, if you do 25 backyard burning, which is illegal,	Page 1290 1 that the work we were doing wasn't good 2 and wasn't genuine, but the fact of 3 the matter is that these authors, 4 including myself, we have to sign a 5 Conflict of Interest or a Disclaimer 6 Statement from the journal or we can't 7 publish the paper; it's a requirement. 8 Does the fact that we signed 9 Disclaimers and Conflict statements, 10 does that mean that there is something 11 wrong? No, it raises no flags; it's 12 required. You see that in all major 13 journals, and I've always had to sign 14 a Disclaimer. 15 A uniform one-size-fits-all 16 warning could mislead consumers into 17 believing that all of these materials 18 pose similar risks, which is not 19 consistent with the available 20 scientific evidence as described above 21 and elsewhere. 22 Q. Dr. K, my final question is 23 how does that concern apply to other 24 Exemptions in the Statute? 25 A. The same concern about
Page 1289 1 sure you can. If you do the 2 destruction and incineration in a 3 regulated facility, and that facility 4 is operating properly, the potential 5 for emissions is extremely low. I 6 can't say it's zero, but extremely 7 low, and many other studies are going 8 on at the moment. 9 In 2018 and 2022 papers that we 10 have talked about as conflicted covered 11 96% of the global fluoropolymer market 12 in terms of polymer types, 18 major 13 types of fluoropolymers. If one 14 actually reads these 2 papers, the 15 actual assessment data and criteria as 16 described in excruciating detail either 17 in the paper or the supplementary 18 information, it is clear that there is 19 complete life cycle discussion 20 particularly in the 2022 paper. 21 The "Conflict" designation, 22 which we've heard a few times in the 23 Testimony, appears to arise because, 24 like myself no longer, but I was an 25 industry guy. That "Conflict" means	Page 1291 1 misleading consumers applies to blanket 2 Labeling of the other exceptions listed 3 in the Statute. 4 PFAS are not monolithic in 5 their properties and uses. Many of 6 the exempted applications involving 7 highly technical market materials are 8 critical in the industry to serve as 9 the underpinning for modern life in 10 numerous contexts such as: 11 Healthcare; 12 Energy systems; 13 Transportation; 14 Electronics; and, 15 Other infrastructure. These 16 substances are essential to: 17 Safety; 18 Durability; and, 19 Performance. 20 Viable alternatives are not 21 reasonably available without 22 compromising function or introducing 23 other risks. 24 Applying a uniform label to 25 these categories would:



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1292 1 Obscure these distinctions; 2 Potentially confuse consumers; 3 and, 4 Fail to reflect the careful 5 policy judgments already embedded in 6 the statutory Exemptions. 7 Due to these concerns the 8 American Chemistry Council is proposing 9 to exclude the proposed Exemptions in 10 Section 20.13.2.10 from the Labeling 11 requirements. 12 Q. I believe that concludes your 13 Testimony. 14 A. It does. 15 MR. TRUJILLO: Madam Hearing 16 Officer, we offer Dr. K up for 17 questioning. 18 HEARING OFFICER ORTH: All 19 right. Thank you very much, 20 Mr. Trujillo. 21 Ms. Fiebig, do you have 22 questions of Dr. K? 23 MS. FIEBIG: Just a couple. 24 Thank you. 25 ///	Page 1294 1 of characteristics. 2 A. Understood, yes. 3 Q. We've also seen some concern 4 raised over the course of the week by 5 different witnesses about, you know, 6 learning information later on about 7 risks. You know, science is such that 8 it evolves. Sometimes we learn later 9 there are risks associated with 10 products that we didn't appreciate 11 earlier. 12 With that context I wanted to 13 ask you if there are any fluoropolymers 14 that have a lengthy history of safe use. 15 A. Well I think I'm going to agree 16 with Barb; I'm not going to use the 17 same, when I was 18, I thought I knew 18 everything. I'm not going to use the 19 same language she did. 20 Barb should have done herself 21 justice. Her and her Gore colleagues 22 published a paper in 2018. This was 23 the first of the 2 "Polymers of Low 24 Concern" studies, but what Barb didn't 25 mention, but is a good example, is
Page 1293 1 CROSS-EXAMINATION 2 BY MS. FIEBIG: 3 Q. Dr. K, you've been present in 4 the hearing room for the duration of 5 these proceedings. 6 A. Monday I was actually online. 7 But yes, I've been here every day, yes. 8 Q. You've been observing how 9 things have gone. 10 A. I have, yes. 11 Q. I wanted to ask you a couple 12 of questions about some of the 13 information that we've learned over 14 the course of the week: 15 In your report, or in your 16 Written Testimony, and as you've 17 described today, you've highlighted 18 the relatively safe nature of 19 fluoropolymers as a subclass of PFAS 20 chemicals; right? 21 A. I have, and Barb has also. We 22 both have, yes. 23 Q. Right, due in large part to 24 they don't really bioaccumulate, they 25 are not soluble in water, those sorts	Page 1295 1 these fluoropolymers, particularly 2 PTFE and things like PTFE, have been 3 used in body for 40-, 50 years as 4 implants and so on. 5 The significant amount of data 6 that Barb put in that paper, as well 7 as all the requirements that 8 fluoropolymers need to be used in the 9 body is a pretty good example of a 40- 10 or 50-year history of safe 11 fluoropolymer use. 12 PTFE is the largest, by the 13 way, about 50% or 65% of the global 14 fluoropolymer use. If we're looking 15 at the majority of the fluoropolymers, 16 and there is various PTFE grades, as 17 Barb talked about, but that's a really 18 good example of in your body and being 19 safe. 20 Q. Are there any other examples 21 of PFAS substances, fluoropolymer or 22 otherwise, that have a long history of 23 safe use? 24 A. Well I think, you know, one of 25 the things that I did as part of my



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1296 1 work with T.J. and his colleagues at 2 ACC is, you know, you've heard about 3 doing your own regulatory Rulemaking 4 process here, but Europe has been very 5 active in this area. 6 One of the things that we 7 needed to do was to provide 8 substantiation of the safety and use 9 and utility of fluoropolymers in 10 commerce. One of the things we 11 heard -- I'm thinking it was Monday or 12 Tuesday -- was from the coatings 13 industry where he was talking about 14 how it would impact coatings. 15 Most people don't appreciate 16 the value of fluoropolymers in coatings 17 and not necessarily in body, but in 18 the external world as an example. 19 There is PBDF, which is a 20 fluoropolymer. There is the Lumiflon 21 fluoropolymer, and these are used in 22 solar panels, building panels, bridges 23 and thinks like that. Without these 24 materials, as an example, you would 25 see your bridges full of scaffolding.	Page 1298 1 for what you're doing, and I don't 2 disagree that labels can have 3 significant importance. 4 I also don't disagree with the 5 fact that Labeling and informing 6 consumers is a really good thing to 7 do; I have no issue with that. I 8 think to the extent that you can 9 educate the consumers on a subject 10 like this is really important. 11 I mean I've been in this a long 12 time, so I've been involved in the ups 13 and downs for all these years and seen 14 all that's gone on in the company I 15 worked for. It is important to 16 educate, and we are learning new 17 things. 18 The question for this label is 19 what is it going to do, particularly 20 an Erlenmeyer flask? I made a model 21 for my cell phone, but it was blue, or 22 about what color your water is. My 23 water was blue. But does it have the 24 appropriate impact on a set of 25 chemistries that are, by the
Page 1297 1 They would have to replace and repair 2 every 5 to 7 years. If you use the 3 fluoropolymers like the Lumiflon or 4 PBDF in solar panels, you're 50- to 5 100-year replacement. They not only 6 work, but they are very effective in 7 what they do. 8 These products are used in 9 sunlight and weather and saltwater, 10 and they function perfectly fine, so 11 it is a good example of how tough they 12 are as an example. 13 Q. My last question: 14 In your Written Testimony, you 15 had referred to the proposal that the 16 Erlenmeyer flask be added. We've been 17 characterizing that as sort of a 18 Warning Label. I think we have heard 19 some evidence this week to suggest 20 that the Department is contending that 21 it's really just intended to be 22 informative and not a warning. I 23 wanted to hear your reaction to that. 24 A. Well I'm going to start off 25 first by saying I've got great respect	Page 1299 1 literature that we see and literature 2 that we're adding every day with 3 properties, hazards, exposure, which 4 is largely completely different than 5 the other PFAS. 6 That's what I was concerned 7 about. Is that label going to have 8 benefit to consumer products when 9 there is no real exposure in most 10 cases? 11 The risk of that exposure, 12 given what I'll cautiously say is the 13 potential inertness of fluoropolymers, 14 that inertness also has a graduated 15 meaning, but I'm not sure it's 16 appropriate. 17 That's my thoughts. Nothing 18 against the Labeling, and noting that 19 it might not have a benefit for other 20 consumer products who want to know 21 what's in their products, and I think 22 it's a good idea. The question is 23 where is that label applied? 24 Q. Do you think it's likely to be 25 perceived as a warning?



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1300 1 A. Well -- 2 MR. ROSEBROUGH: Madam Hearing 3 Officer, I object to the question; he 4 stated he is not an expert on Labeling. 5 HEARING OFFICER ORTH: Can you 6 rephrase this question, Ms. Fiebig. 7 MS. FIEBIG: I will. I was 8 just -- he had referred to it as a 9 "warning" in his papers, and so I just 10 wanted to see if he still perceives it 11 as potentially sending that message. 12 HEARING OFFICER ORTH: I 13 happen to remember that actually. 14 THE WITNESS: When I see a 15 label I try to figure out what it 16 means. Normally when I see a label, 17 it's on products, and it's usually a 18 warning. It's implying some risk. It 19 often will prompt you to go look, 20 especially if you don't know what the 21 label means. 22 If there is an explanation with 23 the label, then you don't have to go 24 look any further. But with an 25 Erlenmeyer flask with "PFAS" in the	Page 1302 1 our fourth Public Comment session. 2 I have at least 3 names here 3 to call on, and I'll issue a general 4 invitation. 5 Just a few things about Public 6 Comment: 7 The hearing is being recorded 8 and transcribed in its entirety by 9 David Lee of Cumbre Reporters, so he 10 will be trying to capture your words. 11 The hearing is also being 12 interpreted between English and 13 Spanish and Spanish and English, so we 14 also have Interpreters trying to catch 15 your words, so I would just ask you to 16 speak slowly and clearly. 17 Ms. O'Grady, would you please 18 tell people how to find the 19 interpretation. 20 MS. O'GRADY: Madam Hearing 21 Officer, clarification: 22 Do you want me to explain for 23 the afternoon session how to find the 24 channels again, or just for the Public 25 Comment?
Page 1301 1 middle, if I weren't doing this for a 2 living I'd be scratching my head. 3 The idea is it might prompt 4 consumers to go look, and if that's 5 what it does, that's probably a good 6 thing, but it is a Warning Label in 7 some form. 8 MS. FIEBIG: Thank you. 9 HEARING OFFICER ORTH: All 10 right. We are 6 minutes before noon, 11 so rather than proceeding to the next 12 examiner, let's take our lunch break. 13 We will return at 1:00 for Public 14 Comment. 15 Sir, as soon as the Public 16 Comment is over we will go back to 17 you. Thank you. 18 (The Evidentiary Hearing 19 recessed from 11:54 a.m. to 1:00 p.m.) 20 HEARING OFFICER ORTH: Good 21 afternoon. Let's come back from the 22 lunch break. 23 We are at Day 4 of the hearing 24 in EIB 25-61, the Per- and Poly- 25 Fluoroalkyl Rulemaking. We've reached	Page 1303 1 HEARING OFFICER ORTH: For the 2 Public Comment. 3 MS. O'GRADY: Thank you. 4 (Speaking Spanish.) 5 If there is anybody present in 6 this hearing room that would also like 7 to offer Public Comment, would you 8 please let us know, and that way we 9 can be ready when you're ready. Thank 10 you. 11 HEARING OFFICER ORTH: Thank 12 you, Ms. O'Grady. 13 Just 2 more things: 14 One, I'll ask you to Comment 15 just once. You can submit as much 16 written Public Comment as you'd like, 17 But I'll ask you to keep your oral 18 Comments to 3 minutes; 19 I will ask you to spell your 20 first and last name; and, 21 Pursuant to the Board rules 22 I'll ask if you swear or affirm to 23 tell the truth. 24 We'll start with 25 Mr. Meiklejohn.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1304 1 Mr. Meiklejohn, if you'd come 2 up to this lighted microphone at the 3 front of the room. 4 MR. DOUGLAS MEIKLEJOHN: Thank 5 you, Madam Hearing Officer. 6 HEARING OFFICER ORTH: Would 7 you spell your first and last name, 8 please. 9 MR. DOUGLAS MEIKLEJOHN: Yes, 10 certainly. 11 The first name is Douglas, 12 D-O-U-G-L-A-S; last name is 13 Meiklejohn, M- as in Mary, 14 E-I-K-L-E-J-O-H-N. That's all one 15 word. 16 HEARING OFFICER ORTH: All 17 right. Thank you. 18 Do you swear or affirm to tell 19 the truth. 20 MR. DOUGLAS MEIKLEJOHN: Yes. 21 HEARING OFFICER ORTH: I'll 22 start your time. 23 MR. DOUGLAS MEIKLEJOHN: Thank 24 you, Madam Hearing Officer, Board 25 Members:	Page 1306 1 On the other hand, some of the 2 Exemptions are discretionary with the 3 Board and possibly also the Department. 4 They are generally classified as 5 Currently Unavoidable Use. 6 Conservation Voters urges that 7 because of the problems that PFAS have 8 caused in the environment, that those 9 and any other discretionary Exemptions 10 be construed and applied as narrowly 11 as possible. 12 Finally, as an Attorney who 13 spent several decades litigating for 14 protection of communities and the 15 environment, I personally am gratified 16 to see the meaningful enforcement 17 provisions that were enacted by the 18 Legislature included in the proposed 19 regulations. Thank you very much. 20 HEARING OFFICER ORTH: Thank 21 you, Mr. Meiklejohn. 22 Is there anyone else in the 23 room here to offer Public Comment? I 24 know we have a few folks online. 25 No. All right.
Page 1305 1 As I said, my name is Douglas 2 Meiklejohn. I'm an Attorney, and I 3 work on water quality issues for 4 Conservation Voters New Mexico. 5 Conservation Voters applauds 6 the Environment Department and the 7 Environmental Improvement Board for 8 addressing the proliferation of 9 PFAS -- pardon me, I can't pronounce 10 the full name of that -- and the 11 pollution that they cause, 12 particularly pollution of water, and 13 especially pollution of groundwater, 14 which, as you know, is the source of 15 drinking water for many people in New 16 Mexico. 17 Conservation Voters has some 18 concern about some of the Exemptions 19 that are in the proposed regulations. 20 We recognize that some of those 21 Exemptions are not discretionary; that 22 is, they are required by the Statute 23 passed by the Legislature or required 24 by the preemptive effect of federal 25 law.	Page 1307 1 Let's turn to Lindsey "Hueer" 2 or "Hueer." If I'm mispronouncing 3 your name, please just let me know. 4 MS. LINDSEY HUEER: No 5 worries. 6 Good afternoon; I'll spell my 7 name. 8 HEARING OFFICER ORTH: Thank 9 you. 10 MS. LINDSEY HUEER: It is 11 L-I-N-D-S-E-Y, and my last name is 12 H-U-E-E-R. 13 HEARING OFFICER ORTH: Do you 14 swear or affirm to tell the truth? 15 MS. LINDSEY HUEER: Yes, I do. 16 HEARING OFFICER ORTH: Thank 17 you. I'll start your time. 18 MS. LINDSEY HUEER: Thank you. 19 Good afternoon, Madam Hearing 20 Officer and Members of the Board: 21 Again, my name is Lindsey Hueer 22 and I'm with The Toy Association. The 23 Toy Association represents more than 24 800 businesses, some inventors, 25 designers, manufacturers, and



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1308 1 retailers, all committed to bringing 2 safe, fun, educational toys to 3 children. 4 In New Mexico specifically the 5 toy sector generates \$238 million in 6 annual economic impact. We're deeply 7 invested in ensuring that children and 8 families in the state continue to have 9 access to safe and affordable play. 10 We share many of the concerns 11 expressed by other associations, but 12 for my public comments today I want to 13 focus specifically on concerns related 14 to toys. 15 Toy safety and environmental 16 stewardship are core values of our 17 industry. PFAS is found only in a 18 small percentage of toys, primarily in 19 internal electronic components. In 20 those cases the materials serve 21 critical fire prevention and heat 22 resistant functions. We don't want 23 Kids' toys to catch fire due to 24 overheating. 25 The components are fully	Page 1310 1 Over-Labeling will lead consumers to 2 not knowing the actual risk presence 3 and leading to consumer fatigue for 4 the label itself. 5 We think that the goals of 6 Senate Bill 212 can be met with a few 7 changes. We submitted comments, but 8 again, for today's Public Comment, I 9 want to focus on a couple of 10 toy-specific items: 11 First, while we appreciate 12 that there has been a label Exemption 13 process in the proposed rules, we ask 14 to outright exempt Labeling 15 requirements where the PFAS in a toy 16 is fully enclosed and inaccessible in 17 those electronic component. A label 18 is inappropriate for these products 19 and should not be required to go 20 through a recurring waiver process. 21 Second is having practical 22 label standards for small toys and 23 packaging. As we all know toys can be 24 incredibly small, and requiring larger 25 packaging to accommodate a label
Page 1309 1 enclosed, inaccessible to children 2 during play, and present no risk of 3 exposure to the child or the 4 caregiver. 5 Additionally, there is no 6 suitable alternative yet available to 7 ensure safety of these products. 8 The products are expressly 9 exempted from the ban in Senate Bill 10 212, but they would fall under the 11 Labeling and reporting requirements in 12 the Proposed Rule. 13 For toys, a mandate to label 14 these products doesn't empower 15 consumer choice over non-exposure. On 16 the contrary, requiring a Warning 17 Label on a product that presents no 18 exposure risk would mislead consumers 19 into believing that a toy poses a 20 danger when it does not, undermining 21 consumer confidence in safe products. 22 As a Mom myself, I know that a 23 Warning Label should be a meaningful 24 notice of a bona fide toxic risk, 25 which is not the case with toys.	Page 1311 1 actually is worse for the environment. 2 Last, toy manufacturers are 3 continually introducing new products. 4 We would like to see streamlined 5 reporting requirements at the product 6 category level rather than SKU by SKU 7 with the fees applying per manufacturer, 8 not per product. 9 I appreciate your 10 consideration of these issues and for 11 the opportunity to provide comment 12 today. 13 HEARING OFFICER ORTH: Thank 14 you, Ms. Hueer. 15 We go now to Mr. Parkhomenko, 16 Konstantin Parkhomenko. 17 MR. KONSTANTIN PARKHOMENKO: 18 Can you hear me? I will spell my 19 name. 20 HEARING OFFICER ORTH: Thank 21 you. 22 MR. KONSTANTIN PARKHOMENKO: 23 K-O-N-S-T-A-N-T-I-N, Konstantin; 24 Parkhomenko is P-A-R-K-H-O-M-E-N-K-O. 25 HEARING OFFICER ORTH: Thank



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1312 1 you. Do you swear or affirm to tell 2 the truth? 3 MR. KONSTANTIN PARKHOMENKO: I 4 do. 5 HEARING OFFICER ORTH: Thanks. 6 I'll start your time. 7 MR. KONSTANTIN PARKHOMENKO: 8 Thank you. Madam Hearing Officer, 9 esteemed members of the Board: 10 My name is Konstantin 11 Parkhomenko. I am an Environmental 12 Attorney for the Sandia National 13 Laboratories complex. 14 You may be asking yourselves, 15 you know, if this is about protecting 16 consumers, why is a National 17 Laboratory Attorney giving Public 18 Comment here? 19 Well as we all understand very 20 well, the devil is really in the 21 details in these kind of rules. We 22 have some concerns about potentially 23 an overbroad, potentially an 24 unintentionally overbroad definition 25 of "consumer" that will rope in	Page 1314 1 definition. We are also aware of the 2 definition of "product," which, 3 strictly speaking, is: 4 "An item created, produced, 5 assembled, packaged, or 6 otherwise prepared for sale 7 to a consumer," and it goes 8 on. 9 The Rule proposes to define 10 "consumer" in a very broad way as: 11 "An individual, 12 partnership, corporation, 13 state agency, or subdivision 14 of a state who seeks or 15 acquires to purchase or lease 16 any goods or services." 17 My comment, my supplemental 18 comment, and I did submit written 19 comments, which I do encourage 20 everybody to review. My supplemental 21 comment deals with the fact that I 22 think the definition of the term 23 "consumer" really should be defined in 24 a way that's compatible with the 25 definition of "consumer product" in
Page 1313 1 organizations such as ours, which are 2 really very sophisticated laboratories 3 who really know what they are doing in 4 the industry and understand the 5 chemicals they are working with, and 6 engaged in very important and sometimes 7 classified work for the good of the 8 nation. E are concerned about 9 potentially overbroad rules that might 10 impact the mission. 11 I do have some more specific 12 comments, and they are a little bit 13 technical, so please bear with me: 14 So we all know the Act defines 15 "consumer product"; right? 16 "'Consumer Product' means 17 tangible personal property 18 that's distributed in 19 commerce, normally used for 20 personal, family, or household 21 use, including product 22 categories that are normally 23 used in households," so on 24 and so forth. 25 We are aware of that	Page 1315 1 the Act such that we don't get 2 overbroad with the definition and rope 3 in unintentional parties that really 4 weren't ever meant to be within that 5 scope. 6 As to Labeling, the Board may 7 adopt rules to carry out the provisions 8 of the Per-Fluoroalkyl Substances Act, 9 including the requirement of Labeling 10 products in English and Spanish. This 11 appears to allow the Labeling of 12 products as defined by the Act, but 13 the Act really only concerns products 14 sold to a consumer. 15 Organizations such as the 16 National Laboratories, we are never 17 really meant to be "consumers" within 18 that scope of the Act. Therefore, I 19 would encourage this body to adopt a 20 suitably broad exception that will 21 exclude or clarify the definition of 22 "consumer" in a way that really makes 23 it clear that it doesn't apply to 24 entities such as ours. 25 HEARING OFFICER ORTH: Thank



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1316 1 you, Mr. Parkhomenko. 2 MR. KONSTANTIN PARKHOMENKO: 3 Thank you. I will submit written 4 comments as well. 5 HEARING OFFICER ORTH: Sir, a 6 Board Member has a question. 7 Chair Ely. 8 CHAIR ELY: Thank you for your 9 comments this afternoon. I'm just 10 wondering if your comments are 11 comments from the lab, or are they 12 your own personal comments? Thank 13 you. 14 MR. KONSTANTIN PARKHOMENKO: 15 Yes, my comments today do represent 16 the position of the Sandia National 17 Laboratories. 18 HEARING OFFICER ORTH: Thank 19 you very much. 20 Let's see. Next we have Bill 21 Rodgers. 22 There you are. 23 Are you unmuted? 24 Mr. Rodgers. 25 Okay. We'll wait a minute.	Page 1318 1 I reported on this for 2 5050MATIC, and my neighbors talk to me 3 about it almost every time they see me 4 because they, like me, are afraid what 5 this means for themselves and their 6 families. 7 Though we are getting a filter 8 system through the State, we have 9 unknowingly drank, ate, and bathed in 10 dangerous cancer-causing chemicals for 11 almost 10 years. I cannot describe 12 the terror we have lived with since 13 getting these results. 14 I don't want people like 15 ourselves to have to navigate this 16 issue on their own. This issue is so 17 esoteric that even my doctor didn't 18 know what to advise when I told her I 19 was exposed to these chemicals. 20 No one should have to live 21 with this fear. No one should suffer 22 fatal health consequences because of 23 the companies who have exposed us to 24 these chemicals and hid information 25 about how harmful they are.
Page 1317 1 MR. BILL RODGERS: How's that? 2 HEARING OFFICER ORTH: Much 3 better, sir. 4 If you would spell your first 5 and last name, please. 6 MR. BILL RODGERS: Yes, my 7 name is Bill Rodgers. That's "B" as 8 in boy, I-L-L; R-O-D as in dog, 9 G-E-R-S. 10 HEARING OFFICER ORTH: Do you 11 swear or affirm to tell the truth? 12 MR. BILL RODGERS: I do. 13 HEARING OFFICER ORTH: I'll 14 start your time. 15 MR. BILL RODGERS: Good 16 afternoon, Members of the Environmental 17 Improvement Board and Hearing Officer: 18 My name is Bill Rodgers and I 19 live in La Cieneguilla. My Wife and I 20 bought our home in 2016 and learned in 21 2025 that we live within a massive 22 groundwater plume of PFAS chemicals. 23 Tests of our water told us that we 24 have 4 times the level of PFAS that 25 the EPA deems safe.	Page 1319 1 I am grateful to see our state 2 working to address these issues. The 3 prohibition of some PFAS and Labeling 4 are good first steps, but New Mexico 5 is offering polluters loopholes that 6 would limit the benefit people could 7 get from these rules. That would be 8 unacceptable to people like myself who 9 cannot do something as simple as drink 10 a glass of water from their tap. 11 We need to ban all PFAS for 12 all the harms from its production, 13 use, and disposal. I hope that this 14 task force approved in this Legislative 15 session will make sure we are truly 16 and fully safe. 17 Please help us. Approve this 18 Rule, but make it stronger by closing 19 any Labeling loopholes and give New 20 Mexicans greater safety, safety that 21 industry and malfeasance has so far 22 kept from us. Thank you. 23 HEARING OFFICER ORTH: Thank 24 you, Mr. Rodgers. 25 Let me ask if there is anyone



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1320 1 else on the platform who would like to 2 offer Public Comment in this Public 3 Comment session, which is very likely 4 our final oral comment session. 5 I see Mr. Holm. John Holm. 6 Can you unmute yourself? 7 Pam or Luis, please... 8 I think you should be able to 9 unmute now. 10 MR. JOHN HOLM: Thank you. 11 Hi, my name is John Holm. 12 HEARING OFFICER ORTH: You're 13 going to have to speak much closer to 14 your microphone. 15 MR. JOHN HOLM: I'm so sorry. 16 Can you hear me now? John Holm. 17 HEARING OFFICER ORTH: Yes, 18 thank you. 19 Spell your first and last 20 name, please. 21 MR. JOHN HOLM: Sure. John, 22 J-O-H-N; last name Holm, H-O-L-M. 23 HEARING OFFICER ORTH: Do you 24 swear or affirm to tell the truth? 25 MR. JOHN HOLM: I do swear to	Page 1322 1 communities of which we're operating 2 in, harming the drinking waters of 3 which is ubiquitous across the United 4 States and across the globe. 5 New Mexico's way of looking 6 and dealing with this within this Rule 7 really provides clear context about 8 how to be proactive about dealing with 9 the PFAS solution by leveraging the 10 power to design out PFAS's from 11 inception and bring in materials that 12 consumers can use that will not have 13 this component in it that is harming 14 and causing so much environmental and 15 human harm. 16 Moving forward, I would really 17 like to say that I thank the 18 Environment Department for drafting 19 such a strong and protective Rule. 20 Thank you to the Board and 21 Hearing Officer for your time and 22 commitment to protect New Mexicans and 23 leveraging this as a model that can 24 potentially be lifted across the other 25 48 states that do not have this type
Page 1321 1 tell the truth. 2 HEARING OFFICER ORTH: Thank 3 you. I'll start your time. 4 MR. JOHN HOLM: Hi. My name 5 is John Holm, and I reside in 6 Washington, D.C. I'm speaking on 7 behalf of my organization, the 8 Circular Supply Chain Coalition, and a 9 lot of the work that we're doing, both 10 in New Mexico and broadly across the 11 United States and the globe. 12 I'm providing this comment 13 today in strong support of the New 14 Mexico Environment Department's 15 Proposed Rule which implements the 16 PFAS protocol. I urge the Board to 17 adopt the Environmental Department's 18 Rule as proposed. 19 Specifically, a lot of the work 20 that we're focusing on is around 21 leveraging urban mining, leveraging 22 material reuse. When we look at PFAS 23 in the space of materials and look at 24 the landscape for materials, PFAS are 25 known to be harmful; harming local	Page 1323 1 of proposal. I strongly urge you to 2 adopt the Environment Department's 3 Rule. Thank you. 4 HEARING OFFICER ORTH: Thank 5 you very much, Mr. Holm. 6 Elena F. 7 MS. ELENA FERNANDEZ: Thank 8 you. My name is Elena Fernandez. I 9 am a Project Specialist for Amigos 10 Bravos. 11 HEARING OFFICER ORTH: Hold on 12 please. 13 If you would spell your first 14 and last name. 15 MS. ELENA FERNANDEZ: My 16 apologies; Elena, E-L-E-N-A, last name 17 Fernandez, F-E-R-N-A-N-D-E-Z. 18 HEARING OFFICER ORTH: Thank 19 you. 20 Do you swear or affirm to tell 21 the truth. 22 MS. ELENA FERNANDEZ: Yes, I 23 do. 24 HEARING OFFICER ORTH: I'll 25 start your time.



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1324 1 MS. ELENA FERNANDEZ: Thank 2 you. 3 Again, my name is Elena 4 Fernandez. I am a Project Specialist 5 with Amigos Bravos. Amigos Bravos 6 serves the entire State of New Mexico 7 for water quality, protection, and 8 restoration. 9 One of my projects is concerned 10 with toxic pollutants across the State. 11 I have worked closely with the 12 Environment Department and communities 13 that are impacted by toxic pollutants. 14 PFAS doesn't cause just 15 physical harm, it causes mental harm 16 or psychological fear from the unknown. 17 I'm asking that the Environmental 18 Improvement Board please adopt the 19 PFAS Substances Consumer Protection 20 Act. 21 New Mexico should adopt this 22 Act to protect the health and well- 23 being of New Mexicans and our State 24 from the harms from intentionally 25 added PFAS in our consumer products,	Page 1326 1 or blame, it is the right thing to do. 2 Industry is good at adapting to 3 business needs, and doing the right 4 thing by consumers would be a positive 5 change. 6 I thank you for your time, and 7 I send my thoughts to the people of La 8 Cieneguilla who have been impacted by 9 the groundwater pollution. Thank you. 10 HEARING OFFICER ORTH: Thank 11 you, Ms. Fernandez. 12 Member Curry, do you have your 13 hand raised? 14 BOARD MEMBER CURRY: I do, 15 Madam Hearing Officer. I just wanted 16 to follow up on Chairman Ely's 17 question from the gentleman from 18 Sandia. He said he had a written 19 statement, and I was just curious if 20 he is still on the line or if we've 21 got it. 22 Does the written statement 23 also reflect the position of Sandia 24 Labs? 25 HEARING OFFICER ORTH: Let's
Page 1325 1 which provide only minor convenience 2 when compared to the very real dangers 3 to ourselves and the State. 4 The choice to reject this Act 5 will have big consequences for New 6 Mexicans' long-term health, negative 7 impacts to medical treatment, and 8 affordability from diseases related to 9 long and constant exposure to PFAS, as 10 well as the constant remediation of 11 waters, lands, and agricultural. 12 Essentially, all New Mexicans 13 and our State's well-being will be 14 negatively affected by continued PFAS 15 pollution and prolonged exposure. 16 Please choose New Mexicans and choose 17 New Mexico to be a leader against PFAS 18 pollution. 19 Lastly, Labeling provides New 20 Mexicans information such that they can 21 make informed personal independent 22 choices and decisions as to which 23 products they deem safe or appropriate 24 for their everyday use and livelihood. 25 Transparency is not punishment	Page 1327 1 see. 2 Mr. Parkhomenko, are you still 3 on the platform? 4 MR. KONSTANTIN PARKHOMENKO: 5 Hello. Can you hear me? 6 HEARING OFFICER ORTH: Yes, 7 hello. 8 MR. KONSTANTIN PARKHOMENKO: 9 Yes, I'm still on the platform. 10 It is on our letterhead, so it 11 should reflect that. There will also 12 be a supplemental set of Public 13 Comments, which will also be on 14 official letterhead and it will also 15 state that it's our official position. 16 BOARD MEMBER CURRY: Thank 17 you. 18 MR. KONSTANTIN PARKHOMENKO: 19 Thank you. 20 HEARING OFFICER ORTH: Thank 21 you, Member Curry, and thank you 22 Mr. Parkhomenko. 23 Is there anyone else on the 24 platform here in what, I believe, will 25 be our final oral Public Comment



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1328 1 session? 2 I see no hands. I don't see 3 that anyone has joined us, and no in 4 the room. 5 I think we'll return to the 6 Technical Case. Please know if you 7 are aware of someone who would like to 8 offer Public Comment for this 9 Rulemaking, written Public Comment may 10 still be submitted here for several 11 days more. 12 All right. Let's see. Dr. K, 13 would you rejoin us at the front of 14 the room? 15 Thank you very much. Good 16 afternoon. 17 Let's see, Mr. Smithkier. 18 All right. Mr. Knight. 19 MR. KNIGHT: Thank you. 20 21 CROSS-EXAMINATION 22 BY MR. KNIGHT: 23 Q. Dr. Korzeniowski, I take it 24 from your Testimony, and I think you 25 may have stated this, that you consider	Page 1330 1 Scotchgard, what specific types of 2 PFAS, as far as you know, are used in 3 a waterproofing product such as 4 Scotchgard? 5 A. Well I mean, you know, 6 Scotchgard wasn't made by us, it was 7 made by 3M. They had a different set 8 of chemistry and different backbone, 9 but they would start with either the 10 PFOS, which we heard about a lot here, 11 as a raw material, or what we would 12 call the sulfonyl chloride, the PFOS 13 here and the sulfonyl chloride here. 14 They would bolt on different additives 15 and make polymers out of it. 16 They would be applied in the 17 same manner. They are different 18 chemistries, but the end function would 19 be the same for particularly oil, oil 20 and grease repellency. 21 Q. How about a product such as 22 Rain-X; are you familiar with that 23 product? 24 A. Rain-X I thought was silicone 25 based.
Page 1329 1 yourself to be an expert on PFAS. Is 2 that correct? 3 A. I don't think anybody can be 4 an expert on all PFAS, but certainly 5 I'm a Subject Matter Expert in telomer 6 chemistry with a fair amount of 7 knowledge in fluoropolymers also, no 8 refrigerants. 9 Q. So what specific type of PFAS, 10 if you know what specific types of 11 PFAS are used in food packaging for 12 example. 13 A. They would have been, in 14 general, fluorotelomer-based polymers. 15 There is also some oxygenated materials 16 from companies like Solvay and others, 17 small PFPEs or small molecules, but 18 largely fluorotelomer-based products. 19 They have largely been phased 20 out, but those were generally what was 21 used to provide the oil and water, 22 particularly the oil or grease 23 repellants that was needed on paper 24 products. 25 Q. And what about a product like	Page 1331 1 Q. So not containing PFAS. 2 A. Not that I know of. 3 Q. Okay. Baking paper or 4 something also known as parchment 5 paper. 6 A. Parchment paper. 7 Q. Yes. 8 A. In the old days, many, many -- 9 this is 25, 30 years ago, they would 10 use some of the fluorotelomer products 11 or some of the PFAS products, 12 particularly polymers to coat the 13 butter paper, but that's long done. 14 That's long been done. 15 People at FDA that I worked 16 with, I personally spent a lot of time 17 at FDA because some of the products 18 that we had made would have to go 19 through FDA registration, so I spent a 20 lot of time there, but never worked on 21 parchment paper. 22 Q. Do you know whether parchment 23 paper commonly contains PFAS as sold 24 today? 25 A. I don't know that. I think, I



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1332 1 mean, we all know, and really know, 2 because of the amount of news on PFAS 3 chemistries, many companies have market 4 deselection. They decided they don't 5 want to deal with PFAS chemistries any 6 longer. 7 Many end-use applications have 8 decided to give up the properties of 9 oil repellency. Textiles is a good 10 example. That industry has largely 11 moved to durable water repellents that 12 have no fluorine. 13 What that means is you will get 14 water repellency, but you couldn't get 15 the durability. You won't get the 16 severe weather protection, and you 17 certainly won't get oil protection, but 18 it works. 19 If you don't need something in 20 hazard areas, then you don't need it, 21 So many markets have moved away for 22 obvious reasons. 23 Q. And what do you know about the 24 use of PFAS in common brands of dental 25 floss? Is; that still something that	Page 1334 1 comb. There is side chains that sit 2 on the side of that backbone of carbon 3 and hydrogen. 4 Now they work relatively well. 5 I mean they do their job. But as 6 we've heard today and during the week 7 and in the literature, they can fall 8 apart. They can hydrolyze. 9 Now it's going to depend on 10 what the media is. We have done 11 studies that show half life of some of 12 these polymers in soil, sediment, and 13 sludge is thousands of years. Others 14 who have done studies say it's hundreds 15 of years, but they will break down. 16 When they break down, they give 17 what we heard about as precursors, And 18 those precursors will break down to 19 PFAAs. That is a fact. It might take 20 a long time, but that'll work. 21 Now fluoropolymers have a 22 backbone of carbon and fluorine. Some 23 of them have oxygen, and that's the 24 perfluoropolyethers. That completely 25 changes the properties. They are not
Page 1333 1 commonly contains PFAS to your 2 knowledge? 3 A. Dental floss is a polymeric, 4 like a floor polymer, not telomer- 5 based, and that's been studied. I 6 believe that dental floss is still FDA 7 approved. 8 Q. Can you briefly describe the 9 differences between a fluorotelomer 10 and a fluoropolymer? 11 A. Sure. You ready? 12 Q. Go ahead. 13 A. I promised I wasn't going to 14 do chemistry; I lied. 15 For fluorotelomer chemistry, 16 we'll do polymer and polymer. I think 17 that's the easiest way because that's 18 what I think we want to compare: 19 A fluorotelomer-based polymer 20 has a hydrocarbon backbone, not a 21 fluorinated backbone, so just carbon 22 and hydrogen in the backbone. It has 23 appendages, like if you look at a comb 24 or pull out a comb, you've got the 25 backbone and you've got tines in the	Page 1335 1 going to break down into the PFAA 2 precursors that we've heard talked 3 about. 4 The fundamental difference is 5 the backbone and how much fluorine is 6 in that molecule. With fluoropolymers 7 it's carbon and fluorine. With 8 fluorotelomer, you've got a hydrocarbon 9 backbone, and the appendages which can 10 be labile depending on what the polymer 11 is and what it's treated with. 12 Q. These side-chain fluorinated 13 polymers represent a high percentage 14 of all PFAS-containing products. Is 15 that correct? 16 A. No, I would not agree with that. 17 Q. What percentage of all PFAS- 18 containing products would you say side- 19 chain fluorinated polymers represent 20 if you could attach a number to it? 21 A. Well I don't think I can 22 answer that now because, as I said a 23 minute ago, there has been very 24 significant market deselection. The 25 textile and carpet industry has



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1336 1 basically gone from these chemicals 2 and they have been for years. 3 The textile market has been 4 under tremendous siege, particularly 5 in Europe and the U.S., so people have 6 gone away from those, or away from 7 fluorine, those were side-chain 8 fluorinated polymers. 9 The paper industries may still 10 use some, but they are largely moving 11 away. They are trying to create non- 12 fluorinated alternatives that may not 13 give you the right performance, but 14 they will give you some. 15 We have firefighting foams. We 16 have talked about that, too, where they 17 have gone to fluorine-free foams, but 18 they don't work as well. 19 The military, at least in land- 20 based systems, not ocean or not water- 21 based systems, land-based system have 22 shifted to fluorine free. 23 I mean a lot of it is public 24 pressure and political pressure, so 25 the market has shifted so	Page 1338 1 normal use, that's not 500 degrees 2 centigrade. It's normal use of what 3 you would cook at home. 4 They would take the oils, 5 they'd take the pan itself, they heat 6 it up, and then you would measure what 7 transferred from that pan or skillet 8 into the oil, and then they'd measure 9 it. They'd calculate the potential 10 hazard based on the hazard of the 11 coating and what extracted. That's 12 how you get FDA certification. As far 13 as I know, it's still certified. 14 FDA obviously continues to look 15 at this because this is an area that's 16 got a lot of people's focus for sure. 17 Q. But you would acknowledge that 18 a non-stick pan that is left on the 19 stove too long and gets too hot is 20 going to emit fluorinated gases or 21 vapors. Is that right? 22 A. I'm not saying -- I think 23 anything you abuse has the potential 24 to do that. I mean you're not supposed 25 to put your pan on and walk away. If
Page 1337 1 dramatically. I mean I can't keep up. 2 All I know is it is 3 significantly different than 10 years 4 ago, and another 5 years from now it 5 will be significantly different also. 6 Q. All right. Your typical non- 7 stick skillet, is that using 8 fluoropolymers or something else? 9 A. Well I mean there are some non- 10 stick skillets that are ceramic and 11 they have other technologies. 12 If you're looking at a skillet 13 coated with PTFE, for example, if it 14 was PTFE from DuPont, now Chemours, it 15 was branded "Teflon," but Teflon is a 16 brand that goes with performance. 17 But yes, this is an FDA- 18 regulated use, and my colleagues -- I 19 wasn't in the fluoropolymer business 20 25 years ago, but they spent a lot of 21 time at FDA. In order for you to get 22 FDA approval, you have to do what they 23 call "Extraction Tests." Those 24 Extraction Tests are based on the use 25 that pan is going to get. That's	Page 1339 1 you put the pan on and walk away or 2 you put the pan on and you turn it up 3 to a degree it's not supposed to use, 4 it has the potential to degrade in 5 some manner. 6 Normally what you will see, 7 and you can argue, if you like, that 8 you're not supposed to do that to the 9 pan. Do people make mistakes? 10 Probably. Should they replace the 11 pan? Absolutely. 12 Q. Thank you for that. 13 A. Sure. 14 Q. Your Testimony acknowledges 15 that there are environmental effects 16 from the manufacture of fluoropolymers. 17 Isn't that correct? 18 A. I think that history is long 19 out there. I mean I think the 20 emissions from the fluoropolymer 21 manufacturers has been probably the 22 major issue for this industry for many 23 years. 24 As I mentioned when T.J. was 25 asking me about my background, myself



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1340 1 and 3 other colleagues, 2 of which 2 were from the University of Stockholm, 3 we decided in 2004 that we wanted to 4 look at particularly PFOA, but it was 5 PFCAs. We wanted to look at where 6 PFOA was coming from, And it was, I 7 guess, all of a 2-year project. 8 What we did is we looked at 9 every emission source or potential 10 source for PFOA in the environment, 11 and fluoropolymer manufacturing was at 12 the top of the list, yes. 13 Q. And as I think I heard in your 14 Testimony, you stated that the 15 manufacture of fluoropolymers still to 16 this day typically involves the use of 17 non-polymeric PFAS. Is that correct? 18 A. What they do is, as I said -- 19 and I don't have a current number, but 20 I think Barb did say this: 21 If the technical end use 22 requires a certain specification of 23 fluoropolymer that the only way you 24 can get that is using a polymerization 25 aid, those companies are still doing	Page 1342 1 industry could find a way to not use 2 them, they would, and that's their 3 goal. 4 Q. Well that's great to hear, but 5 they are not quite there yet. Is that 6 right? 7 A. You're correct. 8 Q. As you pointed out in your 9 Testimony, "low concern" is not the 10 same as "no concern"; correct? 11 A. That's what I said, yes. 12 Q. Okay. 13 MR. KNIGHT: I think that's 14 all the questions I have. 15 THE WITNESS: Thank you. 16 HEARING OFFICER ORTH: Thank 17 you, Mr. Knight. 18 Mr. Harris, any questions? 19 MR. HARRIS: No questions, 20 Madam Hearing Officer. 21 HEARING OFFICER ORTH: He said 22 "No questions..." 23 Mr. Wetherbee, do you have 24 questions of Dr. K? 25 He may have stepped away.
Page 1341 1 that, But they are also doing 2 something else. 3 They are doing everything they 4 can to switch all the other uses over 5 to the non-fluorinated polymerization 6 aids, and they are trying to work on 7 creating new ones. They want to get 8 out of using the small molecules, the 9 fluoropolymerization aids, and I've 10 said that. 11 We've been talking about this 12 for 20 years, And they've made 13 significant progress. I think PVDF, 14 which is the second largest 15 fluoropolymer, is largely out of using 16 the fluorinated polymerization aids. 17 As Barb talked about today, 18 there are some specific uses for PTFE, 19 that's still needed because the 20 customer requirements require it. In 21 other words, the technical purity or 22 the technical properties of the 23 fluoropolymer are required. 24 But the goal is to find a way, 25 and I can tell you this: If the	Page 1343 1 All right. Is there Redirect? 2 MR. TRUJILLO: At this time, I 3 do have some Redirect questions, Madam 4 Hearing Officer. 5 HEARING OFFICER ORTH: Great. 6 Go ahead. 7 8 REDIRECT EXAMINATION 9 BY MR. TRUJILLO: 10 Q. Dr. K, thank you for your 11 Testimony. I do have a couple 12 questions for you: 13 I want to return to your 14 comments on Labeling at the end of 15 your Direct Testimony. 16 A. Okay. Sure. 17 Q. Can you give us some context 18 on your comments? 19 I'm summarizing here, but 20 "Labeling can't be good." Can you 21 give us the context of -- 22 A. What I was saying about that 23 is I was giving credit to the State 24 and for having a program to work with 25 their constituents, and clearly based



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1344 1 on the comments you heard today and 2 yesterday, it's an important thing to 3 do. My comments were particularly 4 related to -- I'll answer your 5 question in a second: 6 In the Bill you have a list of 7 exempted products. Our position is 8 they should not be labeled because of 9 what I had said this morning and again 10 this afternoon, which is that the risk 11 of exposure from a fluoropolymer... 12 In the days that I've been in 13 this industry there is no such thing 14 as zero, but it's vanishingly small if 15 there is going to be any risk of 16 exposure from a fluoropolymer given 17 all the testing that's been done over 18 the years. 19 What I also did say, though, 20 is that if there is consumer products 21 that have PFAS chemicals that can 22 expose the population, and they can 23 and it does potentially have a risk 24 that can be quantified, then it's 25 possible then that a label would be	Page 1346 1 MR. TRUJILLO: That's all of 2 my questions. Thank you very much, 3 Madam Hearing Officer. 4 HEARING OFFICER ORTH: Thank 5 you, Mr. Trujillo, and Dr. K. 6 We'll move to the Board: 7 Vice Chair Suina, do you have 8 questions? 9 VICE CHAIR SUINA: No 10 questions. Thank you. 11 HEARING OFFICER ORTH: All 12 right. Chair Ely. 13 CHAIR ELY: Good afternoon, 14 Dr. K. Thank you for being here, too. 15 I appreciate your Testimony. 16 THE WITNESS: Thank you. 17 18 EXAMINATION 19 BY CHAIR ELY: 20 Q. You talked about some studies 21 that looked at incineration of 22 fluoropolymers and -- 23 A. I did, yes. 24 Q. -- and the potential for a 99+ 25 destruction rate, provided the
Page 1345 1 beneficial. 2 My comments also were -- 3 again, I may get counseled on this, 4 but it is that I'm not sure that label 5 would do it, but that's an aside. I'm 6 not a label expert, but to me, as a 7 Chemist, I wouldn't know what to do 8 with that. 9 Q. One last question: 10 Do you have any final thoughts 11 that you would like to leave with the 12 Board relative to your Testimony? 13 A. Listen, the Board needs to 14 understand that I really do appreciate 15 being able to come here today. 16 I would hope, because you've 17 heard lots of Testimony, and you've 18 heard completely different testimonies 19 from different people, especially Barb 20 and I, but I would hope you would take 21 into consideration our backgrounds, 22 our experience, and then take into 23 consideration some of the things that 24 we've given you to think about today. 25 Thank you.	Page 1347 1 temperature was high enough. Is that 2 right? 3 A. Yeah, there is no question, no 4 question whatsoever that if you don't 5 have something above 900 C, for 6 example, or 980 C, you have a 7 significant potential of not finishing 8 the job, that's true. 9 Most municipal waste 10 incinerators, if they're running on 11 their permit and following their permit, 12 are going to run at 1,000, 1,000 13 degrees. Hazardous waste may be 11-, 14 1150. 15 We have done a lot of work 16 studying this. When you look at the 17 studies that have been done under 18 controlled conditions, as well as 19 commercial conditions, as Barb said, 20 we're getting several '9s destruction, 21 and you need that. 22 Just for the Board to 23 understand, 99.9% is a wonderful 24 thing, but that's 1,000 parts per 25 million that's still left over, and



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1348 1 that is very different from PPTs, which 2 is what we're talking about today. 3 You need several '9s destruction. 4 What you need to do is you need 5 to run the equipment the way it's 6 supposed to. You need to have your 7 proper emission controls in place, and 8 you need to have the right analytical. 9 As long as you do all of that, you 10 have a really good chance of... 11 You know, I mean you're 12 supposed to operate with no emissions, 13 so we're pretty close to that, but we 14 have to get agreement with EPA. 15 Our particular group has been 16 working back and forth with the U.S. 17 EPA; they have extensive experience in 18 incineration. 19 We have been working with a 20 lab out of North Carolina to try to 21 get guidance so that when we do our 22 work, they will say it's okay. They 23 are hard to get to say it's okay, but 24 that's what we're doing. 25 The studies Barb cited and	Page 1350 1 people have done the same thing. 2 There is one study that used a 3 mixture and, you know, I didn't design 4 the study and I find it hard to 5 interpret, but the whole idea is if 6 you can get the PTFE to completely 7 burn, you probably got the conditions 8 you need to be safe. 9 Q. I'm just thinking of conditions 10 where, say in New Mexico, I've seen 11 people burning their trash, you know. 12 What kind of -- 13 A. Do you want me to cringe now 14 or later? 15 Q. It may not be legal, but it 16 happens. 17 A. Yeah. 18 Backyard burning, you can't 19 control it. That's where a public 20 service campaign would probably be 21 good, though I don't work in New 22 Mexico except for this week. 23 Backyard burning is not a good 24 idea, especially with these products. 25 They are likely not to do you any
Page 1349 1 what I cited are really good. The 2 thing that people don't want to see, 3 and you heard this today, is the 4 little things that don't get burned, 5 or the PICS, but the products that get 6 complete combustion. They are the 7 small non-polymeric. 8 Developing the analytical 9 methods to measure those has been a 10 huge challenge, but they are now in 11 place. We can now measure what's 12 coming out to a very, very small 13 amount. 14 Q. So you're talking about 15 needing the 900 C. 16 A. You probably need to be above 17 that. 18 It depends on the polymer also. 19 PTFE is the hardest fluoropolymer to 20 destruct, so if you're using Number 2, 21 which is PPDF, 900 probably would be 22 fine. 23 Q. Okay. 24 A. But we've started with PTFE 25 because that's the hardest, and most	Page 1351 1 harm, but the fact of the matter is 2 you're then putting emissions in the 3 air, and that can travel. 4 And it may not be you, but 5 backyard burning, you know, I worked 6 for many years with the U.S. military 7 and the Department of Defense. A lot 8 of work I had done has been in 9 firefighting foams and related products. 10 I spent a lot of time at DOD, 11 and they are just like us today. You 12 really want to discourage burning of 13 these kinds of products. 14 I mean they have armaments. 15 The military coats a number of their 16 products with fluoropolymers and the 17 like to keep them waterproof, and, you 18 know, they need to destroy them. 19 Armament destruction or 20 warfare destruction is a big program. 21 That's where I read about all the 22 backyard burning stories; not a good 23 idea. 24 Q. I think back to the days when 25 my Mother would burn our family trash;



BEFORE HONORABLE FELICIA L. ORTH
VOL IV HEARING,

Page 1352 1 I shutter and wish I could go back and 2 tell her. 3 A. If I cringe, I'm sorry. 4 Q. Please stop. 5 All right. You mentioned 6 waste-to-energy plants. 7 A. Yes. 8 Q. Those are regulated. 9 A. They are regulated, yes. 10 Q. In New Mexico I think we only 11 have 1, and I believe they are 12 outlawed in the State's jurisdiction. 13 Do you know of waste-to-energy plants 14 in New Mexico? 15 A. I do not. 16 Just to be on the up-and-up, 17 incineration is tough to do because 18 there is not enough incinerators, so 19 that's the second issue. If you 20 wanted... 21 You know, the... 22 A lot of states, for their own 23 reasons, won't take waste like this, 24 hazardous waste. If you try to find a 25 hazardous waste incinerator, sometimes	Page 1354 1 informative. 2 THE WITNESS: Thank you. 3 HEARING OFFICER ORTH: Thank 4 you. 5 Member Curry, do you have 6 questions of Dr. K? 7 All right. Anything further 8 before we excuse Dr. K? 9 No. Thank you very much, sir. 10 THE WITNESS: Pleasure. Thank 11 you. 12 HEARING OFFICER ORTH: Let me 13 ask the parties if there is anything 14 else they are aware of that we would 15 need to do? 16 We do have a request from the 17 Board for a bit of additional 18 Testimony, but let me ask the parties 19 first. No. 20 MR. MOELLENBERG: Madam 21 Hearing Officer, nothing. 22 Our Technical Testimony has 23 concluded and other than the post- 24 hearing proceedings, I don't think we 25 have anything else.
Page 1353 1 you have to go to other states. Then 2 if they will take it, great; if they 3 won't, you have to go to Plan B. 4 CHAIR ELY: All right. That's 5 all of my questions. Thank you. 6 THE WITNESS: Thank you. 7 HEARING OFFICER ORTH: Thank 8 you. 9 On the platform, Member 10 Bitzer, do you have questions of 11 Dr. K? 12 Member Carrasco, do you have 13 questions of Dr. K? 14 BOARD MEMBER BITZER: Sorry, I 15 couldn't get to the button properly; 16 it wasn't expanding for me. 17 HEARING OFFICER ORTH: Okay. 18 BOARD MEMBER BITZER: Yeah, 19 no, I don't have any questions. I'm 20 just also old enough to remember 21 burning trash out in the backyard with 22 my Dad once a week. We lived in the 23 Bay Area of California, too; it was 24 pre-EPA days. 25 Anyway, thank you; it's been	Page 1355 1 HEARING OFFICER ORTH: All 2 right. Thank you very much. 3 Chair Ely, would you like to 4 describe what you would like to hear? 5 I might mangle it otherwise. 6 CHAIR ELY: Probably not any 7 worse than me, Madam Hearing Officer. 8 9 EXAMINATION 10 BY CHAIR ELY: 11 Q. I have a question on Labeling 12 of Complex Durable Products; it's in 13 the Rule. I don't know if Dr. Chapman 14 would be the best person to answer 15 that question probably. It relates to 16 Paragraph 2.13D(1). 17 You were talking about all the 18 "mays" and "shalls" earlier today, and 19 I'm particularly interested in the 20 last sentence there. 21 The way I read this paragraph, 22 it looks like the Erlenmeyer flask 23 with "PFAS" is a requirement, and 24 there is additional language that 25 needs to be included, or an additional



EXHIBIT C**REFERENCES**

Buck, R. C.; Franklin, J.; Berger, U.; Conder, J. M.; Cousins, I. T.; de Voogt, P.; Jensen, A. A.; Kannan, K.; Mabury, S. A.; van Leeuwen, S. P. J. Perfluoroalkyl and Polyfluoroalkyl Substances in the Environment: Terminology, Classification, and Origins. *Integr. Environ. Assess. Manage.* 2011, 7 (4), 513–541. DOI: 10.1002/ieam.258.

Wang, Z.; Buser, A. M.; Cousins, I. T.; Demattio, S.; Drost, W.; Johansson, O.; Ohno, K.; Patlewicz, G.; Richard, A. M.; Walker, G. W.; White, G. S.; Leinala, E. A New OECD Definition for Per- and Polyfluoroalkyl Substances. *Environ. Sci. Technol.* 2021, 55 (23), 15575–15578. DOI: 10.1021/acs.est.1c06896.

Hammel, E.; Webster, T. F.; Gurney, R.; Heiger-Bernays, W. Implications of PFAS Definitions Using Fluorinated Pharmaceuticals. *iScience* 2022, 25 (4), 104020. DOI: 10.1016/j.isci.2022.104020.

Anderson, J. K.; Brecher, R. W.; Cousins, I. T.; DeWitt, J.; Fiedler, H.; Kannan, K.; Kirman, C. R.; Lipscomb, J.; Priestly, B.; Schoeny, R.; Seed, J.; Verner, M.; Hays, S. M. Grouping of PFAS for Human Health Risk Assessment: Findings from an Independent Panel of Experts. *Regul. Toxicol. Pharmacol.* 2022, 134, 105226. DOI: 10.1016/j.yrtph.2022.105226.

Korzeniowski, S. H.; Buck, R. C.; Newkold, R. M.; El kassmi, A.; Laganis, E.; Matsuoka, Y.; Dinelli, B.; Beauchet, S.; Adamsky, F.; Weilandt, K.; Soni, V. K.; Kapoor, D.; Gunasekar, P.; Malvasi, M.; Brinati, G.; Musio, S. A Critical Review of the Application of Polymer of Low Concern Regulatory Criteria to Fluoropolymers II: Fluoroplastics and Fluoroelastomers. *Integr. Environ. Assess. Manage.* 2023, 19 (2), 326–354. DOI: 10.1002/ieam.4646.

Henry, B. J.; Carlin, J. P.; Hammerschmidt, J. A.; Buck, R. C.; Buxton, L. W.; Fiedler, H.; Seed, J.; Hernandez, O. A Critical Review of the Application of Polymer of Low Concern and Regulatory Criteria to Fluoropolymers. *Integr. Environ. Assess. Manage.* 2018, 14 (3), 316–334. DOI: 10.1002/ieam.4035.

U.S. Environmental Protection Agency. TSCA Section 8(a)(7) Reporting and Recordkeeping Requirements for Perfluoroalkyl and Polyfluoroalkyl Substances; 86 Fed. Reg. 33,926 (June 28, 2021).

U.S. Environmental Protection Agency. Toxic Substances Control Act Reporting and Recordkeeping Requirements for Perfluoroalkyl and Polyfluoroalkyl Substances; 88 Fed. Reg. 70,516 (Oct. 11, 2023).

Organisation for Economic Co-operation and Development (OECD). *Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances: Recommendations and Practical Guidance*; Series on Risk Management No. 61; OECD: Paris, July 9, 2021. [https://one.oecd.org/document/ENV/CBC/MONO\(2021\)25/En/pdf](https://one.oecd.org/document/ENV/CBC/MONO(2021)25/En/pdf).

Vermont Agency of Natural Resources, Department of Environmental Conservation, Drinking Water and Groundwater Protection Division. *Advance Notice on the Regulation of Perfluoroalkyl, Polyfluoroalkyl Substances (PFAS) as a Class*; Aug 14, 2020. <https://dec.vermont.gov/sites/dec/files/PFAS/20180814-PFAS-as-a-Class.pdf>.

U.S. Department of Defense. *Report on Critical Per- and Polyfluoroalkyl Substance Uses*; Aug 2023. <https://www.acq.osd.mil/eie/eer/ecc/pfas/docs/reports/Report-on-Critical-PFAS-Substance-Uses.pdf>.

U.S. Food and Drug Administration. *PFAS in Medical Devices*; Aug 6, 2025. <https://www.fda.gov/medical-devices/products-and-medical-procedures/pfas-medical-devices>.

U.S. Environmental Protection Agency. *Fact Sheet: 2010–2015 PFOA Stewardship Program*; Feb. 26, 2026. <https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/fact-sheet-20102015-pfoa-stewardship-program>.

U.S. Environmental Protection Agency. *EPA and 3M Announce Phase Out of PFOS*; May 16, 2000. <https://perma.cc/KA6N-WANC>.

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF SARAHANN M. RACKL, PH.D., P.E.

I, Sarahann M. Rackl, Ph.D., P.E., hereby declare and state as follows:

1. I have been retained by counsel for Plaintiffs as an expert in connection with the above-captioned litigation.

2. I have been asked to provide my expert opinions on the variability of potential risks across the broad range of chemicals that would be considered PFAS under the New Mexico Per- and Poly-Fluoroalkyl Substances Protection Act (“PFAS Act”), N.M. Stat. § 74-15-1 *et seq.* In particular, I have been asked to focus on the differences in PFAS hazards and exposures from the various ways in which PFAS is applied. I have also been asked to discuss the impact of PFAS

treatment and disposal options available to manufacturers which might reduce or limit the release of PFAS into the environment. In addition, I have been asked to consider the essential role that PFAS plays in certain applications, based on its persistent characteristics.

3. I have actual knowledge of the matters stated herein. If called to testify in this matter, I would testify truthfully and based on my expert opinions.

4. In preparing this declaration, I reviewed the PFAS Act, the New Mexico Environmental Improvement Board's (the "EIB") implementing regulation, NMAC § 20.13.2, and all other documents cited herein. I am also relying on my scientific education and training, my industry experience, my research experience, and my knowledge of the scientific literature in the pertinent fields, as set out in my curriculum vitae, attached hereto as **Exhibit A**.

5. The materials I have relied upon in preparing this declaration are the same types of materials that experts in my field regularly rely upon when forming opinions on these subjects. These materials are listed in **Exhibit B** to this Declaration.

6. I reserve the ability to supplement the opinions stated in this declaration or the bases for them as a result of new scientific research or publications or in response to statements and issues that may arise in my area of expertise.

I. BACKGROUND AND QUALIFICATIONS

A. Qualifications

7. I hold a B.S. in biology from the College of William and Mary (1997), a M.S. in civil and environmental engineering from University of Colorado, Boulder (2002), and a Ph.D. in civil and environmental engineering from University of Colorado, Boulder (2004). I have been practicing in the field of environmental science and engineering for more than 25 years as a researcher and consultant.

8. I have extensive, first-hand knowledge of the regulatory, commercial, and scientific dimensions of PFAS.

9. I am currently employed as a Principal Engineer in the Environmental & Earth Sciences practice at Exponent, Inc. where I specialize in conducting human and environmental risk assessments for chemicals of concern, including PFAS. I provide consulting services in the areas of engineering, microbiology, analytical chemistry, water quality, consumer product safety, and human and environmental risk assessments for chemicals of concern.

10. Since 2017, I have been conducting risk assessments for PFAS, including for the purpose of compliance with California's Safe Drinking Water and Toxic Enforcement Act of 1986, which is commonly referred to as "Proposition 65." I rely on my multidisciplinary technical background and industry experience to support manufacturers who have historically utilized PFAS during the manufacturing process. I also work with product manufacturers to identify the presence of PFAS in their products and develop strategies to identify and eliminate unnecessary PFAS sources. I have experience working with a broad range of products—such as food, apparel, textiles, food packaging, and personal care products—to assess the potential presence and impact of PFAS by using different testing methodologies.

11. My work on PFAS is backed by a strong understanding of consumer product and environmental regulations. I have developed numerous compliance and product stewardship programs for companies with extensive product lines; including food and beverage, food packaging, apparel, textiles, cosmetics, personal care products, common consumer household and office products, and specialty industrial products. As part of this work, I support manufacturers in evaluating and conducting root cause analyses for PFAS emissions and discharges. I have also supported clients in evaluating the removal and treatment of water and wastewater for PFAS.

B. Compensation

12. I am being compensated at a rate of \$455 per hour. My compensation does not depend on the outcome of this litigation, the opinions I express, or the testimony I provide.

C. Previous Testimony

13. I have not previously testified as an expert witness.

II. SUMMARY OF OPINIONS

14. New Mexico’s definition of “PFAS” covers thousands of different chemicals, which have diverse and unique chemical properties. That broad coverage comes from the law’s broad definition, which is structural: it defines PFAS as “a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.” N.M. Stat. § 74-15-2(S).

15. Whether a particular chemical poses a risk to human health and the environment cannot be discerned from chemical structure alone; assessing risk requires evaluating the hazards posed by a chemical, and how it might be introduced to a person or into the environment. Chemicals identified as PFAS might be used in different products in different ways; thus, the risk potential for each PFAS and its specific applications can be extremely different.

16. Existing scientific research does not support treating a broadly defined group of PFAS with a broad brush, as if all PFAS posed the same risk to human health and the environment. As explained below, PFAS risk depends on a number of factors, just one of which is chemical structure. Assessing PFAS risk requires an evaluation of hazard and exposure; that evaluation, in turn, requires a holistic examination of factors such as how a PFAS is used and the ways in which humans and the environment might come into contact with the chemical (or not).

17. Moreover, existing and emerging technologies can reduce PFAS emissions by safely disposing of or destroying PFAS from manufacturing facilities that make or utilize PFAS in producing consumer products.

18. Certain PFAS used for specific applications have been identified as having potential risks to human health and environment that outweigh their beneficial use in products. Many of these PFAS applications have been and are being phased out. Other PFAS and their applications do not have the same risk profiles and are essential to the durability and function to many products used by the consumer public every day.

III. BACKGROUND

A. Background on chemical risk assessments

16. Chemical risk assessments are used to characterize risk and inform safety decisions relating to that chemical. These assessments involve a systematic process for identifying and analyzing the potential hazards and exposure scenarios for chemicals or groups of substances—in other words, for determining what dangers a chemical might pose (hazard), and how that chemical might be introduced to people or to the environment (exposure). Risk assessments are the foundation for making decisions to protect public health and the environment, and they help drive regulatory decision making.¹ The potential environmental or human health risk associated with a chemical depends on not just a chemical's structure, but also the hazards associated with the chemical, and exposure to that chemical.²

17. In its simplest form, Risk = Hazard × Exposure.

¹ National Research Council of the National Academies, *Science and Decisions: Advancing Risk Assessment* 422 (2009).

² U.S. EPA, EPA 100-B-00-002, *Risk Characterization* 10 (2000), https://www.epa.gov/sites/default/files/2015-10/documents/osp_risk_characterization_handbook_2000.pdf.

18. “Hazards” are the harmful effects associated with a chemical. A hazard assessment involves identifying the potential harmful effects of a chemical, including relevant routes of exposure, and the dose levels or exposure thresholds at which those effects could occur.³ Assessing hazard to human health, for example, may mean evaluating the levels (or concentration) at which a chemical has been demonstrated to cause cancer. Determining environmental hazard would require examining the levels at which a chemical might cause harm to the environment—either causing harm to organisms directly, or impairing their ability to have viable offspring.

19. “Exposure” is the amount of a chemical that enters and interacts with, or causes biological harm to, the human body and other organisms. An exposure assessment considers the potential magnitude and route of exposure and may also assess the frequency and duration of the exposure at a specific magnitude.⁴ There are many routes of exposure, including inhalation, dermal, and oral (direct ingestion or indirect hand-to-mouth).⁵ The impact of the route of exposure for a specific chemical can also be unique to humans and other organisms. The routes of exposure relevant to a chemical depend on the chemical’s properties.⁶ For example, a chemical's potential to volatilize may affect whether it can be inhaled, its potential to cross skin barriers may determine whether it can be absorbed through the skin, and its solubility in water or food may determine whether it can be ingested.

20. Bioaccumulation occurs when an organism absorbs or consumes chemicals from their environment and retains those chemicals within their tissue faster than they can be eliminated. When an organism consumes (direct ingestion exposure pathway) another organism that has been

³ *Id.*

⁴ *Id.*

⁵ *Id.*

⁶ Hans-Joerg Burger & Michael Schwenk, *Importance of Physicochemical and Physical Properties for Toxicological Risk Assessment*, in *Regulatory Toxicology 1* (Franz-Xaver Reichl & Michael Schwenk eds., 2021).

accumulating a chemical within their tissue (e.g., big fish eating a small fish), this is considered biomagnification. Through this exposure pathway, some chemicals can be passed along within the food web.

21. The fact that a person merely touches a product or material does not mean that the person will be exposed to every chemical in that product or material. The chemicals that make up the material or product would need to migrate, be released, or be leached out of the product or material, so that the chemicals can interact with or enter the body. That is how “exposure” occurs. If a chemical does not migrate, release, or leach out of products, it is often considered chemically inert.⁷ Similarly, if a chemical does not interact with the human body or organisms, it is generally considered biologically inert.⁸ For example, if a person holds a device, it does not mean the person is exposed to internal components or the chemicals that comprise those components. Another example is an implantable medical device—a person relying on the device will obviously come in high contact with the device’s materials, but chemicals that comprise the materials are typically chemically inert or chemically stable and do not leach or interact with the body in any way.

22. Risk can only be meaningfully characterized by considering both hazard and exposure together, such that the risk of a chemical with significant hazards is low if there is no meaningful exposure. For example, lightning can harm people and animals, but lightning becomes a higher risk when standing outside during a thunderstorm versus staying inside a building.

23. The concept of harm and exposure jointly informing “risk” is embodied in many federal and state regulations that require risk assessments in connection with the use of chemicals.

⁷ Int’l Union of Pure & Applied Chemistry, *Inert* in IUPAC Compendium of Chemical Terminology (5th ed. 2025), <https://goldbook.iupac.org/terms/view/I03026>.

⁸ H. Murali Rao et al., *Bioinert and Bioactive Materials – Narrative Review*, 13 J. Pharm. Negative Results 2251, 2251-52 (2022).

The U.S. Environmental Protection Agency (“EPA”), for example, looks at the hazard and potential exposure to evaluate and quantify risk in implementing and enforcement of regulations. EPA’s rules under the Toxic Substances Control Act (“TSCA”) specify that if an eligible chemical substance has a “significant new use,” EPA’s risk assessment for that use must consider potential exposures arising from the conditions of use.

24. California’s Proposition 65, which requires a warning label for consumers if a product contains chemicals that are known to cause cancer, birth defects, or reproductive harm, also takes a hazard- and exposure-focused approach to its labeling requirements. Manufacturers are not required to label a product simply because it contains a chemical that might be carcinogenic; instead, Proposition 65 requires a label only after the state has confirmed the identity of the chemical and the associated hazard, and the manufacturer knows consumers might be significantly exposed to the listed chemical (above a chemical- and hazard-specific threshold).⁹

B. PFAS terminology utilized for purposes of this declaration only

25. New Mexico’s definition of “PFAS” can cover many thousands of molecules with unique structural, chemical, and physical properties. Although there are different ways to group and categorize the subcategories of PFAS, I refer mainly to three categories throughout this declaration, which I describe below.

26. **Non-polymeric or “small molecule” PFAS.** PFAS have different molecular weights. The phrase “small molecule” is used to refer to PFAS that weigh somewhere between 200 to 500 Daltons,¹⁰ as opposed to the fluoropolymers that might have a mass of more than

⁹ Cal. Code Regs. tit. 27, §§ 25701, 25801.

¹⁰ For example: PFBA (C4) is ~300 Daltons and PFDA (C10) is ~500 Daltons. PubChem, *Compound Heptafluorobutyric acid*, National Center for Biotechnology Information, <https://pubchem.ncbi.nlm.nih.gov/compound/9777> (last visited June 29, 2026); PubChem, *Perfluorodecanoic Acid*, National Center for Biotechnology Information, <https://pubchem.ncbi.nlm.nih.gov/compound/9555> (last visited June 29, 2026).

100,000 Daltons.¹¹ Small molecule PFAS include long chain PFAS, generally defined as having six or more fluorinated carbons (“C6”), and short chain PFAS, generally defined as having less than six fluorinated carbons.¹² The chemical structures of small molecule PFAS lend to their surfactant properties, which have historically made them useful in diverse applications (e.g., fire suppression, water- and stain-resistant treatments, lubricants). Many small molecule PFAS are referred to by the number of fluorinated carbons. For example, perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are both called “C8.”

27. **Polymeric PFAS.** “Fluorinated polymeric compounds” include any polymer containing fluorine anywhere in its structure. This includes side-chain fluorinated polymers, polymeric perfluoropolyethers, and other partially fluorinated polymers. These compounds are often designed for surface functionality (e.g., stain resistance, oil/water repellency) and may potentially degrade or break down at different rates to produce small molecule PFAS depending on their structure and environmental conditions.¹³ Fluorinated polymeric substances may contain lower molecular weight components or degradable side chains that can result in environmental mobility and formation of smaller PFAS.¹⁴

28. **“Fluoropolymers”** are a subset of fluorinated polymeric compounds that consist of long, high molecular weight chains of carbon atoms bonded to fluorine atoms, and bonded

¹¹ Barbara J. Henry et al., *A critical review of the application of polymer of low concern and regulatory criteria to fluoropolymers*, 14 Integrated Env’t Assessment & Mgmt. 316, 322 (2018).

¹² Organisation for Economic Co-operation and Development, *Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances: Recommendations and Practical Guidance* 17 (July 9, 2021), https://www.oecd.org/content/dam/oecd/en/publications/reports/2021/07/reconciling-terminology-of-the-universe-of-per-and-polyfluoroalkyl-substances_a7fbcba8/e458e796-en.pdf.

¹³ Organisation for Economic Co-operation and Development, *Synthesis Report on Understanding Side-Chain Fluorinated Polymers and Their Life Cycle* 21, 25, 30-31 (Nov. 15, 2022), https://www.oecd.org/content/dam/oecd/en/publications/reports/2022/11/synthesis-report-on-understanding-side-chain-fluorinated-polymers-and-their-life-cycle_5c473fc6/e13559f7-en.pdf.

¹⁴ Henry, *supra* note 11, at 317.

together in repeating units (i.e., the polymer backbone is carbon-based, and fluorine atoms are attached to the backbone).¹⁵ The large size and lack of water-solubilizing functional groups in fluoropolymers result in materials that do not have surfactant properties (like the small molecule PFAS), are considered immobile in the environment, and are stable under many chemical, biological, and environmental conditions.¹⁶

IV. Opinions

A. The vast physical and chemical differences in PFAS result in significant differences in hazards

29. There is no universally accepted definition of “PFAS” or a universally accepted understanding of what constitutes “PFAS.” As the Department of Defense has noted, the definitions are “structural,” and they do not “inform whether a substance is harmful.”¹⁷ They “only communicate that the substances share common structural traits to varying degrees.”¹⁸

30. Many government bodies and nongovernmental organizations have cautioned that a structural definition alone is not sufficient to identify whether a PFAS chemical poses a risk to human health and the environment. Rather, these bodies have cautioned that any risk assessment must involve evaluation of hazard and exposure, not just consideration of structure alone.

31. The Organisation for Economic Co-operation and Development (“OECD”), for example, published a report in 2021 that defined PFAS as essentially any chemical with at least one fully fluorinated carbon atom (e.g., all hydrogens on a carbon atom are replaced by fluorine),

¹⁵ *Synthesis Report*, *supra* note 13, at 16.

¹⁶ Henry, *supra* note 11, at 330.

¹⁷ U.S. Dep’t of Defense, *Update on Critical Per- and Polyfluoroalkyl Substance Uses* 10 (Jul. 17, 2025) (“2025 DOD Report”), <https://www.denix.osd.mil/cmrmpp/denix-files/sites/14/2025/07/2025-DoD-Update-on-PFAS-Critical-Uses.pdf>.

¹⁸ *Id.*

with a few exceptions.¹⁹ New Mexico has essentially followed this definition for its own PFAS legislation. But OECD stated that it provided this definition of PFAS “from the chemical structure point of view” and that *the definition “does not conclude that all PFASs have the same properties, uses, exposure and risks.”*

32. OECD acknowledged that PFAS, as defined, is a “*broad, general, non-specific term*,” which does not inform whether a compound is harmful or not” and is “not connected to decisions on how PFASs should be grouped in regulatory and voluntary actions.” OECD also recommended using chemical-specific criteria or specifications as a starting point—not an end point—for regulatory or guidance purposes rather than their broad and general PFAS definition.

33. Using only the approximately 13,000 chemistries that meet the EPA TSCA PFAS definition, which is more restrictive than the OECD PFAS definition, EPA scientists employed a category approach to group together different PFAS based on chemical structure, considering key structural characteristics and potential degradation products.²⁰ The scientists identified **more than 100 groups that could be used to approach hazard assessments** for PFAS. They acknowledged that “the landscape of PFAS substances is substantially large and diverse” and requires a strategic approach to hazard and risk assessment.

¹⁹ “PFASs are defined as fluorinated substances that contain at least one **fully fluorinated methyl or methylene carbon atom (without any H/Cl/Br/I atom attached to it)**, i.e. with a few noted exceptions, any chemical with at least a perfluorinated methyl group (–CF₃) or a perfluorinated methylene group (–CF₂–) is a PFAS.” Organisation for Economic Co-operation and Development, *Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances: Recommendations and Practical Guidance* 17 (July 9, 2021), [https://one.oecd.org/document/ENV/CBC/MONO\(2021\)25/En/pdf](https://one.oecd.org/document/ENV/CBC/MONO(2021)25/En/pdf).

²⁰ G. Patlewicz et al., *Development of Chemical Categories for Per- and Polyfluoroalkyl Substances (PFAS) and the Proof-of-Concept Approach to the Identification of Potential Candidates for Tiered Toxicological Testing and Human Health Assessment*, 31 *Computational Toxicology* 5-7 (Sept. 2024).

34. There is significant diversity in PFAS toxicity within subsets of small molecule PFAS,^{21,22} and fluoropolymers are not bioavailable or bioaccumulative (i.e., do not interact with the human body or other organisms) because they are too large to be able to pass through cellular membranes.²³ This demonstrates that not all chemicals that fall under broad PFAS definitions present the same hazards. PFAS are a broad class of chemistries with diverse physicochemical properties and can exhibit different mechanisms of persistence and bioaccumulation potential. A recent peer reviewed publication noted that “PFAS differ significantly in their behavior based on molecular size, structure, perfluorinated chain length, water solubility, vapor pressure, and functional group charges, all of which influence cell membrane penetration and environmental fate.”²⁴

35. Within the subgroups of small molecule PFAS, there are distinct differences in toxicology and hazards. Small molecule PFAS are often grouped together based on their similarities in size, fluorinated chain length, and composition of alkyl chains with either sulfonic or carboxylic ends; however, even these groupings have differences in toxicology despite the structural similarities.²⁵

36. The EPA has published updated interim health advisory levels for PFOA and PFOS, and final health advisory levels for GenX chemicals, and perfluorobutanesulfonic acid

²¹ Agency for Toxic Substances and Disease Registry, *Toxicological Profile for Perfluoroalkyls* 4 (May 2021), <https://www.atsdr.cdc.gov/ToxProfiles/tp200.pdf>.

²² Sara Hearon et al., *A comprehensive review of the regulation of fluorinated pesticide ingredients by the U.S. Environmental Protection Agency*, 2 J. Toxicology and Regulatory Policy 1, 5 (2026).

²³ Henry, *supra* note 11, at 325.

²⁴ Lorenzo Secundo, Pierangelo Metrangolo, & Valentine Dichiarante, *Current Approaches in the Classification of PFAS: An Overview*, 20 Chemistry – An Asian Journal, May 2025, at 4.

²⁵ Hearon, *supra* note 22, at 5.

(PFBS), based on assessments of available animal toxicology and epidemiology studies. EPA based these health advisories on different key adverse effects identified for each PFAS.²⁶

37. Elimination half-lives, indicators of bioaccumulation potential, vary significantly even within a subgroup of similarly structured small molecule PFAS. PFAS elimination half-lives in humans, based on declines in blood serum measures in the same individuals over time after elevated exposure, range from several days to one month for shorter chain PFAS (C4-C6) to several years for longer chain PFAS (C6-C9).²⁷

38. **Polymeric PFAS have significantly different PFAS hazards; this is particularly true of fluoropolymers.** Numerous evaluations by regulatory authorities, toxicologists, and other experts, evaluating the usage of fluoropolymers like polytetrafluoroethylene (“PTFE”) have concluded that fluoropolymers “do not meet the criteria to be mobile or toxic” and “are distinctly different from other polymeric and nonpolymeric PFAS and should be separated from them for hazard assessment or regulatory purposes.”²⁸ Compared to PFAS that are often considered “small molecules,” fluoropolymers are very large molecules that typically do not cross the cell membrane; “[t]he average molecular weight of PTFE is too large for the polymer to cross a cell membrane, which means it is not bioavailable or toxic.”²⁹ Additionally, the available toxicology studies for PTFE demonstrate a lack of toxicity, specifically “the absence

²⁶ See, e.g., U.S. EPA, No. 815R24006, *Human Health Toxicity Assessment for Perfluorooctanoic Acid (PFOA) and Related Salts* (2024), <https://www.epa.gov/system/files/documents/2024-05/final-human-health-toxicity-assessment-pfoa.pdf>; U.S. EPA, No. 815R24007, *Human Health Toxicity Assessment for Perfluorooctane Sulfonic Acid (PFOS) and Related Salts* (2024), <https://www.epa.gov/system/files/documents/2024-05/final-human-health-toxicity-assessment-pfos.pdf>; U.S. EPA, *Human Health Toxicity Assessment for GenX Chemicals: Technical Fact Sheet* (2023), <https://www.epa.gov/system/files/documents/2023-03/GenX-Tox-Assessment-technical-factsheet-March-2023-Update.pdf>; U.S. EPA, *Technical Fact Sheet: Toxicity Assessment for PFBS* (2021), accessible at <https://www.epa.gov/chemical-research/learn-about-human-health-toxicity-assessment-pfbs>.

²⁷ The Interstate Technology & Regulatory Council, *Technical Guidance: Per-and Polyfluoroalkyl Substances (PFAS)* 670, Table 17-6 (2026), https://pfas-1.itrcweb.org/wp-content/uploads/2026/04/2026.01_PFAS-1.pdf.

²⁸ Henry, *supra* note 11, at 317, 329.

²⁹ *Id.* at 330.

of acute or subchronic systemic toxicity, irritation, sensitization, local toxicity on implantation, *in vitro* and *in vivo* genotoxicity, hemolysis, complement activation, or thrombogenicity.”³⁰ In other words, PTFE toxicology studies demonstrate a lack of interaction with the human body or other organisms, meaning that it is biologically inert and not bioavailable.

39. FDA confirmed that fluoropolymers like PTFE have been safely used for decades in high contact medical devices. The U.S. Food and Drug Administration (“FDA”) published an article in August 2025,³¹ which described the history of how PTFE is used in medical devices, and reaffirmed FDA’s position that there is no reason to restrict the use of PTFE in medical devices, including in materials and devices implanted in the body such as hernia mesh and pacemakers. The FDA emphasized that fluoropolymers used in medical devices, like PTFE, are different than small molecule surfactant PFAS like PFOA and PFOS. In the 2025 publication, FDA cited a previous PTFE safety assessment conducted in 2021,³² which reviewed more than 1,750 scientific articles, along with patient safety information provided by an independent safety organization, which included information on patient adverse effects (e.g., inflammation, sensitization, irritation, scarring, cancer, immune responses, pain, cognitive function). Based on this information, the FDA concluded that there was no conclusive evidence of patient health issues associated with PTFE.

40. In 2018, an independent scientific expert panel convened to review PTFE and other fluoropolymers utilized in cosmetics.³³ The panel reviewed available toxicology data for PTFE, including acute, short term, and chronic toxicity studies involving oral, dermal, and inhalation

³⁰ *Id.* at 332.

³¹ FDA, *PFAS in Medical Devices* (Aug. 6, 2025), <https://www.fda.gov/medical-devices/products-and-medical-procedures/pfas-medical-devices>.

³² FDA, *Medical Device Material Performance Study: PTFE Safety Profile* (2021), <https://www.fda.gov/media/158495/download>.

³³ Cosmetic Ingredient Review Expert Panel, *Safety Assessment of Polyfluorinated Polymers as Used in Cosmetics* (2018), <https://www.cir-safety.org/sites/default/files/fluoro092018FR.pdf>.

exposures, as well as carcinogenicity and other endpoints such as genotoxicity and irritation. Based on the results of these studies, along with information about use in cosmetics, the panel concluded that PTFE is safe in cosmetics in the present use practices and concentration described in the safety assessment. Their safety assessment was published by the Cosmetic Ingredient Review.

B. Differences in PFAS physical and chemical properties result in different applications and ultimately exposure

41. The specific PFAS structure determines where and how it is utilized in products and therefore the means of potential exposure.³⁴ Similar to the differences in toxicology, human health and environmental exposure profiles for different types of PFAS vary significantly and are driven by physical and chemical properties of these substances. For example, fluoropolymers are not bioavailable as they cannot cross cell membranes.³⁵ Fluoropolymers and other larger molecule PFAS also are not water soluble and tend to be immobile in the environment.³⁶

42. How a certain PFAS is utilized also impacts exposure. For example, consumer electronics, semiconductors, and lithium-ion batteries may have internal components that contain smaller-molecule PFAS, but people may never be exposed to the PFAS because of the way the products are used—no one touches the inside of a lithium-ion battery to use it, for example.³⁷

43. **FDA assessment of PFAS in food packaging and cookware illustrates differences in structure and application, and how those differences affect potential exposure.** FDA's approach to the use of PFAS in food packaging and cookware demonstrates that evaluating

³⁴ Juliane Glüge et al., *An overview of the uses of per- and polyfluoroalkyl substances (PFAS)*, 22 Env't Sci. Processes & Impacts 2345, 2350 (2020).

³⁵ Henry, *supra* note 11, at 325.

³⁶ *Id.* at 326-27.

³⁷ RECHARGE, *PFAS Restriction Proposal: RECHARGE statement for 2nd Call for Evidence – October 2021*, at B.1.4 (2021), https://rechargebatteries.org/wp-content/uploads/2022/09/Call-for-Evidence_RECHARGE-_PFAS-restriction-V1.pdf.

hazard and risk for PFAS is a nuanced exercise. FDA has noted that, for non-stick appliances and cookware, which use PTFE in their nonstick coating, at most only negligible amounts of PTFE migrate to food, given how tightly PTFE is bound to the cookware.³⁸ FDA also noted that “the manufacturing process vaporizes off virtually all the smaller (i.e., migratable) PFAS molecules.”³⁹

44. Thus, FDA has confirmed that the specifics of not just PFAS chemistry, but also potential hazards and methods of exposure were critical in determining how to regulate PFAS. The FDA stated, **“the extent to which food contact substances, including those that contain PFAS, migrate to food depends on the authorized and intended use, molecular structure of the substance, how the final product is manufactured [emphasis added].”**

45. **Differences in the PFAS used and how they are applied in consumer electronics and semiconductors and lithium-ion batteries can result in differences in contact and exposure.** Americans use consumer electronics in their everyday lives—at home, at school, and at work. PFAS—including fluoropolymers, smaller molecule surfactants, and polymeric fluorinated chemistries, which collectively confer a multitude of chemical and physical properties, including durability, heat and chemical resistance, energy efficiency, and general product safety—provide the chemistries that enable electronic innovations on which we rely.⁴⁰ Many of these PFAS have been identified as particularly hard to replace.⁴¹ The PFAS utilized in these types of products

³⁸ FDA, *Authorized Uses of PFAS in Food Contact Applications* (Jan. 3, 2025), <https://www.fda.gov/food/process-contaminants-food/authorized-uses-pfas-food-contact-applications>.

³⁹ *Id.*

⁴⁰ See, e.g., ZVEI, *Factsheet “PFAS and Consumer Electronics”* (Sept. 18, 2023), https://www.zvei.org/fileadmin/user_upload/Themen/Nachhaltigkeit_Umwelt/PFAS/14-ZVEI_Factsheet_PFAS_in_Consumer_Electronics_final_EN.pdf; Michelle Adams, *Where Are PFAS in Your Electronics Supply Chain?*, Z2 Data (Apr. 21, 2026), <https://www.z2data.com/insights/where-pfas-your-electronics-supply-chain>; American Chemistry Council, *Fluoropolymers*, <https://www.americanchemistry.com/chemistry-in-america-industry-innovation-impact/chemistries/fluoropolymers> (last visited June 30, 2026).

⁴¹ See, e.g., Michelle Adams, *Where Are PFAS in Your Electronics Supply Chain?*, Z2 Data (Apr. 21, 2026), <https://www.z2data.com/insights/where-pfas-your-electronics-supply-chain>; Semiconductor PFAS Consortium,

are often found either inside the electronics, or bound to the materials used to make up a product. Or the PFAS in question may be a fluoropolymer that may not come into contact with, or be exposed to, a product's end user. All told, risk depends on how PFAS is used, how much of it is used, and how people or the environment might come into contact with PFAS—at the time of manufacture, sale, use, and disposal.

46. The same is true of lithium batteries. Like the inside of a consumer electronic product, or a semiconductor, lithium-ion batteries primarily use polymeric PFAS, but they also use other small molecule PFAS for variety of functions, most critically for safety and energy efficiency.⁴² Lithium-ion batteries, when used correctly, are safe to use. They are identified under REACH as “an article with no intended release.”⁴³ This means that, under normal and reasonably foreseeable conditions of use, no end-user of lithium-ion batteries would be exposed to any chemicals, PFAS or otherwise, and that no PFAS emissions are anticipated during the usage.

47. **PFAS structure has a significant impact on the fate and transport and the environmental behavior, resulting in differences in environmental exposures and exposures through food and drinking water.** As a recent publication observed, “PFAS differ significantly in their behavior based on molecular size, structure, perfluorinated chain length, water solubility, vapor pressure, functional group charges, all of which influence...environmental fate” (i.e.,

Background on Semiconductor Manufacturing and PFAS 9 (May 17, 2023), <https://www.semiconductors.org/wp-content/uploads/2023/05/FINAL-PFAS-Consortium-Background-Paper.pdf>.

⁴² See, e.g., RECHARGE, *supra* note 37, at B.1.1; U.S. Chamber of Com., *Essential Chemistries: Providing Benefits Across the U.S. Economy* 11 (Aug. 2024), https://www.uschamber.com/assets/documents/Essential-Chemistries_-_Providing-Benefits-Across-the-U.S.-Economy.pdf.

⁴³ RECHARGE, *supra* note 37, at B.1.4.

exposure).⁴⁴ Fluoropolymers, for example, are practically insoluble in water and too heavy to travel in air; therefore, they are relatively immobile when compared to smaller molecule PFAS.⁴⁵

48. Evich et al. (2022) reviewed the available studies on the fate and transport of small molecule PFAS and their precursors and determined that PFAS mobility in the environment commonly varies with chain length and functional group, and that the interaction of specific PFAS in the air, water, and soil is varied.⁴⁶ As an example, fluorotelomer alcohols (“FTOHs”) are typically more volatile than most PFAS allowing for atmospheric transport, and FTOHs may undergo photochemical transformation.⁴⁷ This means that certain PFAS can travel through the air more easily than most other PFAS, and, even fewer of these PFAS can transform because of their exposure to light.

49. There are many factors that go into how PFAS might interact in the environment. Certain PFAS may degrade, for example, and may break down into smaller molecules (which may be other types of PFAS). Certain PFAS may degrade only under certain conditions. Some PFAS may not degrade at all under typical conditions, while others may degrade several times over. How a PFAS might degrade, and how it is transported throughout the environment, depends on environmental conditions, how well a PFAS sticks to soil or sediment or stays dissolved in water (sorption), and the structure of the specific chemical.⁴⁸

50. Overall, the fate and transport of PFAS is complex and highly variable. Predicting the fate and transport is difficult because the degradation of some PFAS and their transport in the

⁴⁴ Secundo et al., *supra* note 24, at 4.

⁴⁵ Henry, *supra* note 11, at 325.

⁴⁶ Evich et al., *Per- and polyfluoroalkyl substances in the environment*, 375 Sci., at 4 (Feb. 4, 2022).

⁴⁷ *Id.*

⁴⁸ *Id.*

environment is highly dependent on the specific chemical structure and its interaction with the environment.

51. The existing scientific research does not support drawing broad conclusions about effects of human health and the environment based solely on a chemical’s characterization as a “PFAS.” Reaching conclusions about the impact of a particular PFAS will require a close examination of the structure of a particular chemical, how volatile the chemical is, how the manufacturing process may neutralize the presence of the chemical, how a chemical travels (and under what conditions the chemical might break down), and how human beings interact with the chemical (if they do so at all). No regulatory body—not the EPA, FDA, OECD, or any other federal or international entity—has reached sweeping conclusions about the health and environmental impact of PFAS relying solely on the PFAS label alone. Instead, these entities have engaged in a nuanced risk assessment for a particular PFAS or a subclass of PFAS, examining all of the factors relating to hazard and exposure that might inform that assessment.

52. For this reason, a panel of experts representing various stakeholder groups (academia, regulators, consultants), agreed that it is *“inappropriate to assume equal toxicity/potency across the diverse class of PFAS* [emphasis added]” and that PFAS should be grouped based on risk and regulatory paradigm for purposes of human health risk assessment, not based on an overly simplified approach which only considers structure.⁴⁹

53. A risk assessment for an individual chemical also does not fully inform the impact that a PFAS may or may not have on human health and the environment; proactive mitigation is also another important consideration. Through existing and emerging technologies, manufacturing

⁴⁹ Janet K. Anderson et al., *Grouping of PFAS for human health risk assessment: Findings from an independent panel of experts*, Regul. Toxicology and Pharmacology, Oct. 2022, at 7.

facilities are able to reduce potential PFAS emissions and implement effective PFAS disposal and destruction technologies to reduce PFAS environmental exposures. The U.S. EPA issued two guidance documents: one that reviewed PFAS treatment technologies capable of removing or destroying PFAS in manufacturing or industrial waste streams,⁵⁰ and a second report that evaluated the destruction and disposal of PFAS substances and materials containing PFAS.⁵¹ In both reports, the U.S. EPA acknowledges that continued research and innovation is needed, and implementation of these technologies must consider site-specific needs. However, these technologies are successfully being implemented at manufacturing and disposal facilities across the country, as presented in the two examples provided below.

54. Veolia Environnement SA, published a report in 2025 on two pilot studies conducted at its Port Arthur, Texas facility in July and October of 2024. These studies showed complete mineralization (destruction) of PFAS through the incineration process.⁵² Specifically, the report observed “high destruction and removal efficiency for PFAS compounds during the incineration process, with values up to 99.9999%.”⁵³ PFAS was not detected in the majority of liquid and solid residues and the majority of air samples. Veolia concluded that, “hazardous waste incineration, when properly operated under high-temperature conditions, can effectively break down PFAS compounds.”⁵⁴

⁵⁰ U.S. EPA, *Multi-Industry Per- and Polyfluoroalkyl Substances (PFAS) Study – 2021 Preliminary Report* (Sept. 2021), https://www.epa.gov/system/files/documents/2021-09/multi-industry-pfas-study_preliminary-2021-report_508_2021.09.08.pdf.

⁵¹ U.S. EPA, *Interim Guidance on the Destruction and Disposal of Perfluoroalkyl and Polyfluoroalkyl Substances – 2026 Version* (April 20, 2026), <https://www.epa.gov/system/files/documents/2026-04/2026-interim-guidance-on-pfas-destruction-and-disposal.pdf>.

⁵² Veolia Environnement SA SA, *PFAS Destruction Testing at Veolia's Port Arthur Incinerator 4* (June 2025), <https://info.veolianorthamerica.com/hubfs/offers/reports/vna/pfas/pfas-destruction-testing-veolia-port-arthur-incinerator-study.pdf>.

⁵³ *Id.*

⁵⁴ *Id.*

55. The EPA, together with the North Carolina Department of Environmental Quality, monitored Chemours' efforts to install pollution controls to reduce PFAS emissions at its facility in Fayetteville, North Carolina.⁵⁵ Chemours installed an incinerator, as well as carbon beds designed to remove PFAS that could be released from incinerators into the air. EPA stated that, "the total reduction of PFAS emissions from the plant using these controls are effective at meeting the permit's 99% reduction in [PFAS] emissions."⁵⁶

C. PFAS and their applications provide a constellation of properties that provide critical benefits to society

56. PFAS provide a constellation of properties that is currently not available in alternate chemical and material classes; these properties include, but are not limited to, resistance to aggressive chemical environments, ability to maintain material characteristics at extreme temperatures (i.e., flame and fire resistance), low friction, ability to insulate electrical current, good weatherability and durability in outdoor applications, low refractive index, and biocompatibility. As alternatives to PFAS come onto the market, evaluations need to consider regrettable substitutions and overall effectiveness and safety of the alternatives.

57. In 2024, the U.S. Chamber of Commerce ("Chamber") published a report that evaluated the "economic and fiscal impact of specific sectors reliant on essential fluorochemistries across the U.S. economy."⁵⁷ While the Chamber report focuses on the impact on the U.S. economy, the report highlighted the dependence and essential function PFAS play across seven critical market sectors, including aerospace manufacturing, data centers, defense, energy transition and

⁵⁵ U.S. EPA, *EPA Research Partner Support Story: Air Emissions of PFAS at an Industrial Facility* (Apr. 7, 2026), <https://www.epa.gov/research-states/epa-research-partner-support-story-air-emissions-pfas-industrial-facility>.

⁵⁶ *Id.*

⁵⁷ U.S. Chamber of Com., *Essential Chemistries: Providing Benefits Across the U.S. Economy* 3 (Aug. 2024), https://www.uschamber.com/assets/documents/Essential-Chemistries_-_Providing-Benefits-Across-the-U.S.-Economy.pdf.

emerging energy technologies, health care, transportation and semiconductor manufacturing. The Chamber also stated that “today’s fluorochemistries, including many PFAS, possess a unique combination of properties to repel water, withstand heat, and many other critical properties that make them durable, efficient, versatile, reliable, and often irreplaceable across critical sectors.” The Chamber also identified that many industries estimate that potential replacements could take decades.

58. The DOD, in its 2023 *Report on Critical Per- and Polyfluoroalkyl Substance Uses*⁵⁸ and 2025 *Update on Critical Per- and Polyfluoroalkyl Substance Uses*,⁵⁹ identified the essential function of PFAS across the U.S. Armed Forces and highlighted concerns about the continued availability of some PFAS and their applications. In its 2025 update, the DOD stated, “PFAS are critical to the national security of the United States, not because they are used exclusively in military applications (although some are), but also because of the civil-military commonality and the potentially broad impact to the civilian marketplace.”⁶⁰ Many of the categories and products that DOD identified as difficult to replace, essential uses of PFAS are also products purchased by everyday consumers. Overall, the DOD “highlights the challenges and costs related to finding and qualifying equal or improved performing alternatives to existing PFAS materials in sectors of strategic importance to DoD.”⁶¹

59. While in many places, PFAS have been phased out of **textiles and apparel**, a need for PFAS in textiles and apparel remains for more extreme weather and other environmental

⁵⁸ U.S. Dep’t of Defense, *Report on Critical Per- and Polyfluoroalkyl Substance Uses* (Aug. 2023) (“2023 DOD Report”), <https://www.denix.osd.mil/cmrrmp/denix-files/sites/14/2025/03/2023-DoD-Report-on-PFAS-Critical-Uses.pdf>.

⁵⁹ 2025 DOD Report, *supra* note 17.

⁶⁰ *Id.* at 10.

⁶¹ 2023 DOD Report, *supra* note 58, at 1.

conditions not only for the military, but also for industrial workers, first responders, and other kinds of personnel.⁶² The DOD stated “many of the military clothing and equipment performance requirements likely can only be met using PFAS. Currently, known non-PFAS water repellent finishes do not provide the same level of durability as their PFAS counterparts, or the required level of saltwater resistance necessitated for ballistic protection.”⁶³

60. Both the Chamber and DOD reports also highlight the importance of **semiconductors** because they are essential components of all electronic devices that are integral to modern society. An international group of semiconductor industry stakeholders that gathered to formulate an industry approach to PFAS stated that, “based on the consortium’s findings and as documented in each of the accompanying white papers, until the industry can identify, test and qualify suitable substitutes, PFAS-containing materials are essential to semiconductor manufacturing operations and equipment.”⁶⁴

V. CONCLUSION

61. Many toxicologists, regulatory authorities, and experts confirm that PFAS exhibit a wide array of chemical and physical properties that result in a wide range of potential hazard and exposure profiles. Even the same PFAS can have vastly different hazard profiles depending on their application. Due to the necessity of PFAS for the function of our everyday lives, it is important to consider each PFAS and its use in the context of a risk assessment to prevent miscommunication of PFAS risk.

⁶² 2025 DOD Report, *supra* note 17, at 7.

⁶³ *Id.*

⁶⁴ Semiconductor PFAS Consortium, *Background on Semiconductor Manufacturing and PFAS* 34 (May 17, 2023), <https://www.semiconductors.org/wp-content/uploads/2023/05/FINAL-PFAS-Consortium-Background-Paper.pdf>.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on July 1, 2026, in Austin, Texas.

Signed by:

C236DDA157094F2...

Sarahann M. Rackl, Ph.D., P.E.

EXHIBIT A



Exponent®
Engineering & Scientific Consulting

Sarahann Rackl, Ph.D., P.E.

Principal Engineer | Environmental and Earth Sciences
Austin
+1-512-634-2965 | srackl@exponent.com

Professional Profile

Dr. Rackl is a scientist and environmental engineer with a broad interdisciplinary technical and academic background in engineering, microbiology, chemistry, and ecology.

Dr. Rackl excels at gathering and interpreting interdisciplinary technical data and communicating its relevance to regulators, boards of directors, investors, legal counsel, and policy makers. Her research and work experience have focused on evaluating technologies and practices related to water quality, water treatment, wastewater, and constituents in soils and sediment. Through numerous projects with the CalFed Water Quality Program, she developed an expertise in water supply and quality and treatment challenges in California. Dr. Rackl also specializes in federal and state regulatory matters, including the Clean Water Act and California's Proposition 65. She has applied her expertise to the development of new products and business case analyses, and she has extensive expertise in the research, development, manufacturing scale-up, and registration of biopesticides.

Dr. Rackl specializes in evaluating water quality from source to tap and optimizing water quality through advanced treatment technologies. Dr. Rackl has assisted numerous clients in her core academic research areas of disinfection optimization and the minimization of disinfection by-products. She has evaluated disinfection and microbial control strategies for opportunistic pathogens, including *Mycobacterium avium* complex and *Legionella*, in drinking water and for large facilities such as hotels and hospitals. Dr. Rackl has investigated drinking water distribution systems and storage facilities to understand potential sources and causes of microbial contamination.

Dr. Rackl's Proposition 65 and product stewardship work has focused on supporting clients in understanding and addressing current and anticipated future regulations for per- and polyfluoroalkyl substances (PFAS), 1,4-dioxane, and other chemicals. Dr. Rackl works with her clients to identify the presence of PFAS in their products and develop strategies to identify and eliminate the sources. Dr. Rackl has developed numerous Proposition 65 compliance and product stewardship programs for companies with extensive product lines, including both common consumer household and office products and specialty industrial products. Dr. Rackl supports companies in developing supply chain strategies and works with companies to develop tools to maintain sustainable product stewardship programs.

Using the knowledge and skills Dr. Rackl developed while working as product manager and group director of a biopesticide company, she has assisted other biopesticide and antimicrobial companies in product development strategies, regulatory package submissions, communications with the EPA and California Department of Pesticide Regulation (DPR), and numerous registration and regulatory compliance challenges.

Academic Credentials & Professional Honors

Ph.D., Civil and Environmental Engineering, University of Colorado, Boulder, 2004

M.S., Civil and Environmental Engineering, University of Colorado, Boulder, 2002

B.S., Biology, College of William and Mary, 1997

National Water Resources Institute, Fellowship 2002 and 2003

Licenses and Certifications

Professional Engineer Civil, California, #79732

Professional Engineer, North Carolina, #050886

Professional Engineer Civil, Texas, #138126

Prior Experience

Senior Regulatory Scientist, TSG Consulting, 2017-2018

Principal Consultant, Sarahann Rackl Consulting, 2015 - 2017

Director Water Technologies/Product Management, Marrone Bio Innovations (MBI), 2009 - 2014

Water Quality and Technology Specialist, Damon S. Williams Associates, LLC, 2008 - 2009

Principle Scientist, Brown and Caldwell Consultants and Engineers, 2004 - 2008

Professional Affiliations

American Water Works Association 2000-present

Patents

US #9,414,590 – Rackl SM, "Chemical and biological agents for the control of molluscs" August 16, 2016.

Publications

Book Chapters

Rackl, Sarahann and Link, Carolyn. (2015). Biology and Management of Invasive Quagga and Zebra Mussels in the Western United States: Zequanox®: Bio-Based Control of Invasive Dreissena Mussels. 515-535.

Select Peer-Reviewed Publications

Hofius, Jessica, Mandella, Catherine and Rackl, Sarahann. (2015). Evaluation of watercraft quagga mussel decontamination in saltwater. Management of Biological Invasions. 6. 277-286.

Whitledge, Gregory, Weber, Megan, Demartini, Jessi, Oldenburg, John, Roberts, Dave, Link, Carolyn, Rackl, Sarahann, Rude, Neil, Yung, Andrew, Bock, Lindsey and Oliver, Devon. (2014). An evaluation Zequanox ® efficacy and application strategies for targeted control of zebra mussels in shallow-water

habitats in lakes. Management of Biological Invasions. 6.

Meehan, Sara, Shannon, Adam, Gruber, Bridget, Rackl, Sarahann and Lucy, Frances. (2014). Ecotoxicological impact of Zequanox (R), a novel biocide, on selected non-target Irish aquatic species. Ecotoxicology and environmental safety. 107C. 148-153

Meehan, Sara, Lucy, Frances, Gruber, Bridget and Rackl, Sarahann. (2013). Comparing a microbial biocide and chlorine as zebra mussel control strategies in an Irish drinking water treatment plant. Management of Biological Invasions. 4. 113-122.

Dow, Sarahann, Amy, Gary and Hernandez, Mark. (2007). Flocculation and Re-growth of Mycobacterium avium after ozone exposure. Proceedings of the Water Environment Federation. 2007. 74-84.

Dow S.M., von Gunten U., Lively, G., Chandrakanth, M, Amy, G., and Hernandez, M. (2006) The Impact of Selected Water Quality Parameters on the Inactivation of Bacillus subtilis Spores Using Monochloramine and Ozone, Water Research, 40:373. DOI: 10.1016/j.watres.2005.10.018.

Gruden, C. L., Dow S. M., and Hernandez, M. (2001) Fate and Toxicity of Aircraft Deicing Fluid Additives through Anaerobic Digestion. Water Environment Research. 73(1):72. DOI:10.2175/106143001X138714.

Presentations

Dow, Sarahann M. Using Conceptual Models for a Systematic Investigation of Drinking Water Quality -- from Source to Tap. CONFERENCE PROCEEDING by American Water Works Association, 11/01/2008

Cruz, Charles J.; Dow, Sarahann M.; Fryer, Wilton B. 2007. Pilot Scale Evaluation of Membrane Filtration for Turlock Irrigation District's New Surface Water Treatment Facility. CONFERENCE PROCEEDING by American Water Works Association.

Chen, Jennifer J.; Dow, Sarahann; Cruz, Charles J.; Fryer, Wilton. Pre-Ozonation Prior to Microfiltration Membranes - A Pilot Scale Evaluation. CONFERENCE PROCEEDING by American Water Works Association, 11/01/2007

Wilson, Daniel; Dow, Sarahann; Chen, Jennifer; Fryer, Wilton B. Evaluation of High-Rate Clarification Processes as a Pretreatment to Microfiltration of a Surface Water. CONFERENCE PROCEEDING by American Water Works Association, 11/01/2007

EXHIBIT B**REFERENCES**

ACA. 2026. Fluoropolymers. <https://www.americanchemistry.com/chemistry-in-america-industry-innovation-impact/chemistries/fluoropolymers>. Accessed on June 18, 2026. American Chemistry Council, Inc.

Anderson, J.K., R.W. Brecher, I.T. Cousins, J. DeWitt, H. Fiedler, K. Kannan, C.R. Kirman, J. Lipscomb, B. Priestly, R. Schoeny, J. Seed, M. Verner, and S.M. Hays. 2022. Grouping of PFAS for human health risk assessment: Findings from an independent panel of experts. *Regulatory Toxicology and Pharmacology* 134:105226.

ATSDR. 2021. Toxicological profile for perfluoroalkyls. U.S. Department of Health and Human Services, Agency for Toxic Substances and Disease Registry.

Burger, H.-J., and M. Schwenk. 2020. Importance of physicochemical and physical properties for toxicological risk assessment. pp. 1–19. In: *Regulatory Toxicology*. F.-Z. Reichl and M. Schwenk (eds). Available at: https://link.springer.com/rwe/10.1007/978-3-642-36206-4_113-2. Springer Berlin Heidelberg, Berlin, Germany.

CIR. 2018. Safety assessment of polyfluorinated polymers as used in cosmetics. Final report. Available at: <https://www.cir-safety.org/sites/default/files/fluoro092018FR.pdf>. Cosmetic Ingredient Review, Washington, DC.

Evich, M.G., M.J.B. Davis, J.P. McCord, B. Acrey, J.A. Awkerman, D.R.U. Knappe, A.B. Lindstrom, T.F. Speth, C. Tebes-Stevens, M.J. Strynar, Z. Wang, E.J. Weber, W.M. Henderson, and J.W. Washington. 2022. Per- and polyfluoroalkyl substances in the environment. *Science* 375(6580):eabg9065.

FDA. 2021. PTFE safety profile. Medical device material performance study. Prepared by ECRI. U.S. Food & Drug Administration, Center for Devices and Radiological Health.

FDA. 2025a. Authorized uses of PFAS in food contact applications. <https://www.fda.gov/food/process-contaminants-food/authorized-uses-pfas-food-contact-applications#assessing>. Accessed on June 18, 2026. Last updated on January 3, 2025. U.S. Food & Drug Administration.

FDA. 2025b. PFAS in medical devices. <https://www.fda.gov/medical-devices/products-and-medical-procedures/pfas-medical-devices>. Accessed on June 18, 2026. Last updated on August 6, 2025. U.S. Food & Drug Administration.

Glüge, J., M. Scheringer, I.T. Cousins, J.C. DeWitt, G. Goldenman, D. Herzke, R. Lohmann, C.A. Ng, X. Trier, and Z. Wang. 2020. An overview of the uses of per- and polyfluoroalkyl substances (PFAS). *Environmental Science: Processes & Impacts* 22(12):2345–2373.

Hearon, S., V. Yell, K. Morris-Schaffer, and M. Basu. 2026. A comprehensive review of the regulation of fluorinated pesticide ingredients by the U.S. Environmental Protection Agency. *Journal of Toxicology and Regulatory Policy* 2(1):1–21.

Henry, B.J., J.P. Carlin, J.A. Hammerschmidt, R.C. Buck, L.W. Buxton, H. Fiedler, J. Seed, and O. Hernandez. 2018. A critical review of the application of polymer of low concern and regulatory criteria to fluoropolymers. *Integrated Environmental Assessment and Management* 14(3):316–334.

ITRC. 2026. PFAS technical and regulatory guidance document and fact sheets, PFAS-1. Available at: https://pfas-1.itrcweb.org/wp-content/uploads/2026/04/2026.01_PFAS-1.pdf. The Interstate Technology & Regulatory Council, PFAS Team, Washington, DC.

IUPAC. 2026. Inert in IUPAC Compendium of Chemical Terminology, 5th ed. <https://goldbook.iupac.org/terms/view/I03026>. Accessed on June 22, 2026. International Union of Pure and Applied Chemistry.

Kwiatkowski, C.F., D.Q. Andrews, L.S. Birnbaum, T.A. Bruton, J.C. DeWitt, D.R.U. Knappe, M.V. Maffini, M.F. Miller, K.E. Pelch, A. Reade, A. Soehl, X. Trier, M. Venier, C.C. Wagner, Z. Wang, and A. Blum. 2020. Scientific Basis for Managing PFAS as a Chemical Class. *Environmental Science & Technology Letters* 7(8):532–543.

National Research Council. 2009. *Science and Decisions: Advancing Risk Assessment*. The National Academies Press, Washington, DC. p. 422.

OECD. 2021. Reconciling terminology of the universe of per- and polyfluoroalkyl substances: Recommendations and practical guidance. OECD Series on Risk Management of Chemicals No. 61. Available at: https://www.oecd.org/en/publications/reconciling-terminology-of-the-universe-of-per-and-polyfluoroalkyl-substances_e458e796-en.html. Organisation for Economic Co-operation and Development, Paris, France

OECD. 2022. Synthesis report on understanding side-chain fluorinated polymers and their life cycle. Available at: https://www.oecd.org/content/dam/oecd/en/publications/reports/2022/11/synthesis-report-on-understanding-side-chain-fluorinated-polymers-and-their-life-cycle_5c473fc6/e13559f7-en.pdf. Organisation for Economic Co-operation and Development, Paris, France

OECD. 2025. Synthesis report on understanding fluoropolymers and their life cycle. OECD Series on Risk Management of Chemicals. Available at: https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/11/synthesis-report-on-understanding-fluoropolymers-and-their-life-cycle_2ed189aa/35b035df-en.pdf. Organisation for Economic Co-operation and Development, Paris, France

Patlewicz, G., R.S. Judson, A.J. Williams, T. Butler, S. Barone, K.E. Carstens, J. Cowden, J.L. Dawson, S.J. Degitz, K. Fay, T.R. Henry, A. Lowit, S. Padilla, K. Paul Friedman, M.B. Phillips, D. Turk, J.F. Wambaugh, B.A. Wetmore, and R.S. Thomas. 2024. Development of chemical categories for per- and polyfluoroalkyl substances (PFAS) and the proof-of-concept approach to

the identification of potential candidates for tiered toxicological testing and human health assessment. *Computational Toxicology* 31:100327.

PubChem. 2026a. Heptafluorobutyric acid. <https://pubchem.ncbi.nlm.nih.gov/compound/9777>. Accessed on June 18, 2026. National Library of Medicine, National Center for Biotechnology Information, Bethesda, MD.

PubChem. 2026b. Perfluorodecanoic acid. <https://pubchem.ncbi.nlm.nih.gov/compound/9555>. Accessed on June 18, 2026. National Library of Medicine, National Center for Biotechnology Information, Bethesda, MD.

Rao, H.M., K. Rajkumar, V. Narayana, M. Akash, J. Sabu, R. Ramadoss. 2022. Bioinert and bioactive materials – Narrative review. *Journal of Pharmaceutical Negative Results* 13(7):2251–2255.

RECHARGE. 2021. PFAS restriction proposal. RECHARGE statement for 2nd Call for Evidence – October 2021. Available at: https://rechargebatteries.org/wp-content/uploads/2022/09/Call-for-Evidence_RECHARGE-_PFAS-restriction-V1.pdf. RECHARGE Battery Industry Association, Brussels, Belgium.

Secundo, L., P. Metrangolo, and V. Dichiarante. 2025. Current Approaches in the Classification of PFAS: An Overview. *Chemistry – An Asian Journal* 20(9):e202500127.

Semiconductor PFAS Consortium. 2023. Background on semiconductor manufacturing and PFAS. Available at: <https://www.semiconductors.org/wp-content/uploads/2023/05/FINAL-PFAS-Consortium-Background-Paper.pdf>. Semiconductor Industry Association, Washington, DC.

U.S. Chamber. 2024. Essential chemistries: Providing benefits across the U.S. Economy. Available at: https://www.uschamber.com/assets/documents/Essential-Chemistries_-_Providing-Benefits-Across-the-U.S.-Economy.pdf. U.S. Chamber of Commerce.

U.S. DOD. 2023. Report on critical per- and polyfluoroalkyl substances uses. <https://www.denix.osd.mil/cmrrmp/denix-files/sites/14/2025/03/2023-DoD-Report-on-PFAS-Critical-Uses.pdf>. U.S. Department of Defense, Office of the Assistant Secretary of Defense for Energy, Installations, and Environment and Office of the Assistant Secretary of Defense for Industrial Base Policy.

U.S. DOD. 2025. Update on critical per- and polyfluoroalkyl substance uses. Available at: <https://www.denix.osd.mil/cmrrmp/denix-files/sites/14/2025/07/2025-DoD-Update-on-PFAS-Critical-Uses.pdf>. U.S. Department of Defense, Office of the Assistant Secretary of Defense for Energy, Installations, and Environment.

U.S. EPA. 2001. Risk characterization handbook. EPA 100-B-00-002. U.S. Environmental Protection Agency, Science Policy Council, Washington, DC.

U.S. EPA. 2021a. Multi-industry per- and polyfluoroalkyl substances (PFAS) study – 2021 preliminary report. EPA-821-R-21-004. U.S. Environmental Protection Agency, Office of Water, Washington, DC.

U.S. EPA. 2021b. Technical fact sheet: Toxicity assessment for PFBS. Available at: https://ordspub.epa.gov/ords/eims/eimscomm.getfile?p_download_id=542401. U.S. Environmental Protection Agency.

U.S. EPA. 2023. Human health toxicity assessment for GenX chemicals. Technical fact sheet. Available at: <https://www.epa.gov/system/files/documents/2023-03/GenX-Tox-Assessment-technical-factsheet-March-2023-Update.pdf>. U.S. Environmental Protection Agency.

U.S. EPA. 2024a. Human health toxicity assessment for perfluorooctane sulfonic acid (PFOS) and related salts. Final. EPA Document No. 815R24007. Available at: <https://www.epa.gov/system/files/documents/2024-05/final-human-health-toxicity-assessment-pfos.pdf>. U.S. Environmental Protection Agency, Health and Ecological Criteria Division, Washington, DC.

U.S. EPA. 2024b. Human health toxicity assessment for perfluorooctanoic acid (PFOA) and related salts. Final. EPA Document No. 815R24006. Available at: <https://www.epa.gov/system/files/documents/2024-05/final-human-health-toxicity-assessment-pfoa.pdf>. U.S. Environmental Protection Agency, Health and Ecological Criteria Division, Washington, DC.

U.S. EPA. 2025. Key EPA actions to address PFAS. <https://www.epa.gov/pfas/key-epa-actions-address-pfas>. Accessed on June 27, 2026. Last updated July 29, 2025. U.S. Environmental Protection Agency.

U.S. EPA. 2026a. Actions under TSCA Section 5. <https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/actions-under-tsca-section-5>. Accessed on June 18, 2026. Last updated on May 28, 2026. U.S. Environmental Protection Agency.

U.S. EPA. 2026b. EPA research partner support story: Air emissions of PFAS at an industrial facility. <https://www.epa.gov/research-states/epa-research-partner-support-story-air-emissions-pfas-industrial-facility>. Accessed on June 27, 2026. Last updated April 7, 2026. U.S. Environmental Protection Agency.

U.S. EPA. 2026c. Human health risk assessment. <https://www.epa.gov/risk/human-health-risk-assessment>. Accessed on June 18, 2026. Last updated on January 13, 2026. U.S. Environmental Protection Agency.

U.S. EPA. 2026d. Interim guidance on the destruction and disposal of perfluoroalkyl and polyfluoroalkyl substances and materials containing perfluoroalkyl and polyfluoroalkyl substances. 2026 Version. Interim guidance for public comment. April 20, 2026. Available at: <https://www.epa.gov/system/files/documents/2026-04/2026-interim-guidance-on-pfas-destruction-and-disposal.pdf>. U.S. Environmental Protection Agency.

Veolia. 2025. PFAS destruction testing at Veolia's Port Arthur incinerator. Available at: <https://info.veolianorthamerica.com/hubfs/offers/reports/vna/pfas/pfas-destruction-testing-veolia-port-arthur-incinerator-study.pdf>. Veolia Environment SA.

Z2Data. 2026. Where are PFAS in your electronics supply chain? <https://www.z2data.com/insights/where-pfas-your-electronics-supply-chain>. Accessed on June 18, 2026. Last updated on April 21, 2026. Z2Data

ZVEI. 2023. Factsheet “PFAS and Consumer Electronics”. Available at: https://www.zvei.org/fileadmin/user_upload/Themen/Nachhaltigkeit_Umwelt/PFAS/14-ZVEI_Factsheet_PFAS_in_Consumer_Electronics_final_EN.pdf. ZVEI e. V., Frankfurt am Main, Germany.

**THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF KEITH WILCOX, PH.D.

JUNE 30, 2026

TABLE OF CONTENTS

I.	Introduction	1
A.	Qualifications	1
B.	Case Background	3
C.	Assignment	5
II.	Summary of Opinions	6
III.	Academic Framework: How Consumers Make Purchasing Decisions and Process Product Labels and Visual Disclosures	7
A.	The Consumer Buying Decision Process.....	7
B.	Product Labels and Visual Symbols Shape Consumer Perception and Decision-Making	8
1.	Labels Often Serve as Heuristics and Systematic Cues	9
2.	Labels Can Evoke Emotive Responses	12
3.	Labels Can Create Persistent Consumer Associations	14
IV.	Applying the Academic Framework to the New Mexico PFAS Label.....	15
A.	The PFAS Label Can Serve as a Heuristic or Cue for Consumers	16
B.	The PFAS Label May Evoke Emotive Responses Among Consumers.....	18
C.	The PFAS Label May Lead Consumers to Form Persistent Negative Inferences About the Products to Which It Is Affixed	19
V.	The PFAS Label’s Potential Effects on the Consumer Buying Decision Process	21
A.	The Impact of the PFAS Label During Information Search	22
B.	The Impact of the PFAS Label During Evaluation of Alternatives.....	23
C.	The Impact of the PFAS Label During the Purchase Decision	24
D.	The Impact of the PFAS Label During Post-Purchase Evaluation	25

I, Keith Wilcox, Ph.D., hereby declare and state as follows:

I. INTRODUCTION

A. Qualifications

1. I am Professor of Marketing and Ford Endowed Chair in Consumerism/E-Business/E-Commerce at the Mays Business School, Texas A&M University, where I teach several courses on consumer behavior. Prior to joining Mays, I was Associate Professor of Marketing and Barbara and Meyer Feldberg Associate Professor of Business at the Columbia Business School where I taught the core marketing course in the MBA program for over six years. Previously, I was also Assistant Professor of Marketing and Joseph R. Weintraub Term Chair at Babson College and have been employed as a lecturer in marketing at Baruch College, City University of New York. I hold a PhD in marketing and a BA in finance from the Zicklin School of Business, Baruch College. I also hold an MBA from the Haas School of Business at the University of California, Berkeley. Prior to becoming a professor, I spent several years as a marketing consultant working with dozens of companies, including those in the Fortune 500. Specifically, my experience in advertising includes work on accounts such as Camel Cigarettes, where I considered the prominence, placement, and likely consumer impact of warning labels on product packaging.
2. My research examines consumer behavior and decision-making, with a specific focus on consumer self-control and how consumers process information. I have conducted several research projects on consumer decision-making, including several projects examining the factors that influence the choices consumers make related to their health. Specifically, I have examined the factors that influence whether consumers act consistently with their health-related goals.¹ I also have focused on understanding consumer perception and self-

¹ Wilcox, K. et al., “Vicarious Goal Fulfillment: When the Mere Presence of a Healthy Option Leads to an Ironically Indulgent Decision,” *Journal of Consumer Research*, 2009, pp. 380-393; Wilcox, K., et al., “Indulgence or Self-Control: A Dual Process Model of the Effect of Incidental Pride on Indulgent Choice,” *Journal of Consumer Research*, 2011, pp. 151-163; Wilcox, K. and S. Prokopec, “Restraint that Blinds: Attention Narrowing and Consumers’ Response to Numerosity in Self-Control Decisions,” *Journal of*

control behaviors.² My research has been supported by numerous competitive grants.³ My research has been published in several leading academic journals, including *Journal of Consumer Research*, *Journal of Marketing Research*, *Journal of Marketing*, *Journal of Consumer Psychology*, and *Journal of Personality and Social Psychology*. I currently serve as an Associate Editor of *Journal of Marketing Research* and *Journal of Marketing* and *International Journal of Research in Marketing*, and I am a member of the Editorial Boards of *Journal of Consumer Research* and *Journal of Consumer Psychology*. My research has received the Citations of Excellence Award from Emerald Publishing, which recognizes highly cited papers in the areas of Business Management, Finance, Accounting, Economics and Marketing. In addition, my research has been featured in several national and international publications, including *The New York Times*, *Time Magazine*, *The Globe and Mail*, *Business + Strategy*, and *Psychology Today*.

Consumer Research, 2019, pp. 371-387; Wilcox, K. and A. Stephen, "Are Close Friends the Enemy? Online Social Networks, Self-Esteem, and Self-Control," *Journal of Consumer Research*, 2013, at pp. 90-103.

² See, e.g., Wilcox, K., et al., "Vicarious Goal Fulfillment: When the Mere Presence of a Healthy Option Leads to an Ironically Indulgent Decision," *Journal of Consumer Research*, 2009, pp. 380-393; Wilcox, K., et al., "Indulgence or Self-Control: A Dual Process Model of the Effect of Incidental Pride on Indulgent Choice," *Journal of Consumer Research*, 2011, pp.151-163; Wilcox, K. and S. Prokopec, "Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions," *Journal of Consumer Research*, 2019, pp. 371-387; Wilcox, K., et al., "Leave Home Without It? The Effects of Credit Card Debt and Available Credit on Spending," *Journal of Marketing Research*, 2011, pp. 78-91; Wilcox, K. and A. Stephen, "Are Close Friends the Enemy? Online Social Networks, Self-Esteem, and Self-Control," *Journal of Consumer Research*, 2013, pp. 90-103; Wilcox, K., et al., "Shall I Tell You Now or Later? Assimilation and Contrast in the Evaluation of Experiential Products," *Journal of Consumer Research*, 2011, pp. 763-773; Wilcox, K., et al., "How Traditional Production Shapes Perceptions of Product Quality," *Journal of Consumer Research*, 2024, pp. 256-275.

³ See, e.g., "Thinking About Financial Deprivation: Rumination and Decision Making Among the Poor," Qualtrics Behavioral Research Grant, 2015-16, Qualtrics, Principal Investigators: Rachel Meng, Keith Wilcox, and Gita Johar, Award Amount: \$5,000; "Thinking About Financial Deprivation: Rumination and Decision Making Among the Poor," Research Grant, 2015-16, Marketing Science Institute, Principal Investigators: Rachel Meng, Keith Wilcox, and Gita Johar, Award Amount: \$10,000; "Depletion-as-Information," Junior Faculty Provost's Grant, 2013-14, Columbia University, Principal Investigator: Keith Wilcox, Award Amount: \$25,000; "Depletion-as-Information," Eugene M. Lang Support Fund Research Grant, 2013-14, Columbia University Graduate School of Business, Principal Investigator: Keith Wilcox, Award Amount: \$10,000; "Quantity Aversion," CIBER Research Grant, 2012-13, Center for International Business Education and Research, Columbia University, Principal Investigators: Keith Wilcox and Amy Dalton, Award Amount: \$10,000; "The Role of Emotions In-Store," Duke-Ipsos Research Grant, 2012-13, Duke-Ipsos Research Center, Principal Investigators: Keith Wilcox and Amy Dalton, Award Amount: \$10,000; "Pride: A License to Indulge and a Cue for Greater Self-Control," Graduate Center Research Grant, 2007-08, The City University of New York, Graduate Center, Principal Investigator: Keith Wilcox, Award Amount: \$2,000.

3. My curriculum vitae is attached as **Appendix A** to this report and contains more detail on the above, including my expert testimony for the past four years.

B. Case Background

4. The New Mexico Environmental Improvement Board recently finalized regulations regarding per- and poly-fluoroalkyl substances (“PFAS”) in consumer products with effective dates as early as July 1, 2026.⁴ PFAS are complex groups of synthetic chemicals that have been used in consumer products since the 1950s.⁵ I understand that, given the chemical makeup of PFAS, they have a persistent quality, and are therefore often referred to by the public as so-called “forever chemicals.”⁶ The rules introduced by the New Mexico Environmental Department (“NMED”) and approved by the New Mexico Environmental Improvement Board (“NMEIB”) outline prohibitions on products containing PFAS, required reporting, labeling, and testing of consumer products, and fees and penalties for failure to comply.⁷
5. I understand that beginning January 1, 2027, manufacturers must label any product containing intentionally-added PFAS with “an outline of an Erlenmeyer flask with the word ‘PFAS’ inside the flask.”⁸ The regulation appears to require that the label must in all instances be affixed to the product itself, not just the product packaging, and “also” to the packaging in some instances.⁹ The label must be clearly visible and legible prior to sale and the text must be no smaller than the largest font used for other consumer information

⁴ Prohibitions on Products Containing Per- or Poly-Fluoroalkyl Substances; Currently Unavoidable Use; Reporting; Labeling; Testing; Fees and Penalties, New Mexico Environmental Improvement Board, 20.13.2.1-6 NMAC (2026).

⁵ “Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS),” *National Institute of Environmental Health Sciences*, March 6, 2026, available at <https://www.niehs.nih.gov/health/topics/agents/pfc>.

⁶ “Yale Experts Explain PFAS ‘Forever Chemicals’,” *Yale Sustainability*, May 20, 2025, available at <https://sustainability.yale.edu/explainers/yale-experts-explain-pfas-forever-chemicals>.

⁷ 20.13.2.1-23 NMAC.

⁸ 20.13.2.13(C)(1) NMAC.

⁹ 20.13.2.13(C)(2)–(3), (5) NMAC. I understand that the regulation also requires manufacturers of complex durable goods containing intentionally-added PFAS to include the PFAS label in other consumer-facing materials, including (1) the product specification sheet that potential customers are able to review prior to purchase, and (2) the operation and maintenance manual for the complex durable good. 20.13.2.13(D) NMAC.

on the product.¹⁰ The labeling requirement also extends to websites where the product is sold.¹¹ **Figure 1** below shows an example of the labeling to be included on products and product packaging.

Figure 1
Example of PFAS Label¹²



6. Certain product categories are eligible for exemptions from the labeling requirements including used products offered for sale or resale, medical devices or drugs and their packaging, veterinary products, and products for which labeling requirements are preempted pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act or for which labeling requirements currently exist.¹³

¹⁰ 20.13.2.13(C)(1) NMAC.

¹¹ 20.13.2.13(C)(4) NMAC.

¹² I understand that the New Mexico Environment Department has provided the following flask as an example of a conforming image:



See "PFAS Protection Act (HB212)," *New Mexico Environment Department*, available at <https://www.env.nm.gov/pfas/pfas-protection-act-hb212/>, accessed on June 22, 2026.

¹³ 20.13.2.13(B) NMAC.

7. In addition to the labeling requirement, the rules also include the prohibition of sales of products containing intentionally added PFAS. Beginning January 1, 2027, the following products cannot be sold if they contain intentionally added PFAS: cookware, food packaging, dental floss, juvenile products, and firefighting foam.¹⁴ Beginning January 1, 2028, the following products cannot be sold if they contain intentionally added PFAS: carpets or rugs, cleaning products, cosmetics, fabric treatments, feminine hygiene products, textiles, textile furnishings, ski wax, and upholstered furniture.¹⁵ Beginning January 1, 2032, no products containing PFAS can be sold unless the PFAS in the product is a currently unavoidable use or the product is otherwise exempt.¹⁶ Beginning January 1, 2028, products containing PFAS may not be sold unless the manufacturer has provided the New Mexico Environmental Department the relevant information on PFAS.¹⁷

C. Assignment

8. I have been retained by counsel for the American Chemistry Council to evaluate how the PFAS label required by the 20.13.2.13 New Mexico Administrative Code (“NMAC”) is likely to be perceived by ordinary consumers and whether the PFAS label may affect ordinary consumers’ perceptions of labeled products at the point of sale. Specifically, my assignment focuses on consumers’ likely interpretation of the required PFAS label, including whether the label may be perceived as conveying a warning, risk, chemical-content, or product-safety message.
9. In forming my opinions, I have relied on my education and professional experience, as well as documents and materials produced in this matter or obtained from public sources. The documents and materials that I relied upon to form my opinions are identified in **Appendix B.**

¹⁴ 20.13.2.9(A) NMAC.

¹⁵ 20.13.2.9(B) NMAC.

¹⁶ 20.13.2.9(C) NMAC.

¹⁷ 20.13.2.9(D), (E) NMAC.

10. I am being compensated at my standard hourly rate of \$1,050 per hour. In addition, employees of Analysis Group, Inc., an economics research and consulting firm, working under my direction and guidance, have assisted me in this assignment. Neither my compensation nor that of Analysis Group is contingent upon my findings, the testimony I may give, or the outcome of this litigation. I reserve the right to supplement and/or amend my opinions as appropriate based on any additional information provided to me and/or in light of documents or testimony brought forth after the date of my signature below.

II. SUMMARY OF OPINIONS

11. On the basis of my review of the information identified in **Appendix B**, and my education, training, and professional experience, I have reached the following opinions:
 - a. Product labels and visual disclosures may affect perceptions and choices throughout multiple stages of the consumer buying decision process, before, during, and after purchase. Product labels and visual symbols can shape consumer perceptions and decision-making by serving as heuristic cues, evoking emotive responses, and creating persistent product or brand associations that may extend beyond the literal information conveyed. *See Section III.*
 - b. Rather than serving as a neutral disclosure, the PFAS label may instead function as a warning-like cue, evoke negative emotive responses, and lead consumers to form persistent negative inferences about labeled products. As a result, consumers may interpret the label and accompanying imagery as conveying potential health, safety, environmental, or chemical risk, regardless of the actual risk involved, which may in turn affect product evaluations and purchase decisions. *See Section IV.*
 - c. The PFAS label is likely to influence consumers throughout the buying decision process by shaping how consumers interpret, evaluate, and respond to labeled products. However, the extent to which the PFAS label may impact consumers'

purchase decisions is likely to depend on product category, consumer familiarity, purchase context, and the availability and cost of alternatives. *See Section V.*

III. ACADEMIC FRAMEWORK: HOW CONSUMERS MAKE PURCHASING DECISIONS AND PROCESS PRODUCT LABELS AND VISUAL DISCLOSURES

A. The Consumer Buying Decision Process

12. In order to assess the potential impact of the required PFAS label on product evaluation and purchase intent, it is useful to consider the consumer buying decision process, a standard marketing framework that describes how consumers recognize needs, search for information, evaluate alternatives, make purchase decisions, and behave after purchase.¹⁸ Although consumers do not always pass through all five stages—they may skip or reverse the order of some stages—the framework provides a useful structure for evaluating how product labels and visual disclosures may affect consumers’ perceptions and choices before, during, and after purchase.¹⁹
13. The first stage in the buying process is problem recognition, when an internal or external stimulus causes the buyer to recognize a problem or need.²⁰ The second stage is information search in which consumers seek information about brands and products from various information sources: personal (family and friends), commercial (advertising, websites, emails, etc.), public (mass media, social media), and experiential (handling, examining, and using the product).²¹ Next, consumers evaluate alternatives and make tradeoffs between different brands and products.²²

¹⁸ Kotler, P. and K.L. Keller, *Marketing Management*, 15th Edition., Pearson, 2016 (“Kotler and Keller (2016)”), at pp. 172-180.

¹⁹ Kotler and Keller (2016), at p. 173.

²⁰ Kotler and Keller (2016), at p. 173.

²¹ Kotler and Keller (2016), at p. 174.

²² Kotler and Keller (2016), at pp. 175-176.

14. In the fourth stage, consumers make their purchase decision.²³ Consumers may form preferences or an intention to buy a certain brand or product in the evaluation of alternatives stage, but there are sub-decisions and intervening factors such as attitudes of others or unanticipated situational factors that can influence the ultimate purchase decision.²⁴ As Professors Kotler and Keller note in *Marketing Management*, “a consumer’s decision to modify, postpone, or avoid a purchase decision is heavily influenced by one or more types of perceived risk:” functional risk, physical risk, financial risk, social risk, psychological risk, and time risk.²⁵ Thus, for example, a consumer’s purchase intention may not result in an actual purchase if the consumer perceives that the product poses a threat to their health or well-being (or the health or well-being of others).²⁶
15. Finally, the fifth stage in the consumer buying decision process is post purchase behavior including post purchase satisfaction, actions, and use and disposal of the product.²⁷

B. Product Labels and Visual Symbols Shape Consumer Perception and Decision-Making

16. Product labels and visual symbols play a key role in shaping consumer choices and decision-making throughout the consumer buying decision process. Through text, visual imagery, and brand associations, labels serve as a salient touchpoint between brands and consumers and can play an important role in the formation of consumer perceptions (or misperceptions) of a product. Consumer decision-making often occurs under conditions

²³ Kotler and Keller (2016), at pp. 176-178.

²⁴ Kotler and Keller (2016), at pp. 176-178.

²⁵ Kotler and Keller (2016), at p. 178. Functional risk refers to the risk that the product does not perform to expectations; physical risk refers to the risk that the product poses a threat to the physical well-being or health of the user or others; financial risk refers to the risk that the product is not worth the price paid; social risk refers to the risk that the product results in embarrassment in front of others; psychological risk refers to the risk that the product affects the mental well-being of the user; and time risk refers to the risk that the failure of the product results in an opportunity cost of finding another satisfactory product.

²⁶ Kotler and Keller (2016), at p. 178.

²⁷ Kotler and Keller (2016), at pp. 178-179.

of limited information, time pressure, and cognitive constraints.²⁸ In that context, product labels can serve as heuristics or informational cues that consumers use as mental shortcuts to draw broader inferences about a product's attributes, quality, benefits, or risks.

1. Labels Often Serve as Heuristics and Systematic Cues

17. Consumer decision-making often involves fast, intuitive, and low-effort judgments rather than exhaustive evaluation of all available information.²⁹ Dual-process theories of judgment distinguish between such intuitive, automatic processes, often referred to as “System 1,” and more deliberative, effortful processes, often referred to as “System 2.”³⁰ In many contexts, consumers rely on System 1 processes and use heuristics or salient cues to form judgments about products.³¹
18. Heuristics allow consumers to make purchase decisions without exhaustive analysis, especially in contexts where decisions can be habitual or time pressured.³² The concept of “bounded rationality” provides foundational framework for understanding heuristic cues.³³ Bounded rationality suggests consumers cannot analyze all available information in making decisions due to cognitive limits and information asymmetry, and therefore

²⁸ Tversky, A. and D. Kahneman, “Judgment Under Uncertainty: Heuristics and Biases,” *Science*, 1974, pp. 1124–1131, (“Tversky and Kahneman (1974)”); *See also* Kahneman, D., *Thinking, Fast and Slow*, Farrar, Straus and Giroux, 2011 (“Kahneman (2011)”).

²⁹ Kahneman, D., “Maps of Bounded Rationality: Psychology for Behavioral Economics,” *American Economic Review*, 2003, pp. 1449-1475, at p. 1450 (“Kahneman (2003)”). *See also* Kahneman (2011), at pp. 22-26; Motoki, K. and T. Saito, “Thinking Fast, Not Slow: Intuitive Nutrition Labels Increase Healthier Food Preferences Under Time Pressure,” *British Food Journal*, 2024, pp. 2956-2969.

³⁰ Kahneman (2003), at p. 1451 (“The operations of System 1 are fast, automatic, effortless, associative, and often emotionally charged; they are also governed by habit, and are therefore difficult to control or modify. The operations of System 2 are slower, serial, effortful, and deliberately controlled; they are also relatively flexible and potentially rule-governed.”) *See also* Kahneman (2011), at p. 23.

³¹ Kahneman (2003), at p. 1450 (“[M]ost judgments and most choices are made intuitively.”). *See also* Kahneman (2011), at pp. 22-26; Tversky and Kahneman (1974), at p. 1124.

³² Tversky and Kahneman (1974), at p. 1124. *See also* Kahneman (2011), at pp. 22-26; Kahneman (2003), at pp. 1450-1451; Motoki, K. and T. Saito, “Thinking Fast, Not Slow: Intuitive Nutrition Labels Increase Healthier Food Preferences Under Time Pressure,” *British Food Journal*, 2024, pp. 2956-2969.

³³ Simon, H., “Rational Choice and the Structure of the Environment,” *Psychological Review*, 1956, pp. 129-138. *See also* Kahneman (2003), at pp. 1450-1451.

would seek “satisficing” (*i.e.*, the first solution that is satisfactory) over maximizing (or optimal) solutions.³⁴ Heuristics allow consumers to find such solutions by enabling quick judgments through mental shortcuts.³⁵ For example, the affect heuristic is a mental shortcut where invoked emotions influence perceptions and decision-making.³⁶

19. Product labels often serve as heuristic cues for consumers to make broader inferences about the product. For example, the presence of “low-carbohydrate” claims on product packaging may lead consumers to believe the product is more helpful in weight management compared to similar unlabeled products, even if in reality that need not be the case.³⁷ This phenomenon is known as the “halo effect,” whereby the presence of a specific product claim (*e.g.*, organic or natural) may lead consumers to infer broader, unstated product attributes (*e.g.*, the product is healthier).³⁸ Similarly, warnings and regulatory disclosures may be interpreted by consumers as risk cues because such markings are typically applied to “promote either safe use or the moderation/cessation of

³⁴ Simon, H., “Rational Choice and the Structure of the Environment,” *Psychological Review*, 1956, pp. 129-138, at pp. 129-130.

³⁵ Tversky and Kahneman (1974), at p. 1124; Slovic, P. et al., “The affect heuristic,” *European Journal of Operational Research*, 2007, pp. 1333-1352 (“Slovic et al. (2007)”). *See also* Kahneman (2011); Kotler and Keller (2016), at pp. 176-177, 180-182. Kahneman and Tversky originally defined three main heuristics: (i) representativeness, used in judgement of the probability that an object or event A belongs to class or process B; (ii) availability of instances or scenarios, which is often employed when people are asked to assess the frequency of a class or the plausibility of a particular development; and (iii) adjustment from an anchor, which is often used in numerical prediction when a relevant value is available. Slovic et al. (2007) later developed a framework for affect heuristic, which occurs when emotions influence decision-making.

³⁶ Slovic et al. (2007), at p. 1350.

³⁷ Labiner-Wolfe, J. et al., “Effect of Low-Carbohydrate Claims on Consumer Perceptions About Food Products’ Healthfulness and Helpfulness for Weight Management,” *Journal of Nutrition Education and Behavior*, 2010, pp. 315-320.

³⁸ “The Future of US Food Labeling,” NSF, September 25, 2025, available at <https://www.nsf.org/knowledge-library/white-paper-us-food-labeling>.

use.”³⁹ In turn, such inferences may affect consumers’ perceptions of the product’s desirability and consequently increase (or decrease) consumers’ willingness-to-pay.⁴⁰

20. Although labels can simplify consumer decision-making by providing salient product cues, they can also generate confusion and uncertainty when they contain ambiguous, misleading, inadequate, or excessive information.⁴¹ Consumers facing unfamiliar, ambiguous, or confusing claims can experience cognitive uncertainty or difficulty, especially when trying to compare between alternatives.⁴² Because consumers often prefer options with known and quantifiable risks over otherwise similar options involving unknown risks (also known as “ambiguity aversion”), labels including technical, unfamiliar, or unclear terms may increase uncertainty and lead consumers to prefer more familiar options over the labeled product.⁴³ The presence of such information may also reduce decision confidence, which can further increase the likelihood that consumers postpone or forgo purchases.⁴⁴

³⁹ Drury, L. et al., “YOU HAVE BEEN WARNED: The Effect of California’s Proposition 65 Warning on Consumer Perceptions and Evaluations,” *Journal of Consumer Affairs*, 2025, at pp. 2-3; Salvendy, G., *Handbook of Human Factors and Ergonomics*, 4th Edition, John Wiley & Sons, 2012, p. 868; Adasme-Berrios, C., et al., “Effect of Warning Labels on Consumer Motivation and Intention to Avoid Consuming Processed Foods,” *Nutrients*, 2022, pp. 1-16.

⁴⁰ Lim, K. and E. Page, “Consumers’ Interpretation of Food Labels with Production Claims Can Influence Purchases,” *USDA Economic Research Service*, March 7, 2022, available at <https://www.ers.usda.gov/amber-waves/2022/march/consumers-interpretation-of-food-labels-with-production-claims-can-influence-purchases>; McCluskey, J. and M. Loureiro, “Consumer Preferences and Willingness to Pay for Food Labeling: A Discussion of Empirical Studies,” *Journal of Food Distribution Research*, 2003, pp. 95-102; Drury, L. et al., “YOU HAVE BEEN WARNED: The Effect of California’s Proposition 65 Warning on Consumer Perceptions and Evaluations,” *Journal of Consumer Affairs*, 2025, pp. 1-21, at pp. 1-3.

⁴¹ See Tversky and Kahneman (1974), at p. 1124. Mitchell, V. and V. Papavassiliou, “Marketing causes and implications of consumer confusion,” *Journal of Product & Brand Management*, 1999, pp. 319-339 (“Mitchell and Papavassiliou (1999)”); Kahneman (2003), at p. 1460.

⁴² Walsh, G., et al., “Consumer Confusion Proneness: Scale Development, Validation, and Application,” *Journal of Marketing Management*, 2010, pp. 697-721.

⁴³ Ellsberg, D., “Risk, Ambiguity, and the Savage Axioms,” *The Quarterly Journal of Economics*, 1961, pp. 643-669; Mitchell and Papavassiliou (1999). See also Muthukrishnan, A., et al., “Ambiguity Aversion and the Preference for Established Brands,” *Management Science*, 2009, pp. 1933-1941.

⁴⁴ Walsh, G., et al., “Consumer Confusion Proneness: Scale Development, Validation, and Application,” *Journal of Marketing Management*, 2010, pp. 697-721; Mitchell and Papavassiliou (1999).

21. Importantly, labels can affect consumer perceptions not only through text but also visual cues such as font sizes and symbols.⁴⁵ For example, warning labels often couple pictorial warnings with fear appeals—such as graphic images on cigarette packages—to increase effectiveness in building risk perception for consumers.⁴⁶ The visual cues may serve as shortcuts that allow consumers to infer unobservable attributes such as quality, sustainability, or healthfulness.⁴⁷ Research has shown that even the color scheme of a package or label can alter perception of the product and ultimately impact purchase intention.⁴⁸

2. Labels Can Evoke Emotive Responses

22. Labels can often trigger emotive responses that influence consumers' perceptions of a brand or product. For instance, labels that communicate a product's "artificial," "synthetic," or "chemical" characteristics may evoke negative associations and contribute to what is sometimes described as the appeal-to-nature fallacy: the tendency to perceive natural substances as inherently safer or superior, and human-made, synthetic, or "unnatural" substances as inherently riskier or less desirable, regardless of actual risk.⁴⁹ Research also suggests that consumers often associate "chemicals" with poison, death, and danger while "natural" labels are associated with safety and more positive affective

⁴⁵ Griffith, L.J. and S.D. Leonard, "Association of Colors with Warning Signal Words," *International Journal of Industrial Ergonomics*, 1997, pp. 317-325; Eng, L. et al., "Influence of Interpretation Aids on Attentional Capture, Visual Processing, and Understanding of Front-of-Package Nutrition Labels," *Journal of Nutrition Education and Behavior*, 2015, pp. 292-299.

⁴⁶ Purmehdi, M. et al., "The Effectiveness of Warning Labels for Consumers: A Meta-Analytic Investigation into Their Underlying Process and Contingencies," *Journal of Public Policy & Marketing*, 2017, pp. 36-53, at pp. 38-39 ("Purmehdi et al. (2017)").

⁴⁷ Kahneman (2003); Underwood, R. and N. Klein, "Packaging as Brand Communication: Effects of Product Pictures on Consumer Responses to the Package and Brand," *Journal of Marketing Theory and Practice*, 2002, pp. 58-68.

⁴⁸ Huang, L. and J. Lu, "The Impact of Package Color and the Nutrition Content Labels on the Perception of Food Healthiness and Purchase Intention," *Journal of Food Products Marketing*, 2016, pp. 191-218; Schuldt, J.P., "Does Green Mean Healthy? Nutrition Label Color Affects Perceptions of Healthfulness," *Health Communication*, 2013, pp. 814-821.

⁴⁹ Baig, S.A. et al., "Organic," "Natural," and "Additive-Free" Cigarettes: Comparing the Effects of Advertising Claims and Disclaimers on Perceptions of Harm, *Nicotine & Tobacco Research*, 2019, pp. 933-939; Gagliardi, L., "Naturalness seeking minds: the cognitive foundations of naturalness bias in consumer food choice," *Food and Humanity*, 2025.

responses.⁵⁰ Consumers may use perceived naturalness (or “unnaturalness”) as a salient heuristic cue, leading them to draw broader inferences about a product’s quality and safety that may extend beyond the specific attribute communicated on the label.⁵¹ This association is closely related to the halo effect discussed above, in which a judgment about one product attribute is overgeneralized to other characteristics (*e.g.*, healthfulness, safety), even when those characteristics are not necessarily correlated.⁵²

23. An illustrative example of consumers’ immediate and emotional responses to certain product labels is their reaction to labels identifying genetically modified organisms (“GMO”) or genetically modified food (“GMF”). Research suggests that GMOs can evoke negative emotions such as worry, anxiety, anger, or fear and that some consumers perceive GMOs as less healthy and less safe than non-genetically modified products.⁵³ These perceptions of GMOs can negatively impact consumer purchase intentions, with willingness to purchase GMO or GMF products decreasing as perceived risk associations increase.⁵⁴ At the same time, public-health reviews have concluded that GMOs or GMFs currently on the market have passed safety assessments and are not more harmful or unsafe than non-genetically modified products.⁵⁵

⁵⁰ Moreira da Silva, A., and M. Barroca. “Addressing Chemophobia: Bridging Misconceptions in Food Chemistry.” *Applied Sciences*, 2025 (“Moreira da Silva and Barroca (2025)”), at pp. 2, 7.

⁵¹ Baig, S.A, et al., “Organic,” “Natural,” and “Additive-Free” Cigarettes: Comparing the Effects of Advertising Claims and Disclaimers on Perceptions of Harm, *Nicotine & Tobacco Research*, 2019, pp. 933–939; Gagliardi, L., “Naturalness Seeking Minds: the Cognitive Foundations of Naturalness Bias in Consumer Food Choice,” *Food and Humanity*, 2025.

⁵² Nisbett, R., and T. Wilson, “The Halo Effect: Evidence for Unconscious Alteration of Judgments,” *Journal of Personality and Social Psychology*, 1977, pp. 250-256; Gagliardi, L., “Naturalness Seeking Minds: The Cognitive Foundations of Naturalness Bias in Consumer Food Choice,” *Food and Humanity*, 2025, pp. 1-12.

⁵³ See Laros, F. and J. Steenkamp, “Importance of Fear in the Case of Genetically Modified Food,” *Psychology & Marketing*, 2004, pp. 889-908; Yang, S., et al., “No Control, No Consumption: Association of Low Perceived Control and Intention to Accept Genetically Modified Food,” *International Journal of Environmental Research and Public Health*, 2022, pp. 1-13.

⁵⁴ See Laros, F., and J. Steenkamp, “Importance of Fear in the Case of Genetically Modified Food.” *Psychology & Marketing*, 2004, pp. 889-908; Yang, S., et al., “No Control, No Consumption: Association of Low Perceived Control and Intention to Accept Genetically Modified Food,” *International Journal of Environmental Research and Public Health*, 2022.

⁵⁵ See, *e.g.*, “Food, Genetically Modified,” *World Health Organization*, available at <https://www.who.int/news-room/questions-and-answers/item/food-genetically-modified>, accessed on June 22, 2026; “GMOs and Your Health,” *Food and Drug Administration*, available at <https://www.fda.gov/media/135280/download>.

3. Labels Can Create Persistent Consumer Associations

24. To the extent labels trigger emotive responses, such reactions may impact long-term product and/or brand associations that consumers hold. For example, research on classical and evaluative conditioning suggests that the repeated pairing of a product or brand with a negative stimulus can alter consumers' responses to the product and, over time, contribute to more negative brand perceptions.⁵⁶ The literature also suggests that the effect of a negative stimulus is typically stronger than that of a positive stimulus.⁵⁷ Accordingly, the repeated pairing of a product and a warning-like label may create negative associations that can shape product and brand evaluations independently of evidence on the product's actual attributes or risk.⁵⁸
25. Importantly, consumer inferences about a product can persist even when additional corrective or explanatory information is later provided from manufacturers, regulators, or retailers. As marketing scholars have noted, consumers typically rely or "anchor" on the first piece of salient information they encounter, using it to make their initial judgment and as a reference point for subsequent judgments.⁵⁹ Because individuals often insufficiently adjust away from their initial judgement, being presented with new or conflicting information often has a limited effect on revising opinions.⁶⁰ Therefore, if a label highlights a potentially concerning attribute, consumers may anchor on that information and use it as a basis for evaluating the product, even if they later receive

⁵⁶ See De Houwer, J. et al., "Association Learning of Likes and Dislikes: A Review of 25 Years of Research on Human Evaluative Conditioning," *Psychological Bulletin*, 2001, pp. 853-869; Levey, A. and I. Martin. "Classical conditioning of human 'evaluative' responses." *Behaviour Research and Therapy*, 1975, pp. 221-226; Pavlov, I., "Conditioned reflexes: An investigation of the physiological activity of the cerebral cortex." *Annals of Neurosciences*, 2010, pp. 136-141.

⁵⁷ Levey, A. and I. Martin. "Classical conditioning of human 'evaluative' responses." *Behaviour Research and Therapy*, 1975, pp. 221-226.

⁵⁸ See De Houwer, J. et al., "Association Learning of Likes and Dislikes: A Review of 25 Years of Research on Human Evaluative Conditioning," *Psychological Bulletin*, 2001, pp. 853-869; Levey, A. and I. Martin. "Classical conditioning of human 'evaluative' responses." *Behaviour Research and Therapy*, 1975, pp. 221-226; Pavlov, I., "Conditioned reflexes: An investigation of the physiological activity of the cerebral cortex." *Annals of Neurosciences*, 2010, pp. 136-141.

⁵⁹ Kotler and Keller (2016), at p. 182.

⁶⁰ Kotler and Keller (2016), at p. 182.

additional context indicating that the actual risk is low.⁶¹ In turn, this can contribute to persistent negative associations as subsequent experiences are influenced by the initial impression, particularly if the initial impression forms a strong negative attitude.⁶²

26. In sum, the literature demonstrates that product labels can shape perceptions and inferences that extend beyond the actual information conveyed, as consumers frequently rely on heuristics and other simplified decision-making processes when evaluating products and making their purchase decisions. Due in part to anchoring, initial impressions can be difficult to adjust or revise, even when additional information is provided later. As a result, labels—and warning-like labels in particular—can trigger emotional responses that may establish long-lasting positive or negative associations with the brand or product, influencing consumer evaluations and behavior independently of the product’s underlying attributes or objective risks.

IV. APPLYING THE ACADEMIC FRAMEWORK TO THE NEW MEXICO PFAS LABEL

27. As described in **Section III.B**, labels can influence consumers’ product evaluations beyond the exact words used or information directly conveyed. To the extent that consumers perceive a label as a warning-like cue that signals a potential hazard or undesirable product attribute, consumers may (1) form negative associations with the product or brand, (2) associate the warnings and regulatory disclosures with potential risk, which may impact their likelihood of purchase or willingness to pay for the product, and (3) form long-lasting and persistent associations, even if corrective information is provided at a later point in time. Applying the academic framework described in **Section III.B**, it is my opinion that the label, which consists of an Erlenmeyer flask with the word “PFAS,” can serve as a heuristic or cue that consumers use to draw broader inferences about the labeled products beyond the literal information conveyed by the label. In

⁶¹ Moreira da Silva and Barroca (2025), at p. 7.

⁶² See Mussweiler, T., “The Durability of Anchoring Effects,” *European Journal of Social Psychology*, 2001, pp. 431-442; Pomerantz, E., et al., “Attitude Strength and Resistance Processes,” *Journal of Personality and Social Psychology*, 1995, pp. 408-419.

particular, consumers may interpret the label as conveying potential health, safety, environmental, or chemical risks – regardless of the actual risk involved – which may in turn affect product evaluations and ultimately impact consumer purchase decisions.

A. The PFAS Label Can Serve as a Heuristic or Cue for Consumers

28. As discussed in **Section III.B**, consumers often cannot analyze all available information in making decisions due to cognitive limits and information asymmetry, and therefore use heuristics to make quick judgements through mental shortcuts.
29. Research suggests that public awareness and understanding of PFAS remain limited, with many consumers lacking familiarity with PFAS and with the potential sources, exposure pathways, and health risks associated with PFAS.⁶³ Given these gaps in knowledge, the PFAS label that includes Erlenmeyer-flask imagery is likely to be interpreted through consumers' existing associations with that imagery. Because flasks are often perceived as “emblematic icons of chemistry,” consumers may associate the PFAS label with chemicals, poisons, hazards, and environmental pollution.⁶⁴ For example, research on “chemophobia” indicates that consumers often associate “chemical” or “synthetic chemical” language with concepts such as poison, death, danger, pollution, contamination, and harm.⁶⁵ This is particularly likely here as consumers cannot independently evaluate the product-specific significance of PFAS and therefore may be likely to rely on accessible labels and packaging cues to assess technical product

⁶³ In one nationally representative survey conducted in April 2023 in the U.S., 45.1% of respondents had never heard of PFAS and did not know what it was, and another 31.6% had heard of PFAS but did not know what it was. Berthold, T., et al., “Let’s talk about PFAS: Inconsistent public awareness about PFAS and its sources in the United States,” *PLOS ONE*, 2023, 1-20, at pp. 1, 3, 6, 12-13; Rihn, A., et al., “Influence of scientific communications on the acceptance of PFAS alternatives on disposable dinnerware and take-out containers, by information source,” *Journal of Agriculture and Food Research*, 2026, 1-10, at pp. 2, 8.

⁶⁴ Moreira da Silva and Barroca (2025), at pp. 8-10; Schummer, J. et al., *The Public Image of Chemistry*, *World Scientific Publishing*, 2007 (“Schummer et al., (2007)”), at p. 1 (“Popular associations with chemistry range from poisons, hazards, chemical warfare and environmental pollution to alchemical pseudo-science, sorcery and mad scientists”).

⁶⁵ Moreira da Silva and Barroca (2025), at pp. 8-10.

attributes that are difficult to observe or verify.⁶⁶ Accordingly, the associations evoked by the flask imagery may increase perceived product risk rather than operate merely as a neutral disclosure. Put differently, the PFAS label may be perceived as a warning-like cue for the product to which it is affixed, rather than as a neutral disclosure.

30. Consumers are likely to encounter the PFAS label in a variety of contexts. It is my understanding that the PFAS label will be required to appear in a variety of consumer-facing purchase contexts, including but not limited to on the product itself, on the product packaging, and on the website where the product is sold.⁶⁷ For instance, water-resistant jackets that contain intentionally added PFAS will be required to present PFAS labels on the jacket's hang tag and on the product details page of the brand's website or any retailer websites or apps that sell the jacket.⁶⁸ Waterproof mascaras that contain intentionally added PFAS will be required to present PFAS labels on the mascara tube itself, on the packaging that comes with the mascara, and on the product details page of any retailer websites or apps that sell the mascara.⁶⁹ As the literature suggests, the degree to which

⁶⁶ Buchmüller, K., et al., "The influence of packaging on consumers' risk perception of chemical household products," *Applied Ergonomics*, 2022, 100:103676, at pp. 1-2; Berthold, T., et al., "Let's talk about PFAS: Inconsistent public awareness about PFAS and its sources in the United States," *PLOS ONE*, 2023, 1-20, at pp. 12-13.

⁶⁷ 20.13.2.13(C)(2)–(5) NMAC.

⁶⁸ Waterproof jackets may contain PFAS for the added waterproof ability, usually done through treating the fabric through Durable Water Repellent coatings. "Made Without PFAS," Patagonia, available at <https://www.patagonia.com/our-footprint/pfas.html>, accessed on June 22, 2026 ("[T]he DWR (durable water repellent) finishes used in apparel to help moisture bead up and roll off the outer surface have relied on perfluoroalkyl and polyfluoroalkyl substances, part of a chemical family known as PFAS."); "New Study Finds Forever Chemicals in Rain Jackets," Chem Trust, May 22, 2025, available at <https://chemtrust.org/news/forever-chemicals-rain-jackets/> ("PFAS is often added to jackets due to its water repellent properties."). Fabric treatments and textiles will be prohibited to be sold if they contain intentionally added PFAS after January 1, 2028. 20.13.2.9(B) NMAC.

⁶⁹ According to research experiments, waterproof mascaras may contain PFAS chemicals. "PFAS in Cosmetics," Green Science Policy Institute, available at <https://greensciencepolicy.org/pfas-in-cosmetics/>, accessed on June 22, 2026 ("[W]e tested 231 popular makeup products purchased in the U.S. and Canada. We found high fluorine levels—indicating the probable presence of PFAS—in just over half of these products. High levels were especially prevalent in waterproof mascara, liquid lipsticks, and foundations."). Cosmetic products will be prohibited to be sold if they contain intentionally added PFAS after January 1, 2028. 20.13.2.9(B) NMAC.

the inclusion of the PFAS label impacts perceptions and purchase decisions may vary depending on the specific type of product and purchase location.⁷⁰

B. The PFAS Label May Evoke Emotive Responses Among Consumers

31. As discussed in **Section III.B**, labels can often trigger emotive responses that may establish long-lasting positive or negative perceptions of a brand or product. As discussed above, the flask imagery on the PFAS label may trigger chemical, laboratory, and risk-related associations.⁷¹ Research suggests that chemical imageries have long been eliciting negative associations from the public and may lead consumers to treat the label as conveying health- or environmental-risk information.⁷² Specifically, research on chemophobia suggests that consumers tend to perceive products containing chemicals as “inherently inferior or dangerous,” independent of any scientific basis for distinguishing the actual safety or efficacy of the chemicals involved.⁷³ Further, research on hazard communication suggests that pictorial elements can operate as immediate cues of risk and can affect how consumers perceive product danger.⁷⁴
32. Because PFAS is often discussed in connection with persistence, contamination, and human or environmental health concerns, the combined text-and-symbol label may trigger concern, uncertainty, or avoidance among consumers who may be familiar with the term but cannot independently evaluate the product-specific significance of the

⁷⁰ See Argo, J. and K. Main, “Meta-Analyses of the Effectiveness of Warning Labels,” *Journal of Public Policy & Marketing*, 2004, pp. 193-208, at pp. 195-196, 204-205; Purmehdi et al. (2017), at pp. 38-39, 45-46.

⁷¹ See Schummer et al., (2007), at p. 1.

⁷² Schummer et al., (2007), at pp. 240-241; NMAC § 20.13.2.13(C)(1); Hutchins, R., et al., “Efficacy and Threat Language in PFAS Messaging,” at p. 2; Moreira da Silva and Barroca (2025), at pp. 8-10.

⁷³ Moreira da Silva and Barroca (2025), at p. 7.

⁷⁴ Boelhouwer, E., et al., “Comprehension of hazard communication: Effects of pictograms on safety data sheets and labels,” *Journal of Safety Research*, 2013, 145-155, at pp. 146-147; Wogalter, M., et al., “Research-Based Guidelines for Warning Design and Evaluation,” *Applied Ergonomics*, 2002, 219-230, at p. 223.

disclosure.⁷⁵ As scholars have pointed out, “most consumers are risk averse and prefer products with low (vs. high) perceived risk.”⁷⁶

33. In sum, the PFAS label with Erlenmeyer-flask imagery may evoke negative emotive responses among consumers.

C. The PFAS Label May Lead Consumers to Form Persistent Negative Inferences About the Products to Which It Is Affixed

34. Consumers who experience negative emotive responses to the PFAS label and flask imagery may apply these negative associations to the products generally. As discussed above, the presence of a specific product claim may lead consumers to infer broader, unstated product attributes.
35. If fear and perceived dangers become top of mind for consumers after viewing the PFAS label, consumers may assume that the presence of PFAS in a given product presents risk regardless of the actual properties of the product. This conclusion may persist regardless of whether consumers are familiar with PFAS. For those who have not previously heard of PFAS, the PFAS label may trigger uncertainty and ultimately fear, as discussed in **Section IV.A**. For consumers who have heard of PFAS being discussed in connection with human or environmental risks, the PFAS label may trigger concern and fear, as discussed in **Section IV.B**.⁷⁷ Additionally, as I understand it, the umbrella term “PFAS” covers more than 14,000 chemicals with different structures and varying levels of supposed harm or impacts on health.⁷⁸ Consumers may not know that there are different

⁷⁵ Rihn, A., et al., “Influence of scientific communications on the acceptance of PFAS alternatives on disposable dinnerware and take-out containers, by information source,” *Journal of Agriculture and Food Research*, 2026, 1-10, at pp. 1-2, 7-9; Berthold, T., et al., “Let’s talk about PFAS: Inconsistent public awareness about PFAS and its sources in the United States,” *PLOS ONE*, 2023, 1-20, at pp. 1, 12-15.

⁷⁶ Drury, L., et al., “YOU HAVE BEEN WARNED: The Effect of California's Proposition 65 Warning on Consumer Perceptions and Evaluations,” *Journal of Consumer Affairs*, 2025, 1-21, at p. 3.

⁷⁷ See Rihn, A., et al., “Influence of scientific communications on the acceptance of PFAS alternatives on disposable dinnerware and take-out containers, by information source,” *Journal of Agriculture and Food Research*, 2026, 1-10, at pp. 1-2, 7-9; Berthold, T., et al., “Let’s talk about PFAS: Inconsistent public awareness about PFAS and its sources in the United States,” *PLOS ONE*, 2023, 1-20, at pp. 1, 12-15.

⁷⁸ See Rebuttal Testimony of Dr. Stephen Korzeniowski on Behalf of the American Chemistry Council (“ACC”), In the Matter of Proposed Adoption of 20.13.2 NMAC, No. EIB 25-61 (R), February 16, 2026, at p. 3; “Naming

types of PFAS and are unlikely to distinguish among them, much less understand the specific risk associated with each type and accurately apply that risk to the product they are considering purchasing. Given this uncertainty, consumers may be inclined to assume the worst based on the cues presented on the product label, even if the actual risk is low.

36. These interpretive associations are important because risk perception is based not only on technical understanding of the disclosed substance.⁷⁹ The “affect-heuristic” literature shows that negative affect associated with a product or activity can increase perceived risk and reduce perceived benefit, even where consumers do not undertake a detailed analytic assessment.⁸⁰ As discussed above, consumers often treat the mere presence of a “chemical” as itself risk-relevant, rather than evaluating risk based on exposure, dose, or product-specific context.⁸¹ Indeed, while PFAS communicators must balance known threats with uncertainty about exposure amount and duration, everyday consumers may focus on the mere presence of a chemical when weighing potential risk.⁸²
37. That mechanism is likely to be especially relevant here because, as noted above, many consumers have limited baseline knowledge of PFAS and may not be able to assess the product-specific significance of the included PFAS.⁸³ Rather, consumers may rely on the PFAS label to make broader inferences about product safety, naturalness, quality, and

Conventions for Per- and Polyfluoroalkyl Substances (PFAS),” *Interstate Technology Regulatory Council*, September 2023, available at https://pfas-1.itrcweb.org/wp-content/uploads/2023/10/NamingConventions_PFAS_Fact-Sheet_Sept2023_final.pdf; “Our Current Understanding of the Human Health and Environmental Risks of PFAS,” *Environmental Protection Agency*, available at <https://www.epa.gov/pfas/our-current-understanding-human-health-and-environmental-risks-pfas>., accessed on June 22, 2026.

⁷⁹ Peters, E., “Affect and Emotion,” *Communicating Risks and Benefits: An Evidence-Based User’s Guide*, U.S. Food and Drug Administration, 2011, pp. 89-97, at pp. 89-91; Slovic, P., et al., 2007, pp. 1333-1352, at pp. 1333, 1341-1343.

⁸⁰ Slovic et al. (2007), at pp. 1341-1343; Peters, E., “Affect and Emotion,” in Fischhoff, B., Noel T. Brewer, and Julie S. Downs, eds., *Communicating Risks and Benefits: An Evidence-Based User’s Guide*, U.S. Food and Drug Administration, 2011, pp. 89-97, at pp. 90-91.

⁸¹ Moreira da Silva and Barroca (2025), at pp. 8-10.

⁸² Hutchins, R., et al., “Efficacy and Threat Language in PFAS Messaging,” *Risk Analysis*, 2026, 1-12, at p. 2.

⁸³ Berthold, T., et al., “Let’s talk about PFAS: Inconsistent public awareness about PFAS and its sources in the United States,” *PLOS ONE*, 2023, pp. 1-20, at pp. 1, 6, 12-13.

value, particularly because PFAS content is not an attribute consumers can directly verify at the point of purchase. An everyday consumer generally cannot determine, by inspecting a jacket, pan, mascara, textile, or other consumer product, whether it contains PFAS, which type of PFAS it contains, why PFAS was used, at what level it is present in the product, or whether the product poses any meaningful exposure risk in daily use.

38. In that setting, a prominent display of the PFAS label may function as an anchor consumers rely on as a proxy for the otherwise unobservable product attribute. As discussed in **Section III.B**, research has established that consumers routinely rely on such anchors when evaluating products at initial encounters and use these anchors to make subsequent judgements. Any negative associations consumers may establish after reviewing the PFAS label with the flask imagery may shape subsequent purchase decisions and inferences about the product itself even if consumers later receive additional context indicating that the actual risk of engaging with PFAS in that product is low. In other words, as discussed in **Section III.B.3**, such negative associations may be persistent. The PFAS label may lead consumers to infer that the product is less safe, more chemically treated, or lower quality than a comparable unlabeled product. As such, the PFAS label may function as a persistent risk signal about the overall product rather than a neutral technical cue.⁸⁴

V. THE PFAS LABEL'S POTENTIAL EFFECTS ON THE CONSUMER BUYING DECISION PROCESS

39. **Section III.A** describes the consumer buying decision process, which involves problem recognition, information search, evaluation of alternatives, purchase decision, and post-purchase behavior. As discussed above, product labels and visual symbols can shape consumer perception and decision-making by drawing attention to particular product attributes and by serving as cues that consumers may use when evaluating products. As I

⁸⁴ Berthold, T., et al., "Let's talk about PFAS: Inconsistent public awareness about PFAS and its sources in the United States," *PLOS ONE*, 2023, pp. 1-20, at pp. 12-13; Hutchins, R., et al., "Efficacy and Threat Language in PFAS Messaging," at p. 2; Peters, E., "Affect and Emotion," in Fischhoff, B., Noel T. Brewer, and Julie S. Downs, eds., *Communicating Risks and Benefits: An Evidence-Based User's Guide*, U.S. Food and Drug Administration, 2011, pp. 89-97, at pp. 90-91.

explain below, the PFAS label may influence how consumers interpret, evaluate, and respond to labeled products both before and after purchase.⁸⁵

A. The Impact of the PFAS Label During Information Search

40. I understand that New Mexico regulations require that the PFAS label must be visible and legible before sale and must appear in consumer-facing purchase contexts, including the product itself and the websites where covered products are sold.⁸⁶ Research suggests that features such as placement, size, color or contrast, format, and pictorial symbols can increase the likelihood that a warning or disclosure will be noticed.⁸⁷ Specifically, as noted in **Section III.B.1**, research has shown that pictorial elements can increase attention and may convey hazard-related meaning depending on the symbol and context.⁸⁸ These findings suggest that the PFAS label, which combines an Erlenmeyer-flask symbol with text that is no smaller than the largest font used for other consumer information on the product, is more likely to be noticed, especially at the beginning of the consumer buying decision process (*e.g.*, the information search stage).⁸⁹
41. The website requirement extends this attention mechanism to online purchasing.⁹⁰ In e-commerce settings warnings are more likely to be seen, found quickly, and used in consumer decision-making when they are immediately visible, offset from other text,

⁸⁵ 20.13.2.13(C)(1) NMAC; Moreira da Silva and Barroca (2025), at p. 8; Rihn, A., et al., “Influence of Scientific Communications on the Acceptance of PFAS Alternatives on Disposable Dinnerware and Take-Out Containers, by Information Source,” *Journal of Agriculture and Food Research*, 2026, pp. 1-10, at pp. 7-9.

⁸⁶ 20.13.2.13(B), (C)(1), (C)(4) NMAC.

⁸⁷ Laughery, K. and M. Wogalter, “A Three-Stage Model Summarizes Product Warning and Environmental Sign Research,” *Safety Science*, 2014, 3-10, at pp. 5-6; Wogalter, M., et al., “Research-Based Guidelines for Warning Design and Evaluation,” *Applied Ergonomics*, 2002, pp. 219-230, at pp. 221-223.

⁸⁸ 20.13.2.13(C)(1) NMAC; Wogalter, M., et al., “Research-Based Guidelines for Warning Design and Evaluation,” *Applied Ergonomics*, 2002, pp. 219-230, at p. 223; Boelhouwer, E., et al., “Comprehension of Hazard Communication: Effects of Pictograms on Safety Data Sheets and Labels,” *Journal of Safety Research*, 2013, pp. 145-155, at pp. 146, 154.

⁸⁹ 20.13.2.13(C)(1) NMAC. Wogalter, M., et al., “Research-Based Guidelines for Warning Design and Evaluation,” *Applied Ergonomics*, 2002, pp. 219-230, at p. 223; Boelhouwer, E., et al., “Comprehension of Hazard Communication: Effects of Pictograms on Safety Data Sheets and Labels,” *Journal of Safety Research*, 2013, pp. 145-155, at pp. 146, 154.

⁹⁰ 20.13.2.13(C) NMAC.

prominent, and paired with a warning or safety symbol.⁹¹ By requiring the PFAS label on websites where covered products are sold, the rule may further bring attention to the label during consumer's online search and product-comparison process before purchase.⁹²

B. The Impact of the PFAS Label During Evaluation of Alternatives

42. As noted above in **Section III.B**, research has shown that certain label cues can affect product evaluation beyond the literal information disclosed and that a single attribute can be used by consumers to make more general inferences about a product.⁹³ Applied here, and as discussed in **Section IV.A**, the PFAS label may cause consumers to associate the Erlenmeyer-flask with chemical, laboratory, or risk-related concepts, and to generalize from those associations in forming broader negative judgments about the product, particularly relative to products without similar disclosures.⁹⁴ The literature indicates that negative affective associations with a product can increase perceived risk and reduce

⁹¹ “Evidence-Based Recommendations for the Placement and Design of Warning Labels on E-commerce Sites,” *Consumer Product Safety Commission and Fors Marsh Group*, available at <https://www.cpsc.gov/s3fs-public/The-Placement-and-Design-of-Warning-Labels-on-E-commerce-Sites.pdf?VersionId=rOMC7e2xYWXh7SBLSGazsy9s.jYt0zNu>, at pp. 1-2.

⁹² 20.13.2.13(C) NMAC; “Evidence-Based Recommendations for the Placement and Design of Warning Labels on E-commerce Sites,” *Consumer Product Safety Commission and Fors Marsh Group*, available at <https://www.cpsc.gov/s3fs-public/The-Placement-and-Design-of-Warning-Labels-on-E-commerce-Sites.pdf?VersionId=rOMC7e2xYWXh7SBLSGazsy9s.jYt0zNu>, at pp. 1-2. I also understand that warning-label literature generally treats label effectiveness as a staged process, beginning with attention, comprehension, and recall and extending to judgments and behavior. The evidence suggests that warning labels often have more direct and predictable effects on earlier information-processing outcomes than on later behavioral outcomes, although this pattern depends on the type of warning and the behavioral outcome at issue. *See* Purmehdi et al. (2017), at pp. 38-39; Argo, J. and K. Main, “Meta-Analyses of the Effectiveness of Warning Labels,” *Journal of Public Policy & Marketing*, 2004, pp. 193-208, at pp. 193-194, 204-205.

⁹³ For example, in the food-labeling context, consumers exposed to front-of-package low-carbohydrate claims inferred broader benefits about weight management, healthfulness, and calorie content, even though those attributes were not necessarily determined by carbohydrate content alone. Additionally, consumers can use a single attribute, such as perceived naturalness, to infer broader attributes such as safety, healthfulness, quality, or value. Labiner-Wolfe, J., et al., “Effect of Low-carbohydrate Claims on Consumer Perceptions About Food Products’ Healthfulness and Helpfulness for Weight Management,” *Journal of Nutrition Education and Behavior*, 2010, pp. 315-320, at pp. 315, 317-319. Gagliardi, L., “Naturalness Seeking minds: The Cognitive Foundations of Naturalness Bias in Consumer Food Choice,” *Food and Humanity*, 2025, pp. 1-12, at pp. 3-4; Meier, B., et al., “Naturally Better? A Review of the Natural-is-Better Bias,” *Social and Personality Psychology Compass*, 2019, pp. 1-21, at pp. 4-9.

⁹⁴ Moreira da Silva and Barroca (2025), at pp. 8-10; Gagliardi, L., “Naturalness Seeking Minds: The Cognitive Foundations of Naturalness Bias in Consumer Food Choice,” *Food and Humanity*, 2025, pp. 1-12, at pp. 1-4.

perceived benefit, making the product less attractive relative to otherwise comparable alternatives.⁹⁵

43. As such, during evaluation of alternatives—a stage in the buying process where consumers compare products and make attribute tradeoffs before forming a purchase decision⁹⁶—the PFAS label may become one of the product attributes consumers use to evaluate the labeled product relative to unlabeled or PFAS-free alternatives.⁹⁷ As noted in **Section IV.A**, because consumers cannot independently evaluate the product-specific significance of PFAS, they may rely on accessible label and packaging cues to assess such technical product attributes.⁹⁸

C. The Impact of the PFAS Label During the Purchase Decision

44. Product label perceptions may also affect the purchase-decision stage of the consumer buying decision process. As discussed in **Section III.A**, consumers may form preferences during the evaluation-of-alternatives stage, but perceived risk can ultimately cause consumers to modify, postpone, or avoid a purchase decision.⁹⁹ As discussed in **Sections III.B.3** and **IV.B**, the PFAS label with Erlenmeyer-flask imagery may increase perceived product risk and evoke negative affective responses among consumers. Although the research discussed above suggests that such perceptions can negatively impact purchase intentions, as in the GMO/GMF context (*See Section III.B.2*), later-stage behavior depends on additional factors.¹⁰⁰ Accordingly, the effect of the PFAS label on actual

⁹⁵ Slovic et al. (2007), at pp. 1341-1344; Peters, E., “Affect and Emotion,” in Fischhoff, B., Noel T. Brewer, and Julie S. Downs, eds., *Communicating Risks and Benefits: An Evidence-Based User’s Guide*, U.S. Food and Drug Administration, 2011, pp. 89-99, at pp. 90-91.

⁹⁶ Kotler and Keller (2016), at pp. 172-179.

⁹⁷ Buchmüller, K., et al., “The Influence of Packaging on Consumers’ Risk Perception of Chemical Household Products,” *Applied Ergonomics*, 2022, pp. 1-7, at pp. 1-2; Rihn, A., et al., “Influence of Scientific Communications on the Acceptance of PFAS Alternatives on Disposable Dinnerware and Take-out Containers, by Information Source,” *Journal of Agriculture and Food Research*, 2026, pp. 1-10, at pp. 7-9.

⁹⁸ Buchmüller, K., et al., “The Influence of Packaging on Consumers’ Risk Perception of Chemical Household Products,” *Applied Ergonomics*, 2022, at pp. 1-2; Berthold, T., et al., “Let’s Talk About PFAS: Inconsistent Public Awareness About PFAS and its Sources in the United States,” *PLOS ONE*, 2023, pp. 1-20, at pp. 12-13.

⁹⁹ Kotler and Keller (2016), at p. 178.

¹⁰⁰ *See Section III.B.2*; Kotler and Keller (2016), at pp. 177-178.

purchases is likely to vary by product category, consumer familiarity, available substitutes, price, and the perceived cost of avoiding the labeled product.¹⁰¹

45. The PFAS label may also impact willingness to pay because consumers' willingness to pay is affected by perceived product attributes, including perceived safety, naturalness, environmental value, and risk.¹⁰² As discussed in **Section III.B**, research on naturalness bias shows that consumers often treat naturalness as a positive cue and are willing to pay more for products perceived as natural or free from synthetic substances.¹⁰³ Conversely, a label that signals chemical presence or that otherwise projects health or environmental risks may result in reduced consumer willingness-to-pay.¹⁰⁴ Further, any reduction in purchase likelihood or willingness to pay is likely to be more pronounced where consumers perceive a comparable unlabeled or PFAS-free alternative as available and practical to choose.¹⁰⁵

D. The Impact of the PFAS Label During Post-Purchase Evaluation

46. The effect of the PFAS label may also persist beyond the initial point of exposure because early affective associations and anchoring can continue to guide later judgments about risk and benefit. As discussed in **Section IV**, if consumers associate a labeled product with chemical hazard, contamination, or health or environmental risk, that association

¹⁰¹ Argo, J. and K. Main, "Meta-Analyses of the Effectiveness of Warning Labels," *Journal of Public Policy & Marketing*, Fall 2004, pp. 193-208, at pp. 195-196, 204-205; Purmehdi et al. (2017), at pp. 38-39, 45-46.

¹⁰² Migliore, G., et al., "Consumers' Willingness to Pay for Natural Food: Evidence From an Artefactual Field Experiment," *Agricultural and Food Economics*, 2018, pp. 1-10, at pp. 1-2, 6; Slovic et al. (2007), at pp. 1341-1344.

¹⁰³ Meier, B., et al., "Naturally Better? A Review of the Natural-is-Better Bias," *Social and Personality Psychology Compass*, 2019, pp. 1-21, at pp. 3-9; Migliore, G., et al., "Consumers' Willingness to Pay for Natural Food: Evidence From an Artefactual Field Experiment," *Agricultural and Food Economics*, 2018, pp. 1-10, at pp. 1-2, 6.

¹⁰⁴ Moreira da Silva and Barroca (2025), at pp. 8-10; Rihn, A., et al., "Influence of Scientific Communications on the Acceptance of PFAS Alternatives on Disposable Dinnerware and Take-out Containers, by Information Source," *Journal of Agriculture and Food Research*, 2026, pp. 1-10, at pp. 7-9.

¹⁰⁵ Argo, J. and K. Main, "Meta-Analyses of the Effectiveness of Warning Labels," *Journal of Public Policy & Marketing*, Fall 2004, pp. 193-208, at pp. 195-196, 204-205; Purmehdi et al. (2017), at pp. 38-39, 45-46; Rihn, A., et al., "Influence of Scientific Communications on the Acceptance of PFAS Alternatives on Disposable Dinnerware and Take-out Containers, by Information Source," *Journal of Agriculture and Food Research*, 2026, pp. 1-10, at pp. 7-9.

may continue to influence product perception even after consumers encounter additional explanatory or “corrective” information.¹⁰⁶ Additional information can reduce misinterpretation when it is accessible, diagnostic, and used by consumers, but it may not fully offset the initial risk-signaling effect of a visible chemical-related label at the point of sale.¹⁰⁷

47. Even after a consumer decides to purchase a product, the initial impression of the PFAS label may influence consumer satisfaction, actions, and evaluations of the product post-purchase.¹⁰⁸ This may be particularly true due to the repeated pairing of the PFAS label with the product.¹⁰⁹ The negative associations from the PFAS label are therefore likely to be sustained and may influence a consumer’s likelihood of repurchase, their use and disposal of the product, or whether they communicate positive, neutral, or negative information about the product to others.¹¹⁰
48. The PFAS label may therefore influence consumers throughout the consumer buying decision process by not only disclosing the presence of PFAS, but also by making that attribute salient before purchase and giving consumers a chemical- and laboratory-based cue to use when evaluating the product that may persist long after the initial impression. For consumers who do not understand PFAS or cannot evaluate the product-specific significance of PFAS presence, the label may increase uncertainty and perceived risk, which in turn may reduce perceived safety, quality, value, desirability, purchase interest, or willingness to pay. The extent of those effects will depend on product

¹⁰⁶ See Slovic et al. (2007), at pp. 1341-1346; Moreira da Silva and Barroca (2025), at pp. 8-10; Meier, B., et al., “Naturally Better? A Review of the Natural-is-Better Bias,” *Social and Personality Psychology Compass*, 2019, pp. 1-21, at pp. 5-6.

¹⁰⁷ See Labiner-Wolfe, J., et al., “Effect of Low-carbohydrate Claims on Consumer Perceptions About Food Products’ Healthfulness and Helpfulness for Weight Management,” *Journal of Nutrition Education and Behavior*, 2010, pp. 315-320, at pp. 318-319.

¹⁰⁸ Kotler and Keller (2016), at pp. 178-179.


¹⁰⁹ As stated above, the NMAC rules require the PFAS label to be affixed to the product itself and it must be visible and legible, with text “no smaller than the largest font used for other consumer information on the product.” Therefore, it is likely that a consumer will be aware of the label each time they use or interact with the product. 20.13.2.13(C)(1) NMAC.

¹¹⁰ Kotler and Keller (2016), at pp. 178-179.

category, consumer familiarity, purchase context, and the availability and cost of alternatives, but later explanatory information may not fully eliminate the initial label-based inference once the product has been associated with chemical hazard or risk.

I declare under penalty of perjury that the foregoing is true and correct.

Signed on the 30th day of June, 2026.

A handwritten signature in dark ink, appearing to read "Keith Wilcox", is written over a horizontal line.

Keith Wilcox, Ph.D.

APPENDIX A

CURRICULUM VITAE AND RECENT TESTIMONY

Keith Wilcox

Mays Business School, Wehner 220C
College Station, Texas 77843
kwilcox@mays.tamu.edu

Education

2004-2009	The City University of New York, Baruch College (Graduate Center) <i>Ph.D., Marketing, 2009</i>
1999-2001	The University of California, Berkeley, Haas School of Business <i>Master of Business Administration, 2001</i>
1993-1997	The City University of New York, Baruch College <i>Bachelor of Business Administration, Finance, 1997</i>

Professional Appointments

2025-Present	Ford Endowed Chair in Consumerism/E-Business/E-Commerce Mays Business School, Texas A&M University
2021-2025	Macys Foundation Professor Mays Business School, Texas A&M University
2015-2021	Barbara and Meyer Feldberg Associate Professor of Business Columbia University, Columbia Business School
2014-2015	Associate Professor of Marketing Columbia University, Columbia Business School
2012-2014	Assistant Professor of Marketing Columbia University, Columbia Business School
2009-2012	Assistant Professor of Marketing Babson College, Olin School of Business
2005-2009	Lecturer The City University of New York, Baruch College

Honors & Awards

2024	Research Excellence Award Mays Business School
2024	Outstanding Member of the Editorial Review Board International Journal of Research in Marketing
2022	Best Talk Award Society of Consumer Psychology Conference, JDM Track

2020	MSI Scholar Marketing Science Institute
2015	Outstanding Reviewer Award Journal of Consumer Research
2013	Citations of Excellence Award Emerald Group Publishing
2013	Young Marketing Scholar Marketing Science Institute
2009-2012	Joseph R. Weintraub Term Chair Babson College, Olin School of Business
2011	Best Conference Paper La Londe Conference
2009	Best Conference Paper Marketing and Public Policy Conference
2009	Babson Faculty Research Fund Award Babson College, Olin School of Business
2007	AMA-Sheth Foundation Doctoral Consortium Fellow The City University of New York, Baruch College
2006	Valuing Diversity Dissertation Scholarship American Marketing Association
2004-2006	Llewellyn Fellowship The City University of New York
1999-2001	Consortium for Graduate Study in Management Fellow The University of California, Berkeley, Haas School of Business

Publications

- Thompson, Debora, Amna Kirmani, Rebecca Hamilton, Andy Li, Christilene du Plessis, Daniel Fernandes, Guillaume Johnson, Brent McFerran, Jian Ni, Vladimir Pavlov, Francine Petersen, Lisa Scheer, Yan Vieites and Keith Wilcox (2025), “Cycles of Inequality in the Marketplace: Insights from Macro, Marketer and Consumer Perspectives,” *International Journal of Research in Marketing*, <https://doi.org/10.1016/j.ijresmar.2025.09.004>.
- Hoyer, Wayne D., Echo Wen Wan and Keith Wilcox* (2024), “Practical Relevance in Consumer Research,” *Journal of Consumer Research*, 51 (2), 428–438.

- Wilcox, Keith, Sandra Laporte and Gabriel Ward (2024), “How Traditional Production Shapes Perceptions of Product Quality.” *Journal of Consumer Research*, 51 (2), 256-275.
- Köcher, Sören and Keith Wilcox (2021), “I Made It Work: How Using a Self-Assembled Product Increases Task Performance,” *Journal of Consumer Psychology*, 32 (3), 492-499.
- Wilcox, Keith and Sonja Prokopec (2019), “Restraint that Blinds: Attention Narrowing and Consumers’ Response to Numerosity in Self-Control Decisions.” *Journal of Consumer Research*, 46 (2), 371-387.
- Wilcox, Keith, Juliano Laran, Andrew Stephen and Peter Zubcsek (2016), “How Being Busy Can Increase Motivation and Reduce Task Completion Time,” *Journal of Personality and Social Psychology*, 110 (3), 371-384.
- Puccinelli, Nancy, Keith Wilcox and Dhruv Grewal (2015), “Consumers’ Response to Commercials: When the Energy Level in the Commercial Conflicts with the Media Context,” *Journal of Marketing*, 79 (2), 1-18.
- Wilcox, Keith and Andrew Stephen (2013), “Are Close Friends the Enemy? Online Social Networks, Self-Esteem, and Self-Control,” *Journal of Consumer Research*, 40 (1), 90-103.
- Wilcox, Keith, Anne Roggeveen and Dhruv Grewal (2011), “Shall I Tell You Now or Later? Assimilation and Contrast in the Evaluation of Experiential Products,” *Journal of Consumer Research*, 38 (4), 763-773.
- Wilcox, Keith, Lauren Block and Eric Eisenstein (2011), “Leave Home Without It? The Effects of Credit Card Debt and Available Credit on Spending,” *Journal of Marketing Research*, 48 (SPL), S78-S91.
- Laran, Juliano and Keith Wilcox* (2011), “Choice, Rejection, and Elaboration on Preference-Inconsistent Alternatives,” *Journal of Consumer Research*, 38 (2), 229-241.
- Wilcox, Keith and Sangyoung Song (2011), “Discrepant Fluency in Self Customization,” *Journal of Marketing Research*, 48 (4), 729-740.
- Wilcox, Keith, Thomas Kramer and Sankar Sen (2011), “Indulgence or Self-Control: A Dual Process Model of the Effect of Incidental Pride on Indulgent Choice,” *Journal of Consumer Research*, 38 (1), 151-163.
- Wilcox, Keith, Beth Vallen, Lauren Block and Gavan Fitzsimons (2009), “Vicarious Goal Fulfillment: When the Mere Presence of a Healthy Option Leads to an Ironically Indulgent Decision,” *Journal of Consumer Research*, 36 (3), 380-393.
- Wilcox, Keith, Hyeong Min Kim and Sankar Sen (2009), “Why Do Consumers Buy Counterfeit Luxury Brands?” *Journal of Marketing Research*, 46 (1), 247-259.

*Co-first author

Book Chapters

- Wilcox, Keith and Judith Lynne Zaichkowsky (2019), “The Evolution of Counterfeit Luxury Consumption.” *Research Handbook on Luxury Branding*, Eds. Felicitas Morhart, Keith Wilcox and Sandor Czellar, Edward Elgar Publishing, 268-303.
- Wilcox, Keith (2019), “How Signaling Motives and Identity Salience Influence Luxury Consumption.” *Handbook of Research on Identity Theory in Marketing*, Eds. Americus Reed and Mark Forehand, Edward Elgar Publishing, 72-84.
- Block, Lauren and Keith Wilcox (2013), “Self-Control and Spending.” In *The Routledge Companion to Identity and Consumption*, Eds. Ayalla Ruvio and Russell Belk, Routledge, 227-234.

Other Publications

- Wilcox, Keith, Sandra Laporte and Gabriel Ward (2024), “Why Consumers Value Traditionally Made Products.” *Character & Context Blog*.

Work in Progress

- Shiri, Amin, Felipe Affonso and Keith Wilcox. “When Consumers Prefer Point Versus Range Estimates of Product Performance.” Revise & resubmit at *Journal of Marketing Research*.
- Ward, Gabriel, Nicholas Olson and Keith Wilcox. “Buildings from the Past, Brands for the Future: How Adaptive Reuse Increases Perceived Brand Innovativeness.” Revise & resubmit at *Journal of Consumer Research*.
- Mosley, Buffy and Keith Wilcox. “Dynamic Duo: How Text and Image Arousal Shape Consumer Engagement.” Revise & resubmit at *Journal of Marketing Research*.
- Wang, Yusu, Keith Wilcox and Jeffrey Lee. “Conspicuous Expression? How the Expression of Arousal Increases Perceived Status.” Reject & resubmit at *Journal of Consumer Research*.
- Shiri, Amin, Keith Wilcox and Xiang Wang. “How Intolerance for Uncertainty Increases Confidence in the Voracity of Fake News.” Manuscript in preparation for *Psychological Science*.
- Yanar, Evrim, Felicitas Morhart and Keith Wilcox. “Contentment and Satisfaction with Life as a Status Signal.” Data collection in progress.
- Hur, Elina, Nofar Duani, Keith Wilcox and Alix Barasch, “How the Virtual Presence of Others Increases Task Performance.” Data collection in progress.
- Shiri, Amin and Keith Wilcox. “Faith in Falsity: Why "Fake" Labels Resonate More Than Verified Truths.” Data collection in progress.

- Edwards, Devin, Keith Wilcox and Ralph Park, “Suspiciously Positive: How Profile Images Decrease Persuasion in Online Reviews and Social Media.” Data collection in progress.

Cases

- Kate Spade New York: Will Expansion Deepen or Dilute the Brand? (2015) Coauthor: Eva Ascarza.

Grants and Funding

- “The New Rich Life: The Role of Life Satisfaction in Status Signaling.” Qualtrics Behavioral Research Grant. 2021-2024. Swiss National Science Foundation. Principle Investigators: Felicitas Morhart and Keith Wilcox. Award amount: CHF 239,779.
- “Thinking About Financial Deprivation: Rumination and Decision Making Among the Poor.” Qualtrics Behavioral Research Grant. 2015-2016. Qualtrics. Principle Investigators: Rachel Meng, Keith Wilcox and Gita Johar. Award amount: \$5,000.
- “Thinking About Financial Deprivation: Rumination and Decision Making Among the Poor.” Research Grant. 2015-2016. Marketing Science Institute. Principle Investigators: Rachel Meng, Keith Wilcox and Gita Johar. Award amount: \$10,000.
- “Mobile Platforms, Location-Based Services, and their Impact on Consumers.” Research Grant. 2013-2014. Marketing Science Institute. Principle Investigators: Peter Pal Zubcsek, Keith Wilcox and Alan Cook. Award amount: \$14,300.
- “Depletion-as-Information.” Junior Faculty Provost’s Grant. 2013-2014. Columbia University. Principle Investigator: Keith Wilcox. Award amount: \$25,000.
- “Depletion-as-Information.” Eugene M. Lang Support Fund Research Grant. 2013-2014. Columbia University, Graduate School of Business. Principle Investigator: Keith Wilcox. Award amount: \$10,000.
- “Quantity Aversion.” CIBER Research Grant. 2012-2013. Center for International Business Education and Research, Columbia University. Keith Wilcox and Amy Dalton. Award amount: \$10,000.
- “The Role of Emotions In-Store.” Duke-Ipsos Research Grant. 2012-2013. Duke-Ipsos Research Center. Principle Investigators: Keith Wilcox and Amy Dalton. Award amount: \$10,000.
- “Pride: A License to Indulge and a Cue for Greater Self-Control.” Graduate Center Research Grant. 2007-2008. The City University of New York, Graduate Center. Principle Investigator: Keith Wilcox. Award amount: \$2,000.

Editorial Appointments

- Associate Editor *Journal of Consumer Research* (2021-2025)
- Associate Editor *International Journal of Research in Marketing* (2024-Present)
- Associate Editor *Journal of Marketing* (2025-Present)
- Associate Editor *Journal of Marketing Research* (2025-Present)
- Associate Editor *Oxford Bibliographies in Marketing* (2024-2025)
- Editorial Board *Journal of Consumer Psychology* (2015-Present)
- Editorial Board *Journal of Consumer Research* (2025-Present)
- Article Associate Editor *Frontiers in Psychology* (2023)

Peer Reviewing

- Ad Hoc Reviewer *Health Psychology*
- Ad Hoc Reviewer *European Journal of Marketing*
- Ad Hoc Reviewer *PLOS ONE*
- Ad Hoc Reviewer *Journal of Experimental Social Psychology*
- Ad Hoc Reviewer *Psychological Science*
- Ad Hoc Reviewer *Journal of Personality and Social Psychology*
- Ad Hoc Reviewer *Personality and Social Psychology Bulletin*
- Ad Hoc Reviewer *Journal of Public Policy & Marketing*
- Ad Hoc Reviewer *Journal of Cognitive Psychology*
- Ad Hoc Reviewer *Journal of Business Ethics*
- Ad Hoc Reviewer *Marketing Letters*
- Ad Hoc Reviewer *International Marketing Review*
- Ad Hoc Reviewer *Journal of Macromarketing*
- Ad Hoc Reviewer *Journal of the American Society for Information Science and Technology*

Presentations

- When Consumers Prefer Point Versus Range Estimates of Product Performance. (Coauthors: A., Shiri & F. Affonso). Pennsylvania State University, Marketing Speaker Series (2026).
- When Consumers Prefer Point Versus Range Estimates of Product Performance. (Coauthors: A., Shiri & F. Affonso). University of Tennessee, Knoxville, Marketing Speaker Series (2026).
- When Consumers Prefer Point Versus Range Estimates of Product Performance. (Coauthors: A., Shiri & F. Affonso). Oregon State University, Marketing Speaker Series (2025).
- When Consumers Prefer Point Versus Range Estimates of Product Performance. (Coauthors: A., Shiri & F. Affonso). London Business School, Marketing Speaker Series (2025).
- Expressing Contentment on Social Media Increases Status Via Perceived Morality. (Coauthors: E., Yanar & F., Morhart). Society of Consumer Psychology Boutique Conference on Social Impact (2024).
- How Adaptive Reuse Increases Perceived Innovativeness (Coauthors: G. Ward & N Olson). Association for Consumer Research Conference (2024).
- Expressing Contentment on Social Media Increases Status Via Perceived Morality. (Coauthors: E., Yanar & F., Morhart). Vienna University of Economics and Business (2024).

- Expressing Contentment on Social Media Increases Status Via Perceived Morality. (Coauthors: E., Yanar & F., Morhart). Baruch College, City University of New York (2024).
- Faith in Falsity: Why "Fake" Labels Resonate More Than Verified Truths. (Coauthors A. Shiri and X. Wang). Association for Consumer Research Conference (2023).
- Grinners Gain More Followers: Signaling Status through High Arousal Emotional Expressions on Social Media. (Coauthors Y. Wang and J. Lee). Association for Consumer Research Conference (2023).
- Beyond Market Beliefs: The Moderating Role of Self-construal in Copycat Evaluation. (S. Jeon, F. van Horen, P. Verlegh) European Association for Consumer Research Conference (2023).
- Grinners Gain More Followers: Signaling Status through High Arousal Emotional Expressions on Social Media. (Coauthors Y. Wang and J. Lee). Erasmus University Rotterdam (2023).
- Grinners Gain More Followers: Signaling Status through High Arousal Emotional Expressions on Social Media. (Coauthors Y. Wang and J. Lee). University of Groningen (2023).
- Grinners Gain More Followers: Signaling Status through High Arousal Emotional Expressions on Social Media. (Coauthors Y. Wang and J. Lee). Fisher College of Business, Ohio State University, Marketing Camp (2023).
- The Less You Know the Better: How Persuasion Knowledge Increases Preference for Products with Ambiguous Attributes. (Coauthor: A., Shiri). Society of Consumer Psychology Conference (2023).
- Expressing Contentment on Social Media Increases Status Via Perceived Morality. (Coauthors: E., Yanar & F., Morhart). Society of Consumer Psychology Conference (2023).
- The Less You Know the Better: How Persuasion Knowledge Increases Preference for Products with Ambiguous Attributes. (Coauthor: A., Shiri). Association for Consumer Research Conference (2022).
- Contentment and Satisfaction with Life as a Status Signal. (Coauthors: E., Yanar & F., Morhart). Association for Consumer Research Conference (2022).
- Inferring Status from High Arousal Emotions. (Coauthor: Y., Wang, J., Lee). Association for Consumer Research Conference (2022).
- How Intolerance for Uncertainty Shape Sharing of Misinformation. (Coauthors: A., Shiri, X., Wang). Association for Consumer Research Conference (2022).
- How Intolerance for Uncertainty Shape Sharing of Misinformation. (Coauthor: A., Shiri). Society of Consumer Psychology Conference (2022).
- How Traditional Production Shapes Perceptions of Artisanal Product Quality. (Coauthors: G., Ward & S., Laporte). Texas A&M University, New Beginnings Symposium (2021).
- On the Relationship Between Attractiveness and Intelligence. (Coauthors: Y., Jun & S., Matz). ESSEC, Marketing Speaker Series (2021).
- On the Relationship Between Attractiveness and Intelligence. (Coauthors: Y., Jun & S., Matz). Dartmouth, Marketing Speaker Series (2020).
- On the Relationship Between Attractiveness and Intelligence. (Coauthors: Y., Jun & S., Matz). Texas A&M, Marketing Speaker Series (2020).
- "We" Don't Always Like Copycats: How Self-Construal Influences Evaluation of Product Imitation. (Coauthors: S. Jeon, F. van Horen & P. Verlegh). Association for Consumer Research Conference (2020).
- On the Relationship Between Attractiveness and Intelligence. (Coauthors: Y., Jun & S., Matz). Stanford, Marketing Speaker Series (2020).

- Don't Worry, Be Healthy: Subjective Feelings of Busyness Lower Self-Control. (Coauthor: E. Hur). Society of Consumer Psychology Conference (2020).
- On the Relationship Between Attractiveness and Intelligence. (Coauthors: Y., Jun & S., Matz). HEC Paris, Winter Camp (2019).
- On the Relationship Between Attractiveness and Intelligence. (Coauthors: Y., Jun & S., Matz). HEC Montreal, Marketing Speaker Series (2019).
- The Upside of Busyness: How Feeling Busy Influences Consumer Motivation. (Coauthor: J., Laran). Four-School Conference, Stern Business School, New York University (2019).
- On the Relationship Between Attractiveness and Intelligence. (Coauthors: Y., Jun & S., Matz). Boston College, Marketing Speaker Series (2019).
- The Dual Effect of Subjective Busyness on Consumer Motivation. (Coauthor: J., Laran). Georgetown University, Marketing Speaker Series (2019).
- Is Beauty Only Skin-deep? The Self-Confirming Effects of Physical Attractiveness Stereotype. (Coauthors: Y., Jun & S., Matz). Society of Consumer Psychology Conference (2019).
- Do Altruistic Individuals "Share" More on Social Media? (Coauthor: T., Oh). Association for Consumer Research Conference (2018).
- The Costco Effect: When Utilitarian Products Undermine Self-control. (Coauthors: J., Liu & A., Dalton). Association for Consumer Research Conference (2018).
- The Dual Effect of Subjective Busyness on Consumer Motivation. (Coauthor: J., Laran). Association for Consumer Research Conference (2018).
- The Upside of Busyness: How Feeling Busy Can Increase Productivity. (Coauthor: J., Laran). Dortmund - International School of Management ISM, Marketing Speaker Series (Fall 2018)
- The Upside of Busyness: How Feeling Busy Can Increase Productivity. (Coauthor: J., Laran). Vrije Universiteit Amsterdam, Marketing Speaker Series (2018).
- The Upside of Busyness: How Feeling Busy Can Increase Productivity. (Coauthor: J., Laran). Behavioral Science 2018: Customer Experience Conference. Duke University (2018).
- Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions. (Coauthor: S., Prokopec). Boston University, Marketing Speaker Series (2018).
- Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions. (Coauthor: S., Prokopec). American Marketing Association Winter Conference (2018).
- The Dual Effect of Subjective Busyness on Consumer Motivation. (Coauthor: J., Laran). Frontiers in Consumer Psychology Conference (2018).
- Quantity Aversion: Self-Control and Consumers' Response to Product Quantity. (Coauthor: A., Dalton). Society of Consumer Psychology Boutique Conference on Vice and Virtue (2018).
- Is the Glass Half Empty? How Focusing on Energy Consumed Affects Mental Performance. (Coauthor: A., Madzharov). Society of Consumer Psychology Boutique Conference on Vice and Virtue (2018).
- The Downside of Purchase Consideration for Luxury Brands. (Coauthor: F., Petersen). Thought Leaders in Consumer-Based Strategy Conference (2017).
- The Dual Effect of Busyness on Motivation. (Coauthor: J., Laran). University of Miami Marketing Department (2017).
- The Dual Effect of Subjective Busyness on Consumer Motivation. (Coauthor: J., Laran). Association for Consumer Research Conference (2017).

- Is the Glass Half Empty? How Focusing on Energy Consumed Affects Mental Performance. (Coauthor: A., Madzharov). Society of Experimental Social Psychology Conference (2017).
- Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions. (Coauthor: S., Prokopec). University of Pennsylvania, Marketing Camp (2017).
- Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions. (Coauthor: S., Prokopec). Drexel University, Marketing Speaker Series (2017).
- Consumer Empowerment Empowering the Brand: Challenges and Opportunities. (Coauthors: V. Škare, P. Rydén, H. Muhammad, E. Kottika). Fourth International Conference on Contemporary Marketing Issues, Heraklion, Greece (2016).
- How Luxury Brand Consumption Promotes Costly Self-Signaling Behavior. (Coauthors: H., Hagtvedt & B., Kocher). University of St. Gallen, Marketing Speaker Series (2016).
- Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions. (Coauthor: S., Prokopec). Faculty of Business and Economics, HEC Lausanne, Speaker Series (2016).
- Education, Liberalism and Consumers' Response to Luxury Brands. (Coauthor: F., Petersen). Association for Consumer Research Conference (2016).
- Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions. (Coauthor: S., Prokopec). Frank Batten School of Leadership & Public Policy, University of Virginia, Speaker Series (2016).
- How Busyness Affects Motivation & Attentional Control. Northwestern University, Marketing Speaker Series (2016).
- How Busyness Affects Motivation & Attentional Control. Duke University, Marketing Speaker Series (2016).
- How Busyness Affects Motivation & Attentional Control. Saïd Business School, Oxford University, Marketing Camp (2016).
- Education, Liberalism and Consumers' Response to Luxury Brands. (Coauthor: F., Petersen). Association for Consumer Research Conference (2016).
- Rumination and Decision Making Among the Poor. (Coauthors: G., Johar & R., Meng). Boulder Summer Conference on Consumer Financial Decision Making (2016).
- Education, Liberalism and Consumers' Response to Luxury Brands. (Coauthor: F., Petersen). Monaco Symposium on Luxury (2016).
- Thinking About Financial Deprivation: Rumination and Decision Making Among the Poor. (Coauthors: G., Johar & R. Meng). Association for Consumer Research Conference Doctoral Symposium (2015).
- The Downside of Purchase Consideration for Luxury Brands. (Coauthor: F., Petersen). Consumer Competence Research Training Conference (2015).
- Restraint that Blinds: Attention Narrowing and Consumers' Response to Numerosity in Self-Control Decisions. (Coauthor: S., Prokopec). University of Maryland, Marketing Camp (Fall 2015).
- Depletion-as-Information: The Role of Feelings in Resource Depletion. (Coauthor: C., Chen). Society of Consumer Psychology Conference (2015).
- Depletion-as-Information: The Role of Feelings in Resource Depletion. (Coauthor: C., Chen). European Marketing Academy Conference (2015).
- How Being Busy Affects Productivity. (Coauthors: A., Stephen, J., Laran, & P., Zubcsek). Ghent University, Marketing Speaker Series (2015).
- How Being Busy Affects Productivity. (Coauthors: A., Stephen, J., Laran, & P., Zubcsek). American University, Marketing Speaker Series (Spring 2015)

- How Missing Deadlines and Being Busy Affect Productivity. (Coauthors: A., Stephen, J., Laran, & P., Zubcsek). Association for Consumer Research Conference Doctoral Symposium (2014).
- Quantity Aversion: Self-Control and Consumers' Response to Product Quantity. (Coauthor: A., Dalton). University of Pittsburgh, Marketing Speaker Series (2014).
- How Missing Deadlines and Being Busy Affect Productivity. (Coauthors: A., Stephen, J., Laran, & P., Zubcsek). Behavioral Decision Research in Management Conference (2014).
- The Less Conspicuous Road to Virtue: The Influence of Luxury Consumption on Socially Valued Behavior. (Coauthors: H., Hagtvedt & B., Kocher). Marketing in Israel Conference (2014).
- The Less Conspicuous Road to Virtue: The Influence of Luxury Consumption on Socially Valued Behavior. (Coauthors: H., Hagtvedt & B., Kocher). Copenhagen Business School, Marketing Speaker Series (2014).
- Encouraging Ideal Behavior via Luxury Consumption. (Coauthors: H., Hagtvedt & B., Kocher). University of Ghent, Marketing Speaker Series (2013).
- The Less Conspicuous Road to Virtue: The Influence of Luxury Consumption on Socially Valued Behavior. (Coauthors: H., Hagtvedt & B., Kocher). ESSEC, Winter Marketing Camp (2013).
- Depletion-as-Information: The Role of Feelings in Resource Depletion. (Coauthor: C., Chen). Association for Consumer Research Conference (2013).
- Tens, Hundreds or Thousands? How Nutritional Information Numerosity Nonconsciously Affects Unhealthy Food Choices. (Coauthor: S., Prokopec). Association for Consumer Research Conference (2013).
- Quantity Aversion: Self-Control and Consumers' Preference for Quality vs. Quantity. (Coauthor: A., Dalton). Association for Consumer Research Conference (2013).
- The Less Conspicuous Road to Virtue: The Influence of Luxury Consumption on Socially Valued Behavior. (Coauthors: H., Hagtvedt & B., Kocher). University of Miami, Marketing Speaker Series (2013).
- The Less Conspicuous Road to Virtue: The Influence of Luxury Consumption on Socially Valued Behavior. (Coauthors: H., Hagtvedt & B., Kocher). Erasmus University, Marketing Speaker Series (2013).
- The Less Conspicuous Road to Virtue: The Influence of Luxury Consumption on Socially Valued Behavior. (Coauthors: H., Hagtvedt & B., Kocher). Fisher College of Business, Ohio State University, Marketing Camp (2013).
- The Less Conspicuous Road to Virtue: The Influence of Luxury Consumption on Socially Valued Behavior. (Coauthors: H., Hagtvedt & B., Kocher). Marketing Science Institute, Young Scholar's Conference (2013).
- Are Close Friends the Enemy? Online Social Networks, Narcissism, and Self-Control. (Coauthor: A., Stephen). Association for Consumer Research Conference (2012).
- Encouraging Ideal Behavior by Imagining Luxury Consumption. (Coauthors: H., Hagtvedt & B., Kocher). Association for Consumer Research Conference (2012).
- Does Imitation Benefit the Imitated Brand? The Effects of Target Ambiguity and Processing Mindset on Judgment. (Coauthors: J., Laran & S., Sen). KU Leuven, Marketing Camp (2012).
- Does Imitation Benefit the Imitated Brand? The Effects of Target Ambiguity and Processing Mindset on Judgment. (Coauthors: J., Laran & S., Sen). University of Florida, Marketing Speaker Series (2012).
- Does Imitation Benefit the Imitated Brand? The Effects of Target Ambiguity and Processing Mindset on Judgment. (Coauthors: J., Laran & S., Sen). Four-School Conference, Columbia Business School, Columbia University (2012).

- Are Close Friends the Enemy? Online Social Networks, Narcissism, and Self-Control. (Coauthor: A., Stephen). University of Houston, Marketing Speaker Series (2012).
- Are Close Friends the Enemy? Online Social Networks, Narcissism, and Self-Control. (Coauthor: A., Stephen). University of Alberta, Marketing Speaker Series (2012).
- Are Close Friends the Enemy? Online Social Networks, Narcissism, and Self-Control. (Coauthor: A., Stephen). Society of Consumer Psychology Conference (2012).
- Does Imitation Benefit the Imitated Brand? The Effects of Target Ambiguity and Processing Mindset on Judgment. (Coauthors: J., Laran & S., Sen). Society of Consumer Psychology (2012).
- Are Close Friends the Enemy? Online Social Networks, Narcissism, and Self-Control. (Coauthor: A., Stephen). Columbia University, Marketing Speaker Series (2011).
- Are Close Friends the Enemy? Online Social Networks, Narcissism, and Self-Control. (Coauthor: A., Stephen). Boston University, Marketing Speaker Series (2011).
- Far Away or So Close: The Influence of Counterfeits on Genuine Brand Preference. (Coauthors: J., Laran & S., Sen). Association for Consumer Research Conference (2011).
- (In)congruity in the Evaluation of Celebrity Co-Brands. (Coauthor: R., Carroll). Association for Consumer Research Conference (2011).
- Choice, Rejection, and Elaboration on Goal-Inconsistent Alternatives. (Coauthor: J. Laran). La Londe Conference (2011).
- How the Order of Information About an Experiential Product Impacts Affective Evaluation. (Coauthors: A., Roggeveen & D., Grewal). La Londe Conference (2011).
- Choice, Rejection, and Elaboration on Goal-Inconsistent Alternatives. (Coauthor: J., Laran). Society for Consumer Psychology Conference (2011).
- The Ironic Effects of Credit Card Balances and Credit Limits on Consumer Spending. (Coauthors: L., Block & E., Eisenstein). Society for Consumer Psychology Conference (2011).
- How the Order of Information About an Experiential Product Impacts Affective Evaluation. (Coauthors: A., Roggeveen & D., Grewal). Society for Consumer Psychology Conference (2011).
- Vicarious Goal Fulfillment: When the Presence of a Healthy Option Leads to an Indulgent Decision. (Coauthors: B., Vallen, L., Block, & G., Fitzsimons). Society for Personality and Social Psychology Conference (2011).
- How the Order of Information About an Experiential Product Impacts Affective Evaluation. (Coauthors: A., Roggeveen & D., Grewal). Association for Consumer Research Conference (2010).
- The Ironic Effects of Credit Card Balances and Credit Limits on Conspicuous Consumption. (Coauthor: L., Block). Association for Consumer Research Conference (2010).
- The Ironic Effects of Credit Card Balances and Credit Limits on Conspicuous Consumption. (Coauthor: L., Block). Marketing and Public Policy Conference (2010).
- Pride: A License to Indulge or a Cue for Greater Self-Control? (Coauthors: T., Kramer & S. Sen). Association for Consumer Research Conference (2009).
- Vicarious Goal Fulfillment: When the Presence of a Healthy Option Leads to an Ironically Indulgent Decision. (Coauthors: B., Vallen, L., Block, & G., Fitzsimons). Association for Consumer Research Conference (2009).
- Pride: A License to Indulge or a Cue for Greater Self-Control? (Coauthors: T., Kramer & S. Sen). University of Queensland, Marketing Speaker Series (2009).
- Vicarious Goal Fulfillment: When the Presence of a Healthy Option Leads to an Ironically Indulgent Decision. (Coauthors: B., Vallen, L., Block, & G., Fitzsimons). La Londe Conference (2009).

- Vicarious Goal Fulfillment: When the Presence of a Healthy Option Leads to an Ironically Indulgent Decision. (Coauthors: B., Vallen, L., Block, & G., Fitzsimons). Marketing and Public Policy Conference (2009).
- Preference Fluency in Sequential Customization: The Unexpected Ease or Difficulty of Product Feature Decisions. (Coauthor: S., Song). Association for Consumer Research Conference (2008).
- Pride: A License to Indulge or a Cue for Greater Self-Control? (Coauthors: T., Kramer & S. Sen). University of Illinois Urbana Champaign, Marketing Speaker Series (2008).
- Pride: A License to Indulge or a Cue for Greater Self-Control? (Coauthors: T., Kramer & S. Sen). University of Southern California, Marketing Speaker Series (2008).
- Pride: A License to Indulge or a Cue for Greater Self-Control? (Coauthors: T., Kramer & S. Sen). Babson College, Marketing Speaker Series (2008).
- Pride: A License to Indulge or a Cue for Greater Self-Control? (Coauthors: T., Kramer & S. Sen). Lehigh University, Marketing Speaker Series (2008).
- Pride: A License to Indulge or a Cue for Greater Self-Control? (Coauthors: T., Kramer & S. Sen). Rutgers School of Business – Camden, Marketing Speaker Series (2008).
- If I Can Choose Vegetables, then I'll have Dessert: The Mere Presence of Healthy Food Items on Healthy versus Unhealthy Choice. (Coauthors: B., Vallen, L., Block, & G., Fitzsimons). Marketing and Public Policy Conference (2007).
- The Importance of Being Hedonic: Consumer Responsiveness to Promotions for Hedonic and Utilitarian Products. (Coauthor: K., Bawa). Society for Consumer Psychology Conference (2007).
- What's in a Logo: Exploring Motivations to Purchase Counterfeit Brands. (Coauthors: H., Kim & S. Sen). Association for Consumer Research Conference (2006).

Courses Taught

Spring 2025	Analyzing Consumer Behavior, Mays Business School
Spring 2025	Seminar in Consumer Behavior, Mays Business School
Fall 2024	Consumer Behavior, Mays Business School
Fall 2024	Analyzing Consumer Behavior, Mays Business School
Fall 2023	Consumer Behavior, Mays Business School
Fall 2023	Analyzing Consumer Behavior, Mays Business School
Spring 2023	PhD Seminar on Consumer Behavior, Mays Business School
Spring 2023	Consumer Behavior, Mays Business School
Spring 2022	Seminar in Consumer Behavior, Mays Business School
Spring 2021	MBA Core Marketing, Columbia Business School
Fall 2020	MBA Core Marketing, Columbia Business School
Spring 2020	NYC Immersion Seminar: Luxury Brands, Columbia Business School
Fall 2019	MBA Core Marketing, Columbia Business School
Summer 2019	NYC Immersion Seminar: Luxury Brands, Columbia Business School
Fall 2018	MBA Core Marketing, Columbia Business School
Spring 2018	NYC Immersion Seminar: Luxury Brands, Columbia Business School
Fall 2017	MBA Core Marketing, Columbia Business School
Spring 2017	NYC Immersion Seminar: Luxury Brands, Columbia Business School
Fall 2016	MBA Core Marketing, Columbia Business School
Spring 2016	NYC Immersion Seminar: Luxury Brands, Columbia Business School
Fall 2015	MBA Core Marketing, Columbia Business School
Spring 2015	NYC Immersion Seminar: Luxury Brands, Columbia Business School

Fall 2014	MBA Core Marketing, Columbia Business School
Spring 2014	NYC Immersion Seminar: Luxury Brands, Columbia Business School
Fall 2013	EMBA Core Marketing, Columbia Business School
Fall 2013	Marketing Management, Columbia College
Summer 2013	EMBA Core Marketing, Columbia Business School
Fall 2012	EMBA Core Marketing, Columbia Business School
Spring 2011	MBA Core Marketing, Babson College
Spring 2011	MBA Consumer Behavior, Babson College
Fall 2011	Undergraduate Consumer Behavior, Babson College
Spring 2010	MBA Consumer Behavior, Babson College
Fall 2010	Undergraduate Consumer Behavior, Babson College
Spring 2009	MBA Consumer Behavior, Babson College
Fall 2009	Undergraduate Consumer Behavior, Babson College
Spring 2008	Undergraduate Marketing Management, Baruch College

Doctoral Dissertation Service

- Amin Shiri, doctoral student, Texas A&M, (Dissertation Chair)
- Gabriel Ward, doctoral student, Texas A&M, (Dissertation Co-Chair)
- Charlene Chen, Assistant Professor, Nanyang Business School (Dissertation Committee)
- Travis Tae Oh, Assistant Professor, Yeshiva University (Dissertation Committee)
- Youjung Jun, Assistant Professor, Yonsei School of Business (Dissertation Committee)

Service

- Association for Consumer Research Conference 2023 Co-Chair
- Society of Consumer Psychology Conference 2021 Outreach and Fundraising Co-Chair
- Society of Consumer Psychology Conference 2020 Associate Editor
- Society of Consumer Psychology Boutique Conference 2019 Co-Chair
- AMA Winter Academic Conference 2018 Associate Editor
- Society of Consumer Psychology Boutique Conference 2017 Co-Chair
- APA Conference 2012 (Division 23) Co-Chair
- Society of Consumer Psychology Conference, Ad Hoc Reviewer & Program Committee
- Association for Consumer Research Conference, Ad Hoc Reviewer & Program Committee
- MSI Clayton Dissertation Proposal Competition, Ad Hoc Reviewer
- Valuing Diversity Dissertation Scholarship, Ad Hoc Reviewer

Professional Experience

- Associate, Alvarez & Marsal
- Consultant, Seedco
- Advertising Account Executive, CMG Communications
- Advertising Account Executive, Mezzina/Brown

Expert Testimony in the Last 4 Years

William R. Klopfenstein, et al. v. Fifth Third Bank, United States District Court Southern District of Ohio Western Division. Case No. 1:12-CV-00851. Testified in deposition on the effects of Defendant's alleged wrongful acts on Plaintiffs' consumer behavior, August 2022.

BLST Northstar, LLC and BLST Receivables & Servicing, LLC. v. Santander Consumer USA, Inc., United States District Court of Minnesota. Case No. 22-cv-02210-WMW-DJF. Testified in deposition on the effects of Defendant's alleged wrongful acts on the behavior of Plaintiffs' consumers, July 2024.

Anthony Ramirez, Mynor Villatoro Aldana and Janet Hobson v. Bank of America, N.A., United States District Court for the Northern District of California. Case No. 4:22-cv-00859-YGR. Testified in deposition on the effects of Defendant's alleged wrongful acts on Plaintiffs' consumer behavior, February 2025.

Brendan C. Haney v. Costa Del Mar, Inc., Circuit Court, Fourth Judicial Circuit, in and for Duval County, Florida. Case No. 4 16-2017-CA-004794-XXXX-MA DIVISION: CV-E. Testified in deposition on the effects of Defendant's alleged wrongful acts on Plaintiffs' consumer behavior, May 2025.

Donrick Sanderson, et al. v. Whoop, Inc., United States District Court Northern District of California. Case No. 3:23-CV-05477. Testified in deposition on the effects of Defendant's alleged wrongful acts on Plaintiffs' expected consumer behavior, October 2025.

Travelers United, Inc. v. Hyatt Hotels Corporation et al. Superior Court of the District of Columbia Civil Division. Case No. 2023-CAB-005095. Testified in deposition on the effects of Defendant's alleged wrongful acts on Plaintiffs' consumer behavior, January 2026.

Travelers United, Inc. v. Sonesta International Hotels Corporation Superior Court of the District of Columbia Civil Division. Case No. 2023-CAB-005254. Testified in deposition on the effects of Defendant's alleged wrongful acts on Plaintiffs' consumer behavior, March 2026.

APPENDIX B

MATERIALS RELIED UPON

MATERIALS RELIED UPON

Legal Documents

Rebuttal Testimony of Dr. Stephen Korzeniowski on Behalf of the American Chemistry Council (“ACC”), in the Matter of Proposed Adoption of 20.13.2 NMAC, No. EIB 25-61 (R), February 16, 2026.

Academic Articles and Books

- Adasme-Berrios, C., et al., “Effect of Warning Labels on Consumer Motivation and Intention to Avoid Consuming Processed Foods,” *Nutrients*, 2022, pp. 1-16.
- Argo, J. and K. Main, “Meta-Analyses of the Effectiveness of Warning Labels,” *Journal of Public Policy & Marketing*, 2004, pp. 193-208.
- Baig, S., et al., “‘Organic,’ ‘Natural,’ and ‘Additive-Free’ Cigarettes: Comparing the Effects of Advertising Claims and Disclaimers on Perceptions of Harm,” *Nicotine & Tobacco Research*, 2019, pp. 933-939.
- Berthold, T., et al., “Let’s Talk About PFAS: Inconsistent Public Awareness About PFAS and its Sources in the United States,” *PLOS ONE*, 2023, pp. 1-20.
- Boelhouwer, E., et al., “Comprehension of Hazard Communication: Effects of Pictograms on Safety Data Sheets and Labels,” *Journal of Safety Research*, 2013, pp. 145-155.
- Buchmüller, K., et al., “The Influence of Packaging on Consumers’ Risk Perception of Chemical Household Products,” *Applied Ergonomics*, 2022, pp. 1-7.
- De Houwer, J., et al., “Association Learning of Likes and Dislikes: A Review of 25 Years of Research on Human Evaluative Conditioning,” *Psychological Bulletin*, 2001, pp. 853-869.
- Drury, L., et al., “YOU HAVE BEEN WARNED: The Effect of California’s Proposition 65 Warning on Consumer Perceptions and Evaluations,” *Journal of Consumer Affairs*, 2025, pp. 1-21.
- Ellsberg, D., “Risk, Ambiguity, and the Savage Axioms,” *The Quarterly Journal of Economics*, 1961, pp. 643-669.
- Eng, L., et al., “Influence of Interpretation Aids on Attentional Capture, Visual Processing, and Understanding of Front-of-Package Nutrition Labels,” *Journal of Nutrition Education and Behavior*, 2015, pp. 292-299.
- Gagliardi, L., “Naturalness Seeking Minds: the Cognitive Foundations of Naturalness Bias in Consumer Food Choice,” *Food and Humanity*, 2025, pp. 1-12.
- Griffith, L.J. and S.D. Leonard, “Association of Colors With Warning Signal Words,” *International Journal of Industrial Ergonomics*, 1997, pp. 317-325.
- Huang, L. and J. Lu, “The Impact of Package Color and the Nutrition Content Labels on the Perception of Food Healthiness and Purchase Intention,” *Journal of Food Products Marketing*, 2016, pp. 191-218.

- Hutchins, R., et al., “Efficacy and Threat Language in PFAS Messaging,” *Risk Analysis*, 2026, pp. 1-12.
- Kahneman, D., “Maps of Bounded Rationality: Psychology for Behavioral Economics,” *American Economic Review*, 2003, pp. 1449-1475.
- Kahneman, D., *Thinking, Fast and Slow*, Farrar, Straus and Giroux, 2011.
- Kotler, P. and K.L. Keller, *Marketing Management*, 15th Edition, Pearson, 2016.
- Labiner-Wolfe, J., et al., “Effect of Low-Carbohydrate Claims on Consumer Perceptions About Food Products’ Healthfulness and Helpfulness for Weight Management,” *Journal of Nutrition Education and Behavior*, 2010, pp. 315-320.
- Laros, F. and J. Steenkamp, “Importance of Fear in the Case of Genetically Modified Food,” *Psychology & Marketing*, 2004, pp. 889-908.
- Laughery, K. and M. Wogalter, “A Three-Stage Model Summarizes Product Warning and Environmental Sign Research,” *Safety Science*, 2014, pp. 3-10.
- Levey, A. and I. Martin, “Classical Conditioning of Human ‘Evaluative’ Responses,” *Behaviour Research and Therapy*, 1975, pp. 221-226.
- McCluskey, J. and M. Loureiro, “Consumer Preferences and Willingness to Pay for Food Labeling: A Discussion of Empirical Studies,” *Journal of Food Distribution Research*, 2003, pp. 95-102.
- Meier, B., et al., “Naturally Better? A Review of the Natural-is-Better Bias,” *Social and Personality Psychology Compass*, 2019, pp. 1-21.
- Migliore, G., et al., “Consumers’ Willingness to Pay for Natural Food: Evidence From an Artefactual Field Experiment,” *Agricultural and Food Economics*, 2018, pp. 1-10.
- Mitchell, V. and V. Papavassiliou, “Marketing Causes and Implications of Consumer Confusion,” *Journal of Product & Brand Management*, 1999, pp. 319-339.
- Moreira da Silva, A., and M. Barroca, “Addressing Chemophobia: Bridging Misconceptions in Food Chemistry,” *Applied Sciences*, 2025, pp. 1-24.
- Motoki, K. and T. Saito, “Thinking Fast, Not Slow: Intuitive Nutrition Labels Increase Healthier Food Preferences Under Time Pressure,” *British Food Journal*, 2024, pp. 2956-2969.
- Mussweiler, T., “The Durability of Anchoring Effects,” *European Journal of Social Psychology*, 2001, pp. 431-442.
- Muthukrishnan, A., et al., “Ambiguity Aversion and the Preference for Established Brands,” *Management Science*, 2009, pp. 1933-1941.
- Nisbett, R. and T. Wilson, “The Halo Effect: Evidence for Unconscious Alteration of Judgments,” *Journal of Personality and Social Psychology*, 1977, pp. 250-256.
- Pavlov, I., “Conditioned Reflexes: An Investigation of the Physiological Activity of the Cerebral Cortex,” *Annals of Neurosciences*, 2010, pp. 136-141.
- Peters, E., “Affect and Emotion,” *Communicating Risks and Benefits: An Evidence-Based User’s Guide*, U.S. Food and Drug Administration, 2011, pp. 89-97.

- Pomerantz, E., et al., “Attitude Strength and Resistance Processes,” *Journal of Personality and Social Psychology*, 1995, pp. 408-419, at pp. 409-410.
- Purmehdi, M., et al., “The Effectiveness of Warning Labels for Consumers: A Meta-Analytic Investigation into Their Underlying Process and Contingencies,” *Journal of Public Policy & Marketing*, 2017, pp. 36-53.
- Rihn, A., et al., “Influence of Scientific Communications on the Acceptance of PFAS Alternatives on Disposable Dinnerware and Take-out Containers, by Information Source,” *Journal of Agriculture and Food Research*, 2026, pp. 1-10.
- Salvendy, G., *Handbook of Human Factors and Ergonomics*, 4th Edition, John Wiley & Sons, 2012.
- Schuldt, J., “Does Green Mean Healthy? Nutrition Label Color Affects Perceptions of Healthfulness,” *Health Communication*, 2013, pp. 814-821.
- Schummer, J., et al., *The Public Image of Chemistry*, World Scientific Publishing, 2007.
- Simon, H., “Rational Choice and the Structure of the Environment,” *Psychological Review*, 1956, pp. 129-138.
- Slovic, P., et al., “The Affect Heuristic,” *European Journal of Operational Research*, 2007, pp. 1333-1352.
- Tversky, A. and D. Kahneman, “Judgment Under Uncertainty: Heuristics and Biases,” *Science*, 1974, pp. 1124-1131.
- Underwood, R. and N. Klein, “Packaging as Brand Communication: Effects of Product Pictures on Consumer Responses to the Package and Brand,” *Journal of Marketing Theory and Practice*, 2002, pp. 58-68.
- Walsh, G., et al., “Consumer Confusion Proneness: Scale Development, Validation, and Application,” *Journal of Marketing Management*, 2010, pp. 697-721.
- Wogalter, M., et al., “Research-Based Guidelines for Warning Design and Evaluation,” *Applied Ergonomics*, 2002, pp. 219-230.
- Yang, S., et al., “No Control, No Consumption: Association of Low Perceived Control and Intention to Accept Genetically Modified Food,” *International Journal of Environmental Research and Public Health*, 2022, pp. 1-13.

Publicly Available Documents

- “Evidence-Based Recommendations for the Placement and Design of Warning Labels on E-commerce Sites,” *Consumer Product Safety Commission and Fors Marsh Group*, available at <https://www.cpsc.gov/s3fs-public/The-Placement-and-Design-of-Warning-Labels-on-E-commerce-Sites.pdf>.
- “Food, Genetically Modified,” *World Health Organization*, available at <https://www.who.int/news-room/questions-and-answers/item/food-genetically-modified>, accessed on June 22, 2026.
- “GMOs and Your Health,” *Food and Drug Administration*, available at <https://www.fda.gov/media/135280/download>.

- Lim, K. and E. Page, “Consumers’ Interpretation of Food Labels with Production Claims Can Influence Purchases,” *USDA Economic Research Service*, March 7, 2022, available at <https://www.ers.usda.gov/amber-waves/2022/march/consumers-interpretation-of-food-labels-with-production-claims-can-influence-purchases>.
- “Made Without PFAS,” *Patagonia*, available at <https://www.patagonia.com/our-footprint/pfas.html>, accessed on June 22, 2026.
- “Naming Conventions for Per- and Polyfluoroalkyl Substances (PFAS),” *Interstate Technology Regulatory Council*, September 2023, available at https://pfas-1.itrcweb.org/wp-content/uploads/2023/10/NamingConventions_PFAS_Fact-Sheet_Sept2023_final.pdf.
- “New Study Finds Forever Chemicals in Rain Jackets,” *Chem Trust*, May 22, 2025, available at <https://chemtrust.org/news/forever-chemicals-rain-jackets/>.
- “Our Current Understanding of the Human Health and Environmental Risks of PFAS,” *U.S. Environmental Protection Agency*, available at <https://www.epa.gov/pfas/our-current-understanding-human-health-and-environmental-risks-pfas>, accessed on June 22, 2026.
- “Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS),” *National Institute of Environmental Health Sciences*, March 6, 2026, available at <https://www.niehs.nih.gov/health/topics/agents/pfc>.
- “PFAS in Cosmetics,” *Green Science Policy Institute*, available at <https://greensciencepolicy.org/pfas-in-cosmetics/>, accessed on June 22, 2026.
- “PFAS Protection Act (HB212),” *New Mexico Environment Department*, available at <https://www.env.nm.gov/pfas/pfas-protection-act-hb212/>, accessed on June 22, 2026.
- Prohibitions on Products Containing Per- or Poly-Fluoroalkyl Substances; Currently Unavoidable Use; Reporting; Labeling; Testing; Fees and Penalties, *New Mexico Environmental Improvement Board*, 20.13.2 NMAC (2026).
- “The Future of US Food Labeling,” *NSF*, September 25, 2025, available at <https://www.nsf.org/knowledge-library/white-paper-us-food-labeling>.
- “Yale Experts Explain PFAS ‘Forever Chemicals’,” *Yale Sustainability*, May 20, 2025, available at <https://sustainability.yale.edu/explainers/yale-experts-explain-pfas-forever-chemicals>.

**THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF PANKAJ BHALLA

I, Pankaj Bhalla, declare as follows:

1. I am currently employed as Senior Vice President of Grooming and Chief Executive Officer, North America of The Gillette Company LLC (“Gillette”), a subsidiary of The Procter & Gamble Company (“P&G”), for North America.

2. I joined Gillette in early 2000s. I joined P&G in 2005, when P&G acquired Gillette as a wholly-owned subsidiary. From July 2012 through May 2016, I was Senior Marketing Director for P&G’s Global Oral Care division. From June 2016 through January 2017, I was Vice

President for P&G's Global Oral Care division. I became Vice President of P&G's North America Gillette and Venus brands in January 2017; Senior Vice President and General Manager of P&G's Europe Shave Care division in July 2019; and Senior Vice President and General Manager of Grooming for Europe in July 2020. I have held my current position since July 2025.

3. My responsibilities include overseeing the strategic direction, operations, and financial performance of Gillette in North America. In this role, I lead product innovation, marketing, manufacturing, and commercial initiatives, and I am responsible for driving growth, ensuring product quality and safety, and advancing the company's long-term business objectives for products in the Grooming category. I have over 24 years of experience in product development, manufacturing and production, distribution systems, and marketing and sales. Based on my role and day-to-day responsibilities, I am familiar with Gillette's product development, manufacturing and production, distribution systems, and marketing and sales.

4. I have reviewed and am familiar with New Mexico's Per- and Poly-Fluoroalkyl Substances Protection Act, consisting of sections 74-15-1 through 74-15-7 of the New Mexico Statutes and its implementing regulation, N.M. Admin. Code § 20.13.2 (the "Regulation").

5. I understand that P&G is a member of American Chemistry Council and National Association of Manufacturers, which are plaintiffs in this lawsuit challenging the Regulation.

6. I submit this declaration in support of plaintiffs' motion for preliminary injunction in this lawsuit.

I. Gillette Is A Global Shaving Goods Company.

7. Gillette is a wholly owned subsidiary of P&G and is organized under the laws of the State of Delaware, with a principal place of business in Boston, Massachusetts. Gillette has over 1,400 full-time employees in the United States.

8. Gillette was founded in 1901 and, for more than a century, has been one of the world's leading manufacturers and distributors of grooming products. Over the course of approximately 125 years in the marketplace, Gillette razor and blade products have become associated with high quality, safety, comfort and performance.

9. Gillette's products are used throughout the world, with sales in all 50 states and more than 170 countries and territories. Consumers choose Gillette—and often use its products daily for years or even decades—because they trust its safe and effective performance.

10. Like all P&G brands, Gillette follows a consumer-first approach. All of our choices are focused on delivering superiority to consumers in product performance, product packaging, brand communication, retail execution, and value.

11. Consumer safety is our highest priority. A dedicated team of more than 500 scientists and professionals ensure that all of P&G's products, including Gillette's, are held to the highest standards of safety using advanced, globally-recognized methods.

II. The Regulation's Labeling Mandate Would Result In Consumer Confusion.

12. Like all P&G brands, Gillette is committed to ensuring that consumers receive truthful, accurate, and non-misleading information about its products. The company invests substantial resources in product testing, packaging review, and advertising compliance to ensure that its claims about product performance, safety, and benefits are clear and accurate. This goes beyond a commitment to compliance with laws; it is a hallmark of our steadfast focus on putting the consumer first, which begins with clear, accurate and dependable product communications.

13. The warning label at issue in this case falsely conveys safety concerns about blades and razors, harming both consumers and Gillette. That is why Gillette supports this lawsuit. It is not just a question of the cost to Gillette of complying with the labeling mandate, although that cost is substantial, as discussed below. More importantly to Gillette, the warning label would

result in unnecessary consumer confusion and even deception.

14. A brand's performance over years and decades is built on consumer trust and, when that trust erodes, so too does the brand's performance. Gillette's blades and razors have long been proven and trusted as safe for consumer use. Consumers rely on these affordable everyday products for grooming, hygiene and confidence. Requiring Gillette to affix a misleading and alarming warning label to these products would lead to loss of trust and even fear among consumers, alienating them from products they need and a brand they have trusted for years. Gillette would also face clear logistical hurdles in complying with this regulation (e.g., responding to consumer inquiries, developing educational materials, training customer-service personnel, and otherwise explaining that the products are safe for use regardless of the confusing and deceptive warning label—especially for U.S. consumers not located in New Mexico).

III. Razor Blades Contain Microscopic Amounts of PTFE.

15. Like all leading manufacturers of modern razor blades, Gillette uses a microscopic amount of Polytetrafluoroethylene ("PTFE") in certain of its products.

16. PTFE is exempt from New Mexico's product ban, which we understand is an acknowledgement that PTFE does not present the risks that the state intends to target with the ban. However, PTFE is not exempt from the Regulation's labeling mandate.

17. PTFE is applied to blades as a microscopic coating—less than one-thousandth the edge of a sheet of paper—to reduce friction for better performance, skin comfort, and safety.

18. This use of PTFE on razor blades has been an industry standard for decades, with no comparable alternative.

19. PTFE allows the blade to cut cleanly through hair rather than sticking to the hair. Without the addition of PTFE, a blade would work only one or two times before the blade deteriorated and became too uncomfortable to use, resulting in consumers needing to buy more

blades, more often. Blades without PTFE risk pulling hairs out of the skin, rather than cutting cleanly through hairs, which would lead to consumers experiencing significant irritation, nicks, and cuts.

20. The amount of PTFE used in one razor blade is so small it would take the amount of PTFE in four million razor blade edges to equal the amount of PTFE used in just one coated, non-stick pan—which is itself only a microscopic coating.


21. Health and safety are Gillette’s top priorities in designing and manufacturing products. Gillette uses state-of-the-art manufacturing controls and has a long history of environmental protection and compliance globally. Gillette complies with all relevant laws regarding the use of PFAS during manufacturing, and Gillette’s environmental controls have been approved by regulators across all relevant jurisdictions.

IV. Labeling Razor And Blade Products With The Required Warning Would Be Exceptionally Burdensome.

22. Gillette uses complex, highly automated manufacturing processes.

23. Razor and blade products are small, intricately manufactured products with limited space available for labeling.

24. The Regulation suggests that both the product and the product packaging are required to bear the required warning label, consisting of an Erlenmeyer flask labeled “PFAS” in legible typeface:



25. Gillette understands that in order to comply with the Regulation, it must place the required label somewhere on the blade itself or surrounding components. It would be very difficult and costly to do so, costing many millions of dollars and requiring many months to redesign global manufacturing processes.

26. The various components of a modern razor blade cartridge are made using a mold press machine, which is a large machine containing multiple mold cavities. Changing these molds is an exceptionally costly, time-consuming, and delicate process, even for a large corporation—and generally takes at least six to nine months.

27. Due to the lengthy period needed to replace the molds, Gillette anticipates it would not have sufficient time to change its manufacturing processes to comply with the Regulation's January 1, 2027 deadline. Gillette therefore likely will need to proceed with a temporary solution of some sort, which would be costly, complex and potentially generate supply chain disruptions that impact the American consumer.

V. Labeling Product Packaging With The Required Warning Would Be Exceptionally Burdensome.

28. In addition to the product warning label, we understand that the Regulation suggests manufacturers would be required to include the warning label on the *packaging* for razor blade products, too.


29. The process of redesigning product packaging to comply with the Regulation's requirement of an Erlenmeyer flask stamped with "PFAS" in font "no smaller than the font used for other consumer information on the product" would be costly and time-consuming.

30. All told, it would cost Gillette an estimated \$11 million to \$14 million in direct costs *only*, which includes redesigning the manufacturing processes for products and product packaging, to accommodate the required warning label. That estimate does not account for the

significant additional cost of allaying consumer confusion (discussed above) and costs related to carving out a new supply chain for the United States (discussed below). In total, the combined costs—for a label change that does not meet any brand or consumer demand—could be well into the tens of millions.

VI. The Regulation’s Reach Is Overbroad And Would Impact Gillette’s Global Supply Chain For All Razor And Blade Products.

31. The Regulation’s warning-label mandate would affect not only products intended for distribution within New Mexico, but Gillette’s entire global supply chain. Gillette would be required to create separate product streams for the United States, because Gillette cannot risk the confusion that would result if Gillette suddenly began printing the Erlenmeyer flask label, pictured below, on products distributed around the world.



32. But creating a separate supply chain for the United States alone would impose significant additional costs, well above the direct cost estimate above.

33. Even within the U.S., Gillette cannot create a separate product stream for New Mexico alone. For one, Gillette operates a large and complex distribution network and cannot control where within a particular country its retail customers will distribute its products. Gillette’s products are sold through numerous and diverse channels, including but not limited to mass merchandisers, e-commerce channels, grocery stores, membership club stores, drug stores, department stores, distributors and wholesalers. Many of these retail customers operate on a

global, national, or regional scale and do not themselves have the ability to direct products to a single state.

VII. Gillette Does Not Support Regulations That Require False, Misleading Labeling.

34. In summary, like all P&G brands, Gillette supports safe, science-based regulation and complies with a broad swath of laws and regulations involving its products, including laws related to PFAS. But Gillette cannot support misleading laws like the Regulation.


35. Gillette has spent over a century building a reputation for producing high-quality products that meet consumers' daily needs—smooth, safe shaves without nicks or cuts—and for providing consumers with accurate information about those products.

36. Yet the required Erlenmeyer flask label necessarily communicates risk or danger. And the Regulation would require Gillette to affix that provocative label to *all* razor blade products—and their packaging—despite the fact that they only use PTFE, and only microscopic amounts. The Regulation would therefore require Gillette to spend potentially tens of millions of dollars to produce and distribute labels falsely communicating that PTFE is dangerous to human health and the environment.

37. Gillette does not agree with that message. It objects to being compelled to incur a substantial expense to falsely communicate to consumers that its blade and razor products—which have been safely and effectively used in this country for over a century—present a consumer hazard.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 07/01/, 2026.


Pankaj Bhalla
Senior Vice President of Grooming
and CEO of Gillette North America
at P&G

THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMATIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAUL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF JASON ESPINOZA

I, Jason Espinoza, declare as follows:

1. I currently serve as the New Mexico State Director for the National Federation of Independent Business, Inc. ("NFIB"), one of the plaintiffs in this action.
2. NFIB is the nation's leading small business association, representing hundreds of thousands of members across the United States. NFIB's mission is to promote and protect the right of its members to own, operate, and grow their businesses. NFIB represents, in Washington, D.C., and all 50 state capitals, the interests of its members.

3. NFIB represents almost 300,000 members nationwide, including non-New Mexico members who ship goods to New Mexico and sell goods within the State. In New Mexico specifically, NFIB represents over 1,000 members. These members span the spectrum of small and independent businesses—from sole proprietorships to firms with dozens or hundreds of employees—across all industries and sectors of the economy. The average NFIB member has between 8–10 employees.

4. As NFIB's State Director for New Mexico, I am extremely familiar with New Mexico's Per- and Poly-Fluoroalkyl Substances Protection Act, consisting of sections 74-15-1 through 74-15-7 of the New Mexico Statutes ("Act") and its implementing regulation, 20.13.2 NMAC (the "PFAS Regulation").

5. On October 21, 2025, NFIB submitted a comment letter to the Environmental Improvement Board ("Board") urging the Board to deny the New Mexico Environment Department's ("Department") petition for regulatory change and reject the Department's proposed rule in order "to prevent serious costs and harms to small businesses."

6. NFIB has spoken to multiple members located in New Mexico that will be negatively impacted by the Act and the PFAS Regulation.

7. These members own businesses where everyday operation depends on the use of products containing PFAS, or they make products for consumers that contain PFAS.

8. For example, the members spoken to use materials such as cutting fluids, coolants, lacquers, paints, stains, silicones, and sealers, all of which can include PFAS. Without use of these materials, these members would be forced to spend time and money to find alternative PFAS-free materials or expend resources to create the same product without using these materials.

9. Some of the members spoken to sell products that contain PFAS, either for resale or because a PFAS containing substance is one component of the end-product they manufacture. These members will be responsible for ensuring that the products abide by the PFAS Regulation's labeling requirement of an Erlenmeyer flask labeled "PFAS" in legible typeface.

10. No state, besides New Mexico, requires companies to include a pictogram warning on its products—including other states that regulate PFAS.

11. Adding the PFAS Regulation's required warning to the products of NFIB members would require significant expense, as well as considerable time to design and affix the required warning label.

12. As previously indicated in its comment letter and advocacy, NFIB does not support misleading regulations like the PFAS Regulation.


13. The required Erlenmeyer flask label necessarily communicates risk or danger. And the PFAS Regulation would require some of NFIB's members to affix that evocative label to *all* products—and their packaging—that use *any* amount of *any* type of intentionally added PFAS. It would thus require these members to produce labels falsely communicating that all PFAS are dangerous to human health and the environment.

14. NFIB's members do not support government mandates requiring them to communicate messages on their products for which the business does not agree and does not support. The compelled speech that all PFAS are harmful, by way of the Erlenmeyer flask, is one such message.

15. I submit this declaration in support of plaintiffs' motion for preliminary injunction in the above-captioned case challenging the PFAS Regulation.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on the 29th day of June, 2026.



Jason Espinoza

New Mexico State Director
National Federation of Independent
Business, Inc.

**THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE.

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF JEREMY YON

I, Jeremy Yon, declare as follows:

1. I am currently employed as Director, Compliance & Industry Relations for Current Lighting HoldCo, Inc d.b.a. Current Lighting.
2. I joined Current Lighting's preceding parent company, General Electric, on 04/01/2019. My present responsibilities include leading the identification of applicable regulations and facilitating compliance by partnering with internal product teams. I have over 25 years of experience in the lighting industry, with roles ranging from specifying products, product

development, system engineering, and industry/government relations. Based on my role and day-to-day responsibilities, I am familiar with relevant aspects of Current Lighting's product development, manufacturing and production, distribution systems, and marketing.

3. I have reviewed and am familiar with New Mexico's Per- and Poly-Fluoroalkyl Substances Protection Act, consisting of sections 74-15-1 through 74-15-7 of the New Mexico Statutes and its implementing regulation, 20.13.2 NMAC (the "PFAS Regulation").

4. I understand that Current Lighting is a member of plaintiff National Electrical Manufacturers Association (NEMA).

5. I submit this declaration in support of plaintiffs' motion for preliminary injunction in the above-captioned case challenging the PFAS Regulation.

I. Current Lighting Is a National Commercial, Industrial, and Institutional Goods Company.

6. Current Lighting is organized under the laws of the State of Delaware, with a principal place of business in Mayfield Heights, OH.

7. Current Lighting is a national leader in the lighting industry, focused on commercial, institutional, and industrial lighting and lighting controls.

8. Current Lighting manufactures, markets, and distributes traditional and LED lamps, LED luminaires for interior and exterior applications, and lighting controls for interior and exterior applications.

II. Current Lighting Manufactures Lighting Products that incorporate components with PFAS.

9. Some of Current Lighting's products incorporate components that use PFAS to satisfy specific safety and/or performance requirements, including PTFE, FEP, 1-Propene+, Alkyl Vinyl Ether, and PPBS.

10. In particular, components incorporating these chemicals provide: protection from shattering glass (e.g. food service areas), adequate high-temperature ratings with specific electrical products (e.g. molded plastic parts that conceal power components), long-life protection of wires and electrical components that require high-temperature ratings for the safety certification, and in support of high-reflectance surfaces for maximum optical/energy efficiency

III. Labeling Packaging and/or Documentation for Products with the Required Warning Would Be Burdensome.

11. I understand that the PFAS Regulation requires a warning label on packaging and/or documentation.

12. Current Lighting dedicates significant time and money to designing the overall look of products and their packaging and documentation. Due to the complex nature of lighting and controls products, there is extensive amount of information that must be communicated clearly and succinctly

13. The process of redesigning product packaging and/or documentation to comply with the PFAS Regulation would be costly and time-consuming.

14. Only specific products within Current Lighting's expansive product offering include components that utilize PFAS, often existing as a sub-component of a procured component, making accurate identification time consuming and burdensome.

15. Furthermore, the ability to identify the use from casual observation is nearly impossible, making enforcement complicated and almost impractical for NM regulators.

IV. These Problems Affect All Products Distributed within the United States.

16. The scope of the PFAS Regulation's warning-label requirement would affect not only products intended for distribution within New Mexico, but products intended for distribution within *all* states.

17. Current Lighting operates a large and complex distribution network, with multiple models of distribution and intermediaries. Current Lighting's products are sold primarily through distributors and direct to customers who have locations throughout the country.

18. Current Lighting cannot create separate product streams for products intended for installation within New Mexico because it is not feasible from a distribution perspective. Current Lighting does not control where within the United States its customers distribute or install Current Lighting's products. For example, if Current Lighting sold 1,000 units of an LED lamp to an independent distributor, that distribution company would independently choose whether, and how many, units to send to customers in New Mexico. Current Lighting is not involved in that distribution process.

19. Even if Current Lighting could overcome this distribution hurdle, it would be prohibitively expensive and burdensome for Current Lighting to design, create, and maintain an entirely separate stream of products exclusively for New Mexico. Thus, when states have unique labeling and/or documentation requirements for products, Current Lighting must redesign the entire, nationwide product line.

V. Current Lighting Does Not Support Regulations that Require Potentially Misleading Labeling.

20. Current Lighting supports safe, science-based regulation. But Current Lighting cannot support misleading regulations like the blanket making of this PFAS Regulation.

21. The required Erlenmeyer flask label necessarily communicates risk or danger. And the PFAS Regulation would require Current Lighting to mark that evocative symbol to *all* product packaging and/or documentation—that use *any* amount of *any* type of intentionally added PFAS. It would thus require Current Lighting to substantiate that the specific PFAS in the specific

applications are more dangerous to human health and the environment than the safety, energy, lifetime, or other purpose that led to their inclusion.

22. Current Lighting does not agree with that message. It objects to being compelled to communicate the message that all PFAS are always detrimental, given the present complex balance of product requirements.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on June 22, 2026.

A handwritten signature in black ink, appearing to read 'J. Yon', is written above a horizontal line.

Jeremy Yon

Director, Compliance & Industry
Relations - Current Lighting

**THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF MIGUEL HALL

I, Miguel Hall, declare as follows:

1. I am currently employed as Senior Manager, Product Development, R&D by Sunbeam Products, Inc., which produces Calphalon brand home kitchen products (“Calphalon” or the “Company”).

2. I joined the Company in 2016. My responsibilities include product lifecycle management, test lab management, and new product development leadership. I have over 20 years of experience in new product development and manufacturing. Based on my role and day-to-day

responsibilities, I am familiar with Calphalon's product development, manufacturing and production, distribution systems, and marketing.

3. I have reviewed and am familiar with New Mexico's Per- and Poly-Fluoroalkyl Substances Protection Act, consisting of sections 74-15-1 through 74-15-7 of the New Mexico Statutes and its implementing regulation, 20.13.2 NMAC (the "PFAS Regulation").

4. I understand that the Company's ultimate parent company is a member of plaintiff Association of Home Appliance Manufacturers.

5. I submit this declaration in support of plaintiffs' motion for preliminary injunction in the above-captioned case challenging the PFAS Regulation.

I. Calphalon Is a Leading Cookware Brand.

6. Calphalon is a brand of Sunbeam Products, Inc., which is organized under the laws of the State of Delaware, with a principal place of business in Atlanta, Georgia.

7. Calphalon is an industry leader in cookware, known for its high-quality pots, pans, and kitchen products.

8. Calphalon produces, designs, markets, distributes, and sells a wide range of cookware products, including nonstick pans.

II. Certain Calphalon Products Contain PTFE for Nonstick Performance.

9. Of the chemicals in the PFAS family, Calphalon uses only polytetrafluoroethylene ("PTFE").

10. In the Calphalon cookware products that contain PTFE, the PTFE is used exclusively for nonstick purposes. PTFE provides a durable, low-friction cooking surface that allows food to release easily and facilitates cleaning. The U.S. Food and Drug Administration ("FDA") has cleared PTFE for use as a food-contact substance.

III. Calphalon Is Committed to Transparency Regarding PTFE.

11. Calphalon is committed to transparency regarding the materials used in its products.

12. Packaging for Calphalon cookware made with PTFE includes a statement that the product contains PTFE. The packaging also provides a URL and QR code directing consumers to the Calphalon website, which includes the same disclosure.

13. Calphalon includes a statement disclosing that the product contains PTFE on its own online product listings and provides this information to retailers for online listings.

IV. The On-Product Warning Requirement Would Create Substantial Implementation Challenges.

14. I understand that the PFAS Regulation requires products themselves to bear the required warning label, consisting of an Erlenmeyer flask labeled “PFAS” in legible typeface and that the font be no smaller than the largest font used for other consumer information.

15. This requirement to place a label on the cookware product itself—as opposed to packaging or other disclosures—presents unique challenges.

16. Cookware cooking surfaces are functional, must withstand high heat and liquids, and cannot bear typical adhesive labels. Because of these limitations, engraving is the only reasonable option. However, developing and implementing tooling for engraving during manufacture is expensive and time-consuming.

17. Calphalon already complies with California’s AB 1200, which requires disclosure of intentionally added PFAS in cookware on product packaging, on Calphalon’s website, and on retail websites. Calphalon’s product packaging provides the disclosures required under California law. No state other than New Mexico has required Calphalon to include a warning or even a disclosure on the cookware product itself.

18. New Mexico's requirement for a pictographic label on the cookware product itself—rather than on packaging—is uniquely burdensome for the reasons described above.

19. Because it is not commercially feasible to create a separate product line for New Mexico, adding the on-product labeling would affect all products nationwide. Calphalon must decide whether to alter its entire product line—including investing in the specialized tooling required for engraving—to comply with New Mexico's unique requirement or to exit the New Mexico market.

V. The Required Packaging Warning Would Require New Packaging and Would Not Account for FDA-Cleared PTFE Food-Contact Uses.

20. I understand that, in addition to requiring a warning label on products, the PFAS Regulation requires a warning label on packaging in some instances and that the PFAS Regulation would require Calphalon to include the warning label on the packaging for its cookware products.

21. Calphalon dedicates significant time and resources to designing the overall look of products and its packaging. Packaging is an important part of the consumer experience and purchasing decision.

22. The PFAS Regulation's labeling requirement does not distinguish between different substances within the PFAS family or account for the FDA's clearance of PTFE for food-contact use. As a result, Calphalon would be required to place a warning label on products that contain a substance the FDA has cleared for the very use at issue. Currently, product packaging for Calphalon products with PTFE includes a disclosure of PTFE rather than a warning.

VI. Calphalon Does Not Always Control the Ultimate Distribution of Its Products

23. Calphalon operates through a large and complex distribution network, with multiple models of distribution. Calphalon's cookware products are sold through mass merchandisers, its own and third-party e-commerce channels, and other retail channels.


24. Calphalon does not control where its retail customers ultimately distribute its cookware within the United States. Calphalon can control only its own direct distribution and sale of products to New Mexico.

25. It would be prohibitively expensive and burdensome for Calphalon to design, create, and maintain an entirely separate stream of nonstick cookware products exclusively for New Mexico. Even if Calphalon did take on this commercially unreasonable endeavor, unlabeled products sold by Calphalon to other states could be ultimately sold in New Mexico due to the nature of the distribution channels.

[Signature on following page]

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 6/24/2026, 2026.

DocuSigned by:

9B267E098C36457...
Miguel Hall
Senior Manager, Product
Development, R&D, Calphalon

**THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF LEE A. BOWERS

I, Lee A. Bowers, declare as follows:

1. I am currently employed as Vice President of Environmental, Health & Safety for RPM International Inc. (RPM International).

2. I have been serving as RPM International Vice President of Environmental, Health & Safety since December 1, 2021. My responsibilities include executive management and oversight of Environmental, Health & Safety (EH&S), including regulatory affairs and product stewardship functions. I have over 28 years of experience in EH&S and regulatory affairs management with escalating roles and responsibilities in multiple RPM subsidiaries. Based on my

role and day-to-day responsibilities, I am familiar with the product development, manufacturing and production, distribution systems, and marketing and sales functions of RPM International and its subsidiaries (collectively “RPM”).

3. I have reviewed and am familiar with New Mexico’s Per- and Poly-Fluoroalkyl Substances Protection Act, consisting of sections 74-15-1 through 74-15-7 of the New Mexico Statutes and its implementing regulation, 20.13.2 NMAC (the “PFAS Regulation”).

4. I understand that RPM International is a member of plaintiff American Coatings Association and plaintiff National Association of Manufacturers.

5. I submit this declaration in support of plaintiffs’ motion for preliminary injunction in the above-captioned case challenging the PFAS Regulation.

I. RPM is a Global Coatings and Construction Products Company.

6. RPM International is organized under the laws of the State of Delaware, with a principal place of business in Medina, Ohio. As of June 12, 2026, RPM employed approximately 9,876 people in the United States and 12 people in New Mexico.

7. RPM is a global leader in the high performance coatings and construction products industry, focused on easy to use and consumer products, specialized industrial/commercial coatings and construction products.

8. RPM formulates, manufactures, markets, and/or distributes a wide range of value added, high brand recognition coatings and construction products for the consumer, commercial and industrial markets.

II. RPM is Committed to Innovation, Safety, and Environmental Sustainability.

9. RPM is committed to operating responsibly within the markets within which we operate in compliance with all environmental, transportation and safety regulations while

developing new technologies that incorporate technical performance, environmental sustainability and regulatory compliance in the design of our products and packaging.

III. RPM Manufactures high performance consumer and industrial coatings with PFAS.

10. RPM uses a type of PFAS called PCBTF (or Oxsol 100) in its products.

11. In particular, PCBTF is widely used by RPM and the general coatings industry as a high performing, VOC exempt solvent. PCBTF is used by RPM in field applied architectural and industrial Maintenance (AIM) coatings; marine coatings; and in various adhesives and consumer products. The extensive use of PCBTF in industry products is largely due to the U.S. Environmental Protection Agency (EPA) in 1994, exempted PCBTF from its list of volatile organic compounds (VOCs). In addition, PCBTF has more favorable performance properties than other exempt compounds (e.g., it evaporates slower and has a higher flash point and is therefore less flammable than other exempt VOCs, including acetone).

12. RPM's product lines that contain PCBTF typically contain less than 5% of PCBTF in the chemical composition by weight, but can range up to 70% for some niche, high performing coatings products.

IV. RPM Uses State-of-the-Art Environmental Controls that Minimize Any Release of PFAS During Manufacturing

13. RPM uses state-of-the-art environmental controls in its manufacturing processes, which ensure that any release of PFAS during the manufacturing process is either zero or negligible.

14. RPM complies with all relevant laws regarding the use of PFAS during manufacturing, and RPM's environmental controls have been approved by regulators in the various U.S. states where we have permitted operations.

V. Labeling Products with the Required Warning Would Be Highly Burdensome.

15. I understand that the PFAS Regulation requires products themselves to bear the required warning label, consisting of an Erlenmeyer flask labeled “PFAS” in legible typeface.

16. It would be particularly difficult, and perhaps impossible, to add New Mexico’s required warning to several of RPM’s product lines, given those products’ small size, unique shape, existing requirements to meet other federally required labeling standard or other qualities of product and packaging that would make adding the pictogram to the label difficult.

17. Assuming it even can be done, adding the New Mexico PFAS Regulation’s required warning label to RPM products would be extraordinarily expensive and resource-intensive. Preliminary estimates are that it would cost RPM several hundred thousand dollars and take several months to redesign manufacturing, labeling and packaging processes to accommodate the required warning label on the products.

VI. Labeling the Packaging of Products with the Required Warning Would Be Burdensome.

18. I understand that, in addition to requiring a warning label on products, the PFAS Regulation requires a warning label on packaging in some instances. We understand that the PFAS Regulation would require RPM to include the warning label on the packaging for its touch up and repair products, too.

19. RPM dedicates significant time and money to designing the overall look of products and packaging. These small packages are designed to meet consumer needs, ease of application, customer safety and conveyance of required product identification and current consumer product labeling requirements.

20. The process of redesigning product packaging to comply with the PFAS Regulation’s requirement of an Erlenmeyer flask with PFAS in font “no smaller than the font used

for other consumer information on the product” would be costly and extremely time-consuming. RPM’s subsidiaries are already actively working to fully reformulate products containing PFAS, including products containing PCBTF to meet the various U.S. state PFAS in Products Regulations compliance deadlines that eventually ban the use of PFAS in all products sold in these states by 2032, such as New Mexico. RPM’s believes this is a more prudent and responsible use of our valuable time and resources to ensure compliance with the applicable state regulations that ban and/or restrict the use of PFAS in products.

VII. These Problems Affect All RPM Products Containing PFAS Distributed within the United States.

21. The scope of the PFAS Regulation’s warning-label requirement would affect not only RPM products intended for distribution within New Mexico, but also products intended for distribution within *all* states and, in many cases, Mexico and Canada.

22. RPM operates a large and complex distribution network, with multiple models of distribution and intermediaries. RPM products are sold through mass merchandisers, e-commerce (including social commerce) channels, grocery stores, hardware stores, membership club stores, drug stores, value store retailers, distributors, wholesalers, and various professional / industrial channels throughout the United States and abroad.

23. RPM cannot create separate product streams for our affected products lines intended for distribution within New Mexico because it is not feasible from a distribution perspective. RPM does not in all cases control where within the United States its retail customers distribute our affected products. For example, if RPM sold 1,000 units of an affected coatings product to a retailer customer with stores throughout the country, that retailer company would independently choose whether, and how many, units to send to stores in New Mexico. RPM has no involvement in that distribution process.

24. Even if RPM could overcome this distribution hurdle, it would be prohibitively expensive and burdensome for RPM to design, create, and maintain an entirely separate stream of products exclusively for New Mexico while at the same time working to reformulate all PFAS containing products to meet the 2032 deadline. Thus, when states have unique labeling requirements for products, RPM must redesign the entire, nationwide product line.

VIII. RPM Does Not Support Regulations that Require False, Misleading Labeling.

25. RPM supports safe, science-based regulation. But RPM cannot support misleading regulations like the PFAS Regulation.

26. The required Erlenmeyer flask label necessarily communicates risk or danger. And the PFAS Regulation would require RPM to affix that evocative symbol to *all affected* products—and their packaging—that use *any* amount of *any* type of intentionally added PFAS. It would thus require RPM to produce labels falsely communicating that all PFAS are dangerous to human health and the environment.

27. Given the potentially misleading nature of the symbol if applied to all PFAS containing products, RPM advocates that rather than diverting time and resources away from efforts to reformulate PFAS out of products that contain it today to label all products that contain PFAS with the Erlenmeyer flask that New Mexico not adopt this rule and allow companies to continue reformulating affected products that contain PFAS, therefore removing the use of PFAS in affected products from the consumer, commercial and industrial markets by the prescribed compliance deadlines for affected product categories and eventually in all affected product lines by 2032.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on June 15, 2026.

A handwritten signature in black ink, appearing to read 'Lee A. Bowers', with a long horizontal stroke extending to the right.

Lee A. Bowers

Vice President – Environmental,
Health & Safety

**THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW MEXICO**

AMERICAN CHEMISTRY COUNCIL,
ALLIANCE FOR AUTOMOTIVE
INNOVATION, AMERICAN COATINGS
ASSOCIATION, ASSOCIATION OF HOME
APPLIANCE MANUFACTURERS,
NATIONAL ASSOCIATION OF
MANUFACTURERS, NATIONAL
ELECTRICAL MANUFACTURERS
ASSOCIATION, NATIONAL FEDERATION
OF INDEPENDENT BUSINESS, INC., NEW
MEXICO RETAIL ASSOCIATION, and
POWER TOOL INSTITUTE,

Plaintiffs,

v.

JAMES C. KENNEY, *in his official capacity
as Secretary of New Mexico Environment
Department*; and RAÚL TORREZ, *in his
official capacity as Attorney General of New
Mexico,*

Defendants.

Case No.: 1:26-cv-02130

DECLARATION OF STEPHANIE THOMPSON

I, Stephanie Thompson, declare as follows:

1. I am currently employed as Product Standards Manager of Koki Holdings America Ltd. (KHA). KHA is a wholly owned subsidiary of Koki Holdings Company, Ltd., a Japanese company that manufactures and sells handheld power tools worldwide.

2. I joined KHA in November 2017 and am the Product Standards Manager. I hold a degree in mechanical engineering from Georgia Institute of Technology. My responsibilities include liaising with the manufacturing plants and product standards department to ensure product

compliance and marketability in the US and Canada. Based on my role and day-to-day responsibilities, I am familiar with the products sold by KHA as well as KHA's distribution systems, marketing and sales.

3. I have reviewed and am familiar with New Mexico's Per- and Poly-Fluoroalkyl Substances Protection Act, consisting of sections 74-15-1 through 74-15-7 of the New Mexico Statutes and its implementing regulation, 20.13.2 NMAC (the "PFAS Regulation").

4. I understand that Koki Holdings America is a member of plaintiff Power Tool Institute (PTI).

5. I submit this declaration in support of plaintiffs' motion for preliminary injunction in the above-captioned case challenging the PFAS Regulation.

6. KHA is a distributor of handheld power tools in the United States and Canada. Koki Holdings America Ltd. is organized under the laws of the State of Delaware, with a principal place of business Braselton, Georgia. As of June 1, 2026, KHA employed two hundred fifteen people in the United States..

7. KHA is the sole distributor in North America for Metabo HPT and Metabo branded products manufactured by Koki Holdings Co., Ltd. and is a national leader in the power tool industry selling cutting edge, durable, power tools used in the construction industry and by do-it-yourselfers.

I. Koki Holdings Distributes power tools and lithium ion batteries with PFAS.

8. KHA products contain PFAS such as PVDF, PTFE and PFA for the functioning of lithium ion batteries and electric power tools. Without these critical chemicals, which are primarily internal to the product, it would be impossible to manufacture safe, functioning lithium-

ion batteries and electric power tools for which PFAS are used as a waterproofing agent, binders, hardeners, and seals. These properties are crucial to manufacturing safe and functioning tools.

9. In most products the maximum overall concentration of PFAS in the entire product is $< 1\%$.

II. Labeling Products with the Required Warning Would Be Highly Burdensome.

10. I understand that the PFAS Regulation requires products themselves to bear the required warning label, consisting of an Erlenmeyer flask labeled “PFAS” in legible typeface.

11. No state, besides New Mexico, requires KHA to include a pictogram warning on its products—including other states that regulate PFAS.

12. It would be particularly difficult to add New Mexico’s required warning to lithium-ion batteries given those products’ small size and molded casing. Adding an additional, and I believe unnecessary, warning to an already crowded label would dilute the effectiveness of such a warning and require a complete redesigning of the battery casing. For example, as shown in the below image, there is almost no surface area on the label of this representative lithium-ion battery onto which the image of an Erlenmeyer flask labeled “PFAS” in legible typeface can be imprinted or embossed. Redesign of a battery casing also comes with additional costs to have the product re-tested and re-certified for compliance with safety standards. Power tool rating labels are also compact and would have to be reworked to fit a legible Erlenmeyer flask symbol.



Labeling these products thus requires more than merely printing ink; it could require changing the molding and/or engraving directly into hundreds of products.

13. Assuming it even can be done, adding the PFAS Regulation's required warning label to at least 300 models and hundreds of thousands of individual products would be extraordinarily time consuming, expensive and resource intensive. It would take over a year to add the required warning label to all affected products.

III. Labeling the Packaging of KHA's Products with the Required Warning Would Be Burdensome.

14. I understand that, in addition to requiring a warning label on products, the PFAS Regulation requires a warning label on packaging in some instances. We understand that the PFAS Regulation would require KHA to include the warning label on the packaging for its products, too.

15. KHA dedicates significant time and money to designing the overall look of products and their packaging to effectively communicate the specifications, benefits, and uses of their products. Adding a symbol that communicates a confusing or incorrect message to the consumer would be detrimental to its brand.

16. The process of redesigning product packaging to comply with the PFAS Regulation's requirement of an Erlenmeyer flask with PFAS in font "no smaller than the font used for other consumer information on the product" would be costly and time-consuming. The cost of redesigning and reprinting required if the PFAS Regulation were to be applicable to KHA's products could not be recovered without increases in pricing, lost business by delay in product availability, and loss of profits. The cost of adding the Erlenmeyer flask symbol to all products and packaging would cost hundreds of thousands of dollars.

IV. These Problems Affect All 300 Models Distributed within the United States.

17. The scope of the PFAS Regulation's warning-label requirement would affect not only lithium ion batteries and power tools intended for distribution within New Mexico, but lithium ion batteries and power tools intended for distribution within *all* fifty states and Canada.

18. KHA operates a large and complex distribution network, with multiple models of distribution and intermediaries. Metabo HPT power tools are sold through mass merchandisers, e-commerce (including social commerce) channels, and independent distributors in all fifty states, and Canada.

19. KHA cannot create separate product streams for products intended for distribution within New Mexico because it is not feasible from a distribution perspective. KHA does not control where within the United States its retail customers distribute KHA's power tools and batteries. For example, if KHA sold 1,000 batteries and power tools to a retailer customer with

stores throughout the country, that retailer company would independently choose whether, and how many, units to send to stores in New Mexico. KHA has no involvement in that distribution process.

20. Even if KHA could overcome this distribution hurdle, it would be prohibitively expensive and burdensome for KHA to design, create, and maintain an entirely separate stream of products exclusively for New Mexico. Thus, when states have unique labeling requirements for products, the entire North American product lines must be redesigned.

V. KHA Does Not Support Regulations that Require False, Misleading Labeling.

21. KHA supports safe, science-based regulation. But KHA cannot support misleading regulations like the PFAS Regulation.


22. The required Erlenmeyer flask label necessarily communicates risk or danger. And the PFAS Regulation would require KHA to affix that evocative label to *all* products—and their packaging—that use *any* amount of *any* type of intentionally added PFAS. It would thus require KHA to produce labels falsely communicating that all PFAS, and all products containing PFAS are dangerous to human health and the environment.

23. KHA does not agree with that message. It objects to being compelled to communicate the message that all PFAS and all products containing PFAS are harmful.

24. Additionally, the lithium-ion batteries that KHA distributes are recyclable and KHA is a steward as recognized by The Battery Network (a producer responsibility organization) and recognized as a compliant participant in regulated state and voluntary programs. This makes the likelihood of any harm to the people of New Mexico or its land even more improbable.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on July 30, 2026.


Stephanie Thompson
Product Standards Manager